22	O
-	O
oxacalcitriol	O
suppresses	O
secondary	B
hyperparathyroidism	I
without	O
inducing	O
low	B
bone	I
turnover	I
in	O
dogs	O
with	O
renal	B
failure	I
.	O

BACKGROUND	O
:	O
Calcitriol	O
therapy	O
suppresses	O
serum	O
levels	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
in	O
patients	O
with	O
renal	B
failure	I
but	O
has	O
several	O
drawbacks	O
,	O
including	O
hypercalcemia	B
and	O
/	O
or	O
marked	O
suppression	B
of	I
bone	I
turnover	I
,	O
which	O
may	O
lead	O
to	O
adynamic	B
bone	I
disease	I
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effects	O
of	O
OCT	O
on	O
serum	O
PTH	O
levels	O
and	O
bone	O
turnover	O
in	O
states	O
of	O
normal	O
or	O
impaired	B
renal	I
function	I
.	O

RESULTS	O
:	O
In	O
Nx	O
dogs	O
,	O
OCT	O
significantly	O
decreased	O
serum	O
PTH	O
levels	O
soon	O
after	O
the	O
induction	O
of	O
renal	B
insufficiency	I
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
even	O
though	O
OCT	O
does	O
not	O
completely	O
prevent	O
the	O
occurrence	O
of	O
hypercalcemia	B
in	O
experimental	O
dogs	O
with	O
renal	B
insufficiency	I
,	O
it	O
may	O
be	O
of	O
use	O
in	O
the	O
management	O
of	O
secondary	B
hyperparathyroidism	I
because	O
it	O
does	O
not	O
induce	O
low	B
bone	I
turnover	I
and	O
,	O
therefore	O
,	O
does	O
not	O
increase	O
the	O
risk	O
of	O
adynamic	B
bone	I
disease	I
.	O

There	O
was	O
a	O
history	O
of	O
ischemic	B
cardiac	B
disease	I
9	O
years	O
earlier	O
.	O

The	O
patient	O
was	O
admitted	O
with	O
a	O
pulmonary	B
-	I
renal	I
syndrome	I
with	O
hemoptysis	B
,	O
rapidly	O
progressive	O
renal	B
failure	I
,	O
and	O
hypoxemia	B
that	O
required	O
mechanical	O
ventilation	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

The	O
ECG	O
showed	O
a	O
junctional	O
rhythm	O
without	O
ventricular	B
arrhythmia	I
.	O

This	O
study	O
reviews	O
the	O
current	O
proposed	O
mechanisms	O
of	O
sudden	B
death	I
after	O
a	O
high	O
dose	O
of	O
intravenous	O
methylprednisolone	O
(	O
IVMP	O
)	O
.	O

Rapid	O
infusion	O
and	O
underlying	O
cardiac	B
disease	I
were	O
important	O
risk	O
factors	O
in	O
the	O
case	O
reported	O
here	O
,	O
and	O
the	O
authors	O
discount	O
ventricular	B
arrhythmia	I
as	O
the	O
main	O
mechanism	O
.	O

Ten	O
patients	O
who	O
had	O
Parkinson	B
'	I
s	I
disease	I
with	O
disabling	O
dyskinesia	B
were	O
included	O
in	O
this	O
study	O
to	O
evaluate	O
the	O
role	O
of	O
mental	O
(	O
mental	O
calculation	O
)	O
and	O
motor	O
(	O
flexion	O
/	O
extension	O
of	O
right	O
fingers	O
,	O
flexion	O
/	O
extension	O
of	O
left	O
fingers	O
,	O
flexion	O
/	O
extension	O
of	O
the	O
neck	O
,	O
speaking	O
aloud	O
)	O
tasks	O
on	O
the	O
worsening	O
of	O
peak	O
-	O
dose	O
dyskinesia	B
following	O
administration	O
of	O
an	O
effective	O
single	O
dose	O
of	O
apomorphine	O
.	O

BACKGROUND	O
:	O
Although	O
an	O
indicator	O
of	O
renal	B
tubular	I
dysfunction	I
,	O
an	O
increased	O
urinary	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
)	O
activity	O
might	O
reflect	O
increased	O
lysosomal	O
activity	O
in	O
renal	O
tubular	O
cells	O
.	O

METHODS	O
:	O
Puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
was	O
administered	O
to	O
Sprague	O
Dawley	O
rats	O
to	O
induce	O
proteinuria	B
.	O

Peak	O
urine	O
NAG	O
activity	O
and	O
a	O
change	O
in	O
NAG	O
isoenzyme	O
pattern	O
coincided	O
with	O
both	O
the	O
peak	O
proteinuria	B
and	O
the	O
reduction	O
in	O
intracellular	O
protein	O
and	O
NAG	O
droplets	O
(	O
day	O
six	O
onwards	O
)	O
.	O

Cauda	B
equina	I
syndrome	I
after	O
spinal	O
anaesthesia	O
with	O
hyperbaric	O
5	O
%	O
lignocaine	O
:	O
a	O
review	O
of	O
six	O
cases	O
of	O
cauda	B
equina	I
syndrome	I
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
1993	O
-	O
1997	O
.	O

Six	O
cases	O
of	O
cauda	B
equina	I
syndrome	I
with	O
varying	O
severity	O
were	O
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
during	O
the	O
period	O
1993	O
-	O
1997	O
.	O

All	O
cases	O
sustained	O
permanent	O
neurological	B
deficits	I
.	O

Systemic	O
toxicity	B
following	O
administration	O
of	O
sirolimus	O
(	O
formerly	O
rapamycin	O
)	O
for	O
psoriasis	B
:	O
association	O
of	O
capillary	B
leak	I
syndrome	I
with	O
apoptosis	O
of	O
lesional	O
lymphocytes	O
.	O

After	O
2	O
individuals	O
with	O
psoriasis	B
developed	O
a	O
capillary	B
leak	I
syndrome	I
following	O
treatment	O
with	O
oral	O
sirolimus	O
lesional	O
skin	O
cells	O
and	O
activated	O
peripheral	O
blood	O
cells	O
were	O
analyzed	O
for	O
induction	O
of	O
apoptosis	O
.	O

OBSERVATIONS	O
:	O
A	O
keratome	O
skin	O
specimen	O
from	O
1	O
patient	O
with	O
sirolimus	O
-	O
induced	O
capillary	B
leak	I
syndrome	I
had	O
a	O
2	O
.	O
3	O
-	O
fold	O
increase	O
in	O
percentage	O
of	O
apoptotic	O
cells	O
(	O
to	O
48	O
%	O
)	O
compared	O
with	O
an	O
unaffected	O
sirolimus	O
-	O
treated	O
patient	O
with	O
psoriasis	B
(	O
21	O
%	O
)	O
.	O

Activated	O
peripheral	O
blood	O
T	O
cells	O
from	O
patients	O
with	O
psoriasis	B
tended	O
to	O
exhibit	O
greater	O
spontaneous	O
or	O
dexamethasone	O
-	O
induced	O
apoptosis	O
than	O
did	O
normal	O
T	O
cells	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
sirolimus	O
.	O

CONCLUSIONS	O
:	O
Severe	O
adverse	O
effects	O
of	O
sirolimus	O
include	O
fever	B
,	O
anemia	B
,	O
and	O
capillary	B
leak	I
syndrome	I
.	O

Because	O
patients	O
with	O
severe	O
psoriasis	B
may	O
develop	O
capillary	B
leak	I
from	O
various	O
systemic	O
therapies	O
,	O
clinical	O
monitoring	O
is	O
advisable	O
for	O
patients	O
with	O
inflammatory	B
diseases	I
who	O
are	O
treated	O
with	O
immune	O
modulators	O
.	O

These	O
were	O
evaluated	O
with	O
respect	O
to	O
the	O
duration	O
of	O
lithium	O
therapy	O
,	O
age	O
,	O
sex	O
,	O
and	O
family	O
history	O
(	O
whether	O
or	O
not	O
the	O
patient	O
had	O
a	O
first	O
-	O
degree	O
relative	O
with	O
thyroid	B
disease	I
)	O
.	O

PATIENTS	O
:	O
One	O
hundred	O
and	O
one	O
patients	O
(	O
28	O
men	O
and	O
73	O
women	O
)	O
with	O
bipolar	B
disorder	I
receiving	O
lithium	O
maintenance	O
therapy	O
ranging	O
from	O
1	O
year	O
'	O
s	O
to	O
32	O
years	O
'	O
duration	O
.	O

The	O
control	O
group	O
consisted	O
of	O
82	O
patients	O
with	O
no	O
psychiatric	B
or	O
endocrinological	O
diagnoses	O
from	O
the	O
hospital	O
'	O
s	O
out	O
-	O
patient	O
clinics	O
.	O

All	O
patients	O
having	O
first	O
-	O
degree	O
relatives	O
affected	O
by	O
thyroid	B
illness	I
had	O
accelerated	O
onset	O
of	O
hypothyroidism	B
(	O
3	O
.	O
7	O
years	O
after	O
onset	O
of	O
lithium	O
therapy	O
)	O
compared	O
with	O
patients	O
without	O
a	O
family	O
history	O
(	O
8	O
.	O
6	O
years	O
after	O
onset	O
of	O
lithium	O
therapy	O
)	O
.	O

CONCLUSIONS	O
:	O
Familial	O
thyroid	B
illness	I
is	O
a	O
risk	O
factor	O
for	O
hypothyroidism	B
and	O
hypercalcemia	B
during	O
lithium	O
therapy	O
.	O

Severe	O
immune	O
hemolytic	B
anemia	I
associated	O
with	O
prophylactic	O
use	O
of	O
cefotetan	O
in	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Second	O
-	O
and	O
third	O
-	O
generation	O
cephalosporins	O
,	O
especially	O
cefotetan	O
,	O
are	O
increasingly	O
associated	O
with	O
severe	O
,	O
sometimes	O
fatal	O
immune	O
hemolytic	B
anemia	I
.	O

We	O
noticed	O
that	O
10	O
of	O
our	O
35	O
cases	O
of	O
cefotetan	O
-	O
induced	O
hemolytic	B
anemias	I
were	O
in	O
patients	O
who	O
had	O
received	O
cefotetan	O
prophylactically	O
for	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Eight	O
of	O
these	O
cases	O
of	O
severe	O
immune	O
hemolytic	B
anemia	I
are	O
described	O
.	O

Glyceryl	O
trinitrate	O
induces	O
attacks	O
of	O
migraine	B
without	I
aura	I
in	O
sufferers	O
of	O
migraine	B
with	I
aura	I
.	O

Migraine	B
with	I
aura	I
and	O
migraine	B
without	I
aura	I
have	O
the	O
same	O
pain	B
phase	O
,	O
thus	O
indicating	O
that	O
migraine	B
with	I
aura	I
and	O
migraine	B
without	I
aura	I
share	O
a	O
common	O
pathway	O
of	O
nociception	O
.	O

In	O
recent	O
years	O
,	O
increasing	O
evidence	O
has	O
suggested	O
that	O
the	O
messenger	O
molecule	O
nitric	O
oxide	O
(	O
NO	O
)	O
is	O
involved	O
in	O
pain	B
mechanisms	O
of	O
migraine	B
without	I
aura	I
.	O

In	O
order	O
to	O
clarify	O
whether	O
the	O
same	O
is	O
true	O
for	O
migraine	B
with	I
aura	I
,	O
in	O
the	O
present	O
study	O
we	O
examined	O
the	O
headache	B
response	O
to	O
intravenous	O
infusion	O
of	O
glyceryl	O
trinitrate	O
(	O
GTN	O
)	O
(	O
0	O
.	O
5	O
microg	O
/	O
kg	O
/	O
min	O
for	O
20	O
min	O
)	O
in	O
12	O
sufferers	O
of	O
migraine	B
with	I
aura	I
.	O

The	O
specific	O
aim	O
was	O
to	O
elucidate	O
whether	O
an	O
aura	O
and	O
/	O
or	O
an	O
attack	O
of	O
migraine	B
without	I
aura	I
could	O
be	O
induced	O
.	O

At	O
this	O
time	O
the	O
induced	O
headache	B
in	O
6	O
of	O
12	O
migraineurs	B
fulfilled	O
the	O
diagnostic	O
criteria	O
for	O
migraine	B
without	I
aura	I
of	O
the	O
International	O
Headache	B
Society	O
.	O

The	O
results	O
therefore	O
suggest	O
that	O
NO	O
is	O
involved	O
in	O
the	O
pain	B
mechanisms	O
of	O
migraine	B
with	I
aura	I
.	O

Since	O
cortical	O
spreading	O
depression	B
has	O
been	O
shown	O
to	O
liberate	O
NO	O
in	O
animals	O
,	O
this	O
finding	O
may	O
help	O
our	O
understanding	O
of	O
the	O
coupling	O
between	O
cortical	O
spreading	O
depression	B
and	O
headache	B
in	O
migraine	B
with	I
aura	I
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
tetany	B
with	O
sudden	O
respiratory	B
arrest	I
after	O
the	O
infusion	O
of	O
intravenous	O
diltiazem	O
.	O

Predictors	O
of	O
decreased	B
renal	I
function	I
in	O
patients	O
with	O
heart	B
failure	I
during	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
:	O
results	O
from	O
the	O
studies	O
of	O
left	B
ventricular	I
dysfunction	I
(	O
SOLVD	O
)	O

BACKGROUND	O
:	O
Although	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
reduces	O
mortality	O
rates	O
in	O
patients	O
with	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
,	O
it	O
may	O
also	O
cause	O
decreased	B
renal	I
function	I
.	O

OBJECTIVE	O
:	O
To	O
quantify	O
specific	O
clinical	O
predictors	O
of	O
reduction	B
in	I
renal	I
function	I
in	O
patients	O
with	O
CHF	B
who	O
are	O
prescribed	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
.	O

Decreased	B
renal	I
function	I
was	O
defined	O
as	O
a	O
rise	O
in	O
serum	O
creatinine	O
>	O
/	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
from	O
baseline	O
.	O

We	O
used	O
time	O
-	O
to	O
-	O
event	O
analysis	O
to	O
identify	O
potential	O
predictors	O
of	O
decrease	O
in	O
renal	O
function	O
including	O
age	O
,	O
baseline	O
ejection	O
fraction	O
,	O
baseline	O
creatinine	O
,	O
low	O
systolic	O
blood	O
pressure	O
(	O
<	O
100	O
mm	O
Hg	O
)	O
,	O
history	O
of	O
hypertension	B
,	O
diabetes	B
,	O
and	O
use	O
of	O
antiplatelet	O
,	O
diuretic	O
,	O
and	O
beta	O
-	O
blocker	O
therapy	O
.	O

RESULTS	O
:	O
Patients	O
randomly	O
assigned	O
to	O
enalapril	O
had	O
a	O
33	O
%	O
greater	O
likelihood	O
of	O
decreased	B
renal	I
function	I
than	O
controls	O
(	O
P	O
=	O
.	O
003	O
)	O
.	O

By	O
multivariate	O
analysis	O
,	O
in	O
both	O
the	O
placebo	O
and	O
enalapril	O
groups	O
older	O
age	O
,	O
diuretic	O
therapy	O
,	O
and	O
diabetes	B
were	O
associated	O
with	O
decreased	B
renal	I
function	I
,	O
whereas	O
beta	O
-	O
blocker	O
therapy	O
and	O
higher	O
ejection	O
fraction	O
were	O
renoprotective	O
.	O

Older	O
age	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
developing	O
decreased	B
renal	I
function	I
in	O
both	O
groups	O
,	O
but	O
significantly	O
more	O
so	O
in	O
the	O
enalapril	O
group	O
(	O
enalapril	O
:	O
risk	O
ratio	O
[	O
RR	O
]	O
1	O
.	O
42	O
per	O
10	O
years	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
32	O
-	O
1	O
.	O
52	O
with	O
enalapril	O
;	O
placebo	O
:	O
RR	O
1	O
.	O
18	O
,	O
95	O
%	O
CI	O
1	O
.	O
12	O
-	O
1	O
.	O
25	O
)	O
.	O

Diuretic	O
therapy	O
was	O
likewise	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
decreased	B
renal	I
function	I
in	O
the	O
enalapril	O
group	O
(	O
RR	O
1	O
.	O
89	O
,	O
95	O
%	O
CI	O
1	O
.	O
70	O
-	O
2	O
.	O
08	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
RR	O
1	O
.	O
35	O
,	O
95	O
%	O
CI	O
1	O
.	O
09	O
-	O
1	O
.	O
66	O
)	O
.	O

Conversely	O
,	O
enalapril	O
had	O
a	O
relative	O
renoprotective	O
effect	O
(	O
RR	O
1	O
.	O
33	O
,	O
95	O
%	O
CI	O
1	O
.	O
13	O
-	O
1	O
.	O
53	O
)	O
compared	O
with	O
placebo	O
(	O
RR	O
1	O
.	O
96	O
,	O
95	O
%	O
CI	O
1	O
.	O
57	O
-	O
2	O
.	O
44	O
)	O
in	O
patients	O
with	O
diabetes	B
.	O

A	O
lower	O
risk	O
of	O
renal	B
impairment	I
was	O
seen	O
in	O
both	O
groups	O
with	O
beta	O
-	O
blocker	O
therapy	O
(	O
RR	O
0	O
.	O
70	O
,	O
95	O
%	O
CI	O
0	O
.	O
57	O
-	O
0	O
.	O
85	O
)	O
and	O
higher	O
baseline	O
ejection	O
fraction	O
(	O
RR	O
0	O
.	O
93	O
per	O
5	O
%	O
increment	O
,	O
95	O
%	O
CI	O
0	O
.	O
91	O
-	O
0	O
.	O
96	O
)	O
.	O

CONCLUSIONS	O
:	O
Enalapril	O
use	O
caused	O
a	O
33	O
%	O
increase	O
in	O
the	O
risk	O
of	O
decreased	B
renal	I
function	I
in	O
patients	O
with	O
CHF	B
.	O

Diabetes	B
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
renal	B
impairment	I
in	O
all	O
patients	O
with	O
CHF	B
,	O
but	O
this	O
risk	O
was	O
reduced	O
in	O
the	O
enalapril	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

We	O
report	O
a	O
female	O
patient	O
with	O
a	O
diagnosis	O
of	O
a	O
not	O
otherwise	O
specified	O
psychotic	B
disorder	I
(	O
DSM	O
-	O
IV	O
)	O
who	O
developed	O
hypomania	B
shortly	O
after	O
the	O
introduction	O
of	O
olanzapine	O
treatment	O
.	O

Acetazolamide	O
-	O
induced	O
Gerstmann	B
syndrome	I
.	O

Acute	O
confusion	B
induced	O
by	O
acetazolamide	O
is	O
a	O
well	O
known	O
adverse	O
drug	O
reaction	O
in	O
patients	O
with	O
renal	B
impairment	I
.	O

We	O
report	O
a	O
case	O
of	O
acetazolamide	O
-	O
induced	O
Gerstmann	B
syndrome	I
in	O
a	O
patient	O
with	O
normal	O
renal	O
function	O
,	O
to	O
highlight	O
predisposing	O
factors	O
that	O
are	O
frequently	O
overlooked	O
.	O

Vasopressin	O
in	O
the	O
treatment	O
of	O
milrinone	O
-	O
induced	O
hypotension	B
in	O
severe	O
heart	B
failure	I
.	O

The	O
use	O
of	O
phosphodiesterase	O
inhibitors	O
such	O
as	O
milrinone	O
in	O
the	O
treatment	O
of	O
severe	O
heart	B
failure	I
is	O
frequently	O
restricted	O
because	O
they	O
cause	O
vasodilation	O
and	O
hypotension	B
.	O

In	O
patients	O
with	O
decompensated	O
heart	B
failure	I
with	O
hypotension	B
after	O
treatment	O
with	O
milrinone	O
,	O
low	O
doses	O
of	O
vasopressin	O
restored	O
blood	O
pressure	O
without	O
inhibiting	O
the	O
inotropic	O
effect	O
of	O
milrinone	O
.	O

Indications	O
for	O
early	O
conversion	O
were	O
neurotoxicity	B
(	O
20	O
)	O
,	O
(	B
insulin	I
-	I
dependent	I
)	I
diabetes	I
mellitus	I
(	O
IDDM	B
)	O
(	O
5	O
)	O
,	O
nephrotoxicity	B
(	O
3	O
)	O
,	O
gastrointestinal	B
(	I
GI	I
)	I
toxicity	I
(	O
6	O
)	O
,	O
and	O
cardiomyopathy	B
(	O
1	O
)	O
,	O
and	O
for	O
late	O
conversion	O
were	O
neurotoxicity	B
(	O
15	O
)	O
,	O
IDDM	B
(	O
12	O
)	O
,	O
nephrotoxicity	B
(	O
3	O
)	O
,	O
GI	B
toxicity	I
(	O
5	O
)	O
,	O
hepatotoxicity	B
(	O
6	O
)	O
,	O
post	B
-	I
transplant	I
lmphoproliferate	I
disease	I
(	O

PTLD	B
)	O
(	O
2	O
)	O
,	O
cardiomyopathy	B
(	O
1	O
)	O
,	O
hemolytic	B
anemia	I
(	O
1	O
)	O
,	O
and	O
pruritus	B
(	O
1	O
)	O
.	O

Ocular	O
manifestations	O
of	O
juvenile	B
rheumatoid	I
arthritis	I
.	O

We	O
followed	O
210	O
cases	O
of	O
juvenile	B
rheumatoid	I
arthritis	I
closely	O
for	O
eleven	O
years	O
.	O

Iridocyclitis	B
was	O
seen	O
most	O
frequently	O
in	O
young	O
female	O
patients	O
(	O
0	O
to	O
4	O
years	O
)	O
with	O
the	O
monoarticular	O
or	O
pauciatricular	O
form	O
of	O
the	O
arthritis	B
.	O

Forty	O
-	O
four	O
percent	O
of	O
patients	O
with	O
uveitis	B
had	O
one	O
or	O
more	O
identifiable	O
signs	O
or	O
symptoms	O
,	O
such	O
as	O
red	O
eye	O
,	O
ocular	B
pain	I
,	O
decreased	B
visual	I
acuity	I
,	O
or	O
photophobia	B
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
.	O

Systemically	O
administered	O
corticosteroids	O
were	O
used	O
in	O
75	O
of	O
210	O
cases	O
;	O
a	O
significant	O
number	O
of	O
posterior	O
subcapsular	O
cataracts	B
was	O
found	O
.	O

Surgical	O
treatment	O
of	O
cataracts	B
,	O
band	B
keratopathy	I
,	O
and	O
glaucoma	B
achieved	O
uniformly	O
discouraging	O
results	O
.	O

Morphine	O
dose	O
-	O
dependently	O
reversed	O
these	O
behavioral	B
disorders	I
.	O

CONCLUSIONS	O
:	O
Overall	O
,	O
these	O
results	O
indicate	O
that	O
this	O
experimental	O
model	O
of	O
CP	O
-	O
induced	O
cystitis	B
may	O
be	O
an	O
interesting	O
new	O
behavioral	O
model	O
of	O
inflammatory	O
visceral	B
pain	I
,	O
allowing	O
a	O
better	O
understanding	O
of	O
these	O
painful	B
syndromes	I
and	O
thus	O
a	O
better	O
therapeutic	O
approach	O
to	O
them	O
.	O

Prednisolone	O
-	O
induced	O
muscle	B
dysfunction	I
is	O
caused	O
more	O
by	O
atrophy	B
than	O
by	O
altered	O
acetylcholine	O
receptor	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
neuromuscular	B
dysfunction	I
after	O
prednisolone	O
is	O
dose	O
-	O
dependent	O
,	O
and	O
derives	O
primarily	O
from	O
muscle	B
atrophy	I
and	O
derives	O
less	O
so	O
from	O
changes	O
in	O
AChR	O
expression	O
.	O

We	O
suggest	O
that	O
the	O
observed	O
effects	O
are	O
dose	O
-	O
dependent	O
and	O
derive	O
primarily	O
from	O
muscle	B
atrophy	I
and	O
derive	O
less	O
from	O
changes	O
in	O
acetylcholine	O
receptor	O
expression	O
.	O

Apomorphine	O
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	B
'	I
s	I
disease	I
.	O

Apomorphine	O
was	O
the	O
first	O
dopaminergic	O
drug	O
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	B
'	I
s	I
disease	I
.	O

While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	B
'	I
s	I
disease	I
by	O
subcutaneous	O
administration	O
of	O
apomorphine	O
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O

The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	O
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	B
complications	O
play	O
a	O
lesser	O
role	O
.	O

Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	O
treatment	O
in	O
fluctuating	O
Parkinson	B
'	I
s	I
disease	I
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O

OBJECTIVE	O
:	O
The	O
pharmacological	O
response	O
to	O
drugs	O
that	O
act	O
on	O
the	O
cholinergic	O
system	O
of	O
the	O
iris	O
has	O
been	O
used	O
to	O
predict	O
deficits	O
in	O
central	O
cholinergic	O
functioning	O
due	O
to	O
diseases	O
such	O
as	O
Alzheimer	B
'	I
s	I
disease	I
,	O
yet	O
correlations	O
between	O
central	O
and	O
peripheral	O
responses	O
have	O
not	O
been	O
properly	O
studied	O
.	O

OUTCOME	O
MEASURES	O
:	O
Pupil	O
size	O
at	O
time	O
points	O
after	O
administration	O
of	O
tropicamide	O
and	O
pilocarpine	O
;	O
scopolamine	O
-	O
induced	O
impairment	B
in	I
word	I
recall	I
.	O

Compared	O
with	O
the	O
young	O
group	O
,	O
the	O
elderly	O
group	O
had	O
greater	O
scopolamine	O
-	O
induced	O
impairment	B
in	I
word	I
recall	I
60	O
,	O
90	O
and	O
120	O
minutes	O
after	O
administration	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
data	O
indicate	O
that	O
MM	O
opioid	O
abusers	O
represent	O
a	O
pain	B
-	I
intolerant	I
subset	O
of	O
clinical	O
patients	O
.	O

High	O
-	O
dose	O
methylprednisolone	O
may	O
do	O
more	O
harm	O
for	O
spinal	B
cord	I
injury	I
.	O

Because	O
of	O
the	O
National	O
Acute	O
Spinal	B
Cord	I
Injury	I
Studies	O
(	O
NASCIS	O
)	O
,	O
high	O
-	O
dose	O
methylprednisolone	O
became	O
the	O
standard	O
of	O
care	O
for	O
the	O
acute	O
spinal	B
cord	I
injury	I
.	O

In	O
the	O
NASCIS	O
,	O
there	O
was	O
no	O
mention	O
regarding	O
the	O
possibility	O
of	O
acute	O
corticosteroid	O
myopathy	B
that	O
high	O
-	O
dose	O
methylprednisolone	O
may	O
cause	O
.	O

We	O
hypothesize	O
that	O
it	O
may	O
cause	O
some	O
damage	B
to	I
the	I
muscle	I
of	O
spinal	B
cord	I
injury	I
patients	O
.	O

Further	O
,	O
steroid	O
myopathy	B
recovers	O
naturally	O
and	O
the	O
neurological	O
improvement	O
shown	O
in	O
the	O
NASCIS	O
may	O
be	O
just	O
a	O
recording	O
of	O
this	O
natural	O
motor	O
recovery	O
from	O
the	O
steroid	O
myopathy	B
,	O
instead	O
of	O
any	O
protection	O
that	O
methylprednisolone	O
offers	O
to	O
the	O
spinal	B
cord	I
injury	I
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
discussion	O
considering	O
the	O
possibility	O
that	O
the	O
methylprednisolone	O
recommended	O
by	O
NASCIS	O
may	O
cause	O
acute	O
corticosteroid	O
myopathy	B
.	O

The	O
indications	O
for	O
switch	O
were	O
chronic	O
CsA	O
or	O
Tac	O
nephrotoxicity	B
(	O
12	O
)	O
,	O
acute	O
CsA	O
or	O
Tac	O
toxicity	B
(	O
3	O
)	O
,	O
severe	O
facial	B
dysmorphism	I
(	O
2	O
)	O
,	O
posttransplant	B
lymphoproliferative	I
disorder	I
(	O
PTLD	B
)	O
in	O
remission	O
(	O
2	O
)	O
,	O
and	O
hepatotoxicity	B
in	O
1	O
.	O

Five	O
patients	O
developed	O
pneumonia	B
(	O
two	O
Pneumocystis	B
carinii	I
pneumonia	I
,	O
one	O
infectious	B
mononucleosis	I
with	O
polyclonal	O
PTLD	B
lung	O
infiltrate	O
)	O
and	O
two	O
had	O
bronchiolitis	B
obliterans	I
.	O

RAPA	O
was	O
discontinued	O
in	O
four	O
patients	O
,	O
because	O
of	O
pneumonia	B
in	O
two	O
,	O
PTLD	B
in	O
one	O
,	O
and	O
oral	O
aphtous	B
ulcers	I
in	O
one	O
.	O

Electro	O
-	O
oculography	O
,	O
electroretinography	O
,	O
visual	O
evoked	O
potentials	O
,	O
and	O
multifocal	O
electroretinography	O
in	O
patients	O
with	O
vigabatrin	O
-	O
attributed	O
visual	B
field	I
constriction	I
.	O

PURPOSE	O
:	O
Symptomatic	O
visual	B
field	I
constriction	I
thought	O
to	O
be	O
associated	O
with	O
vigabatrin	O
has	O
been	O
reported	O
.	O

The	O
current	O
study	O
investigated	O
the	O
visual	O
fields	O
and	O
visual	O
electrophysiology	O
of	O
eight	O
patients	O
with	O
known	O
vigabatrin	O
-	O
attributed	O
visual	B
field	I
loss	I
,	O
three	O
of	O
whom	O
were	O
reported	O
previously	O
.	O

RESULTS	O
:	O
Seven	O
patients	O
showed	O
marked	O
visual	B
field	I
constriction	I
with	O
some	O
sparing	O
of	O
the	O
temporal	O
visual	O
field	O
.	O

CONCLUSION	O
:	O
Marked	O
visual	B
field	I
constriction	I
appears	O
to	O
be	O
associated	O
with	O
vigabatrin	O
therapy	O
.	O

Myocardial	B
ischemia	I
due	O
to	O
coronary	B
artery	I
spasm	I
during	O
dobutamine	O
stress	O
echocardiography	O
.	O

Until	O
now	O
,	O
the	O
test	O
has	O
been	O
focused	O
only	O
on	O
the	O
organic	O
lesion	O
in	O
the	O
coronary	O
artery	O
,	O
and	O
positive	O
DSE	O
has	O
indicated	O
the	O
presence	O
of	O
significant	O
fixed	O
coronary	B
artery	I
stenosis	I
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether	O
myocardial	B
ischemia	I
due	O
to	O
coronary	B
spasm	I
is	O
induced	O
by	O
dobutamine	O
.	O

We	O
performed	O
DSE	O
on	O
51	O
patients	O
with	O
coronary	B
spastic	I
angina	I
but	O
without	O
significant	O
fixed	O
coronary	B
artery	I
stenosis	I
.	O

Coronary	O
spasm	O
was	O
induced	O
by	O
intracoronary	O
injection	O
of	O
acetylcholine	O
,	O
and	O
no	O
fixed	O
coronary	B
artery	I
stenosis	I
was	O
documented	O
on	O
angiograms	O
in	O
all	O
patients	O
.	O

These	O
findings	O
indicate	O
that	O
dobutamine	O
can	O
provoke	O
coronary	B
spasm	I
in	O
some	O
patients	O
with	O
coronary	B
spastic	I
angina	I
.	O

When	O
DSE	O
is	O
performed	O
to	O
evaluate	O
coronary	B
artery	I
disease	I
,	O
not	O
only	O
fixed	O
coronary	B
stenosis	I
,	O
but	O
also	O
coronary	B
spasm	I
should	O
be	O
considered	O
as	O
a	O
genesis	O
of	O
asynergy	O
.	O

Screening	O
for	O
stimulant	O
use	O
in	O
adult	O
emergency	O
department	O
seizure	B
patients	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
positive	O
plasma	O
drug	O
screening	O
for	O
cocaine	O
or	O
amphetamine	O
in	O
adult	O
emergency	O
department	O
seizure	B
patients	O
.	O

METHODS	O
:	O
This	O
prospective	O
study	O
evaluated	O
consecutive	O
eligible	O
seizure	B
patients	O
who	O
had	O
a	O
plasma	O
sample	O
collected	O
as	O
part	O
of	O
their	O
clinical	O
evaluation	O
.	O

Patient	O
demographics	O
,	O
history	O
of	O
underlying	O
drug	O
or	O
alcohol	O
-	O
related	O
seizure	B
disorder	O
,	O
estimated	O
time	O
from	O
seizure	B
to	O
sample	O
collection	O
,	O
history	O
or	O
suspicion	O
of	O
cocaine	B
or	I
amphetamine	I
abuse	I
,	O
results	O
of	O
clinical	O
urine	O
testing	O
for	O
drugs	O
of	O
abuse	O
,	O
and	O
assay	O
results	O
were	O
recorded	O
without	O
patient	O
identifiers	O
.	O

Positive	O
test	O
results	O
were	O
more	O
common	O
in	O
patient	O
visits	O
where	O
there	O
was	O
a	O
history	O
or	O
suspicion	O
of	O
cocaine	B
or	I
amphetamine	I
abuse	I
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

CONCLUSIONS	O
:	O
During	O
this	O
study	O
period	O
,	O
routine	O
plasma	O
screening	O
for	O
cocaine	O
and	O
amphetamines	O
in	O
adult	O
seizure	B
patients	O
had	O
a	O
low	O
yield	O
.	O

Contribution	O
of	O
sodium	O
valproate	O
to	O
the	O
syndrome	B
of	I
inappropriate	I
secretion	I
of	I
antidiuretic	I
hormone	I
.	O

We	O
report	O
the	O
case	O
of	O
a	O
62	O
-	O
year	O
-	O
old	O
man	O
who	O
was	O
administered	O
sodium	O
valproate	O
(	O
VPA	O
)	O
and	O
who	O
subsequently	O
developed	O
the	O
syndrome	B
of	I
inappropriate	I
secretion	I
of	I
antidiuretic	I
hormone	I
(	O
SIADH	B
)	O
.	O

He	O
had	O
been	O
taking	O
VPA	O
for	O
treatment	O
of	O
idiopathic	O
generalized	O
tonic	B
-	I
clonic	I
convulsions	I
since	O
he	O
was	O
56	O
years	O
old	O
.	O

We	O
consider	O
this	O
episode	O
of	O
SIADH	B
to	O
be	O
the	O
result	O
of	O
a	O
combination	O
of	O
factors	O
including	O
a	O
weakness	B
of	I
the	I
central	I
nervous	I
system	I
and	O
the	O
long	O
-	O
term	O
administration	O
of	O
VPA	O
.	O

Association	O
of	O
nitric	O
oxide	O
production	O
and	O
apoptosis	O
in	O
a	O
model	O
of	O
experimental	O
nephropathy	B
.	O

We	O
have	O
studied	O
the	O
role	O
of	O
NO	O
and	O
its	O
association	O
with	O
apoptosis	O
in	O
an	O
experimental	O
model	O
of	O
nephrotic	B
syndrome	I
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	O
(	O
ADR	O
)	O
.	O

Rats	O
were	O
stratified	O
into	O
control	O
groups	O
and	O
ADR	O
-	O
induced	O
nephropathy	B
groups	O
.	O

RESULTS	O
:	O
Histopathological	O
examination	O
of	O
the	O
kidneys	O
of	O
rats	O
treated	O
with	O
ADR	O
revealed	O
focal	O
areas	O
of	O
mesangial	B
proliferation	I
and	O
mild	O
tubulointerstitial	B
inflammation	I
.	O

They	O
also	O
had	O
significantly	O
higher	O
levels	O
of	O
proteinuria	B
compared	O
with	O
control	O
and	O
treatment	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Urine	O
nitrite	O
levels	O
were	O
significantly	O
increased	O
in	O
the	O
ADR	O
-	O
nephropathy	B
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
IPRK	O
phenylephrine	O
and	O
acetylcholine	O
related	O
responses	O
were	O
significantly	O
impaired	O
in	O
the	O
ADR	O
-	O
nephropathy	B
group	O
.	O

However	O
,	O
in	O
the	O
ADR	O
-	O
nephropathy	B
group	O
,	O
numerous	O
apoptotic	O
cells	O
were	O
identified	O
in	O
the	O
tubulointerstitial	O
areas	O
.	O

Reduced	O
cardiotoxicity	B
and	O
preserved	O
antitumor	O
efficacy	O
of	O
liposome	O
-	O
encapsulated	O
doxorubicin	O
and	O
cyclophosphamide	O
compared	O
with	O
conventional	O
doxorubicin	O
and	O
cyclophosphamide	O
in	O
a	O
randomized	O
,	O
multicenter	O
trial	O
of	O
metastatic	O
breast	B
cancer	I
.	O

PURPOSE	O
:	O
To	O
determine	O
whether	O
Myocet	O
(	O
liposome	O
-	O
encapsulated	O
doxorubicin	O
;	O
The	O
Liposome	O
Company	O
,	O
Elan	O
Corporation	O
,	O
Princeton	O
,	O
NJ	O
)	O
in	O
combination	O
with	O
cyclophosphamide	O
significantly	O
reduces	O
doxorubicin	O
cardiotoxicity	B
while	O
providing	O
comparable	O
antitumor	O
efficacy	O
in	O
first	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B
cancer	I
(	O
MBC	B
)	O
.	O

Cardiotoxicity	B
was	O
defined	O
by	O
reductions	O
in	O
left	O
-	O
ventricular	O
ejection	O
fraction	O
,	O
assessed	O
by	O
serial	O
multigated	O
radionuclide	O
angiography	O
scans	O
,	O
or	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
.	O

Antitumor	O
efficacy	O
was	O
assessed	O
by	O
objective	O
tumor	B
response	O
rates	O
(	O
World	O
Health	O
Organization	O
criteria	O
)	O
,	O
time	O
to	O
progression	O
,	O
and	O
survival	O
.	O

Erythropoietin	O
restores	O
the	O
anemia	B
-	O
induced	O
reduction	O
in	O
cyclophosphamide	O
cytotoxicity	B
in	O
rat	O
tumors	B
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	O
of	O
anemia	B
prevention	O
by	O
recombinant	O
human	O
erythropoietin	O
(	O
rHuEPO	O
)	O
treatment	O
on	O
the	O
cytotoxicity	B
of	O
cyclophosphamide	O
in	O
solid	O
experimental	O
tumors	B
.	O

In	O
a	O
second	O
group	O
,	O
the	O
development	O
of	O
anemia	B
was	O
prevented	O
by	O
rHuEPO	O
(	O
1000	O
IU	O
/	O
kg	O
)	O
administered	O
s	O
.	O
c	O
.	O
three	O
times	O
/	O
week	O
starting	O
7	O
days	O
before	O
carboplatin	O
application	O
.	O

Four	O
days	O
after	O
carboplatin	O
treatment	O
,	O
tumors	B
(	O
DS	O
-	O
sarcoma	B
of	O
the	O
rat	O
)	O
were	O
implanted	O
s	O
.	O
c	O
.	O
onto	O
the	O
hind	O
food	O
dorsum	O
.	O

Neither	O
carboplatin	O
nor	O
rHuEPO	O
treatment	O
influenced	O
tumor	B
growth	O
rate	O
per	O
se	O
.	O

When	O
tumors	B
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
cyclophosphamide	O
(	O
60	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
5	O
days	O
after	O
implantation	O
,	O
a	O
growth	O
delay	O
with	O
a	O
subsequent	O
regrowth	O
of	O
the	O
tumors	B
was	O
observed	O
.	O

In	O
the	O
anemia	B
group	O
,	O
the	O
growth	O
delay	O
was	O
significantly	O
shorter	O
compared	O
with	O
nonanemic	O
controls	O
(	O
13	O
.	O
3	O
days	O
versus	O
8	O
.	O
6	O
days	O
)	O
.	O

In	O
the	O
group	O
where	O
anemia	B
was	O
prevented	O
by	O
rHuEPO	O
treatment	O
,	O
growth	O
delay	O
was	O
comparable	O
with	O
that	O
of	O
nonanemic	O
controls	O
(	O
13	O
.	O
3	O
days	O
)	O
.	O

These	O
results	O
suggest	O
that	O
chemotherapy	O
-	O
induced	O
anemia	B
reduces	O
cytotoxicity	B
of	O
cyclophosphamide	O
in	O
tumors	B
,	O
whereas	O
correction	O
of	O
anemia	B
by	O
rHuEPO	O
treatment	O
(	O
epoetin	O
alpha	O
)	O
increases	O
the	O
sensitivity	O
,	O
probably	O
as	O
a	O
result	O
of	O
an	O
improved	O
oxygen	O
supply	O
to	O
tumor	B
tissue	O
.	O

Fatal	O
haemorrhagic	B
myocarditis	I
secondary	O
to	O
cyclophosphamide	O
therapy	O
.	O

Effects	O
of	O
verapamil	O
on	O
atrial	B
fibrillation	I
and	O
its	O
electrophysiological	O
determinants	O
in	O
dogs	O
.	O

BACKGROUND	O
:	O
Atrial	B
tachycardia	I
-	O
induced	O
remodeling	O
promotes	O
the	O
occurrence	O
and	O
maintenance	O
of	O
atrial	B
fibrillation	I
(	O
AF	B
)	O
and	O
decreases	O
L	O
-	O
type	O
Ca	O
(	O
2	O
+	O
)	O
current	O
.	O

Calcitonin	O
gene	O
-	O
related	O
peptide	O
levels	O
during	O
nitric	O
oxide	O
-	O
induced	O
headache	B
in	O
patients	O
with	O
chronic	O
tension	B
-	I
type	I
headache	I
.	O

It	O
has	O
been	O
proposed	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
induced	O
headache	B
in	O
primary	B
headaches	I
may	O
be	O
associated	O
with	O
release	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
investigate	O
plasma	O
levels	O
of	O
CGRP	O
during	O
headache	B
induced	O
by	O
the	O
NO	O
donor	O
glyceryl	O
trinitrate	O
(	O
GTN	O
)	O
in	O
16	O
patients	O
with	O
chronic	O
tension	B
-	I
type	I
headache	I
and	O
16	O
healthy	O
controls	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
68	O
-	O
year	O
-	O
old	O
white	O
woman	O
with	O
Candida	O
glabrata	O
isolated	O
from	O
a	O
presacral	O
abscess	O
developed	O
TDP	B
eight	O
days	O
after	O
commencing	O
oral	O
fluconazole	O
The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
TDP	B
,	O
including	O
coronary	B
artery	I
disease	I
,	O
cardiomyopathy	B
,	O
congestive	B
heart	I
failure	I
,	O
and	O
electrolyte	O
abnormalities	O
There	O
was	O
a	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
fluconazole	O
and	O
TDP	B
.	O

The	O
TDP	B
resolved	O
when	O
fluconazole	O
was	O
discontinued	O
;	O
however	O
,	O
the	O
patient	O
continued	O
to	O
have	O
premature	B
ventricular	I
contractions	I
and	O
nonsustained	O
ventricular	B
tachycardia	I
(	O
NSVT	B
)	O
until	O
six	O
days	O
after	O
drug	O
cessation	O
DISCUSSION	O
:	O
Use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
use	O
of	O
fluconazole	O
and	O
the	O
development	O
of	O
TDP	B
.	O

In	O
our	O
patient	O
,	O
there	O
was	O
no	O
other	O
etiology	O
identified	O
that	O
could	O
explain	O
QT	B
prolongation	I
or	O
TDP	B
The	O
complete	O
disappearance	O
of	O
NSVT	B
and	O
premature	B
ventricular	I
contractions	I
followed	O
by	O
normalization	O
of	O
QT	O
interval	O
after	O
the	O
drug	O
was	O
stopped	O
strongly	O
suggests	O
fluconazole	O
as	O
the	O
etiology	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
that	O
fluconazole	O
,	O
even	O
at	O
low	O
doses	O
,	O
may	O
cause	O
prolongation	B
of	I
the	I
QT	I
interval	I
,	O
leading	O
to	O
TDP	B
.	O

Cutaneous	B
leucocytoclastic	I
vasculitis	I
associated	O
with	O
oxacillin	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
man	O
who	O
was	O
treated	O
with	O
oxacillin	O
for	O
one	O
week	O
because	O
of	O
Staphylococcus	B
aureus	I
bacteremia	I
,	O
developed	O
renal	B
failure	I
and	O
diffuse	O
,	O
symmetric	O
,	O
palpable	O
purpuric	B
lesions	I
on	O
his	O
feet	O
.	O

Skin	O
biopsies	O
showed	O
findings	O
diagnostic	O
of	O
leucocytoclastic	B
vasculitis	I
.	O

Leucocytoclastic	B
vasculitis	I
presents	O
as	O
palpable	O
purpura	B
of	O
the	O
lower	O
extremities	O
often	O
accompanied	O
by	O
abdominal	B
pain	I
,	O
arthralgia	B
,	O
and	O
renal	B
involvement	I
.	O

Etiologic	O
factors	O
or	O
associated	O
disorders	O
include	O
infections	B
,	O
medications	O
,	O
collagen	B
vascular	I
disease	I
and	O
neoplasia	B
.	O

Oxacillin	O
should	O
be	O
included	O
among	O
the	O
drugs	O
that	O
can	O
cause	O
leucocytoclastic	B
vasculitis	I
.	O

The	O
renal	O
pathology	O
in	O
a	O
case	O
of	O
lithium	O
-	O
induced	O
diabetes	B
insipidus	I
.	O

A	O
case	O
of	O
lithium	O
-	O
induced	O
diabetes	B
insipidus	I
is	O
reported	O
.	O

Cholestatic	B
jaundice	I
associated	O
with	O
the	O
use	O
of	O
metformin	O
.	O

We	O
report	O
a	O
patient	O
who	O
developed	O
cholestatic	B
jaundice	I
shortly	O
after	O
initiation	O
of	O
treatment	O
with	O
metformin	O
hydrochloride	O
.	O

Metformin	O
hydrochloride	O
was	O
discontinued	O
,	O
and	O
the	O
patient	O
'	O
s	O
jaundice	B
resolved	O
slowly	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O

Given	O
the	O
onset	O
of	O
his	O
jaundice	B
2	O
wk	O
after	O
the	O
initiation	O
of	O
metformin	O
,	O
we	O
believe	O
that	O
this	O
case	O
represents	O
an	O
example	O
of	O
metformin	O
-	O
associated	O
hepatotoxicity	B
,	O
the	O
first	O
such	O
case	O
reported	O
.	O

We	O
conclude	O
that	O
the	O
systemic	O
toxicity	B
of	O
levobupivacaine	O
is	O
intermediate	O
between	O
that	O
of	O
ropivacaine	O
and	O
bupivacaine	O
when	O
administered	O
at	O
the	O
same	O
rate	O
and	O
that	O
ropivacaine	O
-	O
induced	O
cardiac	B
arrest	I
appears	O
to	O
be	O
more	O
susceptible	O
to	O
treatment	O
than	O
that	O
induced	O
by	O
bupivacaine	O
or	O
levobupivacaine	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
multiple	O
episodes	O
of	O
seizure	B
activity	O
in	O
an	O
AIDS	B
patent	O
following	O
amphotericin	O
B	O
infusion	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
46	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
man	O
experienced	O
recurrent	O
grand	B
mal	I
seizures	I
during	O
intravenous	O
infusion	O
of	O
amphotericin	O
B	O
,	O
then	O
petit	O
mal	O
seizures	B
as	O
the	O
infusion	O
was	O
stopped	O
and	O
the	O
drug	O
concentrations	O
decreased	O
with	O
time	O
.	O

DISCUSSION	O
:	O
AIDS	B
and	O
cryptococcal	B
meningitis	I
,	O
both	O
of	O
which	O
the	O
patient	O
had	O
,	O
can	O
potentially	O
cause	O
seizures	B
.	O

However	O
,	O
these	O
other	O
potential	O
causes	O
of	O
seizure	B
were	O
ruled	O
out	O
.	O

Tolerability	O
of	O
nimesulide	O
and	O
paracetamol	O
in	O
patients	O
with	O
NSAID	O
-	O
induced	O
urticaria	B
/	O
angioedema	B
.	O

In	O
this	O
study	O
we	O
investigated	O
tolerability	O
and	O
reliability	O
of	O
nimesulide	O
and	O
paracetamol	O
in	O
a	O
very	O
large	O
number	O
of	O
patients	O
with	O
an	O
exclusive	O
well	O
-	O
documented	O
history	O
of	O
NSAID	O
-	O
induced	O
urticaria	B
/	O
angioedema	B
.	O

A	O
single	O
-	O
placebo	O
-	O
controlled	O
oral	O
challenge	O
procedure	O
with	O
nimesulide	O
or	O
paracetamol	O
was	O
applied	O
to	O
829	O
patients	O
with	O
a	O
history	O
of	O
NSAID	O
-	O
induced	O
urticaria	B
/	O
angioedema	B
.	O

Furthermore	O
,	O
18	O
.	O
28	O
%	O
of	O
patients	O
with	O
a	O
history	O
of	O
chronic	O
urticaria	B
and	O
11	O
.	O
8	O
%	O
of	O
subjects	O
with	O
an	O
history	O
of	O
NSAID	O
-	O
induced	O
urticaria	B
/	O
angioedema	B
or	O
angioedema	B
alone	O
(	O
with	O
or	O
without	O
chronic	O
urticaria	B
)	O
resulted	O
to	O
be	O
intolerant	O
to	O
alternative	O
drugs	O
.	O

Taken	O
together	O
,	O
our	O
results	O
confirm	O
the	O
good	O
tolerability	O
of	O
nimesulide	O
and	O
paracetamol	O
in	O
patients	O
who	O
experienced	O
urticaria	B
/	O
angioedema	B
caused	O
by	O
NSAIDs	O
.	O

However	O
,	O
the	O
risk	O
of	O
reaction	O
to	O
these	O
alternative	O
study	O
drugs	O
is	O
statistically	O
increased	O
by	O
a	O
history	O
of	O
chronic	O
urticaria	B
and	O
,	O
above	O
all	O
,	O
by	O
a	O
history	O
of	O
NSAID	O
-	O
induced	O
angioedema	B
.	O

Comparison	O
of	O
aqueous	O
and	O
gellan	O
ophthalmic	O
timolol	O
with	O
placebo	O
on	O
the	O
24	O
-	O
hour	O
heart	O
rate	O
response	O
in	O
patients	O
on	O
treatment	O
for	O
glaucoma	B
.	O

PURPOSE	O
:	O
Topical	O
beta	O
-	O
blocker	O
treatment	O
is	O
routine	O
therapy	O
in	O
the	O
management	O
of	O
patients	O
with	O
glaucoma	B
.	O

DESIGN	O
:	O
This	O
trial	O
evaluated	O
the	O
effect	O
of	O
placebo	O
,	O
0	O
.	O
5	O
%	O
aqueous	O
timolol	O
(	O
timolol	O
solution	O
)	O
and	O
a	O
0	O
.	O
5	O
%	O
timolol	O
suspension	O
that	O
forms	O
a	O
gel	O
on	O
application	O
to	O
the	O
conjunctiva	O
(	O
timolol	O
gellan	O
)	O
on	O
the	O
24	O
-	O
hour	O
heart	O
rate	O
in	O
patients	O
currently	O
being	O
treated	O
for	O
glaucoma	B
to	O
quantify	O
the	O
reduction	O
in	O
mean	O
heart	O
rate	O
.	O

METHODS	O
:	O
Forty	O
-	O
three	O
Caucasian	O
patients	O
with	O
primary	O
open	B
-	I
angle	I
glaucoma	I
or	O
ocular	B
hypertension	I
with	O
a	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
age	O
of	O
63	O
(	O
+	O
/	O
-	O
8	O
)	O
years	O
were	O
randomized	O
and	O
crossed	O
over	O
in	O
a	O
double	O
-	O
masked	O
manner	O
to	O
14	O
days	O
of	O
treatment	O
with	O
placebo	O
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	O
)	O
,	O
timolol	O
solution	O
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	O
)	O
,	O
or	O
timolol	O
gellan	O
(	O
morning	O
in	O
both	O
eyes	O
with	O
placebo	O
in	O
the	O
evening	O
)	O
.	O

These	O
data	O
quantify	O
the	O
modest	O
bradycardia	B
associated	O
with	O
ophthalmic	O
beta	O
-	O
blocker	O
therapy	O
in	O
a	O
typical	O
patient	O
population	O
on	O
therapy	O
for	O
glaucoma	B
.	O

Management	O
strategies	O
for	O
ribavirin	O
-	O
induced	O
hemolytic	B
anemia	I
in	O
the	O
treatment	O
of	O
hepatitis	B
C	I
:	O
clinical	O
and	O
economic	O
implications	O
.	O

OBJECTIVES	O
:	O
Recently	O
published	O
studies	O
have	O
demonstrated	O
increased	O
efficacy	O
and	O
cost	O
-	O
effectiveness	O
of	O
combination	O
therapy	O
with	O
interferon	O
and	O
alpha	O
-	O
2b	O
/	O
ribavirin	O
compared	O
with	O
interferon	O
-	O
alpha	O
monotherapy	O
in	O
the	O
treatment	O
of	O
chronic	B
hepatitis	I
C	I
(	O
CHC	B
)	O
.	O

Combination	O
therapy	O
is	O
associated	O
with	O
a	O
clinically	O
important	O
adverse	O
effect	O
:	O
ribavirin	O
-	O
induced	O
hemolytic	B
anemia	I
(	O
RIHA	B
)	O
.	O

BACKGROUND	O
:	O
Preclinical	O
studies	O
of	O
intrathecal	O
adenosine	O
suggest	O
it	O
may	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
acute	B
and	I
chronic	I
pain	I
in	O
humans	O
,	O
and	O
preliminary	O
studies	O
in	O
volunteers	O
and	O
patients	O
with	O
a	O
Swedish	O
formulation	O
of	O
adenosine	O
suggests	O
it	O
may	O
be	O
effective	O
in	O
hypersensitivity	B
states	O
but	O
not	O
with	O
acute	O
noxious	O
stimulation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
screen	O
for	O
efficacy	O
of	O
a	O
different	O
formulation	O
of	O
adenosine	O
marketed	O
in	O
the	O
US	O
,	O
using	O
both	O
acute	O
noxious	O
stimulation	O
and	O
capsaicin	O
-	O
evoked	O
mechanical	O
hypersensitivity	B
.	O

CONCLUSIONS	O
:	O
These	O
results	O
show	O
selective	O
inhibition	O
by	O
intrathecal	O
adenosine	O
of	O
hypersensitivity	B
,	O
presumed	O
to	O
reflect	O
central	O
sensitization	O
in	O
humans	O
after	O
peripheral	O
capsaicin	O
injection	O
.	O

Delayed	O
-	O
onset	O
heparin	O
-	O
induced	O
thrombocytopenia	B
.	O

BACKGROUND	O
:	O
Heparin	O
-	O
induced	O
thrombocytopenia	B
presents	O
5	O
to	O
12	O
days	O
after	O
heparin	O
exposure	O
,	O
with	O
or	O
without	O
arterial	B
or	I
venous	I
thromboemboli	I
.	O

Delayed	O
recognition	O
and	O
treatment	O
of	O
heparin	O
-	O
induced	O
thrombocytopenia	B
contribute	O
to	O
poor	O
patient	O
outcomes	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
and	O
increase	O
awareness	O
of	O
a	O
clinical	O
scenario	O
in	O
which	O
the	O
onset	O
or	O
manifestations	O
of	O
heparin	O
-	O
induced	O
thrombocytopenia	B
are	O
delayed	O
.	O

PATIENTS	O
:	O
14	O
patients	O
seen	O
over	O
a	O
3	O
-	O
year	O
period	O
in	O
whom	O
heparin	O
-	O
induced	O
thrombocytopenia	B
became	O
apparent	O
on	O
delayed	O
presentation	O
with	O
thromboembolic	B
complications	O
.	O

RESULTS	O
:	O
Patients	O
went	O
home	O
after	O
hospitalizations	O
that	O
had	O
included	O
heparin	O
exposure	O
-	O
-	O
in	O
most	O
cases	O
,	O
with	O
no	O
thrombocytopenia	B
recognized	O
-	O
-	O
only	O
to	O
return	O
to	O
the	O
hospital	O
(	O
median	O
,	O
day	O
14	O
)	O
with	O
thromboembolic	B
complications	O
.	O

CONCLUSIONS	O
:	O
Delayed	O
-	O
onset	O
heparin	O
-	O
induced	O
thrombocytopenia	B
is	O
increasingly	O
being	O
recognized	O
.	O

To	O
avoid	O
disastrous	O
outcomes	O
,	O
physicians	O
must	O
consider	O
heparin	O
-	O
induced	O
thrombocytopenia	B
whenever	O
a	O
recently	O
hospitalized	O
patient	O
returns	O
with	O
thromboembolism	B
;	O
therapy	O
with	O
alternative	O
anticoagulants	O
,	O
not	O
heparin	O
,	O
should	O
be	O
initiated	O
.	O

RESULTS	O
:	O
Four	O
males	O
(	O
age	O
6	O
-	O
11	O
years	O
)	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B
Disorders	I
(	O
fourth	O
edition	O
)	O
bipolar	B
disorder	I
or	O
psychoses	B
,	O
with	O
risperidone	O
-	O
induced	O
elevations	O
in	O
serum	O
prolactin	O
levels	O
(	O
57	O
.	O
5	O
-	O
129	O
ng	O
/	O
mL	O
,	O
normal	O
5	O
-	O
15	O
ng	O
/	O
mL	O
)	O
,	O
were	O
treated	O
with	O
cabergoline	O
(	O
mean	O
dose	O
2	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
09	O
mg	O
/	O
week	O
)	O
.	O

Acute	O
cholestatic	B
hepatitis	I
after	O
exposure	O
to	O
isoflurane	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
acute	O
cholestatic	B
hepatitis	I
following	O
exposure	O
to	O
the	O
inhalational	O
anesthetic	O
isoflurane	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
70	O
-	O
year	O
-	O
old	O
healthy	O
woman	O
from	O
Iraq	O
developed	O
acute	O
cholestatic	B
hepatitis	I
3	O
weeks	O
following	O
repair	O
of	O
the	O
right	O
rotator	O
cuff	O
under	O
general	O
anesthesia	O
.	O

DISCUSSION	O
:	O
The	O
clinical	O
and	O
histologic	O
picture	O
of	O
this	O
case	O
resembles	O
halothane	B
hepatitis	I
,	O
which	O
has	O
a	O
significant	O
mortality	O
rate	O
.	O

CONCLUSIONS	O
:	O
Isoflurane	O
,	O
a	O
common	O
anesthetic	O
agent	O
,	O
can	O
cause	O
severe	O
cholestatic	B
hepatitis	I
.	O

Torsade	B
de	I
pointes	I
induced	O
by	O
metoclopramide	O
in	O
an	O
elderly	O
woman	O
with	O
preexisting	O
complete	O
left	B
bundle	I
branch	I
block	I
.	O

There	O
is	O
a	O
growing	O
list	O
of	O
drugs	O
implicated	O
in	O
acquired	O
long	B
QT	I
syndrome	I
and	O
torsade	B
de	I
pointes	I
.	O

We	O
report	O
on	O
a	O
92	O
-	O
year	O
-	O
old	O
woman	O
with	O
preexisting	O
complete	O
left	B
bundle	I
branch	I
block	I
who	O
developed	O
torsade	B
de	I
pointes	I
after	O
intravenous	O
and	O
oral	O
administration	O
of	O
metoclopramide	O
.	O

Dopamine	O
(	O
DA	O
)	O
,	O
through	O
D1	O
/	O
D2	O
receptor	O
-	O
mediated	O
signaling	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
control	O
of	O
epileptic	B
seizures	I
arising	O
in	O
the	O
limbic	O
system	O
.	O

Moreover	O
,	O
the	O
dopaminergic	O
control	O
of	O
epilepsy	B
-	O
induced	O
neurodegeneration	B
seems	O
to	O
be	O
mediated	O
by	O
distinct	O
interactions	O
of	O
D2R	O
signaling	O
with	O
these	O
two	O
neurotransmitters	O
.	O

Activation	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
contributes	O
to	O
development	O
of	O
doxorubicin	O
-	O
induced	O
heart	B
failure	I
.	O

Using	O
a	O
dual	O
approach	O
of	O
PARP	O
-	O
1	O
suppression	O
,	O
by	O
genetic	O
deletion	O
or	O
pharmacological	O
inhibition	O
with	O
the	O
phenanthridinone	O
PARP	O
inhibitor	O
PJ34	O
,	O
we	O
now	O
demonstrate	O
the	O
role	O
of	O
PARP	O
in	O
the	O
development	O
of	O
cardiac	B
dysfunction	I
induced	O
by	O
DOX	O
.	O

Treatment	O
with	O
a	O
PJ34	O
significantly	O
improved	O
cardiac	B
dysfunction	I
and	O
increased	O
the	O
survival	O
of	O
the	O
animals	O
.	O

PARP	O
inhibitors	O
may	O
exert	O
protective	O
effects	O
against	O
the	O
development	O
of	O
severe	O
cardiac	B
complications	I
associated	O
with	O
the	O
DOX	O
treatment	O
.	O

Spironolactone	O
:	O
is	O
it	O
a	O
novel	O
drug	O
for	O
the	O
prevention	O
of	O
amphotericin	O
B	O
-	O
related	O
hypokalemia	B
in	O
cancer	B
patients	O
?	O

METHODS	O
:	O
In	O
this	O
study	O
26	O
patients	O
with	O
various	O
hematological	B
disorders	I
were	O
randomized	O
to	O
receive	O
either	O
intravenous	O
AmB	O
alone	O
or	O
AmB	O
and	O
oral	O
spironolactone	O
100	O
mg	O
twice	O
daily	O
when	O
developing	O
a	O
proven	O
or	O
suspected	O
fungal	B
infection	I
.	O

Erectile	B
dysfunction	I
occurs	O
following	O
substantia	O
nigra	O
lesions	O
in	O
the	O
rat	O
.	O

Lesions	O
of	O
the	O
substantia	O
nigra	O
are	O
therefore	O
associated	O
with	O
erectile	B
dysfunction	I
in	O
rats	O
and	O
may	O
serve	O
as	O
a	O
model	O
to	O
study	O
erectile	B
dysfunction	I
in	O
Parkinson	B
'	I
s	I
disease	I
.	O

Force	O
overflow	O
and	O
levodopa	O
-	O
induced	O
dyskinesias	B
in	O
Parkinson	B
'	I
s	I
disease	I
.	O

We	O
assessed	O
force	O
coordination	O
of	O
the	O
hand	O
in	O
Parkinson	B
'	I
s	I
disease	I
and	O
its	O
relationship	O
to	O
motor	O
complications	O
of	O
levodopa	O
therapy	O
,	O
particularly	O
to	O
levodopa	O
-	O
induced	O
dyskinesias	B
(	O
LID	B
)	O
.	O

We	O
studied	O
two	O
groups	O
of	O
Parkinson	B
'	I
s	I
disease	I
patients	O
with	O
(	O
Parkinson	B
'	I
s	I
disease	I
+	O
LID	B
,	O
n	O
=	O
23	O
)	O
and	O
without	O
levodopa	O
-	O
induced	O
dyskinesias	B
(	O
Parkinson	B
'	I
s	I
disease	I
-	O
LID	B
,	O
n	O
=	O
10	O
)	O
,	O
and	O
age	O
-	O
matched	O
healthy	O
controls	O
.	O

The	O
motor	O
score	O
of	O
the	O
Unified	O
Parkinson	B
'	I
s	I
Disease	I
Rating	O
Scale	O
,	O
a	O
dyskinesia	B
score	O
and	O
force	O
in	O
a	O
grip	O
-	O
lift	O
paradigm	O
were	O
assessed	O
ON	O
and	O
OFF	O
levodopa	O
.	O

A	O
pathological	O
increase	O
of	O
forces	O
was	O
seen	O
in	O
ON	O
-	O
state	O
in	O
Parkinson	B
'	I
s	I
disease	I
+	O
LID	B
only	O
.	O

In	O
Parkinson	B
'	I
s	I
disease	I
+	O
LID	B
,	O
the	O
force	O
involved	O
in	O
pressing	O
down	O
the	O
object	O
before	O
lifting	O
was	O
significantly	O
increased	O
by	O
levodopa	O
(	O
by	O
61	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
contrast	O
,	O
no	O
excessive	O
force	O
was	O
found	O
in	O
Parkinson	B
'	I
s	I
disease	I
-	O
LID	B
.	O

Peak	O
grip	O
force	O
in	O
ON	O
-	O
state	O
was	O
140	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
in	O
Parkinson	B
'	I
s	I
disease	I
+	O
LID	B
than	O
in	O
Parkinson	B
'	I
s	I
disease	I
-	O
LID	B
,	O
while	O
static	O
grip	O
force	O
was	O
increased	O
by	O
138	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
between	O
groups	O
.	O

This	O
study	O
focuses	O
on	O
behavioral	O
syndromes	O
that	O
may	O
used	O
as	O
models	O
for	O
Parkinson	B
'	I
s	I
disease	I
,	O
or	O
tardive	B
dyskinesia	I
,	O
and	O
its	O
response	O
after	O
glutamatergic	O
blockage	O
.	O

Reserpine	O
also	O
produced	O
tremor	B
and	O
catalepsy	B
,	O
which	O
are	O
signs	O
suggestive	O
of	O
Parkinson	B
'	I
s	I
disease	I
.	O

Reserpine	O
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
administered	O
90	O
min	O
before	O
the	O
test	O
and	O
followed	O
by	O
apomophine	O
injection	O
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
5	O
min	O
before	O
the	O
test	O
,	O
did	O
not	O
produce	O
oral	B
dyskinesia	I
in	O
mice	O
.	O

These	O
results	O
show	O
that	O
reserpine	O
produces	O
different	O
and	O
abnormal	B
movements	I
,	O
which	O
are	O
related	O
to	O
dose	O
and	O
schedule	O
employed	O
and	O
can	O
be	O
considered	O
as	O
parkinsonian	B
-	O
like	O
and	O
tardive	B
dsykinesia	I
signs	O
.	O

Risperidone	O
-	O
associated	O
,	O
benign	O
transient	O
visual	B
disturbances	I
in	O
schizophrenic	B
patients	O
with	O
a	O
past	O
history	O
of	O
LSD	O
abuse	O
.	O

They	O
both	O
reported	O
short	O
episodes	O
of	O
transient	O
visual	B
disturbances	I
,	O
which	O
appeared	O
immediately	O
after	O
starting	O
treatment	O
with	O
risperidone	O
.	O

This	O
imagery	O
resembled	O
visual	B
disturbances	I
previously	O
experienced	O
as	O
"	O
flashbacks	O
"	O
related	O
to	O
prior	O
LSD	O
consumption	O
.	O

Risperidone	O
administration	O
was	O
continued	O
and	O
the	O
visual	B
disturbances	I
gradually	O
wore	O
off	O
.	O

During	O
a	O
six	O
-	O
month	O
follow	O
-	O
up	O
period	O
,	O
there	O
was	O
no	O
recurrence	O
of	O
visual	B
disturbances	I
.	O

Topiramate	O
is	O
a	O
recently	O
developed	O
antiepileptic	O
medication	O
that	O
is	O
becoming	O
more	O
widely	O
prescribed	O
because	O
of	O
its	O
efficacy	O
in	O
treating	O
refractory	B
seizures	I
.	O

Urologists	O
should	O
be	O
aware	O
that	O
this	O
medication	O
can	O
cause	O
metabolic	B
acidosis	I
in	O
patients	O
secondary	O
to	O
inhibition	O
of	O
carbonic	O
anhydrase	O
.	O

Intravenous	O
ribavirin	O
treatment	O
for	O
severe	O
adenovirus	B
disease	I
in	O
immunocompromised	O
children	O
.	O

The	O
incidence	O
of	O
severe	O
adenovirus	B
disease	I
in	O
pediatrics	O
is	O
increasing	O
in	O
association	O
with	O
growing	O
numbers	O
of	O
immunocompromised	O
children	O
,	O
where	O
case	O
fatality	O
rates	O
as	O
high	O
as	O
50	O
%	O
to	O
80	O
%	O
have	O
been	O
reported	O
.	O

There	O
are	O
no	O
approved	O
antiviral	O
agents	O
with	O
proven	O
efficacy	O
for	O
the	O
treatment	O
of	O
severe	O
adenovirus	B
disease	I
,	O
nor	O
are	O
there	O
any	O
prospective	O
randomized	O
,	O
controlled	O
trials	O
of	O
potentially	O
useful	O
anti	O
-	O
adenovirus	O
therapies	O
.	O

Apparent	O
clinical	O
success	O
in	O
the	O
treatment	O
of	O
severe	O
adenovirus	B
disease	I
is	O
limited	O
to	O
a	O
few	O
case	O
reports	O
and	O
small	O
series	O
.	O

Ribavirin	O
is	O
licensed	O
in	O
aerosol	O
form	O
for	O
the	O
treatment	O
of	O
respiratory	B
syncytial	I
virus	I
infection	I
,	O
and	O
orally	O
in	O
combination	O
with	O
interferon	O
to	O
treat	O
hepatitis	B
C	I
.	O

Intravenous	O
ribavirin	O
is	O
the	O
treatment	O
of	O
choice	O
for	O
infection	B
with	I
hemorrhagic	I
fever	I
viruses	I
.	O

The	O
most	O
common	O
adverse	O
effect	O
of	O
intravenous	O
ribavirin	O
is	O
reversible	O
mild	O
anemia	B
.	O

The	O
use	O
of	O
cidofovir	O
in	O
severe	O
adenovirus	B
infection	I
has	O
been	O
limited	O
by	O
adverse	O
effects	O
,	O
the	O
most	O
significant	O
of	O
which	O
is	O
nephrotoxicity	B
.	O

OBJECTIVE	O
:	O
We	O
report	O
our	O
experience	O
with	O
intravenous	O
ribavirin	O
therapy	O
for	O
severe	O
adenovirus	B
disease	I
in	O
a	O
series	O
of	O
immunocompromised	O
children	O
and	O
review	O
the	O
literature	O
.	O

DESIGN	O
/	O
METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
of	O
5	O
children	O
treated	O
with	O
intravenous	O
ribavirin	O
for	O
documented	O
severe	O
adenovirus	B
disease	I
.	O

An	O
additional	O
3	O
children	O
developed	O
adenovirus	B
pneumonia	I
;	O
2	O
were	O
neonates	O
,	O
1	O
of	O
whom	O
had	O
partial	O
DiGeorge	B
syndrome	I
.	O

RESULTS	O
:	O
Complete	O
clinical	O
recovery	O
followed	O
later	O
by	O
viral	O
clearance	O
was	O
observed	O
in	O
2	O
children	O
:	O
the	O
cardiac	O
transplant	O
recipient	O
with	O
adenovirus	O
hemorrhagic	B
cystitis	I
and	O
the	O
immunocompetent	O
neonate	O
with	O
adenovirus	B
pneumonia	I
.	O

The	O
remaining	O
3	O
children	O
died	O
of	O
adenovirus	B
disease	I
.	O

Use	O
of	O
cidofovir	O
in	O
1	O
child	O
was	O
associated	O
with	O
progressive	B
renal	I
failure	I
and	O
neutropenia	B
.	O

DISCUSSION	O
:	O
Our	O
series	O
of	O
patients	O
is	O
representative	O
of	O
the	O
spectrum	O
of	O
immunocompromised	O
children	O
at	O
greatest	O
risk	O
for	O
severe	O
adenovirus	B
disease	I
,	O
namely	O
solid	O
-	O
organ	O
and	O
bone	O
marrow	O
transplant	O
recipients	O
,	O
neonates	O
,	O
and	O
children	O
with	O
immunodeficiency	B
.	O

Although	O
intravenous	O
ribavirin	O
was	O
not	O
effective	O
for	O
all	O
children	O
with	O
severe	O
adenovirus	B
disease	I
in	O
this	O
series	O
or	O
in	O
the	O
literature	O
,	O
therapy	O
is	O
unlikely	O
to	O
be	O
of	O
benefit	O
if	O
begun	O
late	O
in	O
the	O
course	O
of	O
the	O
infection	B
.	O

Early	O
identification	O
,	O
eg	O
by	O
polymerase	O
chain	O
reaction	O
of	O
those	O
patients	O
at	O
risk	O
of	O
disseminated	O
adenovirus	B
disease	I
may	O
permit	O
earlier	O
antiviral	O
treatment	O
and	O
better	O
evaluation	O
of	O
therapeutic	O
response	O
.	O

CONCLUSIONS	O
:	O
Two	O
of	O
5	O
children	O
with	O
severe	O
adenovirus	B
disease	I
treated	O
with	O
intravenous	O
ribavirin	O
recovered	O
.	O

The	O
availability	O
of	O
newer	O
rapid	O
diagnostic	O
techniques	O
,	O
such	O
as	O
polymerase	O
chain	O
reaction	O
,	O
may	O
make	O
earlier	O
,	O
more	O
effective	O
treatment	O
of	O
adenovirus	B
infection	I
possible	O
.	O

Given	O
the	O
seriousness	O
and	O
increasing	O
prevalence	O
of	O
adenovirus	B
disease	I
in	O
certain	O
hosts	O
,	O
especially	O
children	O
,	O
a	O
large	O
,	O
multicenter	O
clinical	O
trial	O
of	O
potentially	O
useful	O
anti	O
-	O
adenoviral	O
therapies	O
,	O
such	O
as	O
intravenous	O
ribavirin	O
,	O
is	O
clearly	O
required	O
to	O
demonstrate	O
the	O
most	O
effective	O
and	O
least	O
toxic	O
therapy	O
.	O

Delayed	O
asystolic	B
cardiac	B
arrest	I
after	O
diltiazem	O
overdose	B
;	O
resuscitation	O
with	O
high	O
dose	O
intravenous	O
calcium	O
.	O

Eighteen	O
hours	O
after	O
the	O
overdose	B
he	O
had	O
two	O
generalised	O
tonic	B
-	I
clonic	I
seizures	I
.	O

It	O
should	O
be	O
considered	O
early	O
in	O
cases	O
of	O
cardiac	B
arrest	I
after	O
diltiazem	O
overdose	B
.	O

Cardiac	B
arrest	I
after	O
intravenous	O
metoclopramide	O
-	O
a	O
case	O
of	O
five	O
repeated	O
injections	O
of	O
metoclopramide	O
causing	O
five	O
episodes	O
of	O
cardiac	B
arrest	I
.	O

We	O
interpret	O
this	O
as	O
episodes	O
of	O
cardiac	B
arrest	I
caused	O
by	O
metoclopramide	O
.	O

Immunohistochemical	O
study	O
on	O
inducible	O
type	O
of	O
nitric	O
oxide	O
(	O
iNOS	O
)	O
,	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
tumor	B
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
arteritis	B
induced	O
in	O
rats	O
by	O
fenoldopam	O
and	O
theophylline	O
,	O
vasodilators	O
.	O

Arteritis	B
induced	O
in	O
rats	O
by	O
vasodilators	O
,	O
fenoldopam	O
and	O
theophylline	O
,	O
was	O
examined	O
immunohistochemically	O
for	O
expressions	O
of	O
inducible	O
type	O
of	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
,	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
tumor	B
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
.	O

Haloperidol	O
(	O
1	O
mg	O
/	O
kg	O
ip	O
)	O
induced	O
parkinsonian	B
-	O
like	O
muscle	B
rigidity	I
,	O
measured	O
as	O
an	O
increased	O
resistance	O
of	O
a	O
rat	O
'	O
s	O
hind	O
foot	O
to	O
passive	O
flexion	O
and	O
extension	O
at	O
the	O
ankle	O
joint	O
.	O

AIDA	O
in	O
doses	O
of	O
7	O
.	O
5	O
-	O
15	O
microg	O
/	O
0	O
.	O
5	O
microl	O
diminished	O
the	O
haloperidol	O
-	O
induced	O
muscle	B
rigidity	I
.	O

The	O
present	O
results	O
may	O
suggest	O
that	O
the	O
blockade	O
of	O
striatal	O
mGluR1	O
,	O
but	O
not	O
the	O
stimulation	O
of	O
group	O
II	O
mGluRs	O
,	O
may	O
ameliorate	O
parkinsonian	B
muscle	B
rigidity	I
.	O

A	O
phase	O
II	O
study	O
of	O
thalidomide	O
in	O
advanced	O
metastatic	O
renal	B
cell	I
carcinoma	I
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
toxicity	B
and	O
activity	O
of	O
thalidomide	O
in	O
patients	O
with	O
advanced	O
metastatic	O
renal	B
cell	I
cancer	I
and	O
to	O
measure	O
changes	O
of	O
one	O
angiogenic	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
165	O
,	O
with	O
therapy	O
.	O

CONCLUSION	O
:	O
These	O
results	O
are	O
consistent	O
with	O
a	O
low	O
level	O
of	O
activity	O
of	O
thalidomide	O
in	O
renal	B
cell	I
carcinoma	I
.	O

The	O
dose	O
-	O
response	O
relationship	O
,	O
if	O
any	O
,	O
of	O
thalidomide	O
for	O
renal	B
cell	I
carcinoma	I
is	O
unclear	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	O
of	O
lidocaine	O
pretreatment	O
on	O
reduction	O
of	O
succinylcholine	O
-	O
induced	O
myalgia	B
in	O
patients	O
undergoing	O
general	O
anesthesia	O
for	O
gynecological	O
surgery	O
.	O

Twenty	O
-	O
four	O
hours	O
later	O
,	O
any	O
myalgia	B
experienced	O
was	O
assessed	O
according	O
to	O
a	O
structured	O
questionaire	O
and	O
graded	O
by	O
a	O
four	O
point	O
scale	O
by	O
one	O
investigator	O
blinded	O
to	O
the	O
intraoperative	O
management	O
.	O

The	O
results	O
indicate	O
that	O
muscle	B
fasciculation	I
was	O
not	O
found	O
in	O
Group	O
PR	O
while	O
the	O
patients	O
in	O
Group	O
LS	O
had	O
a	O
lower	O
incidence	O
of	O
muscle	B
fasciculation	I
than	O
those	O
in	O
Group	O
PS	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

At	O
24	O
h	O
,	O
the	O
incidence	O
of	O
myalgia	B
was	O
higher	O
in	O
Group	O
PS	O
than	O
in	O
Group	O
LS	O
and	O
PR	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
correlation	O
was	O
not	O
found	O
between	O
the	O
incidence	O
of	O
myalgia	B
and	O
the	O
occurrence	O
of	O
muscle	B
fasciculation	I
.	O

Acute	B
liver	I
failure	I
with	O
concurrent	O
bupropion	O
and	O
carbimazole	O
therapy	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
fatal	O
liver	B
failure	I
possibly	O
associated	O
with	O
concurrent	O
use	O
of	O
bupropion	O
and	O
carbimazole	O
.	O

He	O
developed	O
acute	B
liver	I
failure	I
with	O
rapid	O
deterioration	O
of	O
renal	O
function	O
.	O

Liver	O
biopsy	O
showed	O
evidence	O
of	O
nonspecific	O
drug	B
-	I
induced	I
acute	I
liver	I
injury	I
.	O

DISCUSSION	O
:	O
Although	O
there	O
is	O
increasing	O
evidence	O
of	O
hepatotoxicity	B
induced	O
by	O
bupropion	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
fatality	O
that	O
could	O
have	O
resulted	O
from	O
acute	B
liver	I
failure	I
in	O
a	O
patient	O
receiving	O
bupropion	O
while	O
on	O
concomitant	O
treatment	O
with	O
carbimazole	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
acute	B
liver	I
insult	I
induced	O
by	O
bupropion	O
given	O
concurrently	O
with	O
other	O
hepatotoxic	B
drugs	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
iodinated	O
contrast	O
medium	O
can	O
result	O
in	O
nephropathy	B
.	O

The	O
study	O
involved	O
129	O
patients	O
with	O
diabetes	B
with	O
serum	O
creatinine	O
concentrations	O
of	O
1	O
.	O
5	O
to	O
3	O
.	O
5	O
mg	O
per	O
deciliter	O
who	O
underwent	O
coronary	O
or	O
aortofemoral	O
angiography	O
.	O

CONCLUSIONS	O
:	O
Nephropathy	B
induced	O
by	O
contrast	O
medium	O
may	O
be	O
less	O
likely	O
to	O
develop	O
in	O
high	O
-	O
risk	O
patients	O
when	O
iodixanol	O
is	O
used	O
rather	O
than	O
a	O
low	O
-	O
osmolar	O
,	O
nonionic	O
contrast	O
medium	O
.	O

Edaravone	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
has	O
potent	O
free	O
radical	O
quenching	O
action	O
and	O
is	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
cerebral	B
infarction	I
.	O

Levodopa	O
-	O
induced	O
oromandibular	O
dystonia	B
in	O
progressive	B
supranuclear	I
palsy	I
.	O

Levodopa	O
-	O
induced	O
dyskinesias	B
have	O
been	O
reported	O
in	O
Parkinson	B
'	I
s	I
disease	I
and	O
multiple	B
system	I
atrophy	I
.	O

Cranial	O
dystonias	B
are	O
rare	O
in	O
patients	O
with	O
progressive	B
supranuclear	I
palsy	I
(	O
PSP	B
)	O
.	O

In	O
this	O
report	O
we	O
describe	O
an	O
unusual	O
case	O
of	O
reversible	O
levodopa	O
-	O
induced	O
Oromandibular	B
dystonia	I
(	O
OMD	B
)	O
in	O
a	O
PSP	B
patient	O
to	O
highlight	O
the	O
importance	O
of	O
recognizing	O
this	O
drug	O
related	O
complication	O
in	O
the	O
management	O
of	O
PSP	B
,	O
and	O
discuss	O
the	O
possible	O
underlying	O
pathophysiology	O
.	O

Several	O
reports	O
have	O
linked	O
the	O
abuse	O
of	O
PPA	O
with	O
myocardial	B
injury	I
,	O
especially	O
when	O
overdose	B
is	O
involved	O
.	O

We	O
report	O
here	O
the	O
first	O
case	O
of	O
Dexatrim	O
(	O
PPA	O
)	O
-	O
induced	O
myocardial	B
injury	I
in	O
a	O
young	O
woman	O
who	O
was	O
using	O
it	O
at	O
recommended	O
doses	O
for	O
weight	O
control	O
.	O

In	O
addition	O
,	O
we	O
review	O
the	O
7	O
other	O
cases	O
of	O
PPA	O
related	O
myocardial	B
injury	I
that	O
have	O
been	O
reported	O
so	O
far	O
.	O

Differential	O
diagnosis	O
of	O
high	O
serum	O
creatine	O
kinase	O
levels	O
in	O
systemic	B
lupus	I
erythematosus	I
.	O

We	O
report	O
the	O
clinical	O
and	O
bioptic	O
findings	O
for	O
a	O
57	O
-	O
year	O
-	O
old	O
woman	O
with	O
severe	O
chloroquine	O
-	O
induced	O
myopathy	B
.	O

Since	O
1989	O
,	O
she	O
had	O
been	O
suffering	O
from	O
systemic	B
lupus	I
erythematosus	I
(	O
SLE	B
)	O
with	O
renal	B
involvement	I
and	O
undergone	O
periods	O
of	O
treatment	O
with	O
azathioprine	O
and	O
cyclophosphamide	O
.	O

Additional	O
therapy	O
with	O
chloroquine	O
(	O
CQ	O
)	O
was	O
started	O
because	O
of	O
arthralgia	B
.	O

The	O
CK	O
increase	O
persisted	O
,	O
however	O
,	O
and	O
she	O
developed	O
progressive	O
muscular	B
weakness	I
and	O
muscular	B
atrophy	I
.	O

Thus	O
,	O
muscle	O
biopsy	O
of	O
the	O
deltoid	O
muscle	O
was	O
performed	O
in	O
order	O
to	O
exclude	O
polymyositis	B
or	O
toxic	O
myopathy	B
.	O

As	O
it	O
revealed	O
chloroquine	O
-	O
induced	O
myopathy	B
,	O
medication	O
was	O
stopped	O
.	O

Discriminating	O
between	O
primary	O
SLE	B
-	O
induced	O
affection	B
of	I
the	I
musculoskeletal	I
system	I
and	O
drug	O
-	O
induced	O
side	O
effects	O
is	O
important	O
for	O
appropriate	O
treatment	O
of	O
SLE	B
patients	O
.	O

This	O
case	O
report	O
describes	O
a	O
generalized	O
seizure	B
associated	O
with	O
sustained	O
-	O
release	O
bupropion	O
use	O
and	O
sleep	B
deprivation	I
.	O

After	O
5	O
weeks	O
of	O
bupropion	O
use	O
,	O
the	O
subject	O
experienced	O
a	O
generalized	O
tonic	O
clonic	O
seizure	B
after	O
staying	O
up	O
nearly	O
all	O
night	O
packing	O
and	O
moving	O
to	O
a	O
new	O
residence	O
.	O

The	O
pathogenesis	O
of	O
this	O
myalgia	B
is	O
still	O
unclear	O
;	O
inflammation	B
has	O
been	O
suggested	O
but	O
without	O
convincing	O
evidence	O
.	O

We	O
designed	O
the	O
present	O
study	O
to	O
investigate	O
whether	O
an	O
inflammatory	O
reaction	O
contributes	O
to	O
this	O
myalgia	B
.	O

The	O
incidence	O
and	O
severity	O
of	O
succinylcholine	O
-	O
associated	O
myalgia	B
was	O
determined	O
in	O
64	O
patients	O
pretreated	O
with	O
saline	O
or	O
dexamethasone	O
before	O
succinylcholine	O
(	O
n	O
=	O
32	O
for	O
each	O
)	O
.	O

Incidence	O
and	O
severity	O
of	O
myalgia	B
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
15	O
patients	O
in	O
the	O
dexamethasone	O
group	O
complained	O
of	O
myalgia	B
compared	O
with	O
18	O
patients	O
in	O
the	O
saline	O
group	O
,	O
and	O
severe	O
myalgia	B
was	O
reported	O
by	O
five	O
patients	O
and	O
three	O
patients	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
.	O

At	O
48	O
h	O
after	O
surgery	O
,	O
12	O
patients	O
in	O
both	O
groups	O
still	O
suffered	O
from	O
myalgia	B
(	O
not	O
significant	O
)	O
.	O

We	O
found	O
an	O
increase	O
of	O
IL	O
-	O
6	O
for	O
only	O
three	O
patients	O
,	O
but	O
only	O
one	O
patient	O
reported	O
myalgia	B
;	O
no	O
relationship	O
between	O
myalgia	B
and	O
the	O
increase	O
of	O
IL	O
-	O
6	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
of	O
succinylcholine	O
-	O
associated	O
myalgia	B
.	O

Absolute	O
and	O
attributable	O
risk	O
of	O
venous	B
thromboembolism	I
in	O
women	O
on	O
combined	O
cyproterone	O
acetate	O
and	O
ethinylestradiol	O
.	O

OBJECTIVE	O
:	O
To	O
achieve	O
absolute	O
risk	O
estimates	O
of	O
venous	B
thromboembolism	I
(	O
VTE	B
)	O
among	O
women	O
on	O
cyproterone	O
acetate	O
plus	O
ethinylestradiol	O
(	O
CPA	O
/	O
EE	O
)	O
,	O
and	O
among	O
women	O
on	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

BACKGROUND	O
:	O
Analysis	O
of	O
the	O
literature	O
for	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
suggests	O
that	O
a	O
low	O
incidence	O
of	O
developmental	B
anomalies	I
occurs	O
in	O
rats	O
given	O
NSAIDs	O
on	O
specific	O
days	O
during	O
organogenesis	O
.	O

Aspirin	O
(	O
acetylsalicylic	O
acid	O
[	O
ASA	O
]	O
)	O
,	O
an	O
irreversible	O
cyclooxygenase	O
1	O
and	O
2	O
inhibitor	O
,	O
induces	O
developmental	B
anomalies	I
when	O
administered	O
to	O
Wistar	O
rats	O
on	O
gestational	O
day	O
(	O
GD	O
)	O
9	O
,	O
10	O
,	O
or	O
11	O
(	O
Kimmel	O
CA	O
,	O
Wilson	O
JG	O
,	O
Schumacher	O
HJ	O
.	O
Teratology	O
4	O
:	O
15	O
-	O
24	O
,	O
1971	O
)	O
.	O

Objectives	O
of	O
the	O
current	O
study	O
were	O
to	O
compare	O
results	O
between	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
strains	O
when	O
ASA	O
is	O
administered	O
on	O
GD	O
9	O
,	O
10	O
,	O
or	O
11	O
;	O
to	O
compare	O
the	O
malformation	O
patterns	O
following	O
single	O
and	O
multiple	O
dosings	O
during	O
organogenesis	O
in	O
SD	O
rats	O
;	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
maternal	O
gastrointestinal	B
toxicity	I
confounds	O
the	O
detection	O
of	O
low	O
incidence	O
malformations	B
with	O
ASA	O
when	O
a	O
multiple	O
dosing	O
paradigm	O
is	O
used	O
.	O

RESULTS	O
:	O
The	O
literature	O
evaluation	O
suggested	O
that	O
NSAIDs	O
induce	O
ventricular	B
septal	I
defects	I
(	O
VSDs	B
)	O
and	O
midline	B
defects	I
(	O
MDs	B
)	O
in	O
rats	O
and	O
diaphragmatic	B
hernia	I
(	O
DH	B
)	O
,	O
MDs	B
,	O
and	O
VSDs	B
in	O
rabbits	O
(	O
Cook	O
JC	O
et	O
al	O
.	O
,	O
2003	O
)	O
;	O
hence	O
,	O
the	O
present	O
study	O
focused	O
on	O
these	O
malformations	B
,	O
even	O
though	O
ASA	O
induces	O
several	O
other	O
low	O
-	O
incidence	O
malformations	B
.	O

CONCLUSIONS	O
:	O
High	O
concordance	O
in	O
major	O
developmental	B
anomalies	I
between	O
Wistar	O
and	O
SD	O
rats	O
were	O
noted	O
with	O
the	O
exception	O
of	O
VSD	B
in	O
the	O
SD	O
rats	O
and	O
hydrocephalus	B
in	O
the	O
Wistar	O
rats	O
.	O

Methylphenidate	O
-	O
induced	O
obsessive	B
-	I
compulsive	I
symptoms	I
in	O
an	O
elderly	O
man	O
.	O

An	O
82	O
-	O
year	O
-	O
old	O
man	O
with	O
treatment	B
-	I
resistant	I
depression	I
and	O
early	O
Alzheimer	B
'	I
s	I
disease	I
was	O
started	O
on	O
methylphenidate	O
.	O

Significant	O
obsessive	B
-	I
compulsive	I
behavior	I
ensued	O
but	O
diminished	O
over	O
several	O
weeks	O
when	O
methylphenidate	O
was	O
replaced	O
by	O
fluvoxamine	O
.	O

The	O
patient	O
had	O
no	O
prior	O
psychiatric	B
history	O
,	O
but	O
he	O
had	O
a	O
sister	O
with	O
obsessive	B
-	I
compulsive	I
disorder	I
.	O

Ciprofloxacin	O
-	O
induced	O
acute	O
interstitial	B
nephritis	I
and	O
autoimmune	B
hemolytic	I
anemia	I
.	O

Ciprofloxacin	O
has	O
been	O
associated	O
with	O
several	O
side	O
effects	O
including	O
interstitial	B
nephritis	I
and	O
hemolytic	B
anemia	I
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
case	O
of	O
ciprofloxacin	O
-	O
induced	O
interstitial	B
nephritis	I
and	O
autoimmune	B
hemolytic	I
anemia	I
.	O

Hemolytic	B
anemia	I
improved	O
after	O
stopping	O
the	O
drug	O
and	O
initiation	O
of	O
steroid	O
therapy	O
.	O

Unfortunately	O
,	O
acute	O
interstitial	B
nephritis	I
was	O
irreversible	O
and	O
the	O
patient	O
developed	O
end	B
-	I
stage	I
renal	I
disease	I
.	O

Potential	O
deleterious	O
effect	O
of	O
furosemide	O
in	O
radiocontrast	O
nephropathy	B
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
furosemide	O
in	O
addition	O
to	O
intravenous	O
fluids	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	B
.	O

18	O
patients	O
,	O
referred	O
to	O
a	O
radiocontrast	O
study	O
,	O
considered	O
at	O
risk	O
because	O
of	O
preexisting	O
renal	B
insufficiency	I
,	O
were	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
,	O
performed	O
at	O
the	O
secondary	O
care	O
center	O
of	O
a	O
1	O
,	O
100	O
-	O
bed	O
private	O
university	O
hospital	O
.	O

Renal	B
function	I
significantly	I
deteriorated	I
in	O
the	O
group	O
pretreated	O
with	O
furosemide	O
(	O
p	O
<	O
0	O
.	O
005	O
by	O
ANOVA	O
)	O
,	O
with	O
a	O
rise	O
in	O
serum	O
creatinine	O
from	O
145	O
+	O
/	O
-	O
13	O
to	O
182	O
+	O
/	O
-	O
16	O
mumol	O
/	O
l	O
at	O
24	O
h	O
,	O
while	O
no	O
change	O
occurred	O
in	O
the	O
control	O
group	O
(	O
from	O
141	O
+	O
/	O
-	O
6	O
to	O
142	O
+	O
/	O
-	O
7	O
mumol	O
/	O
l	O
)	O
.	O

Renal	B
failure	I
was	O
associated	O
with	O
weight	B
loss	I
in	O
the	O
furosemide	O
-	O
treated	O
group	O
.	O

Furosemide	O
may	O
be	O
deleterious	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	B
.	O

Orthostatic	B
hypotension	I
occurs	O
following	O
alpha	O
2	O
-	O
adrenoceptor	O
blockade	O
in	O
chronic	O
prazosin	O
-	O
pretreated	O
conscious	O
spontaneously	O
hypertensive	B
rats	O
.	O

Orthostatic	B
hypotension	I
was	O
determined	O
by	O
the	O
average	O
decrease	O
(	O
%	O
)	O
in	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
femoral	O
)	O
over	O
the	O
60	O
-	O
s	O
tilt	O
period	O
.	O

However	O
,	O
the	O
head	O
-	O
up	O
tilt	O
induced	O
orthostatic	B
hypotension	I
in	O
the	O
SHR	O
treated	O
with	O
prazosin	O
(	O
-	O
16	O
%	O
MAP	O
,	O
n	O
=	O
6	O
)	O
,	O
but	O
not	O
in	O
the	O
SHR	O
treated	O
with	O
rauwolscine	O
(	O
less	O
than	O
+	O
2	O
%	O
MAP	O
,	O
n	O
=	O
6	O
)	O
.	O

Head	O
-	O
up	O
tilts	O
in	O
these	O
rats	O
did	O
not	O
produce	O
orthostatic	B
hypotension	I
when	O
performed	O
either	O
prior	O
to	O
or	O
after	O
acute	O
dosing	O
of	O
prazosin	O
(	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
.	O

Hemolytic	B
-	I
uremic	I
syndrome	I
associated	O
with	O
ingestion	O
of	O
quinine	O
.	O

Hemolytic	B
-	I
uremic	I
syndrome	I
following	O
quinine	O
ingestion	O
is	O
a	O
newly	O
described	O
phenomenon	O
,	O
with	O
just	O
two	O
previous	O
descriptions	O
of	O
4	O
cases	O
in	O
the	O
literature	O
.	O

Quinine	O
-	O
associated	O
hemolytic	B
-	I
uremic	I
syndrome	I
probably	O
occurs	O
more	O
often	O
than	O
is	O
recognized	O
.	O

Amnestic	B
syndrome	I
associated	O
with	O
propranolol	O
toxicity	B
:	O
a	O
case	O
report	O
.	O

An	O
elderly	O
woman	O
developed	O
an	O
Alzheimer	B
-	O
like	O
subacute	O
dementia	B
as	O
a	O
result	O
of	O
propranolol	O
toxicity	B
.	O

Cefotetan	O
-	O
induced	O
immune	O
hemolytic	B
anemia	I
.	O

Immune	O
hemolytic	B
anemia	I
due	O
to	O
a	O
drug	O
-	O
adsorption	O
mechanism	O
has	O
been	O
described	O
primarily	O
in	O
patients	O
receiving	O
penicillins	O
and	O
first	O
-	O
generation	O
cephalosporins	O
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
anemia	B
while	O
receiving	O
intravenous	O
cefotetan	O
.	O

These	O
observations	O
,	O
in	O
conjunction	O
with	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
extravascular	O
hemolysis	B
,	O
are	O
consistent	O
with	O
drug	O
-	O
induced	O
hemolytic	B
anemia	I
,	O
possibly	O
involving	O
both	O
drug	O
-	O
adsorption	O
and	O
autoantibody	O
formation	O
mechanisms	O
.	O

All	O
-	O
trans	O
-	O
retinoic	O
acid	O
-	O
induced	O
erythema	B
nodosum	I
in	O
patients	O
with	O
acute	B
promyelocytic	I
leukemia	I
.	O

Erythema	B
nodosum	I
associated	O
with	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
for	O
acute	B
promyelocytic	I
leukemia	I
(	O
APL	B
)	O
is	O
very	O
rare	O
.	O

We	O
describe	O
four	O
patients	O
with	O
classic	O
APL	B
who	O
developed	O
erythema	B
nodosum	I
during	O
ATRA	O
therapy	O
.	O

The	O
skin	O
biopsy	O
taken	O
from	O
each	O
patient	O
was	O
consistent	O
with	O
erythema	B
nodosum	I
.	O

ATRA	O
seemed	O
to	O
be	O
the	O
most	O
possible	O
etiology	O
of	O
erythema	B
nodosum	I
in	O
our	O
patients	O
.	O

Short	O
-	O
term	O
use	O
of	O
steroid	O
is	O
very	O
effective	O
in	O
ATRA	O
-	O
induced	O
erythema	B
nodosum	I
.	O

Loreclezole	O
(	O
5	O
mg	O
/	O
kg	O
)	O
exerted	O
a	O
significant	O
protective	O
action	O
in	O
amygdala	O
-	O
kindled	O
rats	O
,	O
reducing	O
both	O
seizure	B
and	O
afterdischarge	O
durations	O
.	O

BACKGROUND	O
:	O
Doxorubicin	O
induces	O
a	O
self	O
-	O
perpetuating	O
nephropathy	B
characterized	O
by	O
early	O
glomerular	B
and	I
late	I
-	I
onset	I
tubular	I
lesions	I
in	O
rats	O
.	O

We	O
investigated	O
the	O
potential	O
role	O
of	O
mitochondrial	B
injury	I
in	O
the	O
onset	O
of	O
these	O
lesions	O
.	O

Glomerular	B
and	I
tubular	I
injury	I
was	O
monitored	O
and	O
correlated	O
to	O
the	O
activity	O
or	O
expression	O
of	O
respiratory	O
chain	O
components	O
.	O

RESULTS	O
:	O
The	O
'	O
long	O
-	O
term	O
'	O
group	O
had	O
significant	O
glomerular	B
and	I
tubular	I
lesions	I
,	O
depressed	O
activities	O
of	O
mtDNA	O
-	O
encoded	O
NADH	O
dehydrogenase	O
and	O
cytochrome	O
-	O
c	O
oxidase	O
(	O
COX	O
)	O
and	O
increased	O
citrate	O
synthase	O
activity	O
.	O

In	O
'	O
short	O
-	O
term	O
'	O
rats	O
,	O
there	O
were	O
fewer	O
tubular	B
lesions	I
,	O
but	O
similar	O
numbers	O
of	O
glomerular	B
lesions	I
activity	O
.	O

Among	O
all	O
animals	O
,	O
glomerular	B
and	I
tubular	I
injury	I
were	O
inversely	O
correlated	O
with	O
mtDNA	O
levels	O
,	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
activities	O
and	O
with	O
the	O
expression	O
of	O
the	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
subunit	O
COX	O
-	O
I	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
an	O
important	O
role	O
for	O
quantitative	O
and	O
qualitative	O
mtDNA	O
alterations	O
through	O
the	O
reduction	O
of	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
function	O
and	O
induction	O
of	O
superoxide	O
in	O
doxorubicin	O
-	O
induced	O
renal	B
lesions	I
.	O

A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
of	O
ephedrine	O
for	O
SSRI	O
-	O
induced	O
female	O
sexual	B
dysfunction	I
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
ephedrine	O
,	O
an	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
agonist	O
previously	O
shown	O
to	O
enhance	O
genital	O
blood	O
flow	O
in	O
women	O
,	O
has	O
beneficial	O
effects	O
in	O
reversing	O
antidepressant	O
-	O
induced	O
sexual	B
dysfunction	I
.	O

Does	O
hormone	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	B
cancer	I
have	O
a	O
detrimental	B
effect	I
on	I
memory	I
and	I
cognition	I
?	O

This	O
pilot	O
study	O
examines	O
whether	O
hormone	O
therapy	O
for	O
breast	B
cancer	I
affects	O
cognition	O
.	O

Patients	O
participating	O
in	O
a	O
randomised	O
trial	O
of	O
anastrozole	O
,	O
tamoxifen	O
alone	O
or	O
combined	O
(	O
ATAC	O
)	O
(	O
n	O
=	O
94	O
)	O
and	O
a	O
group	O
of	O
women	O
without	O
breast	B
cancer	I
(	O
n	O
=	O
35	O
)	O
completed	O
a	O
battery	O
of	O
neuropsychological	O
measures	O
.	O

The	O
results	O
showed	O
specific	O
impairments	O
in	O
processing	O
speed	O
and	O
verbal	O
memory	O
in	O
women	O
receiving	O
hormonal	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	B
cancer	I
.	O

Doxorubicin	O
is	O
an	O
anti	O
-	O
tumor	B
agent	O
that	O
represses	O
cardiac	O
-	O
specific	O
gene	O
expression	O
and	O
induces	O
myocardial	O
cell	O
apoptosis	O
.	O

These	O
findings	O
demonstrate	O
that	O
overexpression	O
of	O
p300	O
protects	O
cardiac	O
myocytes	O
from	O
doxorubicin	O
-	O
induced	O
apoptosis	O
and	O
reduces	O
the	O
extent	O
of	O
acute	O
heart	B
failure	I
in	O
adult	O
mice	O
in	O
vivo	O
.	O

Methimazole	O
-	O
induced	O
cholestatic	B
jaundice	I
.	O

A	O
43	O
-	O
year	O
-	O
old	O
woman	O
had	O
severe	O
jaundice	B
and	O
itching	B
1	O
month	O
after	O
receiving	O
methimazole	O
(	O
10	O
mg	O
tid	O
)	O
and	O
propranolol	O
(	O
20	O
mg	O
tid	O
)	O
for	O
treatment	O
of	O
hyperthyroidism	B
.	O

The	O
patient	O
continued	O
treatment	O
for	O
another	O
4	O
days	O
after	O
the	O
appearance	O
of	O
jaundice	B
until	O
she	O
finished	O
both	O
medications	O
.	O

In	O
rare	O
cases	O
within	O
the	O
first	O
few	O
weeks	O
of	O
therapy	O
,	O
this	O
drug	O
can	O
cause	O
severe	O
and	O
reversible	O
cholestatic	B
jaundice	I
.	O

Atrial	B
fibrillation	I
following	O
chemotherapy	O
for	O
stage	O
IIIE	O
diffuse	O
large	O
B	O
-	O
cell	O
gastric	B
lymphoma	I
in	O
a	O
patient	O
with	O
myotonic	B
dystrophy	I
(	O
Steinert	B
'	I
s	I
disease	I
)	O
.	O

The	O
authors	O
describe	O
the	O
unusual	O
association	O
between	O
diffuse	O
B	O
-	O
cell	O
gastric	B
lymphoma	I
and	O
myotonic	B
dystrophy	I
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B
dystrophy	I
,	O
and	O
sudden	O
atrial	B
fibrillation	I
following	O
one	O
cycle	O
of	O
doxorubicin	O
-	O
based	O
chemotherapy	O
in	O
the	O
same	O
patient	O
.	O

Atrial	B
fibrillation	I
or	O
other	O
cardiac	B
arrhythmias	I
are	O
unusual	O
complications	O
in	O
patients	O
treated	O
with	O
chemotherapy	O
.	O

The	O
cardiac	B
toxicity	I
intrinsically	O
associated	O
with	O
the	O
aggressive	O
chemotherapy	O
employed	O
could	O
function	O
as	O
a	O
triggering	O
factor	O
for	O
the	O
arrhythmia	B
in	O
the	O
predisposed	O
myocardium	O
of	O
this	O
patient	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
lymphocyte	O
reactivity	O
to	O
dilevalol	O
and	O
to	O
serum	O
containing	O
putative	O
ex	O
vivo	O
dilevalol	O
antigens	O
or	O
metabolites	O
in	O
a	O
case	O
of	O
dilevalol	O
-	O
induced	O
liver	B
injury	I
.	O

PATIENT	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
clinical	O
diagnosis	O
of	O
dilevalol	O
-	O
induced	O
liver	B
injury	I
.	O

CONCLUSIONS	O
:	O
The	O
methodology	O
used	O
allowed	O
the	O
detection	O
of	O
lymphocyte	O
sensitization	O
to	O
sera	O
containing	O
ex	O
vivo	O
-	O
prepared	O
dilevalol	O
antigens	O
,	O
suggesting	O
the	O
involvement	O
of	O
an	O
immunologic	O
mechanism	O
in	O
dilevalol	O
-	O
induced	O
liver	B
injury	I
.	O

Increased	O
expression	O
and	O
apical	O
targeting	O
of	O
renal	O
ENaC	O
subunits	O
in	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrotic	B
syndrome	I
in	O
rats	O
.	O

Nephrotic	B
syndrome	I
is	O
often	O
accompanied	O
by	O
sodium	O
retention	O
and	O
generalized	O
edema	B
.	O

After	O
7	O
days	O
,	O
PAN	O
treatment	O
induced	O
significant	O
proteinuria	B
,	O
hypoalbuminemia	B
,	O
decreased	O
urinary	O
sodium	O
excretion	O
,	O
and	O
extensive	O
ascites	B
.	O

In	O
conclusion	O
,	O
the	O
increased	O
or	O
sustained	O
expression	O
of	O
ENaC	O
subunits	O
combined	O
with	O
increased	O
apical	O
targeting	O
in	O
the	O
DCT2	O
,	O
connecting	O
tubule	O
,	O
and	O
collecting	O
duct	O
are	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
sodium	O
retention	O
associated	O
with	O
PAN	O
-	O
induced	O
nephrotic	B
syndrome	I
.	O

A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	O
treatment	O
of	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	O
by	O
Laitinen	O
in	O
1985	O
.	O

Stimulation	O
often	O
produces	O
an	O
improvement	O
in	O
the	O
hyper	B
-	I
or	I
dyskinetic	I
upper	O
limbs	O
,	O
but	O
increases	O
the	O
"	O
freezing	O
"	O
phenomenon	O
in	O
the	O
lower	O
limbs	O
at	O
the	O
same	O
time	O
.	O

Effects	O
of	O
the	O
cyclooxygenase	O
-	O
2	O
specific	O
inhibitor	O
valdecoxib	O
versus	O
nonsteroidal	O
antiinflammatory	O
agents	O
and	O
placebo	O
on	O
cardiovascular	O
thrombotic	B
events	O
in	O
patients	O
with	O
arthritis	B
.	O

We	O
evaluated	O
cardiovascular	O
event	O
data	O
for	O
valdecoxib	O
,	O
a	O
new	O
COX	O
-	O
2	O
-	O
specific	O
inhibitor	O
in	O
approximately	O
8000	O
patients	O
with	O
osteoarthritis	B
and	O
rheumatoid	B
arthritis	I
treated	O
with	O
this	O
agent	O
in	O
randomized	O
clinical	O
trials	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
thrombotic	B
events	O
(	O
cardiac	O
,	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
,	O
or	O
arterial	O
thrombotic	B
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	O
(	O
10	O
-	O
80	O
mg	O
daily	O
)	O
,	O
nonselective	O
NSAID	O
(	O
diclofenac	O
75	O
mg	O
bid	O
,	O
ibuprofen	O
800	O
mg	O
tid	O
,	O
or	O
naproxen	O
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	B
and	O
rheumatoid	B
arthritis	I
trials	O
that	O
were	O
6	O
-	O
52	O
weeks	O
in	O
duration	O
.	O

Short	O
-	O
and	O
intermediate	O
-	O
term	O
treatment	O
with	O
therapeutic	O
(	O
10	O
or	O
20	O
mg	O
daily	O
)	O
and	O
supratherapeutic	O
(	O
40	O
or	O
80	O
mg	O
daily	O
)	O
valdecoxib	O
doses	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
thrombotic	B
events	O
relative	O
to	O
nonselective	O
NSAIDs	O
or	O
placebo	O
in	O
osteoarthritis	B
and	O
rheumatoid	B
arthritis	I
patients	O
in	O
controlled	O
clinical	O
trials	O
.	O

Hypersensitivity	B
myocarditis	B
complicating	O
hypertrophic	B
cardiomyopathy	I
heart	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
eosinophilic	B
myocarditis	I
complicating	O
hypertrophic	B
cardiomyopathy	I
.	O

The	O
47	O
-	O
year	O
-	O
old	O
female	O
patient	O
,	O
known	O
to	O
have	O
hypertrophic	B
cardiomyopathy	I
,	O
was	O
admitted	O
with	O
biventricular	B
failure	I
and	O
managed	O
aggressively	O
with	O
dobutamine	O
infusion	O
and	O
other	O
drugs	O
while	O
being	O
assessed	O
for	O
heart	O
transplantation	O
.	O

On	O
transthoracic	O
echocardiogram	O
,	O
she	O
had	O
moderate	O
left	B
ventricular	I
dysfunction	I
with	O
regional	O
variability	O
and	O
moderate	O
mitral	B
regurgitation	I
.	O

The	O
recipient	O
'	O
s	O
heart	O
showed	O
the	O
features	O
of	O
apical	O
hypertrophic	B
cardiomyopathy	I
and	O
myocarditis	B
with	O
abundant	O
eosinophils	O
.	O

It	O
is	O
likely	O
that	O
the	O
hypersensitivity	B
(	O
eosinophilic	B
)	O
myocarditis	B
was	O
related	O
to	O
dobutamine	O
infusion	O
therapy	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
major	O
and	O
intracranial	B
bleeding	I
increased	O
from	O
20	O
.	O
2	O
%	O
and	O
1	O
.	O
9	O
%	O
,	O
respectively	O
,	O
in	O
the	O
first	O
time	O
period	O
,	O
to	O
33	O
.	O
3	O
%	O
and	O
7	O
.	O
8	O
%	O
,	O
respectively	O
,	O
in	O
the	O
second	O
.	O

BACKGROUND	O
:	O
Preclinical	O
and	O
clinical	O
studies	O
suggest	O
that	O
yohimbine	O
facilitates	O
sexual	O
behavior	O
and	O
may	O
be	O
helpful	O
in	O
the	O
treatment	O
of	O
male	B
impotence	I
.	O

METHOD	O
:	O
Six	O
patients	O
with	O
either	O
obsessive	B
compulsive	I
disorder	I
,	O
trichotillomania	B
,	O
anxiety	B
,	O
or	O
affective	B
disorders	I
who	O
suffered	O
sexual	B
side	I
effects	I
after	O
treatment	O
with	O
serotonin	O
reuptake	O
blockers	O
were	O
given	O
yohimbine	O
on	O
a	O
p	O
.	O
r	O
.	O
n	O
.	O
basis	O
in	O
an	O
open	O
clinical	O
trial	O
.	O

Side	O
effects	O
of	O
yohimbine	O
included	O
excessive	O
sweating	O
,	O
increased	O
anxiety	B
,	O
and	O
a	O
wound	O
-	O
up	O
feeling	O
in	O
some	O
patients	O
.	O

Consensus	O
statement	O
concerning	O
cardiotoxicity	B
occurring	O
during	O
haematopoietic	O
stem	O
cell	O
transplantation	O
in	O
the	O
treatment	O
of	O
autoimmune	B
diseases	I
,	O
with	O
special	O
reference	O
to	O
systemic	B
sclerosis	I
and	O
multiple	B
sclerosis	I
.	O

Autologous	O
haematopoietic	O
stem	O
cell	O
transplantation	O
is	O
now	O
a	O
feasible	O
and	O
effective	O
treatment	O
for	O
selected	O
patients	O
with	O
severe	O
autoimmune	B
diseases	I
.	O

The	O
number	O
of	O
deaths	O
related	O
to	O
cardiac	B
toxicity	I
is	O
low	O
.	O

However	O
,	O
caution	O
is	O
required	O
when	O
cyclophosphamide	O
or	O
anthracyclines	O
such	O
as	O
mitoxantrone	O
are	O
used	O
in	O
patients	O
with	O
a	O
possible	O
underlying	O
heart	B
damage	I
,	O
for	O
example	O
,	O
systemic	B
sclerosis	I
patients	O
.	O

The	O
object	O
of	O
the	O
meeting	O
was	O
to	O
analyse	O
existing	O
data	O
,	O
both	O
published	O
or	O
available	O
,	O
in	O
the	O
European	O
Group	O
for	O
Blood	O
and	O
Marrow	O
Transplantation	O
autoimmune	B
disease	I
database	O
,	O
and	O
to	O
propose	O
a	O
safe	O
approach	O
to	O
such	O
patients	O
.	O

Does	O
supplemental	O
vitamin	O
C	O
increase	O
cardiovascular	B
disease	I
risk	O
in	O
women	O
with	O
diabetes	B
?	O

These	O
observations	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
high	O
intake	O
of	O
vitamin	O
C	O
in	O
diabetic	B
persons	O
might	O
promote	O
atherosclerosis	B
.	O

OBJECTIVE	O
:	O
The	O
objective	O
was	O
to	O
examine	O
the	O
relation	O
between	O
vitamin	O
C	O
intake	O
and	O
mortality	O
from	O
cardiovascular	B
disease	I
.	O

DESIGN	O
:	O
We	O
studied	O
the	O
relation	O
between	O
vitamin	O
C	O
intake	O
and	O
mortality	O
from	O
total	O
cardiovascular	B
disease	I
(	O
n	O
=	O
281	O
)	O
,	O
coronary	B
artery	I
disease	I
(	O
n	O
=	O
175	O
)	O
,	O
and	O
stroke	B
(	O
n	O
=	O
57	O
)	O
in	O
1923	O
postmenopausal	O
women	O
who	O
reported	O
being	O
diabetic	B
at	O
baseline	O
.	O

Diet	O
was	O
assessed	O
with	O
a	O
food	O
-	O
frequency	O
questionnaire	O
at	O
baseline	O
,	O
and	O
subjects	O
initially	O
free	O
of	O
coronary	B
artery	I
disease	I
were	O
prospectively	O
followed	O
for	O
15	O
y	O
.	O

RESULTS	O
:	O
After	O
adjustment	O
for	O
cardiovascular	B
disease	I
risk	O
factors	O
,	O
type	O
of	O
diabetes	B
medication	O
used	O
,	O
duration	O
of	O
diabetes	B
,	O
and	O
intakes	O
of	O
folate	O
,	O
vitamin	O
E	O
,	O
and	O
beta	O
-	O
carotene	O
,	O
the	O
adjusted	O
relative	O
risks	O
of	O
total	O
cardiovascular	B
disease	I
mortality	O
were	O
1	O
.	O
0	O
,	O
0	O
.	O
97	O
,	O
1	O
.	O
11	O
,	O
1	O
.	O
47	O
,	O
and	O
1	O
.	O
84	O
(	O
P	O
for	O
trend	O
<	O
0	O
.	O
01	O
)	O
across	O
quintiles	O
of	O
total	O
vitamin	O
C	O
intake	O
from	O
food	O
and	O
supplements	O
.	O

Adjusted	O
relative	O
risks	O
of	O
coronary	B
artery	I
disease	I
were	O
1	O
.	O
0	O
,	O
0	O
.	O
81	O
,	O
0	O
.	O
99	O
,	O
1	O
.	O
26	O
,	O
and	O
1	O
.	O
91	O
(	O
P	O
for	O
trend	O
=	O
0	O
.	O
01	O
)	O
and	O
of	O
stroke	B
were	O
1	O
.	O
0	O
,	O
0	O
.	O
52	O
,	O
1	O
.	O
23	O
,	O
2	O
.	O
22	O
,	O
and	O
2	O
.	O
57	O
(	O
P	O
for	O
trend	O
<	O
0	O
.	O
01	O
)	O
.	O

Vitamin	O
C	O
intake	O
was	O
unrelated	O
to	O
mortality	O
from	O
cardiovascular	B
disease	I
in	O
the	O
nondiabetic	O
subjects	O
at	O
baseline	O
.	O

CONCLUSION	O
:	O
A	O
high	O
vitamin	O
C	O
intake	O
from	O
supplements	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cardiovascular	B
disease	I
mortality	O
in	O
postmenopausal	O
women	O
with	O
diabetes	B
.	O

Optical	O
coherence	O
tomography	O
can	O
measure	O
axonal	O
loss	O
in	O
patients	O
with	O
ethambutol	O
-	O
induced	O
optic	B
neuropathy	I
.	O

PURPOSE	O
:	O
To	O
map	O
and	O
identify	O
the	O
pattern	O
,	O
in	O
vivo	O
,	O
of	O
axonal	B
degeneration	I
in	O
ethambutol	O
-	O
induced	O
optic	B
neuropathy	I
using	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
.	O

A	O
serious	O
complication	O
of	O
ethambutol	O
is	O
an	O
optic	B
neuropathy	I
that	O
impairs	O
visual	O
acuity	O
,	O
contrast	O
sensitivity	O
,	O
and	O
color	O
vision	O
.	O

However	O
,	O
early	O
on	O
,	O
when	O
the	O
toxic	O
optic	B
neuropathy	I
is	O
mild	O
and	O
partly	O
reversible	O
,	O
the	O
funduscopic	O
findings	O
are	O
often	O
subtle	O
and	O
easy	O
to	O
miss	O
.	O

METHODS	O
:	O
Three	O
subjects	O
with	O
a	O
history	O
of	O
ethambutol	O
(	O
EMB	O
)	O
-	O
induced	O
optic	B
neuropathy	I
of	O
short	O
-	O
,	O
intermediate	O
-	O
,	O
and	O
long	O
-	O
term	O
visual	B
deficits	I
were	O
administered	O
a	O
full	O
neuro	O
-	O
ophthalmologic	O
examination	O
including	O
visual	O
acuity	O
,	O
color	O
vision	O
,	O
contrast	O
sensitivity	O
,	O
and	O
fundus	O
examination	O
.	O

In	O
all	O
subjects	O
with	O
history	O
of	O
EMB	O
-	O
induced	O
optic	B
neuropathy	I
,	O
there	O
was	O
a	O
mean	O
loss	O
of	O
72	O
%	O
nerve	O
fiber	O
layer	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
(	O
patient	O
A	O
,	O
with	O
eventual	O
recovery	O
of	O
visual	O
acuity	O
and	O
fields	O
,	O
58	O
%	O
loss	O
;	O
patient	O
B	O
,	O
with	O
intermediate	O
visual	B
deficits	I
,	O
68	O
%	O
loss	O
;	O
patient	O
C	O
,	O
with	O
chronic	O
visual	B
deficits	I
,	O
90	O
%	O
loss	O
)	O
,	O
with	O
an	O
average	O
mean	O
optic	O
nerve	O
thickness	O
of	O
26	O
+	O
/	O
-	O
16	O
microm	O
.	O

In	O
both	O
sets	O
(	O
four	O
)	O
of	O
eyes	O
of	O
the	O
subjects	O
with	O
persistent	O
visual	B
deficits	I
(	O
patients	O
B	O
and	O
C	O
)	O
,	O
there	O
was	O
an	O
average	O
loss	O
of	O
79	O
%	O
of	O
nerve	O
fiber	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
.	O

CONCLUSIONS	O
:	O
The	O
OCT	O
results	O
in	O
these	O
patients	O
with	O
EMB	O
-	O
induced	O
optic	B
neuropathy	I
show	O
considerable	O
loss	O
especially	O
of	O
the	O
temporal	O
fibers	O
.	O

This	O
is	O
consistent	O
with	O
prior	O
histopathological	O
studies	O
that	O
show	O
predominant	O
loss	O
of	O
parvo	O
-	O
cellular	O
axons	O
(	O
or	O
small	O
-	O
caliber	O
axons	O
)	O
within	O
the	O
papillo	O
-	O
macular	O
bundle	O
in	O
toxic	O
or	O
hereditary	O
optic	B
neuropathies	I
.	O

OCT	O
can	O
be	O
a	O
valuable	O
tool	O
in	O
the	O
quantitative	O
analysis	O
of	O
optic	B
neuropathies	I
.	O

Additionally	O
,	O
in	O
terms	O
of	O
management	O
of	O
EMB	O
-	O
induced	O
optic	B
neuropathy	I
,	O
it	O
is	O
important	O
to	O
properly	O
manage	O
ethambutol	O
dosing	O
in	O
patients	O
with	O
renal	B
impairment	I
and	O
to	O
achieve	O
proper	O
transition	O
to	O
a	O
maintenance	O
dose	O
once	O
an	O
appropriate	O
loading	O
dose	O
has	O
been	O
reached	O
.	O

Hypoxia	B
in	O
renal	B
disease	I
with	O
proteinuria	B
and	O
/	O
or	O
glomerular	O
hypertension	B
.	O

We	O
then	O
applied	O
this	O
animal	O
model	O
to	O
the	O
detection	O
of	O
tubulointerstitial	O
hypoxia	B
in	O
the	O
diseased	B
kidney	I
.	O

With	O
this	O
model	O
,	O
we	O
were	O
able	O
to	O
identify	O
diffuse	O
cortical	O
hypoxia	B
in	O
the	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrotic	B
syndrome	I
and	O
focal	O
and	O
segmental	O
hypoxia	B
in	O
the	O
remnant	O
kidney	O
model	O
.	O

The	O
degree	O
of	O
hypoxia	B
showed	O
a	O
positive	O
correlation	O
with	O
microscopic	O
tubulointerstitial	B
injury	I
in	O
both	O
models	O
.	O

We	O
propose	O
here	O
a	O
possible	O
pathological	O
tie	O
between	O
chronic	O
tubulointerstitial	O
hypoxia	B
and	O
progressive	O
glomerular	B
diseases	I
.	O

Adequate	O
timing	O
of	O
ribavirin	O
reduction	O
in	O
patients	O
with	O
hemolysis	B
during	O
combination	O
therapy	O
of	O
interferon	O
and	O
ribavirin	O
for	O
chronic	B
hepatitis	I
C	I
.	O

BACKGROUND	O
:	O
Hemolytic	B
anemia	I
is	O
one	O
of	O
the	O
major	O
adverse	O
events	O
of	O
the	O
combination	O
therapy	O
of	O
interferon	O
and	O
ribavirin	O
.	O

Because	O
of	O
ribavirin	O
-	O
related	O
hemolytic	B
anemia	I
,	O
dose	O
reduction	O
is	O
a	O
common	O
event	O
in	O
this	O
therapy	O
.	O

In	O
this	O
clinical	O
retrospective	O
cohort	O
study	O
we	O
have	O
examined	O
the	O
suitable	O
timing	O
of	O
ribavirin	O
reduction	O
in	O
patients	O
with	O
hemolysis	B
during	O
combination	O
therapy	O
.	O

METHODS	O
:	O
Thirty	O
-	O
seven	O
of	O
160	O
patients	O
who	O
had	O
HCV	O
-	O
genotype	O
1b	O
,	O
had	O
high	O
virus	O
load	O
,	O
and	O
received	O
24	O
-	O
week	O
combination	O
therapy	O
developed	O
anemia	B
with	O
hemoglobin	O
level	O
<	O
10	O
g	O
/	O
dl	O
or	O
anemia	B
-	O
related	O
signs	O
during	O
therapy	O
.	O

However	O
,	O
10	O
of	O
37	O
patients	O
with	O
reduction	O
of	O
ribavirin	O
could	O
not	O
continue	O
combination	O
therapy	O
because	O
their	O
<	O
8	O
.	O
5	O
g	O
/	O
dl	O
hemoglobin	O
values	O
decreased	O
to	O
or	O
anemia	B
-	O
related	O
severe	O
side	O
effects	O
occurred	O
(	O
group	O
B	O
)	O
.	O

Relation	O
of	O
perfusion	O
defects	O
observed	O
with	O
myocardial	O
contrast	O
echocardiography	O
to	O
the	O
severity	O
of	O
coronary	B
stenosis	I
:	O
correlation	O
with	O
thallium	O
-	O
201	O
single	O
-	O
photon	O
emission	O
tomography	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
myocardial	O
contrast	O
echocardiography	O
is	O
a	O
valuable	O
technique	O
for	O
delineating	O
regions	O
of	O
myocardial	O
underperfusion	O
secondary	O
to	O
coronary	B
occlusion	I
and	O
to	O
critical	O
coronary	B
stenoses	I
in	O
the	O
presence	O
of	O
hyperemic	B
stimulation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
myocardial	O
contrast	O
echocardiography	O
performed	O
with	O
a	O
stable	O
solution	O
of	O
sonicated	O
albumin	O
could	O
detect	O
regions	O
of	O
myocardial	O
underperfusion	O
resulting	O
from	O
various	O
degrees	O
of	O
coronary	B
stenosis	I
.	O

During	O
a	O
transient	O
(	O
20	O
-	O
s	O
)	O
coronary	B
occlusion	I
,	O
a	O
perfusion	O
defect	O
was	O
observed	O
with	O
contrast	O
echocardiography	O
in	O
14	O
of	O
the	O
15	O
dogs	O
in	O
which	O
the	O
occlusion	O
was	O
produced	O
.	O

During	O
dipyridamole	O
-	O
induced	O
hyperemia	B
,	O
12	O
of	O
the	O
16	O
dogs	O
with	O
a	O
partial	O
coronary	B
stenosis	I
had	O
a	O
visible	O
area	O
of	O
hypoperfusion	O
by	O
contrast	O
echocardiography	O
.	O

Thus	O
,	O
myocardial	O
contrast	O
echocardiography	O
can	O
be	O
used	O
to	O
visualize	O
and	O
quantitate	O
the	O
amount	O
of	O
jeopardized	O
myocardium	O
during	O
moderate	O
to	O
severe	O
degrees	O
of	O
coronary	B
stenosis	I
.	O

The	O
activation	O
of	O
spinal	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
receptors	O
may	O
contribute	O
to	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
induced	O
by	O
neuraxial	O
morphine	O
after	O
a	O
noninjurious	O
interval	O
of	O
spinal	B
cord	I
ischemia	I
.	O

Spinal	B
cord	I
ischemia	I
was	O
induced	O
by	O
aortic	B
occlusion	I
for	O
6	O
min	O
with	O
a	O
balloon	O
catheter	O
.	O

We	O
suggest	O
that	O
opioids	O
may	O
be	O
neurotoxic	B
in	O
the	O
setting	O
of	O
spinal	B
cord	I
ischemia	I
via	O
NMDA	O
receptor	O
activation	O
.	O

Acute	O
low	B
back	I
pain	I
during	O
intravenous	O
administration	O
of	O
amiodarone	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Amiodarone	O
represents	O
an	O
effective	O
antiarrhythmic	O
drug	O
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	B
fibrillation	I
(	O
AF	B
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O

We	O
briefly	O
describe	O
two	O
patients	O
suffering	O
from	O
recent	O
-	O
onset	O
atrial	B
fibrillation	I
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	B
back	I
pain	I
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	O
loading	O
.	O

To	O
examine	O
the	O
relationship	O
between	O
quantitative	O
stimulant	O
drug	O
levels	O
,	O
catecholamines	O
,	O
and	O
psychotic	B
symptoms	I
,	O
nineteen	O
patients	O
in	O
a	O
psychiatric	B
emergency	O
service	O
with	O
a	O
diagnosis	O
of	O
amphetamine	O
-	O
or	O
cocaine	O
-	O
induced	O
psychosis	B
were	O
interviewed	O
,	O
and	O
plasma	O
and	O
urine	O
were	O
collected	O
for	O
quantitative	O
assays	O
of	O
stimulant	O
drug	O
and	O
catecholamine	O
metabolite	O
levels	O
.	O

Although	O
many	O
other	O
factors	O
such	O
as	O
sensitization	O
may	O
play	O
a	O
role	O
,	O
intensity	O
of	O
stimulant	O
-	O
induced	O
psychotic	B
symptoms	I
and	O
stereotypies	B
appears	O
to	O
be	O
at	O
least	O
in	O
part	O
dose	O
-	O
related	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
unmasking	O
of	O
pheochromocytoma	B
in	O
a	O
patient	O
treated	O
with	O
amisulpride	O
and	O
tiapride	O
.	O

Abdominal	O
ultrasound	O
showed	O
an	O
adrenal	O
mass	O
,	O
and	O
postoperative	O
histologic	O
examination	O
confirmed	O
the	O
diagnosis	O
of	O
pheochromocytoma	B
.	O

DISCUSSION	O
:	O
Drug	O
-	O
induced	O
symptoms	O
of	O
pheochromocytoma	B
are	O
often	O
associated	O
with	O
the	O
use	O
of	O
substituted	O
benzamide	O
drugs	O
,	O
but	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O

CONCLUSIONS	O
:	O
As	O
of	O
March	O
24	O
,	O
2005	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
amisulpride	O
-	O
and	O
tiapride	O
-	O
induced	O
hypertensive	B
crisis	O
in	O
a	O
patient	O
with	O
pheochromocytoma	B
.	O

Minor	O
neurological	B
dysfunction	I
,	O
cognitive	O
development	O
,	O
and	O
somatic	O
development	O
at	O
the	O
age	O
of	O
3	O
to	O
7	O
years	O
after	O
dexamethasone	O
treatment	O
in	O
very	O
-	O
low	O
birth	O
-	O
weight	O
infants	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
minor	O
neurological	B
dysfunction	I
,	O
cognitive	O
development	O
,	O
and	O
somatic	O
development	O
after	O
dexamethasone	O
therapy	O
in	O
very	O
-	O
low	O
-	O
birthweight	O
infants	O
.	O

Exclusion	O
criteria	O
were	O
asphyxia	B
,	O
malformations	B
,	O
major	O
surgical	O
interventions	O
,	O
small	O
for	O
gestational	O
age	O
,	O
intraventricular	O
haemorrhage	B
grades	O
III	O
and	O
IV	O
,	O
periventricular	B
leukomalacia	I
,	O
and	O
severe	O
psychomotor	B
retardation	I
.	O

Each	O
child	O
was	O
examined	O
by	O
a	O
neuropediatrician	O
for	O
minor	O
neurological	B
dysfunctions	I
and	O
tested	O
by	O
a	O
psychologist	O
for	O
cognitive	O
development	O
with	O
a	O
Kaufman	O
Assessment	O
Battery	O
for	O
Children	O
and	O
a	O
Draw	O
-	O
a	O
-	O
Man	O
Test	O
.	O

After	O
dexamethasone	O
treatment	O
,	O
children	O
showed	O
a	O
higher	O
rate	O
of	O
minor	O
neurological	B
dysfunctions	I
.	O

Valproic	O
acid	O
I	O
:	O
time	O
course	O
of	O
lipid	O
peroxidation	O
biomarkers	O
,	O
liver	B
toxicity	I
,	O
and	O
valproic	O
acid	O
metabolite	O
levels	O
in	O
rats	O
.	O

Liver	B
toxicity	I
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha	O
-	O
glutathione	O
S	O
-	O
transferase	O
(	O
alpha	O
-	O
GST	O
)	O
and	O
by	O
histology	O
.	O

Assessment	O
of	O
perinatal	O
hepatitis	B
B	I
and	O
rubella	B
prevention	O
in	O
New	O
Hampshire	O
delivery	O
hospitals	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
current	O
performance	O
on	O
recommended	O
perinatal	O
hepatitis	B
B	I
and	O
rubella	B
prevention	O
practices	O
in	O
New	O
Hampshire	O
.	O

Assessment	O
was	O
done	O
on	O
the	O
following	O
:	O
prenatal	O
screening	O
for	O
hepatitis	B
B	I
and	O
rubella	B
,	O
administration	O
of	O
the	O
hepatitis	B
B	I
vaccine	O
birth	O
dose	O
to	O
all	O
infants	O
,	O
administration	O
of	O
hepatitis	B
B	I
immune	O
globulin	O
to	O
infants	O
who	O
were	O
born	O
to	O
hepatitis	O
B	O
surface	O
antigen	O
-	O
positive	O
mothers	O
,	O
rubella	B
immunity	O
,	O
and	O
administration	O
of	O
in	O
-	O
hospital	O
postpartum	O
rubella	B
vaccine	O
to	O
rubella	B
nonimmune	O
women	O
.	O

RESULTS	O
:	O
Prenatal	O
screening	O
rates	O
for	O
hepatitis	B
B	I
(	O
98	O
.	O
8	O
%	O
)	O
and	O
rubella	B
(	O
99	O
.	O
4	O
%	O
)	O
were	O
high	O
.	O

Hepatitis	B
B	I
vaccine	O
birth	O
dose	O
was	O
administered	O
to	O
76	O
.	O
2	O
%	O
of	O
all	O
infants	O
.	O

All	O
infants	O
who	O
were	O
born	O
to	O
hepatitis	O
B	O
surface	O
antigen	O
-	O
positive	O
mothers	O
also	O
received	O
hepatitis	B
B	I
immune	O
globulin	O
.	O

Multivariate	O
logistic	O
regression	O
showed	O
that	O
the	O
month	O
of	O
delivery	O
and	O
infant	O
birth	O
weight	O
were	O
independent	O
predictors	O
of	O
hepatitis	B
B	I
vaccination	O
.	O

CONCLUSION	O
:	O
This	O
study	O
documents	O
good	O
compliance	O
in	O
New	O
Hampshire	O
'	O
s	O
birthing	O
hospitals	O
with	O
national	O
guidelines	O
for	O
perinatal	O
hepatitis	B
B	I
and	O
rubella	B
prevention	O
and	O
highlights	O
potential	O
areas	O
for	O
improvement	O
.	O

Succinylcholine	O
-	O
induced	O
masseter	B
muscle	I
rigidity	I
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Masseter	B
muscle	I
rigidity	I
during	O
general	O
anesthesia	O
is	O
considered	O
an	O
early	O
warning	O
sign	O
of	O
a	O
possible	O
episode	O
of	O
malignant	B
hyperthermia	I
.	O

The	O
decision	O
whether	O
to	O
continue	O
or	O
discontinue	O
the	O
procedure	O
depends	O
on	O
the	O
urgency	O
of	O
the	O
surgery	O
and	O
severity	O
of	O
masseter	B
muscle	I
rigidity	I
.	O

Here	O
,	O
we	O
describe	O
a	O
case	O
of	O
severe	O
masseter	B
muscle	I
rigidity	I
(	O
jaw	B
of	I
steel	I
)	O
after	O
succinylcholine	O
(	O
Sch	O
)	O
administration	O
during	O
general	O
anesthetic	O
management	O
for	O
rigid	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Anesthesia	O
was	O
continued	O
uneventfully	O
with	O
propofol	O
infusion	O
while	O
all	O
facilities	O
were	O
available	O
to	O
detect	O
and	O
treat	O
malignant	B
hyperthermia	I
.	O

PURPOSE	O
:	O
The	O
anthracyclines	O
daunorubicin	O
and	O
doxorubicin	O
and	O
the	O
epipodophyllotoxin	O
etoposide	O
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	B
and	O
cardiac	B
toxicity	I
limit	O
their	O
use	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	B
toxicity	I
following	O
coadministration	O
of	O
dexrazoxane	O
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	O
and	O
murine	O
blood	O
progenitor	O
cells	O
to	O
etoposide	O
,	O
daunorubicin	O
,	O
and	O
doxorubicin	O
+	O
/	O
-	O
dexrazoxane	O
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O

RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	O
reduced	O
myelosuppression	B
and	O
weight	B
loss	I
from	O
daunorubicin	O
and	O
etoposide	O
in	O
mice	O
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	O
neither	O
reduced	O
myelosuppression	B
,	O
weight	B
loss	I
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	B
from	O
doxorubicin	O
.	O

Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	B
combining	O
dexrazoxane	O
and	O
high	O
doses	O
of	O
etoposide	O
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	B
toxicity	I
.	O

The	O
mean	O
highest	O
BIS	O
score	O
corresponding	O
to	O
the	O
inability	B
to	I
repeat	I
words	I
was	O
81	O
.	O
5	O
(	O
95	O
%	O
CI	O
=	O
78	O
.	O
1	O
to	O
84	O
.	O
8	O
)	O
.	O

Amiodarone	O
pulmonary	B
toxicity	I
.	O

The	O
pulmonary	B
toxicity	I
of	O
amiodarone	O
is	O
thought	O
to	O
result	O
from	O
direct	O
injury	O
related	O
to	O
the	O
intracellular	O
accumulation	O
of	O
phospholipid	O
and	O
T	O
cell	O
-	O
mediated	O
hypersensitivity	B
pneumonitis	I
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
amiodarone	O
-	O
induced	O
pulmonary	B
toxicity	I
are	O
characteristic	O
but	O
nonspecific	O
.	O

The	O
diagnosis	O
depends	O
on	O
exclusion	O
of	O
other	O
entities	O
,	O
such	O
as	O
heart	B
failure	I
,	O
infection	B
,	O
and	O
malignancy	B
.	O

Calcium	O
carbonate	O
toxicity	B
:	O
the	O
updated	O
milk	B
-	I
alkali	I
syndrome	I
;	O
report	O
of	O
3	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
3	O
patients	O
with	O
calcium	O
carbonate	O
-	O
induced	O
hypercalcemia	B
and	O
gain	O
insights	O
into	O
the	O
cause	O
and	O
management	O
of	O
the	O
milk	B
-	I
alkali	I
syndrome	I
.	O

METHODS	O
:	O
We	O
report	O
the	O
clinical	O
and	O
laboratory	O
data	O
in	O
3	O
patients	O
who	O
presented	O
with	O
severe	O
hypercalcemia	B
(	O
corrected	O
serum	O
calcium	O
>	O
or	O
=	O
14	O
mg	O
/	O
dL	O
)	O
and	O
review	O
the	O
pertinent	O
literature	O
on	O
milk	B
-	I
alkali	I
syndrome	I
.	O

RESULTS	O
:	O
The	O
3	O
patients	O
had	O
acute	B
renal	I
insufficiency	I
,	O
relative	O
metabolic	B
alkalosis	I
,	O
and	O
low	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
,	O
PTH	O
-	O
related	O
peptide	O
,	O
and	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
concentrations	O
.	O

In	O
addition	O
to	O
our	O
highlighted	O
cases	O
,	O
we	O
review	O
the	O
history	O
,	O
classification	O
,	O
pathophysiologic	O
features	O
,	O
and	O
treatment	O
of	O
milk	B
-	I
alkali	I
syndrome	I
and	O
summarize	O
the	O
cases	O
reported	O
from	O
early	O
1995	O
to	O
November	O
2003	O
.	O

CONCLUSION	O
:	O
Milk	B
-	I
alkali	I
syndrome	I
may	O
be	O
a	O
common	O
cause	O
of	O
unexplained	O
hypercalcemia	B
and	O
can	O
be	O
precipitated	O
by	O
small	O
amounts	O
of	O
orally	O
ingested	O
calcium	O
carbonate	O
in	O
susceptible	O
persons	O
.	O

Warfarin	O
-	O
induced	O
leukocytoclastic	B
vasculitis	I
.	O

Leukocytoclastic	B
vasculitis	I
(	O
LV	B
)	O
is	O
primarily	O
a	O
cutaneous	B
small	I
vessel	I
vasculitis	I
,	O
though	O
systemic	O
involvement	O
may	O
be	O
encountered	O
.	O

All	O
4	O
patients	O
presented	O
with	O
skin	B
eruptions	I
that	O
developed	O
after	O
receiving	O
warfarin	O
for	O
several	O
years	O
.	O

The	O
results	O
of	O
skin	B
lesion	I
biopsies	O
were	O
available	O
in	O
3	O
patients	O
,	O
confirming	O
LV	B
Cutaneous	I
lesions	I
resolved	O
in	O
all	O
patients	O
after	O
warfarin	O
was	O
discontinued	O
.	O

The	O
abnormal	O
behaviors	O
were	O
yawning	O
,	O
retrocollis	O
,	O
hyperactivity	B
,	O
hypersensitivity	B
,	O
"	O
beating	O
drum	O
"	O
behavior	O
,	O
squealing	O
,	O
head	O
bobbing	O
,	O
circling	O
,	O
sniffing	O
,	O
abnormal	O
posturing	O
,	O
and	O
facial	O
twitching	O
.	O

rTMS	O
of	O
supplementary	O
motor	O
area	O
modulates	O
therapy	O
-	O
induced	O
dyskinesias	B
in	O
Parkinson	B
disease	I
.	O

Using	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
over	O
the	O
supplementary	O
motor	O
area	O
(	O
SMA	O
)	O
in	O
a	O
group	O
of	O
patients	O
with	O
advanced	O
Parkinson	B
disease	I
,	O
the	O
authors	O
investigated	O
whether	O
modulation	O
of	O
SMA	O
excitability	O
may	O
result	O
in	O
a	O
modification	O
of	O
a	O
dyskinetic	B
state	O
induced	O
by	O
continuous	O
apomorphine	O
infusion	O
.	O

rTMS	O
at	O
1	O
Hz	O
was	O
observed	O
to	O
markedly	O
reduce	O
drug	B
-	I
induced	I
dyskinesias	I
,	O
whereas	O
5	O
-	O
Hz	O
rTMS	O
induced	O
a	O
slight	O
but	O
not	O
significant	O
increase	O
.	O

Human	O
malignant	O
brain	B
tumors	I
have	O
a	O
poor	O
prognosis	O
in	O
spite	O
of	O
surgery	O
and	O
radiation	O
therapy	O
.	O

Six	O
of	O
the	O
patients	O
received	O
more	O
than	O
15	O
mg	O
paclitaxel	O
and	O
suffered	O
from	O
moderate	O
to	O
severe	O
brain	B
edema	I
,	O
while	O
the	O
remaining	O
patients	O
received	O
only	O
a	O
total	O
of	O
15	O
mg	O
paclitaxel	O
.	O

In	O
the	O
latter	O
group	O
,	O
brain	B
edema	I
was	O
markedly	O
reduced	O
and	O
dealt	O
medically	O
.	O

Lamotrigine	O
associated	O
with	O
exacerbation	O
or	O
de	O
novo	O
myoclonus	B
in	O
idiopathic	B
generalized	I
epilepsies	I
.	O

Five	O
patients	O
with	O
idiopathic	B
generalized	I
epilepsies	I
(	O
IGE	B
)	O
treated	O
with	O
lamotrigine	O
(	O
LTG	O
)	O
experienced	O
exacerbation	O
or	O
de	O
novo	O
appearance	O
of	O
myoclonic	B
jerks	I
(	O
MJ	B
)	O
.	O

INTRODUCTION	O
:	O
Cocaine	O
use	O
has	O
been	O
associated	O
with	O
neurovascular	B
complications	I
,	O
including	O
arterial	O
vasoconstriction	O
and	O
vasculitis	B
.	O

CONCLUSION	O
:	O
No	O
quantitative	O
evidence	O
for	O
narrowing	O
of	O
large	O
cerebral	O
arteries	O
or	O
qualitative	O
angiographic	O
evidence	O
for	O
distal	O
narrowing	O
or	O
vasculitis	B
could	O
be	O
found	O
in	O
patients	O
who	O
underwent	O
angiography	O
after	O
aneurysmal	B
SAH	B
associated	O
with	O
cocaine	O
use	O
.	O

Aggressive	B
behaviors	I
have	O
been	O
reported	O
in	O
patients	O
who	O
suffer	O
from	O
some	O
psychiatric	B
disorders	I
,	O
and	O
are	O
common	O
in	O
methamphetamine	O
(	O
METH	O
)	O
abusers	O
.	O

Amisulpride	O
related	O
tic	B
-	I
like	I
symptoms	I
in	O
an	O
adolescent	O
schizophrenic	B
.	O

Tic	B
disorders	I
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	O
such	O
as	O
risperidone	O
,	O
olanzapine	O
and	O
ziprasidone	O
.	O

However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	B
-	I
like	I
symptoms	I
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	O
or	O
clozapine	O
.	O

We	O
present	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
schizophrenic	B
who	O
developed	O
frequent	O
involuntary	B
eye	I
-	I
blinking	I
movements	I
after	O
5	O
months	O
of	O
amisulpride	O
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O

The	O
tic	B
-	I
like	I
symptoms	I
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	O
down	O
to	O
800	O
mg	O
per	O
day	O
.	O

No	O
more	O
tic	B
-	I
like	I
symptoms	I
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O

Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	O
suggests	O
that	O
tic	B
-	I
like	I
symptoms	I
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
such	O
as	O
quetiapine	O
,	O
clozapine	O
,	O
or	O
amisulpride	O
.	O

Chloroquine	O
related	O
complete	O
heart	B
block	I
with	O
blindness	B
:	O
case	O
report	O
.	O

A	O
27	O
-	O
year	O
old	O
African	O
woman	O
with	O
history	O
of	O
regular	O
chloroquine	O
ingestion	O
presented	O
with	O
progressive	O
deterioration	B
of	I
vision	I
,	O
easy	O
fatiguability	B
,	O
dyspnoea	B
,	O
dizziness	B
progressing	O
to	O
syncopal	B
attacks	I
.	O

Ophthalmological	O
assessment	O
revealed	O
features	O
of	O
chloroquine	O
retinopathy	B
,	O
cardiac	O
assessment	O
revealed	O
features	O
of	O
heart	B
failure	I
and	O
a	O
complete	O
heart	B
block	I
with	O
right	B
bundle	I
branch	I
block	I
pattern	O
.	O

The	O
heart	B
block	I
was	O
treated	O
by	O
pacemaker	O
insertion	O
and	O
the	O
heart	B
failure	I
resolved	O
spontaneously	O
following	O
chloroquine	O
discontinuation	O
.	O

Although	O
suprofen	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
acute	B
renal	I
failure	I
in	O
greater	O
than	O
100	O
subjects	O
,	O
the	O
mechanism	O
of	O
damage	O
remains	O
unclear	O
.	O

In	O
summary	O
,	O
suprofen	O
causes	O
acute	B
declines	I
in	I
renal	I
function	I
,	O
most	O
likely	O
by	O
directly	O
altering	O
the	O
intrarenal	O
distribution	O
of	O
uric	O
acid	O
.	O

PTU	O
-	O
associated	O
vasculitis	B
in	O
a	O
girl	O
with	O
Turner	B
Syndrome	I
and	O
Graves	B
'	I
disease	I
.	O

A	O
rare	O
cause	O
,	O
drug	O
-	O
induced	O
vasculitis	B
,	O
may	O
result	O
from	O
the	O
production	O
of	O
antineutrophil	O
cytoplasmic	O
antibodies	O
(	O
ANCAs	O
)	O
in	O
response	O
to	O
a	O
medication	O
.	O

We	O
report	O
a	O
girl	O
with	O
Turner	B
syndrome	I
and	O
Graves	B
'	I
disease	I
who	O
presented	O
with	O
palpable	O
purpuric	B
lesions	I
.	O

The	O
diagnosis	O
of	O
propylthiouracil	O
(	O
PTU	O
)	O
-	O
associated	O
vasculitis	B
was	O
made	O
by	O
observation	O
of	O
consistent	O
clinical	O
features	O
,	O
the	O
detection	O
of	O
elevated	O
ANA	O
and	O
ANCA	O
in	O
the	O
blood	O
,	O
and	O
the	O
observed	O
clinical	O
resolution	O
of	O
symptoms	O
following	O
withdrawal	O
of	O
PTU	O
.	O

Subsequent	O
treatment	O
of	O
persistent	O
hyperthyroidism	B
with	O
radioablation	O
did	O
not	O
result	O
in	O
an	O
exacerbation	O
of	O
the	O
vasculitis	B
,	O
a	O
complication	O
described	O
in	O
prior	O
case	O
reports	O
.	O

The	O
choline	O
acetyltransferase	O
(	O
ChAT	O
)	O
activator	O
,	O
which	O
enhances	O
cholinergic	O
transmission	O
via	O
an	O
augmentation	O
of	O
the	O
enzymatic	O
production	O
of	O
acetylcholine	O
(	O
ACh	O
)	O
,	O
is	O
an	O
important	O
factor	O
in	O
the	O
treatment	O
of	O
Alzheimer	B
'	I
s	I
disease	I
(	O
AD	B
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
effects	O
of	O
daidzein	O
from	O
Pueraria	O
thunbergiana	O
on	O
scopolamine	O
-	O
induced	O
impairments	B
of	I
learning	I
and	I
memory	I
,	O
we	O
conducted	O
a	O
series	O
of	O
in	O
vivo	O
tests	O
.	O

Although	O
3	O
,	O
4	O
-	O
methylenedioxymethamphetamine	O
(	O
MDMA	O
or	O
ecstasy	O
)	O
has	O
been	O
shown	O
to	O
damage	O
brain	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
neurons	O
in	O
animals	O
and	O
possibly	O
humans	O
,	O
little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
consequences	O
of	O
MDMA	O
-	O
induced	O
5	O
-	O
HT	O
neurotoxic	B
lesions	I
on	O
functions	O
in	O
which	O
5	O
-	O
HT	O
is	O
involved	O
,	O
such	O
as	O
cognitive	O
function	O
.	O

In	O
contrast	O
,	O
no	O
evidence	O
of	O
memory	B
impairment	I
was	O
observed	O
in	O
moderate	O
MDMA	O
users	O
.	O

While	O
the	O
use	O
of	O
MDMA	O
in	O
quantities	O
that	O
may	O
be	O
considered	O
"	O
moderate	O
"	O
is	O
not	O
associated	O
with	O
impaired	B
memory	I
functioning	I
,	O
heavy	O
use	O
of	O
MDMA	O
use	O
may	O
lead	O
to	O
long	O
lasting	O
memory	B
impairments	I
.	O

Subcutaneous	O
injection	O
of	O
ISPH	O
(	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
in	O
1	O
ml	O
saline	O
)	O
to	O
rats	O
for	O
2	O
consecutive	O
days	O
caused	O
myocardial	B
damage	I
in	O
rat	O
heart	O
,	O
which	O
was	O
determined	O
by	O
the	O
increased	O
activity	O
of	O
serum	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
and	O
creatine	O
phosphokinase	O
isoenzymes	O
(	O
CK	O
-	O
MB	O
)	O
,	O
increased	O
uric	O
acid	O
level	O
and	O
reduced	O
plasma	O
iron	O
binding	O
capacity	O
.	O

The	O
protective	O
role	O
of	O
mangiferin	O
was	O
analyzed	O
by	O
triphenyl	O
tetrazolium	O
chloride	O
(	O
TTC	O
)	O
test	O
used	O
for	O
macroscopic	O
enzyme	O
mapping	O
assay	O
of	O
the	O
ischemic	B
myocardium	I
.	O

From	O
the	O
present	O
study	O
it	O
is	O
concluded	O
that	O
mangiferin	O
exerts	O
a	O
beneficial	O
effect	O
against	O
ISPH	O
-	O
induced	O
MI	B
due	O
to	O
its	O
antioxidant	O
potential	O
,	O
which	O
regulated	O
the	O
tissues	O
defense	O
system	O
against	O
cardiac	B
damage	I
.	O

Randomised	O
clinical	O
trials	O
and	O
observational	O
studies	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
myocardial	B
infarction	I
,	O
stroke	B
,	O
hypertension	B
and	O
heart	B
failure	I
during	O
treatment	O
with	O
cyclooxygenase	O
inhibitors	O
.	O

Diagnostic	O
markers	O
such	O
as	O
N	O
-	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
(	O
NT	O
-	O
proBNP	O
)	O
or	O
high	O
-	O
sensitive	O
C	O
-	O
reactive	O
protein	O
might	O
help	O
in	O
the	O
early	O
identification	O
of	O
patients	O
at	O
risk	O
,	O
thus	O
avoiding	O
the	O
occurrence	O
of	O
serious	O
cardiovascular	B
toxicity	I
.	O

Pilocarpine	O
seizures	B
cause	O
age	O
-	O
dependent	O
impairment	B
in	I
auditory	I
location	I
discrimination	I
.	O

The	O
extent	O
to	O
which	O
status	B
epilepticus	I
causes	O
deficits	B
in	I
auditory	I
discrimination	I
is	O
unknown	O
.	O

Status	B
epilepticus	I
in	O
rat	O
causes	O
an	O
age	O
-	O
dependent	O
,	O
long	O
-	O
term	O
impairment	B
in	I
auditory	I
discrimination	I
.	O

This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	B
auditory	I
location	I
discrimination	I
in	O
humans	O
.	O

Definition	O
and	O
management	O
of	O
anemia	B
in	O
patients	O
infected	B
with	I
hepatitis	I
C	I
virus	I
.	O

Chronic	B
infection	I
with	I
hepatitis	I
C	I
virus	I
(	O
HCV	O
)	O
can	O
progress	O
to	O
cirrhosis	B
,	O
hepatocellular	B
carcinoma	I
,	O
and	O
end	B
-	I
stage	I
liver	I
disease	I
.	O

The	O
current	O
best	O
treatment	O
for	O
HCV	B
infection	I
is	O
combination	O
therapy	O
with	O
pegylated	O
interferon	O
and	O
ribavirin	O
.	O

Although	O
this	O
regimen	O
produces	O
sustained	O
virologic	O
responses	O
(	O
SVRs	O
)	O
in	O
approximately	O
50	O
%	O
of	O
patients	O
,	O
it	O
can	O
be	O
associated	O
with	O
a	O
potentially	O
dose	O
-	O
limiting	O
hemolytic	B
anemia	I
.	O

Hemoglobin	O
concentrations	O
decrease	O
mainly	O
as	O
a	O
result	O
of	O
ribavirin	O
-	O
induced	O
hemolysis	B
,	O
and	O
this	O
anemia	B
can	O
be	O
problematic	O
in	O
patients	O
with	O
HCV	B
infection	I
,	O
especially	O
those	O
who	O
have	O
comorbid	O
renal	B
or	I
cardiovascular	I
disorders	I
.	O

In	O
general	O
,	O
anemia	B
can	O
increase	O
the	O
risk	O
of	O
morbidity	O
and	O
mortality	O
,	O
and	O
may	O
have	O
negative	O
effects	O
on	O
cerebral	O
function	O
and	O
quality	O
of	O
life	O
.	O

Although	O
ribavirin	O
-	O
associated	O
anemia	B
can	O
be	O
reversed	O
by	O
dose	O
reduction	O
or	O
discontinuation	O
,	O
this	O
approach	O
compromises	O
outcomes	O
by	O
significantly	O
decreasing	O
SVR	O
rates	O
.	O

Recombinant	O
human	O
erythropoietin	O
has	O
been	O
used	O
to	O
manage	O
ribavirin	O
-	O
associated	O
anemia	B
but	O
has	O
other	O
potential	O
disadvantages	O
.	O

Viramidine	O
,	O
a	O
liver	O
-	O
targeting	O
prodrug	O
of	O
ribavirin	O
,	O
has	O
the	O
potential	O
to	O
maintain	O
the	O
virologic	O
efficacy	O
of	O
ribavirin	O
while	O
decreasing	O
the	O
risk	O
of	O
hemolytic	B
anemia	I
in	O
patients	O
with	O
chronic	B
hepatitis	I
C	I
.	O

This	O
study	O
examined	O
the	O
utility	O
of	O
biometry	O
for	O
detecting	O
alcohol	O
-	O
related	O
fetal	O
growth	B
impairment	I
.	O

Any	O
alcohol	O
consumption	O
postpregnancy	O
recognition	O
among	O
the	O
heavy	O
drinkers	O
resulted	O
in	O
reduced	B
cerebellar	I
growth	I
as	O
well	O
as	O
decreased	B
cranial	I
to	I
body	I
growth	I
in	O
comparison	O
with	O
women	O
who	O
either	O
quit	O
drinking	O
or	O
who	O
were	O
nondrinkers	O
.	O

Ethambutol	O
-	O
associated	O
optic	B
neuropathy	I
.	O

INTRODUCTION	O
:	O
Ethambutol	O
is	O
used	O
in	O
the	O
treatment	O
of	O
tuberculosis	B
,	O
which	O
is	O
still	O
prevalent	O
in	O
Southeast	O
Asia	O
,	O
and	O
can	O
be	O
associated	O
with	O
permanent	O
visual	B
loss	I
.	O

CLINICAL	O
PICTURE	O
:	O
Three	O
patients	O
with	O
ethambutol	O
-	O
associated	O
toxic	O
optic	B
neuropathy	I
are	O
described	O
.	O

All	O
3	O
patients	O
had	O
loss	B
of	I
central	I
visual	I
acuity	I
,	I
colour	I
vision	I
(	I
Ishihara	I
)	I
and	I
visual	I
field	I
.	O

The	O
visual	B
field	I
loss	I
had	O
a	O
bitemporal	O
flavour	O
,	O
suggesting	O
involvement	O
of	O
the	O
optic	O
chiasm	O
.	O

OUTCOME	O
:	O
All	O
3	O
patients	O
had	O
some	O
permanent	O
loss	B
of	I
visual	I
function	I
.	O

CONCLUSIONS	O
:	O
Ethambutol	O
usage	O
is	O
associated	O
with	O
permanent	O
visual	B
loss	I
and	O
should	O
be	O
avoided	O
if	O
possible	O
or	O
used	O
with	O
caution	O
and	O
proper	O
ophthalmological	O
follow	O
-	O
up	O
.	O

Possible	O
neuroleptic	B
malignant	I
syndrome	I
related	O
to	O
concomitant	O
treatment	O
with	O
paroxetine	O
and	O
alprazolam	O
.	O

A	O
74	O
-	O
year	O
-	O
old	O
man	O
with	O
depressive	B
symptoms	I
was	O
admitted	O
to	O
a	O
psychiatric	B
hospital	O
due	O
to	O
insomnia	B
,	O
loss	B
of	I
appetite	I
,	O
exhaustion	O
,	O
and	O
agitation	B
.	O

On	O
the	O
10th	O
day	O
of	O
paroxetine	O
and	O
alprazolam	O
treatment	O
,	O
the	O
patient	O
exhibited	O
marked	O
psychomotor	B
retardation	I
,	O
disorientation	O
,	O
and	O
severe	O
muscle	B
rigidity	I
with	O
tremors	B
.	O

The	O
patient	O
had	O
a	O
fever	B
(	O
38	O
.	O
2	O
degrees	O
C	O
)	O
,	O
fluctuating	O
blood	O
pressure	O
(	O
between	O
165	O
/	O
90	O
and	O
130	O
/	O
70	O
mg	O
mm	O
Hg	O
)	O
,	O
and	O
severe	O
extrapyramidal	B
symptoms	I
.	O

7	O
days	O
later	O
,	O
the	O
fever	B
disappeared	O
and	O
the	O
patient	O
'	O
s	O
serum	O
CPK	O
levels	O
were	O
normalized	O
(	O
175	O
IU	O
/	O
L	O
)	O
.	O

This	O
patient	O
presented	O
with	O
symptoms	O
of	O
neuroleptic	B
malignant	I
syndrome	I
(	O
NMS	B
)	O
,	O
thus	O
demonstrating	O
that	O
NMS	B
-	O
like	O
symptoms	O
can	O
occur	O
after	O
combined	O
paroxetine	O
and	O
alprazolam	O
treatment	O
.	O

Several	O
risk	O
factors	O
for	O
NMS	B
should	O
be	O
noted	O
in	O
elderly	O
depressive	B
patients	O
whose	O
symptoms	O
often	O
include	O
dehydration	B
,	O
agitation	B
,	O
malnutrition	B
,	O
and	O
exhaustion	O
.	O

Co	O
-	O
administration	O
of	O
lidocaine	O
with	O
desipramine	O
reversed	O
the	O
changes	O
of	O
convulsive	B
activity	O
of	O
lidocaine	O
and	O
cocaine	O
induced	O
by	O
repeated	O
administration	O
of	O
desipramine	O
.	O

Peripheral	B
neuropathy	I
caused	O
by	O
high	O
-	O
dose	O
cytosine	O
arabinoside	O
treatment	O
in	O
a	O
patient	O
with	O
acute	B
myeloid	I
leukemia	I
.	O

A	O
49	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
was	O
diagnosed	O
with	O
acute	B
myeloid	I
leukemia	I
.	O

Electromyogram	O
and	O
nerve	O
-	O
conduction	O
studies	O
showed	O
peripheral	B
neuropathy	I
in	O
both	O
peroneal	O
nerves	O
.	O

This	O
neuropathy	B
was	O
gradually	O
resolving	O
;	O
however	O
,	O
after	O
the	O
patient	O
received	O
allogeneic	O
bone	O
marrow	O
transplantation	O
,	O
the	O
symptoms	O
worsened	O
,	O
with	O
the	O
development	O
of	O
graft	B
-	I
versus	I
-	I
host	I
disease	I
,	O
and	O
the	O
symptoms	O
subsequently	O
responded	O
to	O
methylprednisolone	O
.	O

Although	O
the	O
mechanisms	O
of	O
peripheral	B
neuropathy	I
are	O
still	O
unclear	O
,	O
high	O
-	O
dose	O
cytosine	O
arabinoside	O
is	O
a	O
therapy	O
that	O
is	O
potentially	O
toxic	O
to	O
the	O
peripheral	O
nervous	O
system	O
,	O
and	O
auto	O
/	O
alloimmunity	O
may	O
play	O
an	O
important	O
role	O
in	O
these	O
mechanisms	O
.	O

This	O
suggests	O
that	O
alpha	O
-	O
TC	O
and	O
DFO	O
ameliorate	O
the	O
MA	O
-	O
induced	O
neuronal	B
damage	I
by	O
decreasing	O
the	O
level	O
of	O
oxidative	O
stress	O
.	O

Sustained	O
clinical	O
improvement	O
of	O
a	O
patient	O
with	O
decompensated	O
hepatitis	B
B	I
virus	O
-	O
related	O
cirrhosis	B
after	O
treatment	O
with	O
lamivudine	O
monotherapy	O
.	O

Hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
infection	I
,	O
which	O
causes	O
liver	B
cirrhosis	I
and	O
hepatocellular	B
carcinoma	I
,	O
remains	O
a	O
major	O
health	O
problem	O
in	O
Asian	O
countries	O
.	O

In	O
this	O
report	O
,	O
we	O
encountered	O
a	O
patient	O
with	O
decompensated	O
HBV	O
-	O
related	O
cirrhosis	B
who	O
exhibited	O
the	O
dramatic	O
improvements	O
after	O
antiviral	O
therapy	O
.	O

The	O
administration	O
of	O
lamivudine	O
to	O
patients	O
with	O
HBV	O
-	O
related	O
cirrhosis	B
,	O
like	O
our	O
present	O
case	O
,	O
should	O
be	O
considered	O
as	O
an	O
initial	O
medical	O
therapeutic	O
option	O
,	O
especially	O
in	O
countries	O
where	O
liver	O
transplantation	O
is	O
not	O
reliably	O
available	O
.	O

Antiarrhythmic	O
effects	O
of	O
(	O
+	O
)	O
-	O
cibenzoline	O
and	O
(	O
-	O
)	O
-	O
cibenzoline	O
were	O
examined	O
using	O
two	O
canine	O
ventricular	B
arrhythmia	I
models	O
.	O

Adrenaline	B
arrhythmia	I
,	O
which	O
is	O
suppressed	O
by	O
Ca	O
channel	O
blockers	O
,	O
was	O
induced	O
by	O
adrenaline	O
infusion	O
in	O
halothane	O
-	O
anesthetized	O
dogs	O
.	O

Passage	O
of	O
mannitol	O
into	O
the	O
brain	O
around	O
gliomas	B
:	O
a	O
potential	O
cause	O
of	O
rebound	O
phenomenon	O
.	O

AIM	O
:	O
Widespread	O
use	O
of	O
mannitol	O
to	O
reduce	O
brain	B
edema	I
and	O
lower	O
elevated	B
ICP	I
in	O
brain	B
tumor	I
patients	O
continues	O
to	O
be	O
afflicted	O
by	O
the	O
so	O
-	O
called	O
rebound	O
phenomenon	O
.	O

As	O
a	O
contribution	O
to	O
this	O
issue	O
we	O
decided	O
to	O
research	O
the	O
possible	O
passage	O
of	O
mannitol	O
into	O
the	O
brain	O
after	O
administration	O
to	O
21	O
brain	B
tumor	I
patients	O
.	O

METHODS	O
:	O
Mannitol	O
(	O
18	O
%	O
solution	O
;	O
1	O
g	O
/	O
kg	O
)	O
was	O
administered	O
as	O
a	O
bolus	O
to	O
patients	O
(	O
ten	O
had	O
malignant	B
glioma	I
,	O
seven	O
brain	O
metastases	B
and	O
four	O
meningioma	B
)	O
about	O
30	O
minutes	O
before	O
craniotomy	O
.	O

RESULTS	O
:	O
In	O
most	O
glioma	B
patients	O
,	O
mannitol	O
concentrations	O
in	O
white	O
matter	O
were	O
2	O
to	O
6	O
times	O
higher	O
than	O
in	O
plasma	O
(	O
mean	O
3	O
.	O
5	O
times	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
of	O
our	O
study	O
show	O
that	O
even	O
after	O
a	O
single	O
bolus	O
,	O
mannitol	O
may	O
leak	O
through	O
the	O
altered	O
BBB	O
near	O
gliomas	B
,	O
reversing	O
the	O
initial	O
plasma	O
-	O
to	O
-	O
blood	O
osmotic	O
gradient	O
,	O
aggravating	O
peritumoral	O
edema	B
and	O
promoting	O
rebound	O
of	O
ICP	O
.	O

Placebo	O
-	O
level	O
incidence	O
of	O
extrapyramidal	B
symptoms	I
(	O
EPS	B
)	O
with	O
quetiapine	O
in	O
controlled	O
studies	O
of	O
patients	O
with	O
bipolar	B
mania	I
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
extrapyramidal	B
symptoms	I
(	O
EPS	B
)	O
,	O
including	O
akathisia	B
,	O
with	O
quetiapine	O
in	O
patients	O
with	O
bipolar	B
mania	I
.	O

Extrapyramidal	B
symptoms	I
were	O
evaluated	O
using	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
(	O
SAS	O
)	O
,	O
the	O
Barnes	O
Akathisia	O
Rating	O
Scale	O
(	O
BARS	O
)	O
,	O
adverse	O
event	O
reports	O
and	O
anticholinergic	O
drug	O
usage	O
.	O

Haloperidol	O
induced	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
of	O
akathisia	B
(	O
33	O
.	O
3	O
%	O
versus	O
5	O
.	O
9	O
%	O
)	O
,	O
tremor	B
(	O
30	O
.	O
3	O
%	O
versus	O
7	O
.	O
8	O
%	O
)	O
,	O
and	O
extrapyramidal	B
syndrome	I
(	O
35	O
.	O
4	O
%	O
versus	O
5	O
.	O
9	O
%	O
)	O
than	O
quetiapine	O
.	O

CONCLUSIONS	O
:	O
In	O
bipolar	B
mania	I
,	O
the	O
incidence	O
of	O
EPS	B
,	O
including	O
akathisia	B
,	O
with	O
quetiapine	O
therapy	O
is	O
similar	O
to	O
that	O
with	O
placebo	O
.	O

A	O
male	O
neonate	O
with	O
a	O
Chiari	B
malformation	I
and	O
a	O
leaking	O
myelomeningocoele	O
underwent	O
ventriculoperitoneal	O
shunt	O
insertion	O
followed	O
by	O
repair	O
of	O
myelomeningocoele	O
.	O

Intravenous	O
phenytoin	O
was	O
administered	O
during	O
the	O
later	O
part	O
of	O
the	O
surgery	O
for	O
seizure	B
prophylaxis	O
.	O

Valproate	O
-	O
induced	O
chorea	B
and	O
encephalopathy	B
in	O
atypical	O
nonketotic	B
hyperglycinemia	I
.	O

Nonketotic	B
hyperglycinemia	I
is	O
a	O
disorder	B
of	I
amino	I
acid	I
metabolism	I
in	O
which	O
a	O
defect	O
in	O
the	O
glycine	O
cleavage	O
system	O
leads	O
to	O
an	O
accumulation	O
of	O
glycine	O
in	O
the	O
brain	O
and	O
other	O
body	O
compartments	O
.	O

In	O
the	O
classical	O
form	O
it	O
presents	O
as	O
neonatal	O
apnea	B
,	O
intractable	O
seizures	B
,	O
and	O
hypotonia	B
,	O
followed	O
by	O
significant	O
psychomotor	B
retardation	I
.	O

An	O
important	O
subset	O
of	O
children	O
with	O
nonketotic	B
hyperglycinemia	I
are	O
atypical	O
variants	O
who	O
present	O
in	O
a	O
heterogeneous	O
manner	O
.	O

This	O
report	O
describes	O
a	O
patient	O
with	O
mild	O
language	B
delay	I
and	O
mental	B
retardation	I
,	O
who	O
was	O
found	O
to	O
have	O
nonketotic	B
hyperglycinemia	I
following	O
her	O
presentation	O
with	O
acute	O
encephalopathy	B
and	O
chorea	B
shortly	O
after	O
initiation	O
of	O
valproate	O
therapy	O
.	O

Delayed	O
institution	O
of	O
hypertension	B
during	O
focal	O
cerebral	B
ischemia	I
:	O
effect	O
on	O
brain	B
edema	I
.	O

The	O
effect	O
of	O
induced	O
hypertension	B
instituted	O
after	O
a	O
2	O
-	O
h	O
delay	O
following	O
middle	B
cerebral	I
artery	I
occlusion	I
(	O
MCAO	B
)	O
on	O
brain	B
edema	I
formation	O
and	O
histochemical	O
injury	O
was	O
studied	O
.	O

Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	B
territory	O
)	O
.	O

The	O
extent	O
of	O
neuronal	B
injury	I
was	O
determined	O
by	O
2	O
,	O
3	O
,	O
5	O
-	O
triphenyltetrazolium	O
staining	O
.	O

In	O
the	O
ischemic	B
core	O
,	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O

In	O
the	O
periphery	O
of	O
the	O
ischemic	B
territory	O
,	O
SG	O
in	O
the	O
cortex	O
was	O
greater	O
(	O
less	O
edema	B
accumulation	O
)	O
in	O
the	O
hypertensive	B
group	O
(	O
1	O
.	O
041	O
+	O
/	O
-	O
0	O
.	O
001	O
vs	O
1	O
.	O
039	O
+	O
/	O
-	O
0	O
.	O
001	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
data	O
indicate	O
that	O
phenylephrine	O
-	O
induced	O
hypertension	B
instituted	O
2	O
h	O
after	O
MCAO	B
does	O
not	O
aggravate	O
edema	B
in	O
the	O
ischemic	B
core	O
,	O
that	O
it	O
improves	O
edema	B
in	O
the	O
periphery	O
of	O
the	O
ischemic	B
territory	O
,	O
and	O
that	O
it	O
reduces	O
the	O
area	O
of	O
histochemical	O
neuronal	B
dysfunction	I
.	O

Earlier	O
studies	O
have	O
demonstrated	O
that	O
antagonism	O
of	O
sigma1	O
receptors	O
attenuates	O
the	O
convulsive	B
,	O
lethal	O
,	O
locomotor	O
stimulatory	O
and	O
rewarding	O
actions	O
of	O
cocaine	O
in	O
mice	O
.	O

Cardiac	B
arrest	I
in	O
a	O
child	O
with	O
cerebral	B
palsy	I
undergoing	O
sevoflurane	O
induction	O
of	O
anesthesia	O
after	O
preoperative	O
clonidine	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
child	O
with	O
cerebral	B
palsy	I
and	O
seizure	B
disorder	I
,	O
receiving	O
clonidine	O
for	O
restlessness	B
,	O
who	O
presented	O
for	O
placement	O
of	O
a	O
baclofen	O
pump	O
.	O

Without	O
the	O
knowledge	O
of	O
the	O
medical	O
personnel	O
,	O
the	O
patient	O
'	O
s	O
mother	O
administered	O
three	O
doses	O
of	O
clonidine	O
during	O
the	O
evening	O
before	O
and	O
morning	O
of	O
surgery	O
to	O
reduce	O
anxiety	B
.	O

There	O
are	O
no	O
previous	O
reports	O
of	O
clonidine	O
-	O
associated	O
cardiac	B
arrest	I
in	O
a	O
child	O
undergoing	O
induction	O
of	O
anesthesia	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
-	O
associated	O
angioedema	B
of	O
the	O
stomach	O
and	O
small	O
intestine	O
:	O
a	O
case	O
report	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
(	O
ACEI	O
)	O
-	O
induced	O
angioedema	B
was	O
suspected	O
,	O
and	O
anti	O
-	O
hypertensive	B
medications	O
were	O
discontinued	O
.	O

Carbamazepine	O
-	O
induced	O
cardiac	B
dysfunction	I
.	O

A	O
patient	O
with	O
sinus	O
bradycardia	B
and	O
atrioventricular	B
block	I
,	O
induced	O
by	O
carbamazepine	O
,	O
prompted	O
an	O
extensive	O
literature	O
review	O
of	O
all	O
previously	O
reported	O
cases	O
.	O

From	O
the	O
analysis	O
of	O
these	O
cases	O
,	O
two	O
distinct	O
forms	O
of	O
carbamazepine	O
-	O
associated	O
cardiac	B
dysfunction	I
emerged	O
.	O

The	O
second	O
group	O
consisted	O
almost	O
exclusively	O
of	O
elderly	O
women	O
who	O
developed	O
potentially	O
life	O
-	O
threatening	O
bradyarrhythmias	B
or	O
atrioventricular	B
conduction	I
delay	I
,	O
associated	O
with	O
either	O
therapeutic	O
or	O
modestly	O
elevated	O
carbamazepine	O
serum	O
levels	O
.	O

Because	O
carbamazepine	O
is	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
many	O
neurologic	O
and	O
psychiatric	B
conditions	O
,	O
the	O
recognition	O
of	O
the	O
latter	O
syndrome	O
has	O
important	O
implications	O
for	O
the	O
use	O
of	O
this	O
drug	O
in	O
elderly	O
patients	O
.	O

Detection	O
of	O
abnormal	O
cardiac	O
adrenergic	O
neuron	O
activity	O
in	O
adriamycin	O
-	O
induced	O
cardiomyopathy	B
with	O
iodine	O
-	O
125	O
-	O
metaiodobenzylguanidine	O
.	O

Using	O
a	O
rat	O
model	O
of	O
adriamycin	O
-	O
induced	O
cardiomyopathy	B
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
abnormal	O
cardiac	O
adrenergic	O
neuron	O
activity	O
may	O
appear	O
and	O
be	O
exacerbated	O
dose	O
-	O
dependently	O
in	O
adriamycin	O
cardiomyopathy	B
.	O

The	O
degree	O
of	O
vacuolar	B
degeneration	I
of	I
myocardial	I
cells	I
was	O
analyzed	O
in	O
relation	O
to	O
the	O
duration	O
of	O
adriamycin	O
treatment	O
(	O
2	O
mg	O
/	O
kg	O
,	O
once	O
a	O
week	O
)	O
.	O

The	O
appearance	O
of	O
impaired	O
cardiac	O
adrenergic	O
neuron	O
activity	O
in	O
the	O
presence	O
of	O
slight	O
myocardial	B
impairment	I
(	O
scattered	O
or	O
focal	O
vacuolar	B
degeneration	I
)	O
indicates	O
that	O
MIBG	O
scintigraphy	O
may	O
be	O
a	O
useful	O
method	O
for	O
detection	O
of	O
adriamycin	O
-	O
induced	O
cardiomyopathy	B
.	O

Neuroleptic	B
malignant	I
syndrome	I
induced	O
by	O
ziprasidone	O
on	O
the	O
second	O
day	O
of	O
treatment	O
.	O

Neuroleptic	B
malignant	I
syndrome	I
(	O
NMS	B
)	O
is	O
the	O
rarest	O
and	O
most	O
serious	O
of	O
the	O
neuroleptic	O
-	O
induced	O
movement	B
disorders	I
.	O

We	O
describe	O
a	O
case	O
of	O
neuroleptic	B
malignant	I
syndrome	I
(	O
NMS	B
)	O
associated	O
with	O
the	O
use	O
of	O
ziprasidone	O
.	O

Peripheral	O
iron	O
dextran	O
induced	O
degeneration	B
of	I
dopaminergic	I
neurons	I
in	O
rat	O
substantia	O
nigra	O
.	O

Iron	O
accumulation	O
is	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	B
'	I
s	I
disease	I
.	O

To	O
demonstrate	O
the	O
relationship	O
between	O
peripheral	O
iron	O
overload	O
and	O
dopaminergic	O
neuron	O
loss	O
in	O
rat	O
substantia	O
nigra	O
(	O
SN	O
)	O
,	O
in	O
the	O
present	O
study	O
we	O
used	O
fast	O
cyclic	O
voltammetry	O
,	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
immunohistochemistry	O
,	O
Perls	O
'	O
iron	O
staining	O
,	O
and	O
high	O
performance	O
liquid	O
chromatography	O
-	O
electrochemical	O
detection	O
to	O
study	O
the	O
degeneration	B
of	I
dopaminergic	I
neurons	I
and	O
increased	O
iron	O
content	O
in	O
the	O
SN	O
of	O
iron	O
dextran	O
overloaded	O
animals	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
iron	O
dextran	O
can	O
increase	O
the	O
iron	O
level	O
in	O
the	O
SN	O
,	O
where	O
excessive	O
iron	O
causes	O
the	O
degeneration	B
of	I
dopaminergic	I
neurons	I
.	O

An	O
extremely	O
rare	O
case	O
of	O
delusional	B
parasitosis	I
in	O
a	O
chronic	B
hepatitis	I
C	I
patient	O
during	O
pegylated	O
interferon	O
alpha	O
-	O
2b	O
and	O
ribavirin	O
treatment	O
.	O

During	O
treatment	O
of	O
chronic	B
hepatitis	I
C	I
patients	O
with	O
interferon	O
and	O
ribavirin	O
,	O
a	O
lot	O
of	O
side	O
effects	O
are	O
described	O
.	O

Phenobarbital	O
(	O
PB	O
)	O
has	O
a	O
reputation	O
for	O
safety	O
,	O
and	O
it	O
is	O
commonly	O
believed	O
that	O
PB	O
-	O
related	O
increases	O
in	O
serum	O
aminotransferase	O
levels	O
do	O
not	O
indicate	O
or	O
predict	O
the	O
development	O
of	O
significant	O
chronic	O
liver	B
disease	I
.	O

Here	O
we	O
report	O
of	O
two	O
adult	O
patients	O
with	O
a	O
long	O
history	O
of	O
epilepsy	B
treated	O
with	O
PB	O
who	O
died	O
suddenly	O
:	O
one	O
as	O
consequence	O
of	O
cardiac	B
arrest	I
,	O
the	O
other	O
of	O
acute	O
bronchopneumonia	B
.	O

Our	O
findings	O
illustrate	O
that	O
PB	O
may	O
be	O
associated	O
with	O
chronic	O
liver	B
damage	I
,	O
which	O
may	O
lead	O
to	O
more	O
serious	O
and	O
deleterious	O
consequences	O
.	O

For	O
this	O
reason	O
,	O
each	O
clinician	O
should	O
recognize	O
this	O
entity	O
in	O
the	O
differential	O
diagnosis	O
of	O
PB	O
-	O
related	O
asymptomatic	O
chronic	B
hepatic	I
enzyme	I
dysfunction	I
.	O

Delayed	O
leukoencephalopathy	B
with	O
stroke	B
-	O
like	O
presentation	O
in	O
chemotherapy	O
recipients	O
.	O

BACKGROUND	O
:	O
A	O
transient	O
leukoencephalopathy	B
mimicking	O
cerebrovascular	B
accident	I
has	O
been	O
described	O
as	O
a	O
complication	O
of	O
chemotherapy	O
,	O
most	O
commonly	O
in	O
recipients	O
of	O
intrathecal	O
methotrexate	O
for	O
childhood	O
leukaemia	B
.	O

RESULTS	O
:	O
We	O
identified	O
27	O
reports	O
of	O
toxic	O
leukoencephalopathy	B
in	O
patients	O
treated	O
with	O
methotrexate	O
(	O
intrathecal	O
,	O
systemic	O
)	O
,	O
5	O
-	O
fluorouracil	O
and	O
its	O
derivative	O
carmofur	O
,	O
and	O
capecitabine	O
.	O

Diffusion	O
weighted	O
imaging	O
(	O
DWI	O
)	O
of	O
all	O
patients	O
revealed	O
well	O
demarcated	O
hyperintense	O
lesions	B
within	I
the	I
subcortical	I
white	I
matter	I
of	O
the	O
cerebral	O
hemispheres	O
and	O
the	O
corpus	O
callosum	O
,	O
corresponding	O
to	O
areas	O
of	O
decreased	O
proton	O
diffusion	O
on	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
maps	O
(	O
available	O
in	O
21	O
/	O
27	O
patients	O
)	O
.	O

However	O
,	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
sequences	O
frequently	O
revealed	O
persistent	O
white	B
matter	I
abnormalities	I
.	O

CONCLUSIONS	O
:	O
Several	O
pathophysiological	O
models	O
of	O
delayed	O
leukoencephalopathy	B
after	O
exposure	O
to	O
intrathecal	O
or	O
systemic	O
chemotherapy	O
have	O
been	O
proposed	O
.	O

DWI	O
findings	O
in	O
this	O
cohort	O
are	O
indicative	O
of	O
cytotoxic	B
oedema	I
within	I
cerebral	I
white	I
matter	I
and	O
lend	O
support	O
to	O
an	O
at	O
least	O
partially	O
reversible	O
metabolic	O
derangement	O
as	O
the	O
basis	O
for	O
this	O
syndrome	O
.	O

Epidemiological	O
data	O
suggest	O
that	O
fluoxetine	O
exposure	O
prenatally	O
increases	O
the	O
prevalence	O
of	O
persistent	O
pulmonary	B
hypertension	I
syndrome	I
of	O
the	O
newborn	O
.	O

Disulfiram	O
-	O
induced	O
transient	O
optic	B
and	I
peripheral	I
neuropathy	I
:	O
a	O
case	O
report	O
.	O

AIM	O
:	O
To	O
report	O
a	O
case	O
of	O
optic	B
and	I
peripheral	I
neuropathy	I
after	O
chronic	O
use	O
of	O
disulfiram	O
for	O
alcohol	B
dependence	I
management	O
.	O

RESULTS	O
:	O
A	O
57	O
-	O
year	O
-	O
old	O
male	O
presented	O
with	O
gradual	O
loss	B
of	I
vision	I
in	O
both	O
eyes	O
with	O
intermittent	O
headaches	B
for	O
2	O
months	O
.	O

Myocardial	O
Fas	O
ligand	O
expression	O
increases	O
susceptibility	O
to	O
AZT	O
-	O
induced	O
cardiomyopathy	B
.	O

BACKGROUND	O
:	O
Dilated	B
cardiomyopathy	I
(	O
DCM	B
)	O
and	O
myocarditis	B
occur	O
in	O
many	O
HIV	B
-	I
infected	I
individuals	O
,	O
resulting	O
in	O
symptomatic	O
heart	B
failure	I
in	O
up	O
to	O
5	O
%	O
of	O
patients	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
significantly	O
reduced	O
morbidity	O
and	O
mortality	O
of	O
acquired	B
immunodeficiency	I
syndrome	I
(	O
AIDS	B
)	O
,	O
but	O
has	O
resulted	O
in	O
an	O
increase	O
in	O
cardiac	B
and	I
skeletal	I
myopathies	I
.	O

In	O
contrast	O
,	O
AZT	O
-	O
treated	O
FasL	O
Tg	O
mice	O
developed	O
cardiac	B
dilation	I
and	O
depressed	O
cardiac	O
function	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
concomitant	O
inflammatory	O
infiltration	O
of	O
both	O
ventricles	O
.	O

CONCLUSIONS	O
:	O
The	O
expression	O
of	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
,	O
as	O
identified	O
in	O
HIV	O
-	O
positive	O
patients	O
,	O
might	O
increase	O
the	O
susceptibility	O
to	O
HAART	O
-	O
induced	O
cardiomyopathy	B
due	O
to	O
activation	O
of	O
apoptotic	O
pathways	O
,	O
resulting	O
in	O
cardiac	B
dilation	I
and	I
dysfunction	I
.	O

Gastrointestinal	O
tolerability	O
of	O
etoricoxib	O
in	O
rheumatoid	B
arthritis	I
patients	O
:	O
results	O
of	O
the	O
etoricoxib	O
vs	O
diclofenac	O
sodium	O
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE	O
-	O
II	O
)	O
.	O

OBJECTIVE	O
:	O
A	O
randomised	O
,	O
double	O
-	O
blind	O
study	O
to	O
compare	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tolerability	O
,	O
safety	O
and	O
efficacy	O
of	O
etoricoxib	O
and	O
diclofenac	O
in	O
patients	O
with	O
rheumatoid	B
arthritis	I
(	O
RA	B
)	O
.	O

General	O
safety	O
was	O
also	O
assessed	O
,	O
including	O
adjudicated	O
thrombotic	B
cardiovascular	I
event	O
data	O
.	O

Spontaneous	O
coronary	B
thrombosis	I
or	O
thromboembolism	B
with	O
subsequent	O
clot	O
lysis	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
myocardial	B
infarction	I
(	O
MI	B
)	O
during	O
pregnancy	O
,	O
with	O
a	O
subsequently	O
normal	O
coronary	O
angiogram	O
.	O

At	O
the	O
time	O
of	O
admission	O
,	O
the	O
patient	O
was	O
at	O
high	O
risk	O
of	O
radiation	B
injury	I
to	O
the	O
fetus	O
,	O
so	O
a	O
coronary	O
angiogram	O
was	O
postponed	O
until	O
the	O
second	O
trimester	O
.	O

Reverse	O
or	O
inverted	O
left	B
ventricular	I
apical	I
ballooning	I
syndrome	I
(	O
reverse	O
Takotsubo	B
cardiomyopathy	I
)	O
in	O
a	O
young	O
woman	O
in	O
the	O
setting	O
of	O
amphetamine	O
use	O
.	O

Transient	O
left	B
ventricular	I
apical	I
ballooning	I
syndrome	I
was	O
first	O
described	O
in	O
Japan	O
as	O
"	O
Takotsubo	B
cardiomyopathy	I
.	O
"	O
This	O
syndrome	O
has	O
been	O
identified	O
in	O
many	O
other	O
countries	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
an	O
interesting	O
case	O
of	O
a	O
young	O
woman	O
who	O
presented	O
with	O
this	O
rare	O
type	O
of	O
reverse	O
apical	B
ballooning	I
syndrome	I
occurring	O
after	O
amphetamine	O
use	O
.	O

The	O
incidences	O
of	O
headache	B
,	O
dizziness	B
,	O
and	O
diarrhea	B
were	O
similar	O
between	O
the	O
2	O
groups	O
.	O

Increased	O
mental	B
slowing	I
associated	O
with	O
the	O
APOE	O
epsilon4	O
allele	O
after	O
trihexyphenidyl	O
oral	O
anticholinergic	O
challenge	O
in	O
healthy	O
elderly	O
.	O

RESULTS	O
:	O
A	O
2	O
.	O
0	O
-	O
mg	O
oral	O
dose	O
of	O
trihexyphenidyl	O
resulted	O
in	O
increased	O
subjective	O
ratings	O
of	O
mental	B
slowness	I
in	O
carriers	O
of	O
the	O
APOE	O
epsilon4	O
allele	O
only	O
.	O

Drug	O
effects	O
as	O
determined	O
by	O
difference	O
scores	O
between	O
2	O
.	O
0	O
mg	O
trihexyphenidyl	O
and	O
placebo	O
on	O
ratings	O
of	O
mental	B
slowness	I
significantly	O
correlated	O
with	O
total	O
and	O
delayed	O
recall	O
on	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
in	O
carriers	O
of	O
the	O
APOE	O
epsilon4	O
allele	O
only	O
.	O

CONCLUSION	O
:	O
The	O
epsilon4	O
allele	O
in	O
healthy	O
elderly	O
was	O
associated	O
with	O
increased	O
subjective	O
mental	B
slowing	I
after	O
trihexyphenidyl	O
anticholinergic	O
challenge	O
.	O

Forty	O
patients	O
with	O
a	O
diagnosis	O
consistent	O
with	O
a	O
hematologic	B
/	I
oncologic	I
disorder	I
that	O
required	O
treatment	O
with	O
an	O
aminoglycoside	O
were	O
randomized	O
to	O
either	O
conventional	O
or	O
extended	O
-	O
interval	O
amikacin	O
.	O

Hepatotoxicity	B
associated	O
with	O
sulfasalazine	O
in	O
inflammatory	O
arthritis	B
:	O
A	O
case	O
series	O
from	O
a	O
local	O
surveillance	O
of	O
serious	O
adverse	O
events	O
.	O

We	O
report	O
an	O
investigation	O
from	O
a	O
local	O
surveillance	O
for	O
serious	O
adverse	O
drug	O
reactions	O
associated	O
with	O
disease	O
modifying	O
anti	O
-	O
rheumatic	O
drugs	O
that	O
was	O
triggered	O
by	O
the	O
occurrence	O
of	O
liver	B
failure	I
in	O
two	O
of	O
our	O
patients	O
.	O

Eight	O
patients	O
were	O
hospitalised	O
,	O
two	O
in	O
hepatic	B
failure	I
-	O
one	O
died	O
after	O
a	O
liver	O
transplant	O
.	O

Seven	O
patients	O
had	O
a	O
skin	B
rash	I
,	O
three	O
eosinophilia	B
and	O
one	O
interstitial	B
nephritis	I
.	O

Complete	O
atrioventricular	B
block	I
secondary	O
to	O
lithium	O
therapy	O
.	O

Sinus	B
node	I
dysfunction	I
has	O
been	O
reported	O
most	O
frequently	O
among	O
the	O
adverse	O
cardiovascular	O
effects	O
of	O
lithium	O
.	O

In	O
the	O
present	O
case	O
,	O
complete	O
atrioventricular	B
(	I
AV	I
)	I
block	I
with	O
syncopal	B
attacks	I
developed	O
secondary	O
to	O
lithium	O
therapy	O
,	O
necessitating	O
permanent	O
pacemaker	O
implantation	O
.	O

Serum	O
lithium	O
levels	O
remained	O
under	O
or	O
within	O
the	O
therapeutic	O
range	O
during	O
the	O
syncopal	B
attacks	I
.	O

The	O
data	O
suggest	O
that	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
bladder	B
inflammation	I
,	O
inflammatory	O
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	O
.	O

This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	B
dysfunction	I
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
bladder	B
inflammation	I
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O

Oxytocin	O
-	O
induced	O
hypotension	B
at	O
cesarean	O
delivery	O
may	O
be	O
incorrectly	O
attributed	O
to	O
blood	B
loss	I
.	O

We	O
investigated	O
the	O
effects	O
of	O
antithrombin	O
,	O
a	O
plasma	O
inhibitor	O
of	O
coagulation	O
factors	O
,	O
in	O
rats	O
with	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrosis	B
,	O
which	O
is	O
an	O
experimental	O
model	O
of	O
human	O
nephrotic	B
syndrome	I
.	O

Treatment	O
with	O
antithrombin	O
attenuated	O
the	O
puromycin	O
aminonucleoside	O
-	O
induced	O
hematological	B
abnormalities	I
.	O

Puromycin	O
aminonucleoside	O
-	O
induced	O
renal	B
dysfunction	I
and	O
hyperlipidemia	B
were	O
also	O
suppressed	O
.	O

Histopathological	O
examination	O
revealed	O
severe	O
renal	B
damage	I
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	O
expansion	O
in	O
the	O
kidney	O
of	O
control	O
rats	O
,	O
while	O
an	O
improvement	O
of	O
the	O
damage	O
was	O
seen	O
in	O
antithrombin	O
-	O
treated	O
rats	O
.	O

These	O
findings	O
suggest	O
that	O
thrombin	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrotic	B
syndrome	I
.	O

Treatment	O
with	O
antithrombin	O
may	O
be	O
clinically	O
effective	O
in	O
patients	O
with	O
nephrotic	B
syndrome	I
.	O

Heparin	O
-	O
induced	O
thrombocytopenia	B
after	O
liver	O
transplantation	O
.	O

BACKGROUND	O
:	O
Unfractionated	O
heparin	O
sodium	O
(	O
UFH	O
)	O
or	O
low	O
-	O
molecular	O
weight	O
heparin	O
(	O
LMWH	O
)	O
is	O
used	O
in	O
anticoagulant	O
protocols	O
at	O
several	O
institutions	O
to	O
prevent	O
thrombosis	B
after	O
liver	O
transplantation	O
.	O

Heparin	O
-	O
induced	O
thrombocytopenia	B
(	O
HIT	B
)	O
is	O
an	O
adverse	O
immune	O
-	O
mediated	O
reaction	O
to	O
heparin	O
,	O
resulting	O
in	O
platelet	O
count	O
decreases	O
of	O
more	O
than	O
50	O
%	O
.	O

Two	O
patients	O
developed	O
hepatic	O
artery	O
thrombosis	B
on	O
POD	O
11	O
and	O
19	O
,	O
respectively	O
,	O
although	O
they	O
were	O
HIT	B
antibody	O
-	O
negative	O
and	O
their	O
platelet	O
counts	O
were	O
stable	O
.	O

Doxorubicin	O
cardiomyopathy	B
-	O
induced	O
inflammation	B
and	O
apoptosis	O
are	O
attenuated	O
by	O
gene	O
deletion	O
of	O
the	O
kinin	O
B1	O
receptor	O
.	O

To	O
elucidate	O
the	O
possible	O
role	O
of	O
the	O
kinin	O
B1	O
receptor	O
(	O
B1R	O
)	O
during	O
the	O
development	O
of	O
DOX	O
cardiomyopathy	B
,	O
we	O
studied	O
B1R	O
knockout	O
mice	O
(	O
B1R	O
(	O
-	O
/	O
-	O
)	O
)	O
by	O
investigating	O
cardiac	O
inflammation	B
and	O
apoptosis	O
after	O
induction	O
of	O
DOX	O
-	O
induced	O
cardiomyopathy	B
.	O

DOX	O
control	O
mice	O
showed	O
cardiac	B
dysfunction	I
measured	O
by	O
pressure	O
-	O
volume	O
loops	O
in	O
vivo	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduced	O
activation	O
state	O
of	O
AKT	O
,	O
as	O
well	O
as	O
an	O
increased	O
bax	O
/	O
bcl2	O
ratio	O
in	O
Western	O
blots	O
,	O
indicating	O
cardiac	B
apoptosis	I
.	O

In	O
DOX	O
B1R	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
cardiac	B
dysfunction	I
was	O
improved	O
compared	O
to	O
DOX	O
control	O
mice	O
,	O
which	O
was	O
associated	O
with	O
normalization	O
of	O
the	O
bax	O
/	O
bcl	O
-	O
2	O
ratio	O
and	O
interleukin	O
6	O
,	O
as	O
well	O
as	O
AKT	O
activation	O
state	O
.	O

These	O
findings	O
suggest	O
that	O
B1R	O
is	O
detrimental	O
in	O
DOX	O
cardiomyopathy	B
in	O
that	O
it	O
mediates	O
the	O
inflammatory	O
response	O
and	O
apoptosis	O
.	O

These	O
insights	O
might	O
have	O
useful	O
implications	O
for	O
future	O
studies	O
utilizing	O
B1R	O
antagonists	O
for	O
treatment	O
of	O
human	O
DOX	O
cardiomyopathy	B
.	O

Detailed	O
spectral	O
profile	O
analysis	O
of	O
penicillin	O
-	O
induced	O
epileptiform	B
activity	I
in	O
anesthetized	O
rats	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
portray	O
a	O
detailed	O
spectral	O
analysis	O
of	O
penicillin	O
-	O
induced	O
epileptiform	B
activity	I
in	O
comparison	O
with	O
basal	O
brain	O
activity	O
in	O
anesthetized	O
Wistar	O
rats	O
.	O

Basal	O
activity	O
,	O
latent	O
period	O
and	O
the	O
penicillin	O
-	O
induced	O
epileptiform	B
activity	I
periods	O
were	O
then	O
analyzed	O
using	O
both	O
conventional	O
methods	O
and	O
spectral	O
analysis	O
.	O

Our	O
results	O
show	O
that	O
the	O
most	O
affected	O
frequency	O
bands	O
were	O
delta	O
,	O
theta	O
,	O
beta	O
-	O
2	O
and	O
gamma	O
-	O
2	O
bands	O
during	O
the	O
epileptiform	B
activity	I
and	O
there	O
were	O
marked	O
differences	O
in	O
terms	O
of	O
spectral	O
densities	O
between	O
three	O
investigated	O
episodes	O
(	O
basal	O
activity	O
,	O
latent	O
period	O
and	O
epileptiform	B
activity	I
)	O
.	O

High	O
fat	O
diet	O
-	O
fed	O
obese	B
rats	O
are	O
highly	O
sensitive	O
to	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40	O
%	O
high	O
fat	O
diet	O
(	O
HFD	O
)	O
,	O
which	O
induces	O
obesity	B
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
(	O
250	O
-	O
275	O
g	O
)	O
,	O
sensitizes	O
to	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
.	O

A	O
LD	O
(	O
10	O
)	O
dose	O
(	O
8	O
mg	O
doxorubicin	O
/	O
kg	O
,	O
ip	O
)	O
administered	O
on	O
day	O
43	O
of	O
the	O
HFD	O
feeding	O
regimen	O
led	O
to	O
higher	O
cardiotoxicity	B
,	O
cardiac	B
dysfunction	I
,	O
lipid	O
peroxidation	O
,	O
and	O
80	O
%	O
mortality	O
in	O
the	O
obese	B
(	O
OB	B
)	O
rats	O
in	O
the	O
absence	O
of	O
any	O
significant	O
renal	B
or	I
hepatic	I
toxicity	I
.	O

In	O
conclusion	O
,	O
HFD	O
-	O
induced	O
obese	B
rats	O
are	O
highly	O
sensitized	O
to	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B
by	O
substantially	O
downregulating	O
cardiac	O
mitochondrial	O
ATP	O
generation	O
,	O
increasing	O
oxidative	O
stress	O
and	O
downregulating	O
the	O
JAK	O
/	O
STAT3	O
pathway	O
.	O

Isoproterenol	O
induces	O
primary	O
loss	O
of	O
dystrophin	O
in	O
rat	O
hearts	O
:	O
correlation	O
with	O
myocardial	B
injury	I
.	O

The	O
mechanism	O
of	O
isoproterenol	O
-	O
induced	O
myocardial	B
damage	I
is	O
unknown	O
,	O
but	O
a	O
mismatch	O
of	O
oxygen	O
supply	O
vs	O
.	O
demand	O
following	O
coronary	O
hypotension	B
and	O
myocardial	B
hyperactivity	I
is	O
the	O
best	O
explanation	O
for	O
the	O
complex	O
morphological	O
alterations	O
observed	O
.	O

These	O
changes	O
,	O
related	O
to	O
ischaemic	B
injury	I
,	O
explain	O
the	O
severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	O
and	O
irreversible	O
injury	O
induced	O
by	O
isoproterenol	O
.	O

Etiologic	O
factors	O
in	O
the	O
pathogenesis	O
of	O
liver	B
tumors	I
associated	O
with	O
oral	O
contraceptives	O
.	O

Within	O
the	O
last	O
several	O
years	O
,	O
previously	O
rare	O
liver	B
tumors	I
have	O
been	O
seen	O
in	O
young	O
women	O
using	O
oral	O
contraceptive	O
steroids	O
.	O

Common	O
to	O
these	O
71	O
cases	O
has	O
been	O
a	O
histopathologic	O
diagnosis	O
of	O
focal	B
nodular	I
hyperplasia	I
,	O
adenoma	B
,	O
hamartoma	B
,	O
and	O
hepatoma	B
.	O

Suboptimal	O
seizure	B
duration	O
is	O
commonly	O
encountered	O
in	O
electroconvulsive	O
therapy	O
practice	O
,	O
especially	O
in	O
older	O
patients	O
with	O
higher	O
seizure	B
thresholds	O
.	O

Intravenous	O
caffeine	O
is	O
commonly	O
used	O
to	O
improve	O
seizure	B
duration	O
and	O
quality	O
in	O
such	O
patients	O
and	O
is	O
generally	O
well	O
tolerated	O
aside	O
from	O
occasional	O
reports	O
of	O
relatively	O
benign	O
ventricular	B
ectopy	I
.	O

We	O
describe	O
a	O
patient	O
with	O
no	O
previous	O
history	O
of	O
cardiac	B
disease	I
or	O
arrhythmia	B
who	O
developed	O
sustained	O
bigeminy	O
and	O
2	O
brief	O
runs	O
of	O
ventricular	B
tachycardia	I
after	O
caffeine	O
administration	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
varying	O
the	O
intraperitoneal	O
infusion	O
rates	O
of	O
bupropion	O
HCl	O
120	O
mg	O
/	O
kg	O
,	O
a	O
known	O
convulsive	B
dose	O
50	O
(	O
CD50	O
)	O
,	O
on	O
the	O
incidence	O
and	O
severity	O
of	O
bupropion	O
-	O
induced	O
convulsions	B
in	O
the	O
Swiss	O
albino	O
mice	O
.	O

CONCLUSION	O
:	O
In	O
conclusion	O
,	O
the	O
demonstration	O
of	O
an	O
inverse	O
relationship	O
between	O
infusion	O
time	O
of	O
a	O
fixed	O
and	O
convulsive	B
dose	O
of	O
bupropion	O
and	O
the	O
risk	O
of	O
convulsions	B
in	O
a	O
prospective	O
study	O
is	O
novel	O
.	O

Graft	B
-	I
versus	I
-	I
host	I
disease	I
prophylaxis	O
with	O
everolimus	O
and	O
tacrolimus	O
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
sinusoidal	B
obstruction	I
syndrome	I
and	O
microangiopathy	B
:	O
results	O
of	O
the	O
EVTAC	O
trial	O
.	O

A	O
calcineurin	O
inhibitor	O
combined	O
with	O
methotrexate	O
is	O
the	O
standard	O
prophylaxis	O
for	O
graft	B
-	I
versus	I
-	I
host	I
disease	I
(	O
GVHD	B
)	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
.	O

We	O
report	O
on	O
a	O
combination	O
of	O
everolimus	O
and	O
tacrolimus	O
in	O
24	O
patients	O
(	O
median	O
age	O
,	O
62	O
years	O
)	O
with	O
either	O
myelodysplastic	B
syndrome	I
(	O
MDS	B
;	O
n	O
=	O
17	O
)	O
or	O
acute	B
myeloid	I
leukemia	I
(	O
AML	B
;	O
n	O
=	O
7	O
)	O
undergoing	O
intensive	O
conditioning	O
followed	O
by	O
HSCT	O
from	O
related	O
(	O
n	O
=	O
4	O
)	O
or	O
unrelated	O
(	O
n	O
=	O
20	O
)	O
donors	O
.	O

Transplantation	B
-	I
associated	I
microangiopathy	I
(	O
TMA	B
)	O
occurred	O
in	O
7	O
patients	O
(	O
29	O
%	O
)	O
,	O
with	O
2	O
cases	O
of	O
acute	B
renal	I
failure	I
.	O

The	O
study	O
was	O
terminated	O
prematurely	O
because	O
an	O
additional	O
6	O
patients	O
(	O
25	O
%	O
)	O
developed	O
sinusoidal	B
obstruction	I
syndrome	I
(	O
SOS	B
)	O
,	O
which	O
was	O
fatal	O
in	O
2	O
cases	O
.	O

Longitudinal	O
assessment	O
of	O
air	O
conduction	O
audiograms	O
in	O
a	O
phase	O
III	O
clinical	O
trial	O
of	O
difluoromethylornithine	O
and	O
sulindac	O
for	O
prevention	O
of	O
sporadic	O
colorectal	B
adenomas	I
.	O

A	O
phase	O
III	O
clinical	O
trial	O
assessed	O
the	O
recurrence	O
of	O
adenomatous	B
polyps	I
after	O
treatment	O
for	O
36	O
months	O
with	O
difluoromethylornithine	O
(	O
DFMO	O
)	O
plus	O
sulindac	O
or	O
matched	O
placebos	O
.	O

Temporary	O
hearing	B
loss	I
is	O
a	O
known	O
toxicity	B
of	O
treatment	O
with	O
DFMO	O
,	O
thus	O
a	O
comprehensive	O
approach	O
was	O
developed	O
to	O
analyze	O
serial	O
air	O
conduction	O
audiograms	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
proportion	O
of	O
subjects	O
in	O
the	O
DFMO	O
plus	O
sulindac	O
group	O
who	O
experienced	O
clinically	O
significant	O
hearing	B
loss	I
compared	O
with	O
the	O
placebo	O
group	O
.	O

Proteinase	O
3	O
-	O
antineutrophil	O
cytoplasmic	O
antibody	O
-	O
(	O
PR3	O
-	O
ANCA	O
)	O
positive	O
necrotizing	O
glomerulonephritis	B
after	O
restarting	O
sulphasalazine	O
treatment	O
.	O

A	O
59	O
-	O
year	O
-	O
old	O
woman	O
with	O
ulcerative	B
colitis	I
developed	O
red	B
eyes	I
,	O
pleural	B
effusion	I
,	O
eosinophilia	B
and	O
urinary	B
abnormalities	I
after	O
restarting	O
of	O
sulphasalazine	O
treatment	O
.	O

Light	O
microscopy	O
of	O
a	O
kidney	O
biopsy	O
revealed	O
segmental	B
necrotizing	I
glomerulonephritis	I
without	O
deposition	O
of	O
immunoglobulin	O
or	O
complement	O
.	O

Although	O
cessation	O
of	O
sulphasalazine	O
treatment	O
resulted	O
in	O
improvements	O
in	O
fever	B
,	O
red	B
eyes	I
,	O
chest	B
pain	I
,	O
titer	O
of	O
C	O
-	O
reactive	O
protein	O
and	O
volume	O
of	O
the	O
pleural	B
effusions	I
,	O
we	O
initiated	O
steroid	O
therapy	O
,	O
because	O
PR3	O
-	O
ANCA	O
titer	O
rose	O
to	O
320	O
EU	O
,	O
eosinophil	O
count	O
increased	O
to	O
1	O
,	O
100	O
cells	O
/	O
microl	O
,	O
and	O
the	O
pleural	B
effusion	I
remained	O
.	O

This	O
case	O
suggests	O
that	O
sulphasalazine	O
can	O
induce	O
PR3	O
-	O
ANCA	O
-	O
positive	O
necrotizing	O
glomerulonephritis	B
.	O

Comparison	O
of	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
findings	O
in	O
advanced	O
idiopathic	B
Parkinson	I
'	I
s	I
disease	I
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
pilot	O
study	O
to	O
compare	O
the	O
results	O
of	O
stereotactic	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
in	O
advanced	O
idiopathic	B
Parkinson	I
'	I
s	I
disease	I
(	O
PD	B
)	O
refractory	O
to	O
medical	O
treatment	O
was	O
designed	O
.	O

Clinical	O
evaluation	O
included	O
the	O
use	O
of	O
the	O
Unified	O
Parkinson	B
'	I
s	I
Disease	I
Rating	O
Scale	O
(	O
UPDRS	O
)	O
,	O
Hoehn	O
_	O
Yahr	O
score	O
and	O
Schwab	O
England	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
score	O
in	O
'	O
on	O
'	O
-	O
and	O
'	O
off	O
'	O
-	O
drug	O
conditions	O
before	O
surgery	O
and	O
6	O
months	O
after	O
surgery	O
.	O

A	O
clinical	O
trial	O
was	O
initiated	O
to	O
evaluate	O
the	O
recommended	O
dose	O
of	O
cyclophosphamide	O
in	O
combination	O
with	O
bortezomib	O
and	O
dexamethasone	O
as	O
induction	O
treatment	O
before	O
stem	O
cell	O
transplantation	O
for	O
younger	O
patients	O
with	O
newly	O
diagnosed	O
multiple	B
myeloma	I
(	O
MM	B
)	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
were	O
hematological	B
and	I
gastrointestinal	I
toxicities	I
as	O
well	O
as	O
neuropathy	B
.	O

5	O
flourouracil	O
-	O
induced	O
apical	B
ballooning	I
syndrome	I
:	O
a	O
case	O
report	O
.	O

The	O
apical	B
ballooning	I
syndrome	I
(	O
ABS	B
)	O
is	O
a	O
recently	O
described	O
stress	O
-	O
mediated	O
acute	B
cardiac	I
syndrome	I
characterized	O
by	O
transient	O
wall	O
-	O
motion	O
abnormalities	O
involving	O
the	O
apex	O
and	O
midventricle	O
with	O
hyperkinesis	B
of	O
the	O
basal	O
left	O
ventricular	O
(	O
LV	O
)	O
segments	O
without	O
obstructive	O
epicardial	B
coronary	I
disease	I
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
woman	O
who	O
developed	O
the	O
syndrome	O
after	O
chemotherapy	O
for	O
metastatic	O
cancer	B
.	O

A	O
79	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
typical	O
ischemic	B
chest	B
pain	I
,	O
elevated	O
cardiac	O
enzymes	O
with	O
significant	O
ST	O
-	O
segment	O
abnormalities	O
on	O
her	O
electrocardiogram	O
.	O

She	O
underwent	O
recent	O
chemotherapy	O
with	O
fluorouracil	O
for	O
metastatic	O
colorectal	B
cancer	I
.	O

Pathogenetic	O
mechanisms	O
of	O
cardiac	B
complications	I
in	O
cancer	B
patients	O
undergoing	O
chemotherapy	O
include	O
coronary	B
vasospasm	I
,	O
endothelial	O
damage	O
and	O
consequent	O
thrombus	B
formation	O
.	O

In	O
our	O
patient	O
,	O
both	O
supraphysiologic	O
levels	O
of	O
plasma	O
catecholamines	O
and	O
stress	O
related	O
neuropeptides	O
caused	O
by	O
cancer	B
diagnosis	O
as	O
well	O
as	O
chemotherapy	O
may	O
have	O
contributed	O
the	O
development	O
of	O
ABS	B
.	O

BACKGROUND	O
:	O
Hormone	O
therapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	O
symptoms	O
and	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	B
disease	I
,	O
osteoporosis	B
and	O
dementia	B
in	O
older	O
women	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortality	O
,	O
cardiovascular	O
outcomes	O
,	O
cancer	B
,	O
gallbladder	B
disease	I
,	O
cognition	O
,	O
fractures	B
and	O
quality	O
of	O
life	O
.	O

In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B
thrombo	I
-	I
embolism	I
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
'	O
s	O
use	O
)	O
,	O
stroke	B
(	O
after	O
three	O
years	O
)	O
,	O
breast	B
cancer	I
and	O
gallbladder	B
disease	I
.	O

Long	O
-	O
term	O
oestrogen	O
-	O
only	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B
thrombo	I
-	I
embolism	I
,	O
stroke	B
and	O
gallbladder	B
disease	I
(	O
after	O
one	O
to	O
two	O
years	O
,	O
three	O
years	O
and	O
seven	O
years	O
'	O
use	O
respectively	O
)	O
,	O
but	O
did	O
not	O
significantly	O
increase	O
the	O
risk	O
of	O
breast	B
cancer	I
.	O

The	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	B
and	O
(	O
for	O
combined	O
HT	O
)	O
colon	B
cancer	I
,	O
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
women	O
with	O
cardiovascular	B
disease	I
,	O
long	O
-	O
term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B
thrombo	I
-	I
embolism	I
.	O
One	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year	O
old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen	O
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
sized	O
placebo	O
groups	O
.	O

The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	B
thrombo	I
-	I
embolism	I
in	O
women	O
taking	O
combined	O
continuous	O
HT	O
:	O
their	O
absolute	O
risk	O
remained	O
low	O
,	O
at	O
less	O
than	O
1	O
/	O
500	O
.	O

Acute	B
renal	I
failure	I
in	O
patients	O
with	O
AIDS	B
on	O
tenofovir	O
while	O
receiving	O
prolonged	O
vancomycin	O
course	O
for	O
osteomyelitis	B
.	O

Renal	B
failure	I
developed	O
after	O
a	O
prolonged	O
course	O
of	O
vancomycin	O
therapy	O
in	O
2	O
patients	O
who	O
were	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
as	O
part	O
of	O
an	O
antiretroviral	O
regimen	O
.	O

Tenofovir	O
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
Fanconi	B
syndrome	I
and	O
renal	B
insufficiency	I
because	O
of	O
its	O
effects	O
on	O
the	O
proximal	O
renal	O
tubule	O
.	O

Clinicians	O
should	O
be	O
aware	O
that	O
tenofovir	O
may	O
raise	O
the	O
risk	O
of	O
renal	B
failure	I
during	O
prolonged	O
administration	O
of	O
vancomycin	O
.	O

Pyrazinamide	O
can	O
have	O
adverse	O
effects	O
such	O
as	O
hepatic	B
toxicity	I
,	O
hyperuricemia	B
or	O
digestive	O
disorders	O
.	O

We	O
report	O
a	O
case	O
of	O
reversible	O
olfactory	B
disorder	I
related	O
to	O
pyrazinamide	O
in	O
a	O
woman	O
,	O
with	O
a	O
positive	O
rechallenge	O
.	O

The	O
current	O
data	O
showed	O
that	O
pilocarpine	O
significantly	O
delayed	O
onset	O
of	O
arrhythmias	B
,	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	B
tachycardia	I
and	I
fibrillation	I
,	O
reduced	O
arrhythmia	B
score	O
,	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	B
rats	O
and	O
guinea	O
pigs	O
.	O

Dynamic	O
response	O
of	O
blood	O
vessel	O
in	O
acute	B
renal	I
failure	I
.	O

In	O
this	O
study	O
we	O
postulated	O
that	O
during	O
acute	B
renal	I
failure	I
induced	O
by	O
gentamicin	O
the	O
transient	O
or	O
dynamic	O
response	O
of	O
blood	O
vessels	O
could	O
be	O
affected	O
,	O
and	O
that	O
antioxidants	O
can	O
prevent	O
the	O
changes	O
in	O
dynamic	O
responses	O
of	O
blood	O
vessels	O
.	O

Reversible	O
myocardial	B
hypertrophy	I
induced	O
by	O
tacrolimus	O
in	O
a	O
pediatric	O
heart	O
transplant	O
recipient	O
:	O
case	O
report	O
.	O

However	O
,	O
adverse	O
effects	O
include	O
cardiac	B
toxicity	I
.	O

Herein	O
we	O
describe	O
transient	O
myocardial	B
hypertrophy	I
induced	O
by	O
tacrolimus	O
after	O
heart	O
transplantation	O
.	O

Initially	O
,	O
allograft	O
rejection	O
was	O
feared	O
;	O
however	O
,	O
myocardial	O
biopsy	O
samples	O
revealed	O
only	O
interstitial	O
edema	B
and	O
mild	O
myocardial	B
hypertrophy	I
;	O
neither	O
cellular	O
nor	O
humoral	O
rejection	O
was	O
detected	O
.	O

Myocardial	B
hypertrophy	I
completely	O
resolved	O
upon	O
reducing	O
the	O
target	O
concentration	O
of	O
tacrolimus	O
and	O
did	O
not	O
recur	O
,	O
as	O
confirmed	O
at	O
echocardiography	O
and	O
myocardial	O
biopsy	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
tacrolimus	O
induces	O
reversible	O
myocardial	B
hypertrophy	I
.	O

Nimodipine	O
prevents	O
memory	B
impairment	I
caused	O
by	O
nitroglycerin	O
-	O
induced	O
hypotension	B
in	O
adult	O
mice	O
.	O

BACKGROUND	O
:	O
Hypotension	B
and	O
a	O
resultant	O
decrease	O
in	O
cerebral	O
blood	O
flow	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
cognitive	B
dysfunction	I
.	O

Metabotropic	O
glutamate	O
7	O
receptor	O
subtype	O
modulates	O
motor	O
symptoms	O
in	O
rodent	O
models	O
of	O
Parkinson	B
'	I
s	I
disease	I
.	O

Metabotropic	O
glutamate	O
(	O
mGlu	O
)	O
receptors	O
modulate	O
synaptic	O
transmission	O
in	O
the	O
central	O
nervous	O
system	O
and	O
represent	O
promising	O
therapeutic	O
targets	O
for	O
symptomatic	O
treatment	O
of	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
.	O

Sorafenib	O
-	O
induced	O
acute	O
myocardial	B
infarction	I
due	O
to	O
coronary	B
artery	I
spasm	I
.	O

A	O
65	O
-	O
year	O
-	O
old	O
man	O
with	O
advanced	O
renal	B
cell	I
carcinoma	I
was	O
admitted	O
due	O
to	O
continuing	O
chest	B
pain	I
at	O
rest	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
sorafenib	O
-	O
induced	O
coronary	B
artery	I
spasm	I
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
Rho	O
/	O
ROCK	O
pathway	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
coronary	B
artery	I
spasm	I
.	O

Tacrine	O
,	O
administered	O
in	O
LiCl	O
pre	O
-	O
treated	O
rats	O
,	O
induces	O
electrocorticographic	O
seizures	B
and	O
delayed	O
hippocampal	B
damage	I
.	O

In	O
addition	O
,	O
tacrine	O
-	O
loaded	O
nanoparticles	O
administration	O
induced	O
damage	B
of	I
neuronal	I
cells	I
in	O
CA1	O
field	O
of	O
the	O
hippocampus	O
in	O
all	O
treated	O
animals	O
,	O
while	O
the	O
saline	O
solution	O
of	O
tacrine	O
only	O
in	O
60	O
%	O
of	O
animals	O
.	O

BACKGROUND	O
:	O
In	O
2	O
separate	O
centers	O
,	O
we	O
observed	O
a	O
notable	O
increase	O
in	O
the	O
incidence	O
of	O
postoperative	O
convulsive	B
seizures	B
from	O
1	O
.	O
3	O
%	O
to	O
3	O
.	O
8	O
%	O
in	O
patients	O
having	O
undergone	O
major	O
cardiac	O
surgical	O
procedures	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
one	O
of	O
the	O
24	O
patients	O
did	O
not	O
have	O
evidence	O
of	O
new	O
cerebral	B
ischemic	I
injury	I
,	O
but	O
seizures	B
were	O
likely	O
due	O
to	O
ischemic	B
brain	I
injury	I
in	O
3	O
patients	O
.	O

All	O
patients	O
with	O
seizures	B
did	O
not	O
have	O
permanent	O
neurological	B
abnormalities	I
.	O

No	O
evidence	O
of	O
brain	B
ischemic	I
,	O
metabolic	O
,	O
or	O
hyperthermia	B
-	O
induced	O
causes	O
for	O
their	O
seizures	B
was	O
apparent	O
.	O

Electrocardiographic	O
changes	O
and	O
cardiac	B
arrhythmias	I
in	O
patients	O
receiving	O
psychotropic	O
drugs	O
.	O

Aventyl	O
(	O
nortriptyline	O
)	O
and	O
Elavil	O
(	O
amitriptyline	O
)	O
each	O
produced	O
left	B
bundle	I
branch	I
block	I
in	O
a	O
73	O
year	O
old	O
woman	O
.	O

Five	O
of	O
the	O
eight	O
patients	O
were	O
50	O
years	O
of	O
age	O
or	O
younger	O
;	O
only	O
one	O
clearly	O
had	O
antecedent	O
heart	B
disease	I
.	O

Major	O
cardiac	B
arrhythmias	I
are	O
a	O
potential	O
hazard	O
in	O
patients	O
without	O
heart	B
disease	I
who	O
are	O
receiving	O
customary	O
therapeutic	O
doses	O
of	O
psychotropic	O
drugs	O
.	O

A	O
prospective	O
clinical	O
trial	O
is	O
suggested	O
to	O
quantify	O
the	O
risk	O
of	O
cardiac	B
complications	I
to	O
patients	O
receiving	O
phenothiazines	O
or	O
tricyclic	O
antidepressant	O
drugs	O
.	O

Sedation	O
depth	O
during	O
spinal	O
anesthesia	O
and	O
the	O
development	O
of	O
postoperative	B
delirium	I
in	O
elderly	O
patients	O
undergoing	O
hip	B
fracture	I
repair	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
limiting	O
intraoperative	O
sedation	O
depth	O
during	O
spinal	O
anesthesia	O
for	O
hip	B
fracture	I
repair	O
in	O
elderly	O
patients	O
can	O
decrease	O
the	O
prevalence	O
of	O
postoperative	B
delirium	I
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
performed	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
controlled	O
trial	O
at	O
an	O
academic	O
medical	O
center	O
of	O
elderly	O
patients	O
(	O
>	O
or	O
=	O
65	O
years	O
)	O
without	O
preoperative	O
delirium	B
or	O
severe	O
dementia	B
who	O
underwent	O
hip	B
fracture	I
repair	O
under	O
spinal	O
anesthesia	O
with	O
propofol	O
sedation	O
.	O

OBJECTIVE	O
:	O
Diabetic	B
nephropathy	I
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
renal	B
failure	I
,	O
which	O
is	O
accompanied	O
by	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

In	O
the	O
animal	O
study	O
,	O
Nrf2	O
was	O
demonstrated	O
to	O
be	O
crucial	O
in	O
ameliorating	O
streptozotocin	O
-	O
induced	O
renal	B
damage	I
.	O

This	O
is	O
evident	O
by	O
Nrf2	O
(	O
-	O
/	O
-	O
)	O
mice	O
having	O
higher	O
ROS	O
production	O
and	O
suffering	O
from	O
greater	O
oxidative	O
DNA	O
damage	O
and	O
renal	B
injury	I
compared	O
with	O
Nrf2	O
(	O
+	O
/	O
+	O
)	O
mice	O
.	O

Metformin	O
prevents	O
experimental	O
gentamicin	O
-	O
induced	O
nephropathy	B
by	O
a	O
mitochondria	O
-	O
dependent	O
pathway	O
.	O

The	O
antidiabetic	O
drug	O
metformin	O
can	O
diminish	O
apoptosis	O
induced	O
by	O
oxidative	O
stress	O
in	O
endothelial	O
cells	O
and	O
prevent	O
vascular	B
dysfunction	I
even	O
in	O
nondiabetic	O
patients	O
.	O

Metformin	O
treatment	O
fully	O
blocked	O
gentamicin	O
-	O
mediated	O
acute	B
renal	I
failure	I
.	O

These	O
in	O
vivo	O
markers	O
of	O
kidney	B
dysfunction	I
and	O
their	O
correction	O
by	O
metformin	O
were	O
complemented	O
by	O
in	O
vitro	O
studies	O
of	O
mitochondrial	O
function	O
.	O

Risk	O
of	O
nephropathy	B
after	O
consumption	O
of	O
nonionic	O
contrast	O
media	O
by	O
children	O
undergoing	O
cardiac	O
angiography	O
:	O
a	O
prospective	O
study	O
.	O

Despite	O
increasing	O
reports	O
on	O
nonionic	O
contrast	O
media	O
-	O
induced	O
nephropathy	B
(	O
CIN	B
)	O
in	O
hospitalized	O
adult	O
patients	O
during	O
cardiac	O
procedures	O
,	O
the	O
studies	O
in	O
pediatrics	O
are	O
limited	O
,	O
with	O
even	O
less	O
focus	O
on	O
possible	O
predisposing	O
factors	O
and	O
preventive	O
measures	O
for	O
patients	O
undergoing	O
cardiac	O
angiography	O
.	O

Risk	O
of	O
renal	B
failure	I
,	O
Injury	B
to	I
the	I
kidney	I
,	O
Failure	B
of	I
kidney	I
function	I
,	O
Loss	B
of	I
kidney	I
function	I
,	O
and	O
End	O
-	O
stage	O
renal	B
damage	I
(	O
RIFLE	O
criteria	O
)	O
were	O
used	O
to	O
define	O
CIN	B
and	O
its	O
incidence	O
in	O
the	O
study	O
population	O
.	O

Accordingly	O
,	O
among	O
the	O
15	O
CIN	B
patients	O
(	O
18	O
.	O
75	O
%	O
)	O
,	O
7	O
.	O
5	O
%	O
of	O
the	O
patients	O
in	O
group	O
A	O
had	O
increased	O
risk	O
and	O
3	O
.	O
75	O
%	O
had	O
renal	B
injury	I
,	O
whereas	O
5	O
%	O
of	O
group	O
B	O
had	O
increased	O
risk	O
and	O
2	O
.	O
5	O
%	O
had	O
renal	B
injury	I
.	O

Among	O
the	O
15	O
patients	O
with	O
CIN	B
,	O
6	O
had	O
cyanotic	O
congenital	B
heart	I
diseases	I
,	O
but	O
the	O
incidence	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
for	O
the	O
noncyanotic	O
patients	O
(	O
p	O
=	O
0	O
.	O
243	O
)	O
.	O

Vasoconstriction	O
appears	O
to	O
be	O
the	O
common	O
mechanism	O
of	O
action	O
leading	O
to	O
a	O
wide	O
range	O
of	O
fetal	B
anomalies	I
.	O

We	O
report	O
on	O
an	O
infant	O
with	O
multiple	B
cranial	I
-	I
nerve	I
involvement	I
attributable	O
to	O
brainstem	B
dysgenesis	I
,	O
born	O
to	O
a	O
cocaine	B
-	I
addicted	I
mother	O
.	O

RATIONALE	O
AND	O
OBJECTIVES	O
:	O
The	O
light	O
-	O
enhanced	O
startle	B
paradigm	O
(	O
LES	O
)	O
is	O
suggested	O
to	O
model	O
anxiety	B
,	O
because	O
of	O
the	O
non	O
-	O
specific	O
cue	O
and	O
the	O
long	O
-	O
term	O
effect	O
.	O

We	O
describe	O
herein	O
3	O
patients	O
who	O
developed	O
rosacea	B
-	O
like	O
dermatitis	B
eruptions	B
while	O
using	O
0	O
.	O
03	O
%	O
or	O
0	O
.	O
1	O
%	O
tacrolimus	O
ointment	O
for	O
facial	B
dermatitis	I
.	O

The	O
nephroprotective	O
effect	O
of	O
coenzyme	O
Q10	O
was	O
investigated	O
in	O
mice	O
with	O
acute	B
renal	I
injury	I
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
cisplatin	O
(	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Coenzyme	O
Q10	O
significantly	O
compensated	O
deficits	O
in	O
the	O
antioxidant	O
defense	O
mechanisms	O
(	O
reduced	O
glutathione	O
level	O
and	O
superoxide	O
dismutase	O
activity	O
)	O
,	O
suppressed	O
lipid	O
peroxidation	O
,	O
decreased	O
the	O
elevations	O
of	O
tumor	B
necrosis	B
factor	O
-	O
alpha	O
,	O
nitric	O
oxide	O
and	O
platinum	O
ion	O
concentration	O
,	O
and	O
attenuated	O
the	O
reductions	O
of	O
selenium	O
and	O
zinc	O
ions	O
in	O
renal	O
tissue	O
resulted	O
from	O
cisplatin	O
administration	O
.	O

Also	O
,	O
histopathological	O
renal	B
tissue	I
damage	I
mediated	O
by	O
cisplatin	O
was	O
ameliorated	O
by	O
coenzyme	O
Q10	O
treatment	O
.	O

Reversible	O
cholestasis	B
with	O
bile	B
duct	I
injury	I
following	O
azathioprine	O
therapy	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
patient	O
,	O
with	O
primary	O
polymyositis	B
and	O
without	O
previous	O
evidence	O
of	O
liver	B
disease	I
,	O
developed	O
clinical	O
and	O
biochemical	O
features	O
of	O
severe	O
cholestasis	B
3	O
months	O
after	O
initiation	O
of	O
azathioprine	O
therapy	O
.	O

It	O
is	O
believed	O
that	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
reversible	O
azathioprine	O
-	O
induced	O
cholestasis	B
associated	O
with	O
histological	O
evidence	O
of	O
bile	B
duct	I
injury	I
.	O

The	O
ability	O
of	O
insulin	O
treatment	O
to	O
reverse	O
or	O
prevent	O
the	O
changes	O
in	O
urinary	O
bladder	O
function	O
caused	O
by	O
streptozotocin	O
-	O
induced	O
diabetes	B
mellitus	I
.	O

The	O
data	O
indicate	O
that	O
the	O
effects	O
of	O
streptozotocin	O
-	O
induced	O
diabetes	B
on	O
urinary	O
bladder	O
function	O
are	O
both	O
prevented	O
and	O
reversed	O
by	O
insulin	O
treatment	O
.	O

Severe	O
congestive	B
heart	I
failure	I
patient	O
on	O
amiodarone	O
presenting	O
with	O
myxedemic	B
coma	I
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
myxedema	B
coma	I
secondary	O
to	O
amiodarone	O
-	O
induced	O
hypothyroidism	B
in	O
a	O
patient	O
with	O
severe	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
.	O

The	O
myriad	O
clinical	O
presentation	O
of	O
myxedema	B
coma	I
and	O
its	O
serious	O
morbidity	O
and	O
mortality	O
stresses	O
the	O
need	O
to	O
suspect	O
this	O
clinical	O
syndrome	O
among	O
CHF	B
patients	O
presenting	O
with	O
hypotension	B
,	O
weakness	B
or	O
other	O
unexplained	O
symptoms	O
.	O

Effects	O
of	O
active	O
constituents	O
of	O
Crocus	O
sativus	O
L	O
.	O
,	O
crocin	O
on	O
streptozocin	O
-	O
induced	O
model	O
of	O
sporadic	O
Alzheimer	B
'	I
s	I
disease	I
in	O
male	O
rats	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
crocins	O
on	O
sporadic	O
Alzheimer	B
'	I
s	I
disease	I
induced	O
by	O
intracerebroventricular	O
(	O
icv	O
)	O
streptozocin	O
(	O
STZ	O
)	O
in	O
male	O
rats	O
was	O
investigated	O
.	O

In	O
Alzheimer	B
'	I
s	I
disease	I
groups	O
,	O
rats	O
were	O
injected	O
with	O
STZ	O
-	O
icv	O
bilaterally	O
(	O
3	O
mg	O
/	O
kg	O
)	O
in	O
first	O
day	O
and	O
3	O
days	O
later	O
,	O
a	O
similar	O
STZ	O
-	O
icv	O
application	O
was	O
repeated	O
.	O

In	O
addition	O
,	O
crocin	O
in	O
the	O
mentioned	O
dose	O
could	O
significantly	O
attenuated	O
learning	B
and	I
memory	I
impairment	I
in	O
treated	O
STZ	O
-	O
injected	O
group	O
in	O
passive	O
avoidance	O
test	O
.	O

CONCLUSION	O
:	O
Therefore	O
,	O
these	O
results	O
demonstrate	O
the	O
effectiveness	O
of	O
crocin	O
(	O
30	O
mg	O
/	O
kg	O
)	O
in	O
antagonizing	O
the	O
cognitive	B
deficits	I
caused	O
by	O
STZ	O
-	O
icv	O
in	O
rats	O
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
neurodegenerative	B
diseases	I
such	O
as	O
Alzheimer	B
'	I
s	I
disease	I
.	O

BACKGROUND	O
:	O
Altered	O
serotonergic	O
neural	O
transmission	O
is	O
hypothesized	O
to	O
be	O
a	O
susceptibility	O
factor	O
for	O
psychotic	B
disorders	I
such	O
as	O
schizophrenia	B
.	O

These	O
animal	O
models	O
were	O
considered	O
to	O
reflect	O
the	O
positive	O
symptoms	O
of	O
schizophrenia	B
,	O
and	O
the	O
above	O
evidence	O
suggests	O
that	O
altered	O
5	O
-	O
HT6	O
receptors	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
psychotic	B
disorders	I
.	O

The	O
symptoms	O
of	O
methamphetamine	O
(	O
METH	O
)	O
-	O
induced	O
psychosis	B
are	O
similar	O
to	O
those	O
of	O
paranoid	B
type	I
schizophrenia	I
.	O

In	O
patients	O
with	O
schizophrenia	B
,	O
ketamine	O
exacerbates	O
the	O
core	O
symptoms	O
of	O
illness	O
,	O
supporting	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	B
dysfunction	I
.	O

Long	O
-	O
term	O
prognosis	O
for	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	O
-	O
induced	O
acute	B
liver	I
failure	I
.	O

BACKGROUND	O
:	O
The	O
prognosis	O
for	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	O
-	O
induced	O
acute	B
liver	I
failure	I
remains	O
unknown	O
.	O

AIM	O
:	O
To	O
examine	O
whether	O
paracetamol	O
-	O
induced	O
acute	B
liver	I
failure	I
increases	O
long	O
-	O
term	O
mortality	O
.	O

METHODS	O
:	O
We	O
followed	O
up	O
all	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	O
-	O
induced	O
acute	B
liver	I
injury	I
,	O
hospitalized	O
in	O
a	O
Danish	O
national	O
referral	O
centre	O
during	O
1984	O
-	O
2004	O
.	O

We	O
compared	O
age	O
-	O
specific	O
mortality	O
rates	O
from	O
1	O
year	O
post	O
-	O
discharge	O
through	O
2008	O
between	O
those	O
in	O
whom	O
the	O
liver	B
injury	I
led	O
to	O
an	O
acute	B
liver	I
failure	I
and	O
those	O
in	O
whom	O
it	O
did	O
not	O
.	O

On	O
average	O
,	O
age	O
-	O
specific	O
mortality	O
rates	O
were	O
slightly	O
higher	O
for	O
the	O
101	O
patients	O
whose	O
paracetamol	O
-	O
induced	O
liver	B
injury	I
had	O
caused	O
an	O
acute	B
liver	I
failure	I
(	O
adjusted	O
mortality	O
rate	O
ratio	O
=	O
1	O
.	O
70	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
-	O
2	O
.	O
85	O
)	O
,	O
but	O
the	O
association	O
was	O
age	O
-	O
dependent	O
,	O
and	O
no	O
survivors	O
of	O
acute	B
liver	I
failure	I
died	O
of	O
liver	B
disease	I
,	O
whereas	O
suicides	O
were	O
frequent	O
in	O
both	O
groups	O
.	O

These	O
observations	O
speak	O
against	O
long	O
-	O
term	O
effects	O
of	O
acute	B
liver	I
failure	I
.	O

More	O
likely	O
,	O
the	O
elevated	O
mortality	O
rate	O
ratio	O
resulted	O
from	O
incomplete	O
adjustment	O
for	O
the	O
greater	O
prevalence	O
of	O
substance	B
abuse	I
among	O
survivors	O
of	O
acute	B
liver	I
failure	I
.	O

CONCLUSIONS	O
:	O
Paracetamol	O
-	O
induced	O
acute	B
liver	I
failure	I
did	O
not	O
affect	O
long	O
-	O
term	O
mortality	O
.	O

Clinical	O
follow	O
-	O
up	O
may	O
be	O
justified	O
by	O
the	O
cause	O
of	O
the	O
liver	B
failure	I
,	O
but	O
not	O
by	O
the	O
liver	B
failure	I
itself	O
.	O

In	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	O
A2A	O
/	O
A1	O
receptor	O
antagonist	O
in	O
animal	O
models	O
of	O
Parkinson	B
'	I
s	I
disease	I
.	O

The	O
in	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	O
A	O
(	O
2A	O
)	O
/	O
A	O
(	O
1	O
)	O
receptor	O
antagonist	O
in	O
several	O
animal	O
models	O
of	O
Parkinson	B
'	I
s	I
disease	I
is	O
described	O
.	O

Compound	O
1	O
is	O
a	O
potent	O
A	O
(	O
2A	O
)	O
/	O
A	O
(	O
1	O
)	O
receptor	O
antagonist	O
in	O
vitro	O
(	O
A	O
(	O
2A	O
)	O
K	O
(	O
i	O
)	O
=	O
4	O
.	O
1	O
nM	O
;	O
A	O
(	O
1	O
)	O
K	O
(	O
i	O
)	O
=	O
17	O
.	O
0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	O
,	O
after	O
oral	O
administration	O
,	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	B
'	I
s	I
disease	I
including	O
mouse	O
and	O
rat	O
models	O
of	O
haloperidol	O
-	O
induced	O
catalepsy	B
,	O
mouse	O
model	O
of	O
reserpine	O
-	O
induced	O
akinesia	B
,	O
rat	O
6	O
-	O
hydroxydopamine	O
(	O
6	O
-	O
OHDA	O
)	O
lesion	O
model	O
of	O
drug	O
-	O
induced	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
incidence	O
of	O
haematological	B
,	I
renal	I
,	I
hepatic	I
and	I
gastrointestinal	I
toxicities	I
in	O
tumour	O
-	O
bearing	O
dogs	O
receiving	O
1	O
-	O
(	O
2	O
-	O
chloroethyl	O
)	O
-	O
3	O
-	O
cyclohexyl	O
-	O
1	O
-	O
nitrosourea	O
(	O
CCNU	O
)	O
.	O

CCNU	O
was	O
used	O
most	O
commonly	O
in	O
the	O
treatment	O
of	O
lymphoma	B
,	O
mast	B
cell	I
tumour	I
,	O
brain	B
tumour	I
,	O
histiocytic	B
tumours	I
and	O
epitheliotropic	B
lymphoma	I
.	O

Throughout	O
treatment	O
,	O
56	O
.	O
9	O
%	O
of	O
dogs	O
experienced	O
neutropenia	B
,	O
34	O
.	O
2	O
%	O
experienced	O
anaemia	B
and	O
14	O
.	O
2	O
%	O
experienced	O
thrombocytopenia	B
.	O

The	O
incidence	O
of	O
hepatic	B
failure	I
was	O
1	O
.	O
2	O
%	O
.	O

Central	O
vein	B
thrombosis	I
and	O
topical	O
dipivalyl	O
epinephrine	O
.	O

A	O
report	O
is	O
given	O
on	O
an	O
83	O
-	O
year	O
-	O
old	O
female	O
who	O
acquired	O
central	O
vein	B
thrombosis	I
in	O
her	O
seeing	O
eye	O
one	O
day	O
after	O
having	O
started	O
topical	O
medication	O
with	O
dipivalyl	O
epinephrine	O
for	O
advanced	O
glaucoma	B
discovered	O
in	O
the	O
other	O
eye	O
.	O

Benzylacyclouridine	O
reverses	O
azidothymidine	O
-	O
induced	O
marrow	B
suppression	I
without	O
impairment	O
of	O
anti	O
-	O
human	O
immunodeficiency	B
virus	O
activity	O
.	O

Increased	O
extracellular	O
concentrations	O
of	O
uridine	O
(	O
Urd	O
)	O
have	O
been	O
reported	O
to	O
reduce	O
,	O
in	O
vitro	O
,	O
azidothymidine	O
(	O
AZT	O
)	O
-	O
induced	O
inhibition	O
of	O
human	O
granulocyte	O
-	O
macrophage	O
progenitor	O
cells	O
without	O
impairment	O
of	O
its	O
antihuman	O
immunodeficiency	B
virus	O
(	O
HIV	O
)	O
activity	O
.	O

Because	O
of	O
the	O
clinical	O
toxicities	B
associated	O
with	O
chronic	O
Urd	O
administration	O
,	O
the	O
ability	O
of	O
benzylacyclouridine	O
(	O
BAU	O
)	O
to	O
effect	O
,	O
in	O
vivo	O
,	O
AZT	O
-	O
induced	O
anemia	B
and	O
leukopenia	B
was	O
assessed	O
.	O

In	O
mice	O
rendered	O
anemic	B
and	O
leukopenic	B
by	O
the	O
administration	O
of	O
AZT	O
for	O
28	O
days	O
in	O
drinking	O
water	O
(	O
1	O
.	O
5	O
mg	O
/	O
mL	O
)	O
,	O
the	O
continued	O
administration	O
of	O
AZT	O
plus	O
daily	O
BAU	O
(	O
300	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
partially	O
reversed	O
AZT	O
-	O
induced	O
anemia	B
and	O
leukopenia	B
(	O
P	O
less	O
than	O
.	O
05	O
)	O
,	O
increased	O
peripheral	O
reticulocytes	O
(	O
to	O
4	O
.	O
9	O
%	O
,	O
P	O
less	O
than	O
.	O
01	O
)	O
,	O
increased	O
cellularity	O
in	O
the	O
marrow	O
,	O
and	O
improved	O
megaloblastosis	B
.	O

When	O
coadministered	O
with	O
AZT	O
from	O
the	O
onset	O
of	O
drug	O
administration	O
,	O
BAU	O
reduced	O
AZT	O
-	O
induced	O
marrow	B
toxicity	I
.	O

Lethal	O
anuria	B
complicating	O
high	O
dose	O
ifosfamide	O
chemotherapy	O
in	O
a	O
breast	B
cancer	I
patient	O
with	O
an	O
impaired	B
renal	I
function	I
.	O

A	O
sixty	O
-	O
year	O
-	O
old	O
woman	O
with	O
advanced	O
breast	B
cancer	I
,	O
previously	O
treated	O
with	O
cisplatin	O
,	O
developed	O
an	O
irreversible	O
lethal	O
renal	B
failure	I
with	O
anuria	B
,	O
the	O
day	O
after	O
5	O
g	O
/	O
m2	O
bolus	O
ifosfamide	O
.	O

Postrenal	B
failure	I
was	O
excluded	O
by	O
echography	O
.	O

A	O
prerenal	O
component	O
could	O
have	O
contributed	O
to	O
renal	B
failure	I
because	O
of	O
a	O
transient	O
hypotension	B
,	O
due	O
to	O
an	O
increasing	O
ascitis	O
,	O
occurring	O
just	O
before	O
anuria	B
.	O

Joint	O
stiffness	O
and	O
contractures	B
also	O
improved	O
.	O

D	O
-	O
Penicillamine	O
caused	O
nephrotic	B
syndrome	I
in	O
1	O
patient	O
and	O
milder	O
reversible	O
proteinuria	B
in	O
3	O
other	O
patients	O
;	O
none	O
developed	O
renal	B
insufficiency	I
.	O

Cerebral	B
sinus	I
thrombosis	I
as	O
a	O
potential	O
hazard	O
of	O
antifibrinolytic	O
treatment	O
in	O
menorrhagia	B
.	O

We	O
describe	O
a	O
42	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
superior	O
sagittal	B
and	I
left	I
transverse	I
sinus	I
thrombosis	I
associated	O
with	O
prolonged	O
epsilon	O
-	O
aminocaproic	O
acid	O
therapy	O
for	O
menorrhagia	B
.	O

This	O
antifibrinolytic	O
agent	O
has	O
been	O
used	O
in	O
women	O
with	O
menorrhagia	B
to	O
promote	O
clotting	O
and	O
reduce	O
blood	B
loss	I
.	O

Although	O
increased	O
risk	O
of	O
thromboembolic	B
disease	I
has	O
been	O
reported	O
during	O
treatment	O
with	O
epsilon	O
-	O
aminocaproic	O
acid	O
,	O
cerebral	B
sinus	I
thrombosis	I
has	O
not	O
been	O
previously	O
described	O
.	O

Two	O
elderly	O
patients	O
with	O
a	O
history	O
of	O
either	O
cerebral	B
vascular	I
accident	I
(	O
CVA	B
)	O
or	O
head	B
trauma	I
and	O
no	O
evidence	O
of	O
renal	B
disease	I
developed	O
seizures	B
while	O
receiving	O
maximum	O
doses	O
of	O
imipenem	O
/	O
cilastatin	O
.	O

Neither	O
patient	O
had	O
reported	O
previous	O
seizures	B
or	O
seizure	B
-	O
like	O
activity	O
nor	O
was	O
receiving	O
anticonvulsant	O
agents	O
.	O

Both	O
patients	O
had	O
received	O
maximum	O
doses	O
of	O
other	O
beta	O
-	O
lactam	O
antibiotics	O
without	O
evidence	O
of	O
seizure	B
activity	O
.	O

Although	O
there	O
have	O
been	O
anecdotal	O
reports	O
of	O
cardiac	B
toxicity	I
associated	O
with	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
therapy	O
,	O
this	O
phenomenon	O
has	O
not	O
been	O
studied	O
in	O
a	O
systematic	O
fashion	O
.	O

We	O
prospectively	O
performed	O
continuous	O
ambulatory	O
ECG	O
monitoring	O
on	O
25	O
patients	O
undergoing	O
5	O
-	O
FU	O
infusion	O
for	O
treatment	O
of	O
solid	O
tumors	B
in	O
order	O
to	O
assess	O
the	O
incidence	O
of	O
ischemic	B
ST	O
changes	O
.	O

The	O
incidence	O
of	O
ischemic	B
episodes	O
per	O
patient	O
per	O
hour	O
was	O
0	O
.	O
05	O
+	O
/	O
-	O
0	O
.	O
02	O
prior	O
to	O
5	O
-	O
FU	O
infusion	O
v	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
03	O
during	O
5	O
-	O
FU	O
infusion	O
(	O
P	O
less	O
than	O
.	O
001	O
)	O
;	O
the	O
duration	O
of	O
ECG	O
changes	O
was	O
0	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
3	O
minutes	O
per	O
patient	O
per	O
hour	O
before	O
5	O
-	O
FU	O
v	O
1	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
5	O
minutes	O
per	O
patient	O
per	O
hour	O
during	O
5	O
-	O
FU	O
(	O
P	O
less	O
than	O
.	O
01	O
)	O
.	O

ECG	O
changes	O
were	O
more	O
common	O
among	O
patients	O
with	O
known	O
coronary	B
artery	I
disease	I
.	O

There	O
were	O
two	O
cases	O
of	O
sudden	B
death	I
,	O
both	O
of	O
which	O
occurred	O
at	O
the	O
end	O
of	O
the	O
chemotherapy	O
course	O
.	O

We	O
conclude	O
that	O
5	O
-	O
FU	O
infusion	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
silent	O
ST	O
segment	O
deviation	O
suggestive	O
of	O
ischemia	B
,	O
particularly	O
among	O
patients	O
with	O
coronary	B
artery	I
disease	I
.	O

Our	O
study	O
group	O
consisted	O
of	O
74	O
HIV	O
-	O
positive	O
homosexual	O
men	O
belonging	O
to	O
groups	O
II	O
B	O
,	O
III	O
and	O
IV	O
C2	O
from	O
the	O
Centers	O
for	O
Disease	O
Control	O
(	O
CDC	O
)	O
classification	O
of	O
HIV	B
disease	I
.	O

National	O
project	O
on	O
the	O
prevention	O
of	O
mother	O
-	O
to	O
-	O
infant	O
infection	B
by	I
hepatitis	I
B	I
virus	I
in	O
Japan	O
.	O

In	O
Japan	O
,	O
a	O
nationwide	O
prevention	O
program	O
against	O
mother	O
-	O
to	O
-	O
infant	O
infection	B
by	I
hepatitis	I
B	I
virus	I
(	O
HBV	O
)	O
started	O
in	O
1985	O
.	O

These	O
infants	O
are	O
treated	O
with	O
two	O
injections	O
of	O
hepatitis	B
B	I
immune	O
globulin	O
(	O
HBIG	O
)	O
and	O
at	O
least	O
three	O
injections	O
of	O
plasma	O
derived	O
hepatitis	O
B	O
vaccine	O
.	O

Involvement	O
of	O
locus	O
coeruleus	O
and	O
noradrenergic	O
neurotransmission	O
in	O
fentanyl	O
-	O
induced	O
muscular	B
rigidity	I
in	O
the	O
rat	O
.	O

Whereas	O
muscular	B
rigidity	I
is	O
a	O
well	O
-	O
known	O
side	O
effect	O
that	O
is	O
associated	O
with	O
high	O
-	O
dose	O
fentanyl	O
anesthesia	O
,	O
a	O
paucity	O
of	O
information	O
exists	O
with	O
regard	O
to	O
its	O
underlying	O
mechanism	O
(	O
s	O
)	O
.	O

Such	O
an	O
induced	O
muscular	B
rigidity	I
by	O
the	O
narcotic	O
agent	O
was	O
significantly	O
antagonized	O
or	O
even	O
reduced	O
by	O
prior	O
electrolytic	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
or	O
pretreatment	O
with	O
the	O
alpha	O
-	O
adrenoceptor	O
blocker	O
,	O
prazosin	O
.	O

It	O
is	O
speculated	O
that	O
the	O
induction	O
of	O
muscular	B
rigidity	I
by	O
fentanyl	O
may	O
involve	O
the	O
coerulospinal	O
noradrenergic	O
fibers	O
to	O
the	O
spinal	O
motoneurons	O
.	O

Dexmedetomidine	O
,	O
acting	O
through	O
central	O
alpha	O
-	O
2	O
adrenoceptors	O
,	O
prevents	O
opiate	O
-	O
induced	O
muscle	B
rigidity	I
in	O
the	O
rat	O
.	O

The	O
highly	O
-	O
selective	O
alpha	O
-	O
2	O
adrenergic	O
agonist	O
dexmedetomidine	O
(	O
D	O
-	O
MED	O
)	O
is	O
capable	O
of	O
inducing	O
muscle	B
flaccidity	I
and	O
anesthesia	O
in	O
rats	O
and	O
dogs	O
.	O

Intense	O
generalized	O
muscle	B
rigidity	I
is	O
an	O
undesirable	O
side	O
effect	O
of	O
potent	O
opiate	O
agonists	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
determined	O
if	O
treatment	O
with	O
D	O
-	O
MED	O
prevents	O
the	O
muscle	B
rigidity	I
caused	O
by	O
high	O
-	O
dose	O
alfentanil	O
anesthesia	O
in	O
the	O
rat	O
.	O

In	O
contrast	O
,	O
D	O
-	O
MED	O
prevented	O
alfentanil	O
-	O
induced	O
muscle	B
rigidity	I
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

Protective	O
effect	O
of	O
a	O
specific	O
platelet	O
-	O
activating	O
factor	O
antagonist	O
,	O
BN	O
52021	O
,	O
on	O
bupivacaine	O
-	O
induced	O
cardiovascular	B
impairments	I
in	O
rats	O
.	O

Administration	O
of	O
the	O
local	O
anaesthetic	O
bupivacaine	O
(	O
1	O
.	O
5	O
or	O
2	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
)	O
to	O
rats	O
elicited	O
a	O
marked	O
decrease	B
of	I
mean	I
arterial	I
blood	I
pressure	I
(	I
MBP	I
)	I
and	I
heart	I
rate	I
(	I
HR	I
)	I
leading	O
to	O
death	O
(	O
in	O
67	O
%	O
or	O
90	O
%	O
of	O
animals	O
respectively	O
)	O
.	O

Intravenous	O
injection	O
of	O
the	O
specific	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
antagonist	O
BN	O
52021	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
30	O
min	O
before	O
bupivacaine	O
administration	O
(	O
2	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
suppressed	O
both	O
the	O
decrease	B
of	I
MBP	I
and	I
HR	I
.	O

When	O
BN	O
52021	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
was	O
injected	O
immediately	O
after	O
bupivacaine	O
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
a	O
partial	O
reversion	O
of	O
the	O
decrease	B
of	I
MBP	I
and	I
HR	I
was	O
observed	O
,	O
whereas	O
the	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
was	O
ineffective	O
.	O

Since	O
the	O
administration	O
of	O
BN	O
52021	O
,	O
at	O
all	O
doses	O
studied	O
,	O
did	O
not	O
alter	O
MBP	O
and	O
HR	O
at	O
the	O
doses	O
used	O
,	O
the	O
bulk	O
of	O
these	O
results	O
clearly	O
demonstrate	O
a	O
protective	O
action	O
of	O
BN	O
52021	O
,	O
a	O
specific	O
antagonist	O
of	O
PAF	O
,	O
against	O
bupivacaine	O
-	O
induced	O
cardiovascular	B
toxicity	I
.	O

Thus	O
,	O
consistent	O
with	O
its	O
direct	O
effect	O
on	O
heart	O
,	O
PAF	O
appears	O
to	O
be	O
implicated	O
in	O
bupivacaine	O
-	O
induced	O
cardiovascular	B
alterations	I
.	O

Case	O
patients	O
were	O
more	O
likely	O
to	O
be	O
men	O
(	O
odds	O
ratio	O
,	O
3	O
.	O
8	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
12	O
.	O
1	O
)	O
,	O
suffer	O
from	O
hay	B
fever	I
and	O
asthma	B
(	O
odds	O
ratio	O
,	O
3	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
0	O
-	O
11	O
.	O
9	O
)	O
;	O
to	O
participate	O
in	O
regular	O
exercise	O
(	O
odds	O
ratio	O
,	O
5	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
1	O
-	O
30	O
.	O
7	O
)	O
,	O
especially	O
in	O
the	O
use	O
of	O
Nautilus	O
equipment	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
;	O
and	O
to	O
use	O
alcohol	O
(	O
odds	O
ratio	O
,	O
4	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
1	O
-	O
17	O

Possible	O
risk	O
factors	O
included	O
young	O
age	O
,	O
concurrent	O
use	O
of	O
other	O
analgesic	O
agents	O
(	O
especially	O
ibuprofen	O
)	O
,	O
preexisting	O
renal	B
disease	I
,	O
a	O
history	O
of	O
kidney	B
stones	I
,	O
a	O
history	O
of	O
gout	B
,	O
a	O
recent	O
increase	O
in	O
activity	O
,	O
a	O
recent	O
increase	O
in	O
sun	O
exposure	O
,	O
and	O
residence	O
in	O
the	O
Sunbelt	O
.	O

Because	O
rats	O
with	O
streptozotocin	O
-	O
induced	O
diabetes	B
mellitus	I
(	O
DM	B
)	O
have	O
a	O
high	O
solute	O
diuresis	O
(	O
glycosuria	B
of	O
10	O
to	O
12	O
g	O
/	O
day	O
)	O
,	O
we	O
have	O
suggested	O
that	O
this	O
may	O
in	O
part	O
be	O
responsible	O
for	O
their	O
resistance	O
to	O
gentamicin	O
-	O
induced	O
acute	B
renal	I
failure	I
(	O
ARF	B
)	O
.	O

DM	B
rats	O
with	O
mild	O
glycosuria	B
(	O
similar	O
in	O
degree	O
to	O
that	O
of	O
the	O
P	O
treated	O
animals	O
)	O
were	O
also	O
studied	O
.	O

Group	O
1	O
(	O
P	O
alone	O
)	O
received	O
P	O
,	O
360	O
mg	O
/	O
day	O
,	O
for	O
15	O
days	O
;	O
Group	O
II	O
(	O
P	O
+	O
gentamicin	O
)	O
;	O
Group	O
III	O
(	O
gentamicin	O
alone	O
)	O
and	O
Group	O
IV	O
(	O
mild	O
DM	B
+	O
gentamicin	O
)	O
.	O

In	O
Group	O
I	O
,	O
P	O
induced	O
a	O
moderate	O
and	O
stable	O
glycosuria	B
(	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
day	O
,	O
SE	O
)	O
,	O
and	O
no	O
functional	O
or	O
morphologic	O
evidence	O
of	O
renal	B
dysfunction	I
(	O
baseline	O
CCr	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
ml	O
/	O
min	O
,	O
undetectable	O
lysozymuria	O
)	O
or	O
damage	O
(	O
tubular	B
necrosis	I
score	O
[	O
maximum	O
4	O
]	O
,	O
zero	O
)	O
.	O

Although	O
diastolic	O
blood	O
pressure	O
remained	O
unchanged	O
,	O
systolic	O
blood	O
pressure	O
increased	O
from	O
119	O
to	O
135	O
mm	O
Hg	O
(	O
SED	O
+	O
/	O
-	O
3	O
.	O
4	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
associated	O
with	O
an	O
increased	B
cardiac	I
output	I
(	O
5	O
.	O
85	O
-	O
7	O
.	O
73	O
l	O
/	O
min	O
,	O
SED	O
+	O
/	O
-	O
0	O
.	O
46	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
rise	B
in	I
resting	I
blood	I
pressure	I
with	O
hydrocortisone	O
is	O
associated	O
with	O
an	O
increased	B
cardiac	I
output	I
(	O
presumably	O
due	O
to	O
increased	O
blood	O
volume	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
patient	O
who	O
received	O
tocolysis	O
with	O
nifedipine	O
developed	O
neuromuscular	B
blockade	I
after	O
500	O
mg	O
of	O
magnesium	O
sulfate	O
was	O
administered	O
.	O

Chronic	O
CBZ	O
also	O
decreased	O
the	O
incidence	O
of	O
seizure	B
-	O
related	O
mortality	O
in	O
the	O
cocaine	O
-	O
injected	O
rats	O
.	O

The	O
differential	O
effects	O
of	O
CBZ	O
depending	O
upon	O
stage	O
of	O
seizure	B
development	O
suggest	O
that	O
distinct	O
mechanisms	O
underlie	O
the	O
development	O
versus	O
maintenance	O
of	O
local	O
anesthetic	O
-	O
kindled	O
seizures	B
.	O

Magnetic	O
resonance	O
imaging	O
of	O
cerebral	O
venous	B
thrombosis	I
secondary	O
to	O
"	O
low	O
-	O
dose	O
"	O
birth	O
control	O
pills	O
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
cerebral	O
deep	B
venous	I
thrombosis	I
in	O
a	O
21	O
-	O
year	O
-	O
old	O
white	O
woman	O
are	O
presented	O
.	O

A	O
dystonia	B
-	O
like	O
syndrome	O
after	O
neuropeptide	O
(	O
MSH	O
/	O
ACTH	O
)	O
stimulation	O
of	O
the	O
rat	O
locus	O
ceruleus	O
.	O

The	O
movement	B
disorder	I
investigated	O
in	O
these	O
studies	O
has	O
some	O
features	O
in	O
common	O
with	O
human	O
idiopathic	O
dystonia	B
,	O
and	O
information	O
obtained	O
in	O
these	O
studies	O
may	O
be	O
of	O
potential	O
clinical	O
benefit	O
.	O

However	O
,	O
it	O
is	O
not	O
certain	O
as	O
to	O
the	O
following	O
:	O
(	O
a	O
)	O
what	O
receptors	O
were	O
stimulated	O
by	O
the	O
ACTH	O
N	O
-	O
terminal	O
fragments	O
at	O
the	O
LC	O
that	O
resulted	O
in	O
this	O
disorder	O
;	O
(	O
b	O
)	O
whether	O
NE	O
,	O
released	O
onto	O
Purkinje	O
cell	O
synapses	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	O
pathway	O
,	O
did	O
indeed	O
cause	O
the	O
long	O
-	O
term	O
depression	B
at	O
Purkinje	O
cell	O
synapses	O
(	O
previously	O
described	O
by	O
others	O
)	O
that	O
resulted	O
in	O
the	O
long	O
duration	O
of	O
the	O
movement	B
disorder	I
;	O
(	O
c	O
)	O
whether	O
the	O
inhibition	O
of	O
inhibitory	O
Purkinje	O
cells	O
resulted	O
in	O
disinhibition	O
or	O

50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
thiopental	O
produced	O
respiratory	B
arrest	I
with	O
further	O
increase	O
in	O
GABA	O
and	O
decrease	O
in	O
glutamate	O
again	O
in	O
cortex	O
and	O
brain	O
stem	O
without	O
affecting	O
any	O
of	O
the	O
amino	O
acids	O
studied	O
in	O
four	O
regions	O
of	O
rat	O
brain	O
.	O

Induction	O
of	O
ventricular	B
fibrillation	I
and	O
decrease	O
of	O
aortic	O
pressure	O
.	O

Frequencies	O
of	O
ventricular	B
fibrillation	I
were	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
after	O
iopentol	O
(	O
0	O
%	O
)	O
and	O
iohexol	O
(	O
3	O
%	O
)	O
than	O
after	O
metrizoate	O
(	O
22	O
%	O
)	O
.	O

It	O
has	O
been	O
suggested	O
that	O
adenylate	O
cyclase	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
development	O
of	O
both	O
nephrogenic	B
diabetes	I
insipidus	I
and	O
hypothyroidism	B
during	O
lithium	O
treatment	O
.	O

Toxicity	B
due	O
to	O
remission	O
inducing	O
drugs	O
in	O
rheumatoid	B
arthritis	I
.	O

Twenty	O
-	O
five	O
patients	O
with	O
rheumatoid	B
arthritis	I
(	O
RA	B
)	O
who	O
developed	O
toxicity	B
while	O
taking	O
remission	O
inducing	O
drugs	O
and	O
30	O
without	O
toxicity	B
were	O
studied	O
for	O
possible	O
associations	O
with	O
class	O
I	O
and	O
II	O
HLA	O
antigens	O
.	O

A	O
strong	O
association	O
has	O
been	O
found	O
between	O
nephritis	B
and	O
dermatitis	B
due	O
to	O
Tiopronin	O
(	O
a	O
D	O
-	O
Penicillamine	O
like	O
compound	O
)	O
and	O
class	O
I	O
antigens	O
B35	O
-	O
Cw4	O
,	O
and	O
between	O
dermatitis	B
due	O
to	O
gold	O
thiosulphate	O
and	O
B35	O
.	O

Compared	O
to	O
healthy	O
controls	O
a	O
lower	O
DR5	O
frequency	O
was	O
observed	O
in	O
patients	O
with	O
RA	B
except	O
for	O
the	O
Tiopronin	O
related	O
nephritis	B
group	O
.	O

Transient	O
contralateral	B
rotation	I
following	O
unilateral	O
substantia	B
nigra	I
lesion	I
reflects	O
susceptibility	O
of	O
the	O
nigrostriatal	O
system	O
to	O
exhaustion	O
by	O
amphetamine	O
.	O

Following	O
unilateral	O
6	O
-	O
OHDA	O
induced	O
SN	B
lesion	I
,	O
a	O
transient	O
period	O
of	O
contralateral	B
rotation	I
has	O
been	O
reported	O
to	O
precede	O
the	O
predominant	O
ipsilateral	B
circling	I
.	O

Mitomycin	O
C	O
associated	O
hemolytic	B
uremic	I
syndrome	I
.	O

Mitomycin	O
C	O
associated	O
Hemolytic	B
Uremic	I
Syndrome	I
(	O
HUS	B
)	O
is	O
a	O
potentially	O
fatal	O
but	O
uncommon	O
condition	O
that	O
is	O
not	O
yet	O
widely	O
recognised	O
.	O

It	O
consists	O
of	O
microangiopathic	O
hemolytic	B
anemia	I
,	O
thrombocytopenia	B
and	O
progressive	O
renal	B
failure	I
associated	O
with	O
mitomycin	O
C	O
treatment	O
and	O
affects	O
about	O
10	O
%	O
of	O
patients	O
treated	O
with	O
this	O
agent	O
.	O

The	O
renal	B
failure	I
usually	O
develops	O
about	O
8	O
-	O
10	O
mth	O
after	O
start	O
of	O
mitomycin	O
C	O
treatment	O
and	O
the	O
mortality	O
is	O
approximately	O
60	O
%	O
from	O
renal	B
failure	I
or	O
pulmonary	B
edema	I
.	O

Renal	B
lesions	I
are	O
similar	O
to	O
those	O
seen	O
in	O
idiopathic	O
HUS	B
and	O
include	O
arteriolar	O
fibrin	O
thrombi	B
,	O
expanded	O
subendothelial	O
zones	O
in	O
glomerular	O
capillary	O
walls	O
,	O
ischemic	B
wrinkling	O
of	O
glomerular	O
basement	O
membranes	O
and	O
mesangiolysis	O
.	O

We	O
describe	O
the	O
clinical	O
course	O
and	O
pathological	O
findings	O
in	O
a	O
65	O
yr	O
-	O
old	O
man	O
with	O
gastric	B
adenocarcinoma	I
who	O
developed	O
renal	B
failure	I
and	O
thrombocytopenia	B
while	O
on	O
treatment	O
with	O
mitomycin	O
C	O
and	O
died	O
in	O
pulmonary	B
edema	I
.	O

Ketanserin	O
pretreatment	O
reverses	O
alfentanil	O
-	O
induced	O
muscle	B
rigidity	I
.	O

Systemic	O
pretreatment	O
with	O
ketanserin	O
,	O
a	O
relatively	O
specific	O
type	O
-	O
2	O
serotonin	O
receptor	O
antagonist	O
,	O
significantly	O
attenuated	O
the	O
muscle	B
rigidity	I
produced	O
in	O
rats	O
by	O
the	O
potent	O
short	O
-	O
acting	O
opiate	O
agonist	O
alfentanil	O
.	O

These	O
results	O
,	O
in	O
combination	O
with	O
previous	O
work	O
,	O
suggest	O
that	O
muscle	B
rigidity	I
,	O
a	O
clinically	O
relevant	O
side	O
-	O
effect	O
of	O
parenteral	O
narcotic	O
administration	O
,	O
may	O
be	O
partly	O
mediated	O
via	O
serotonergic	O
pathways	O
.	O

Pretreatment	O
with	O
type	O
-	O
2	O
serotonin	O
antagonists	O
may	O
be	O
clinically	O
useful	O
in	O
attenuating	O
opiate	O
-	O
induced	O
rigidity	B
,	O
although	O
further	O
studies	O
will	O
be	O
necessary	O
to	O
assess	O
the	O
interaction	O
of	O
possibly	O
enhanced	O
CNS	O
,	O
cardiovascular	B
,	I
and	I
respiratory	I
depression	I
.	O

Prolonged	O
administration	O
of	O
female	O
sex	O
hormones	O
is	O
a	O
possible	O
cause	O
of	O
chorea	B
in	O
women	O
who	O
have	O
not	O
previously	O
had	O
chorea	B
or	O
rheumatic	B
fever	I
.	O

The	O
potential	O
modifying	O
effect	O
of	O
retinyl	O
acetate	O
(	O
RA	O
)	O
on	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
-	O
induced	O
rat	O
forestomach	B
tumorigenesis	I
was	O
examined	O
.	O

In	O
groups	O
given	O
2	O
%	O
BHA	O
,	O
although	O
marked	O
hyperplastic	O
changes	O
of	O
the	O
forestomach	O
epithelium	O
were	O
observed	O
in	O
all	O
animals	O
,	O
co	O
-	O
administration	O
of	O
0	O
.	O
25	O
%	O
RA	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
increased	O
the	O
incidence	O
of	O
forestomach	B
tumors	I
(	O
squamous	B
cell	I
papilloma	I
and	O
carcinoma	B
)	O
to	O
60	O
%	O
(	O
9	O
/	O
15	O
,	O
2	O
rats	O
with	O
carcinoma	B
)	O
from	O
15	O
%	O
(	O
3	O
/	O
20	O
,	O
one	O
rat	O
with	O
carcinoma	B
)	O
in	O
the	O
group	O
given	O
RA	O
-	O
free	O
water	O
.	O

One	O
of	O
the	O
patients	O
developed	O
cardiac	B
failure	I
after	O
30	O
mg	O
m	O
-	O
2	O
MMC	O
and	O
only	O
150	O
mg	O
m	O
-	O
2	O
doxorubicin	O
.	O

The	O
cardiac	B
failure	I
was	O
predicted	O
by	O
a	O
drop	O
in	O
EF	O
determined	O
during	O
a	O
cold	O
pressor	O
test	O
.	O

Reversible	O
cerebral	B
lesions	I
associated	O
with	O
tiazofurin	O
usage	O
:	O
MR	O
demonstration	O
.	O

We	O
report	O
our	O
results	O
with	O
magnetic	O
resonance	O
(	O
MR	O
)	O
in	O
demonstrating	O
reversible	O
cerebral	B
abnormalities	I
concurrent	O
with	O
the	O
use	O
of	O
this	O
drug	O
.	O

St	B
.	I

Anthony	B
'	I
s	I
fire	I
,	O
then	O
and	O
now	O
:	O
a	O
case	O
report	O
and	O
historical	O
review	O
.	O

A	O
discussion	O
of	O
the	O
history	O
of	O
ergot	O
includes	O
its	O
original	O
discovery	O
,	O
the	O
epidemics	O
of	O
gangrene	B
that	O
it	O
has	O
caused	O
through	O
the	O
ages	O
and	O
its	O
past	O
and	O
present	O
role	O
in	O
the	O
management	O
of	O
migraine	B
headache	I
.	O

Despite	O
the	O
advent	O
of	O
calcium	O
channel	O
blockers	O
and	O
beta	O
-	O
adrenergic	O
antagonists	O
,	O
ergot	O
preparations	O
continue	O
to	O
play	O
a	O
major	O
role	O
in	O
migraine	B
therapy	O
,	O
so	O
that	O
the	O
danger	O
of	O
St	B
.	I

Anthony	B
'	I
s	I
fire	I
persists	O
.	O

Ethopropazine	O
and	O
benztropine	O
were	O
found	O
to	O
be	O
equally	O
effective	O
in	O
controlling	O
parkinsonian	B
symptoms	I
and	O
were	O
as	O
efficacious	O
as	O
procyclidine	O
,	O
their	O
previous	O
antiparkinsonian	O
drug	O
.	O

However	O
,	O
benztropine	O
treated	O
patients	O
had	O
a	O
significant	O
increase	O
in	O
tardive	B
dyskinesia	I
compared	O
to	O
their	O
condition	O
during	O
procyclindine	O
treatment	O
,	O
and	O
significantly	O
more	O
anxiety	B
and	O
depression	B
than	O
ethopropazine	O
treated	O
patients	O
.	O

This	O
suggests	O
that	O
benztropine	O
is	O
not	O
the	O
anticholinergic	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
neuroleptic	O
-	O
induced	O
parkinsonian	B
symptoms	I
,	O
because	O
of	O
its	O
more	O
toxic	O
central	O
and	O
peripheral	O
atropinic	O
effect	O
.	O

The	O
role	O
of	O
epinephrine	O
in	O
eliciting	O
myocardial	B
ischemia	I
was	O
examined	O
in	O
patients	O
with	O
coronary	B
artery	I
disease	I
.	O

In	O
early	O
clinical	O
studies	O
with	O
CB	O
3717	O
,	O
activity	O
has	O
been	O
seen	O
in	O
breast	B
cancer	I
,	O
ovarian	B
cancer	I
,	O
hepatoma	B
,	O
and	O
mesothelioma	B
.	O

Preliminary	O
results	O
at	O
400	O
and	O
500	O
mg	O
/	O
m2	O
suggest	O
that	O
a	O
reduction	O
in	O
nephrotoxicity	B
may	O
have	O
been	O
achieved	O
with	O
only	O
1	O
instance	O
of	O
renal	B
toxicity	I
in	O
10	O
patients	O
.	O

Type	B
B	I
hepatitis	I
after	O
needle	O
-	O
stick	O
exposure	O
:	O
prevention	O
with	O
hepatitis	B
B	I
immune	O
globulin	O
.	O

Hepatitis	B
B	I
immune	O
globulin	O
(	O
HBIG	O
)	O
and	O
immune	O
serum	O
globulin	O
(	O
ISG	O
)	O
were	O
examined	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
to	O
assess	O
their	O
relative	O
efficacies	O
in	O
preventing	O
type	B
B	I
hepatitis	I
after	O
needle	O
-	O
stick	O
exposure	O
to	O
hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAG	O
)	O
-	O
positive	O
donors	O
.	O

Hepatitis	B
B	I
immune	O
globulin	O
remained	O
significantly	O
superior	O
to	O
ISG	O
in	O
preventing	O
type	B
B	I
hepatitis	I
even	O
when	O
the	O
analysis	O
was	O
confined	O
to	O
these	O
two	O
high	O
-	O
risk	O
subgroups	O
.	O

The	O
efficacy	O
of	O
ISG	O
in	O
preventing	O
type	B
B	I
hepatitis	I
cannot	O
be	O
ascertained	O
because	O
a	O
true	O
placebo	O
group	O
was	O
not	O
included	O
.	O

Production	O
of	O
autochthonous	O
prostate	B
cancer	I
in	O
Lobund	O
-	O
Wistar	O
rats	O
by	O
treatments	O
with	O
N	O
-	O
nitroso	O
-	O
N	O
-	O
methylurea	O
and	O
testosterone	O
.	O

More	O
than	O
50	O
%	O
of	O
Lobund	O
-	O
Wistar	O
(	O
L	O
-	O
W	O
)	O
strain	O
rats	O
developed	O
large	O
,	O
palpable	O
prostate	B
adenocarcinomas	I
(	O
PAs	B
)	O
following	O
treatments	O
with	O
N	O
-	O
nitroso	O
-	O
N	O
-	O
methylurea	O
(	O
CAS	O
:	O
684	O
-	O
93	O
-	O
5	O
)	O
and	O
testosterone	O
propionate	O
[	O
(	O
TP	O
)	O
CAS	O
:	O
57	O
-	O
85	O
-	O
2	O
]	O
,	O
and	O
most	O
of	O
the	O
tumor	B
-	O
bearing	O
rats	O
manifested	O
metastatic	O
lesions	O
.	O

In	O
L	O
-	O
W	O
rats	O
,	O
TP	O
acted	O
as	O
a	O
tumor	B
enhancement	O
agent	O
,	O
with	O
primary	O
emphasis	O
on	O
the	O
development	O
of	O
prostate	B
cancer	I
.	O

Urinary	O
enzymes	O
and	O
protein	O
patterns	O
as	O
indicators	O
of	O
injury	B
to	I
different	I
regions	I
of	I
the	I
kidney	I
.	O

Acute	B
experimental	I
models	I
of	I
renal	I
damage	I
to	O
the	O
proximal	O
tubular	O
,	O
glomerular	O
,	O
and	O
papillary	O
regions	O
of	O
the	O
rat	O
were	O
produced	O
by	O
administration	O
of	O
hexachloro	O
-	O
1	O
:	O
3	O
-	O
butadiene	O
(	O
HCBD	O
)	O
,	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
,	O
and	O
2	O
-	O
bromoethylamine	O
(	O
BEA	O
)	O
,	O
respectively	O
.	O

Several	O
routine	O
indicators	O
of	O
nephrotoxicity	B
,	O
the	O
enzymes	O
alkaline	O
phosphatase	O
and	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
glucosaminidase	O
,	O
and	O
the	O
molecular	O
weight	O
of	O
protein	B
excretion	I
were	O
determined	O
on	O
urine	O
samples	O
.	O

Tubular	O
damage	O
produced	O
by	O
HCBD	O
or	O
BEA	O
was	O
discriminated	O
both	O
quantitatively	O
and	O
qualitatively	O
from	O
glomerular	B
damage	I
produced	O
by	O
PAN	O
.	O

The	O
latter	O
was	O
characterized	O
by	O
a	O
pronounced	O
increase	O
in	O
protein	B
excretion	I
,	O
especially	O
proteins	O
with	O
molecular	O
weight	O
greater	O
than	O
40	O
,	O
000	O
Da	O
.	O

In	O
contrast	O
,	O
protein	B
excretion	I
in	O
tubular	O
damage	O
was	O
raised	O
only	O
slightly	O
and	O
characterized	O
by	O
excretion	B
of	I
proteins	I
of	O
a	O
wide	O
range	O
of	O
molecular	O
weights	O
.	O

It	O
is	O
concluded	O
that	O
both	O
selective	O
urinary	O
enzymes	O
and	O
the	O
molecular	O
weight	O
pattern	O
of	O
urinary	O
proteins	O
can	O
be	O
used	O
to	O
provide	O
diagnostic	O
information	O
about	O
the	O
possible	O
site	O
of	O
renal	B
damage	I
.	O

Twenty	O
-	O
six	O
cases	O
of	O
Reye	B
syndrome	I
from	O
The	O
Children	O
'	O
s	O
Hospital	O
,	O
Camperdown	O
,	O
Australia	O
,	O
occurring	O
between	O
1973	O
and	O
1982	O
were	O
reviewed	O
.	O

Of	O
these	O
,	O
20	O
cases	O
met	O
the	O
US	O
Public	O
Health	O
Service	O
Centers	O
for	O
Disease	O
Control	O
criteria	O
for	O
the	O
diagnosis	O
of	O
Reye	B
syndrome	I
.	O

Pathologic	O
confirmation	O
of	O
the	O
diagnosis	O
of	O
Reye	B
syndrome	I
was	O
accomplished	O
in	O
90	O
%	O
of	O
the	O
cases	O
.	O

The	O
incidence	O
of	O
Reye	B
syndrome	I
in	O
New	O
South	O
Wales	O
,	O
Australia	O
,	O
is	O
estimated	O
from	O
this	O
study	O
to	O
be	O
approximately	O
nine	O
cases	O
per	O
1	O
million	O
children	O
compared	O
with	O
recent	O
US	O
data	O
of	O
ten	O
to	O
20	O
cases	O
per	O
1	O
million	O
children	O
and	O
three	O
to	O
seven	O
cases	O
per	O
1	O
million	O
children	O
in	O
Great	O
Britain	O
.	O

The	O
mortality	O
for	O
these	O
Reye	B
syndrome	I
cases	O
in	O
Australia	O
was	O
45	O
%	O
as	O
compared	O
with	O
a	O
32	O
%	O
case	O
-	O
fatality	O
rate	O
in	O
the	O
United	O
States	O
.	O

Reye	B
syndrome	I
may	O
be	O
disappearing	O
from	O
Australia	O
despite	O
a	O
total	O
lack	O
of	O
association	O
with	O
salicylates	O
or	O
aspirin	O
ingestion	O
,	O
since	O
there	O
were	O
no	O
cases	O
found	O
at	O
The	O
Children	O
'	O
s	O
Hospital	O
in	O
1983	O
,	O
1984	O
,	O
or	O
1985	O
.	O

Two	O
multigravida	O
patients	O
with	O
no	O
prior	O
psychiatric	B
history	O
were	O
seen	O
with	O
postpartum	O
psychosis	B
,	O
having	O
received	O
bromocriptine	O
for	O
inhibition	B
of	I
lactation	I
.	O

Bromocriptine	O
given	O
in	O
high	O
doses	O
has	O
been	O
associated	O
with	O
psychosis	B
in	O
patients	O
receiving	O
the	O
drug	O
for	O
Parkinson	B
'	I
s	I
disease	I
.	O

Hyperglycemic	B
acidotic	I
coma	I
and	O
death	O
in	O
Kearns	B
-	I
Sayre	I
syndrome	I
.	O

This	O
paper	O
presents	O
the	O
clinical	O
and	O
metabolic	O
findings	O
in	O
two	O
young	O
boys	O
with	O
long	O
-	O
standing	O
Kearns	B
-	I
Sayre	I
syndrome	I
.	O

Respiratory	B
failure	I
rapidly	O
ensued	O
and	O
both	O
patients	O
expired	O
in	O
spite	O
of	O
efforts	O
at	O
resuscitation	O
.	O

We	O
believe	O
these	O
two	O
cases	O
represent	O
a	O
newly	O
described	O
and	O
catastrophic	O
metabolic	B
-	I
endocrine	I
failure	I
in	O
the	O
Kearns	B
-	I
Sayre	I
syndrome	I
.	O

The	O
role	O
of	O
cyclosporine	O
(	O
CSA	O
)	O
alone	O
or	O
in	O
combination	O
with	O
various	O
chemotherapeutics	O
in	O
the	O
development	O
of	O
renal	B
toxicity	I
was	O
evaluated	O
in	O
rats	O
.	O

Diuretics	O
,	O
potassium	O
and	O
arrhythmias	B
in	O
hypertensive	B
coronary	B
disease	I
.	O

It	O
has	O
been	O
proposed	O
that	O
modest	O
changes	O
in	O
plasma	O
potassium	O
can	O
alter	O
the	O
tendency	O
towards	O
cardiac	B
arrhythmias	I
.	O

If	O
this	O
were	O
so	O
,	O
patients	O
with	O
coronary	B
artery	I
disease	I
might	O
be	O
especially	O
susceptible	O
.	O

Thus	O
,	O
myocardial	O
electrical	O
excitability	O
was	O
measured	O
in	O
patients	O
with	O
mild	O
essential	O
hypertension	B
and	O
known	O
coronary	B
artery	I
disease	I
after	O
8	O
weeks	O
of	O
treatment	O
with	O
a	O
potassium	O
-	O
conserving	O
diuretic	O
(	O
amiloride	O
)	O
and	O
a	O
similar	O
period	O
on	O
a	O
potassium	O
-	O
losing	O
diuretic	O
(	O
chlorthalidone	O
)	O
in	O
a	O
randomised	O
study	O
.	O

The	O
above	O
results	O
indicate	O
that	O
because	O
potassium	O
-	O
losing	O
diuretic	O
therapy	O
can	O
increase	O
myocardial	O
electrical	O
excitability	O
in	O
patients	O
with	O
ischaemic	B
heart	I
disease	I
,	O
even	O
minor	O
falls	O
in	O
plasma	O
potassium	O
concentrations	O
are	O
probably	O
best	O
avoided	O
in	O
such	O
patients	O
.	O

Transketolase	O
abnormality	O
in	O
tolazamide	O
-	O
induced	O
Wernicke	B
'	I
s	I
encephalopathy	I
.	O

We	O
studied	O
a	O
thiamine	O
-	O
dependent	O
enzyme	O
,	O
transketolase	O
,	O
from	O
fibroblasts	O
of	O
a	O
diabetic	B
patient	O
who	O
developed	O
Wernicke	B
'	I
s	I
encephalopathy	I
when	O
treated	O
with	O
tolazamide	O
,	O
in	O
order	O
to	O
delineate	O
if	O
this	O
patient	O
also	O
had	O
transketolase	O
abnormality	O
[	O
high	O
Km	O
for	O
thiamine	O
pyrophosphate	O
(	O
TPP	O
)	O
]	O
,	O
as	O
previously	O
reported	O
in	O
postalcoholic	O
Wernicke	B
-	I
Korsakoff	I
syndrome	I
.	O

In	O
addition	O
to	O
this	O
patient	O
,	O
we	O
also	O
studied	O
this	O
enzyme	O
from	O
three	O
diabetic	B
kindreds	O
without	O
any	O
history	O
of	O
Wernicke	B
'	I
s	I
encephalopathy	I
and	O
from	O
four	O
normal	O
controls	O
.	O

We	O
found	O
that	O
the	O
above	O
-	O
mentioned	O
patient	O
and	O
one	O
of	O
the	O
diabetic	B
kindreds	O
with	O
no	O
history	O
of	O
Wernicke	B
'	I
s	I
encephalopathy	I
had	O
abnormal	O
transketolase	O
as	O
determined	O
by	O
its	O
Km	O
for	O
TPP	O
.	O

These	O
data	O
suggest	O
a	O
similarity	O
between	O
postalcoholic	O
Wernicke	B
-	I
Korsakoff	I
syndrome	I
and	O
the	O
patient	O
with	O
tolazamide	O
-	O
induced	O
Wernicke	B
'	I
s	I
encephalopathy	I
from	O
the	O
standpoint	O
of	O
transketolase	O
abnormality	O
.	O

This	O
antidyskinetic	O
drug	O
is	O
widely	O
used	O
in	O
clinical	O
psychiatric	B
practice	O
and	O
physicians	O
should	O
be	O
aware	O
of	O
this	O
side	O
effect	O
.	O

A	O
case	O
of	O
thoraco	O
-	O
abdominal	O
rigidity	B
leading	O
to	O
respiratory	B
failure	I
is	O
described	O
in	O
the	O
post	O
-	O
operative	O
period	O
in	O
an	O
elderly	O
patient	O
who	O
received	O
a	O
moderate	O
dose	O
of	O
fentanyl	O
.	O

In	O
DEN	O
+	O
PB	O
treated	O
rats	O
,	O
the	O
survival	O
was	O
prolonged	O
and	O
the	O
tumor	B
incidence	O
decreased	O
as	O
compared	O
with	O
the	O
results	O
obtained	O
by	O
DEN	O
alone	O
.	O

This	O
'	O
anti	O
-	O
carcinogen	O
'	O
effect	O
acts	O
on	O
the	O
initiation	O
as	O
well	O
as	O
on	O
the	O
promotion	O
of	O
the	O
precancerous	B
lesions	I
.	O

Bilateral	B
optic	I
neuropathy	I
due	O
to	O
combined	O
ethambutol	O
and	O
isoniazid	O
treatment	O
.	O

A	O
bilateral	B
retrobulbar	I
neuropathy	I
with	O
an	O
unusual	O
central	O
bitemporal	O
hemianopic	O
scotoma	B
was	O
found	O
.	O

Reactions	O
included	O
thrombophlebitis	B
(	O
20	O
of	O
54	O
patients	O
)	O
,	O
rash	B
(	O
4	O
of	O
54	O
)	O
,	O
nephrotoxicity	B
(	O
4	O
of	O
50	O
)	O
,	O
proteinuria	B
(	O
1	O
of	O
50	O
)	O
and	O
ototoxicity	B
(	O
1	O
of	O
11	O
patients	O
tested	O
by	O
audiometry	O
)	O
.	O

Cardiac	B
toxicity	I
of	O
5	O
-	O
fluorouracil	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
colon	B
carcinoma	I
and	O
liver	O
metastasis	B
who	O
presented	O
chest	B
pain	I
after	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
administration	O
.	O

Clinical	O
electrocardiographic	O
evolution	O
was	O
similar	O
to	O
that	O
observed	O
in	O
Prinzmetal	B
'	I
s	I
angina	I
,	O
and	O
chest	B
pain	I
promptly	O
resolved	O
with	O
nifedipine	O
.	O

These	O
data	O
suggest	O
that	O
coronary	B
spasm	I
may	O
be	O
the	O
cause	O
of	O
cardiotoxicity	B
due	O
to	O
5	O
-	O
FU	O
,	O
and	O
that	O
calcium	O
antagonists	O
may	O
probably	O
be	O
used	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
5	O
-	O
FU	O
cardiotoxicity	B
.	O

A	O
patient	O
with	O
cholestatic	B
hepatitis	I
due	O
to	O
amiodarone	O
treatment	O
is	O
presented	O
below	O
and	O
a	O
review	O
of	O
the	O
hepatotoxicity	B
of	O
amiodarone	O
is	O
given	O
.	O

It	O
is	O
concluded	O
that	O
solid	O
evidence	O
exists	O
of	O
hepatic	B
injury	I
due	O
to	O
amiodarone	O
treatment	O
,	O
including	O
steatosis	B
,	O
alterations	O
resembling	O
alcoholic	B
hepatitis	I
,	O
cholestatic	B
hepatitis	I
and	O
micronodular	O
cirrhosis	B
of	I
the	I
liver	I
.	O

Therapy	O
should	O
be	O
discontinued	O
on	O
the	O
suspicion	O
of	O
cholestatic	B
injury	I
or	O
hepatomegaly	B
.	O

Germfree	O
(	O
GF	O
)	O
Lobund	O
strain	O
Wistar	O
(	O
LW	O
)	O
rats	O
,	O
fed	O
vegetable	O
diet	O
L	O
-	O
485	O
,	O
have	O
developed	O
prostate	B
adenocarcinomas	I
spontaneously	O
(	O
10	O
%	O
incidence	O
)	O
at	O
average	O
age	O
34	O
months	O
.	O

Conventional	O
LW	O
rats	O
,	O
implanted	O
with	O
testosterone	O
at	O
age	O
4	O
months	O
,	O
developed	O
a	O
higher	O
incidence	O
of	O
prostate	B
cancer	I
after	O
an	O
average	O
interval	O
of	O
14	O
months	O
:	O
24	O
%	O
had	O
developed	O
gross	O
tumors	B
,	O
and	O
40	O
%	O
when	O
it	O
included	O
microscopic	O
tumors	B
.	O

Preliminary	O
results	O
indicate	O
that	O
testosterone	O
-	O
treated	O
LW	O
rats	O
that	O
were	O
fed	O
the	O
same	O
diet	O
,	O
which	O
was	O
supplemented	O
with	O
corn	O
oil	O
up	O
to	O
20	O
%	O
fat	O
,	O
developed	O
prostate	B
cancer	I
after	O
intervals	O
of	O
6	O
-	O
12	O
months	O
.	O

Aged	O
GF	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
have	O
not	O
developed	O
prostate	B
cancer	I
spontaneously	O
.	O

Experimental	O
designs	O
should	O
consider	O
genetic	O
susceptibility	O
as	O
a	O
basic	O
prerequisite	O
for	O
studies	O
on	O
experimental	O
prostate	B
cancer	I
.	O

Muscle	B
degeneration	I
is	O
followed	O
by	O
regeneration	O
of	O
the	O
damaged	O
muscle	O
fibers	O
.	O

In	O
addition	O
to	O
muscle	B
damage	I
,	O
severe	O
damage	O
was	O
also	O
seen	O
in	O
harderian	O
glands	O
,	O
especially	O
after	O
exposure	O
to	O
mepivacaine	O
and	O
lidocaine	O
plus	O
epinephrine	O
.	O

Gentamicin	O
nephropathy	B
in	O
a	O
neonate	O
.	O

The	O
clinical	O
and	O
autopsy	O
findings	O
in	O
a	O
premature	O
baby	O
who	O
died	O
of	O
acute	B
renal	I
failure	I
after	O
therapy	O
with	O
gentamicin	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
penicillin	O
are	O
presented	O
.	O

Induction	O
by	O
paracetamol	O
of	O
bladder	B
and	I
liver	I
tumours	I
in	O
the	O
rat	O
.	O

Papillomas	B
of	O
the	O
transitional	O
epithelium	O
of	O
the	O
bladder	O
developed	O
in	O
all	O
paracetamol	O
-	O
treated	O
groups	O
,	O
and	O
three	O
rats	O
bore	O
bladder	B
carcinomas	I
.	O

However	O
,	O
significant	O
yields	O
of	O
bladder	B
tumours	I
were	O
only	O
obtained	O
from	O
low	O
dosage	O
females	O
and	O
high	O
dosage	O
males	O
.	O

Additionally	O
,	O
20	O
to	O
25	O
%	O
of	O
paracetamol	O
-	O
treated	O
rats	O
developed	O
hyperplasia	B
of	O
the	O
bladder	O
epithelium	O
,	O
which	O
was	O
not	O
coincident	O
with	O
the	O
presence	O
of	O
bladder	B
calculi	I
.	O

A	O
low	O
yield	O
of	O
tumours	B
at	O
various	O
other	O
sites	O
also	O
arose	O
following	O
paracetamol	O
feeding	O
.	O

Among	O
the	O
common	O
side	O
effects	O
of	O
diphenylhydantoin	O
(	O
DPH	O
)	O
overdose	B
,	O
the	O
most	O
frequently	O
encountered	O
neurological	O
signs	O
are	O
those	O
of	O
cerebellar	B
dysfunction	I
.	O

It	O
is	O
assumed	O
that	O
patients	O
with	O
some	O
cerebral	B
damage	I
are	O
liable	O
to	O
manifest	O
DPH	O
toxicity	B
as	O
focal	O
neurological	O
signs	O
.	O

Tiapride	O
,	O
a	O
substituted	O
benzamide	O
derivative	O
closely	O
related	O
to	O
metoclopramide	O
,	O
reduced	O
levodopa	O
-	O
induced	O
peak	O
dose	O
involuntary	B
movements	I
in	O
16	O
patients	O
with	O
idiopathic	B
Parkinson	I
'	I
s	I
disease	I
.	O

Tiapride	O
had	O
no	O
effect	O
on	O
levodopa	O
-	O
induced	O
early	O
morning	O
of	O
"	O
off	O
-	O
period	O
"	O
segmental	O
dystonia	B
.	O

This	O
report	O
also	O
suggests	O
that	O
,	O
even	O
after	O
long	O
-	O
term	O
administration	O
,	O
the	O
hepatic	B
toxicity	I
is	O
reversible	O
.	O

Arterial	O
thromboembolism	B
in	O
patients	O
receiving	O
systemic	O
heparin	O
therapy	O
:	O
a	O
complication	O
associated	O
with	O
heparin	O
-	O
induced	O
thrombocytopenia	B
.	O

Characteristic	O
of	O
the	O
entity	O
is	O
arterial	B
occlusion	I
by	O
platelet	O
-	O
fibrin	O
thrombi	B
with	O
distal	O
ischemia	B
occurring	O
four	O
to	O
twenty	O
days	O
after	O
the	O
initiation	O
of	O
heparin	O
therapy	O
,	O
preceded	O
by	O
profound	O
thrombocytopenia	B
with	O
platelet	O
counts	O
in	O
the	O
range	O
of	O
30	O
,	O
000	O
to	O
40	O
,	O
000	O
per	O
cubic	O
millimeter	O
.	O

The	O
clinically	O
apparent	O
occlusion	O
may	O
be	O
preceded	O
by	O
gastrointestinal	B
and	I
musculoskeletal	I
symptoms	I
that	O
appear	O
to	O
be	O
ischemic	B
in	O
origin	O
,	O
and	O
might	O
serve	O
to	O
warn	O
the	O
clinician	O
of	O
these	O
complications	O
.	O

The	O
common	O
factor	O
relating	O
thromboembolism	B
and	O
thrombocytopenia	B
is	O
heparin	O
-	O
induced	O
platelet	B
aggregation	I
.	O

Other	O
adverse	O
reactions	O
significantly	O
linked	O
with	O
active	O
drugs	O
include	O
impaired	B
glucose	I
tolerance	I
in	O
men	O
and	O
women	O
and	O
gout	B
in	O
men	O
,	O
associated	O
with	O
bendrofluazide	O
treatment	O
,	O
and	O
Raynaud	B
'	I
s	I
phenomenon	I
and	O
dyspnoea	B
in	O
men	O
and	O
women	O
taking	O
propranolol	O
.	O

No	O
corneal	B
disease	I
is	O
known	O
to	O
have	O
occurred	O
in	O
the	O
propranolol	O
group	O
.	O

Three	O
patients	O
with	O
ischaemic	B
heart	I
disease	I
developed	O
profound	O
cardiac	B
failure	I
,	O
hypotension	B
and	O
bradycardia	B
during	O
combined	O
therapy	O
with	O
verapamil	O
and	O
beta	O
-	O
adrenergic	O
blocking	O
drugs	O
.	O

Nineteen	O
patients	O
had	O
Zollinger	B
-	I
Ellison	I
syndrome	I
,	O
one	O
patient	O
had	O
systemic	B
mastocytosis	I
,	O
and	O
two	O
patients	O
had	O
idiopathic	O
hypersecretion	O
.	O

Treatment	O
with	O
high	O
doses	O
of	O
cimetidine	O
(	O
one	O
to	O
60	O
months	O
;	O
median	O
,	O
11	O
months	O
)	O
or	O
ranitidine	O
(	O
two	O
to	O
31	O
months	O
;	O
median	O
,	O
14	O
months	O
)	O
was	O
not	O
associated	O
with	O
hepatic	B
or	I
hematologic	I
toxicity	I
or	O
alterations	O
of	O
serum	O
gastrin	O
concentrations	O
,	O
but	O
ranitidine	O
therapy	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
serum	O
creatinine	O
level	O
than	O
seen	O
with	O
cimetidine	O
therapy	O
.	O

Epileptic	B
foci	O
delineated	O
and	O
activated	O
by	O
enflurane	O
were	O
surgically	O
ablated	O
and	O
the	O
patients	O
are	O
now	O
seizure	B
-	O
free	O
.	O

Development	O
of	O
isoproterenol	O
-	O
induced	O
cardiac	B
hypertrophy	I
.	O

The	O
development	O
of	O
cardiac	B
hypertrophy	I
was	O
studied	O
in	O
adult	O
female	O
Wistar	O
rats	O
following	O
daily	O
subcutaneous	O
injections	O
of	O
isoproterenol	O
(	O
ISO	O
)	O
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Ventricular	O
DNA	O
content	O
was	O
unchanged	O
during	O
the	O
early	O
stage	O
(	O
1	O
-	O
4	O
days	O
)	O
of	O
hypertrophic	B
growth	O
but	O
increased	O
to	O
a	O
new	O
steady	O
-	O
state	O
level	O
19	O
%	O
above	O
the	O
controls	O
after	O
8	O
days	O
of	O
treatment	O
.	O

These	O
data	O
indicate	O
that	O
the	O
adaptive	O
response	O
to	O
ISO	O
shows	O
an	O
early	O
hypertrophic	B
phase	O
(	O
1	O
-	O
4	O
days	O
)	O
characterized	O
by	O
a	O
substantial	O
increase	O
in	O
RNA	O
content	O
and	O
cardiac	O
mass	O
in	O
the	O
absence	O
of	O
changes	O
in	O
DNA	O
.	O

Multiple	O
side	O
effects	O
of	O
penicillamine	O
therapy	O
in	O
one	O
patient	O
with	O
rheumatoid	B
arthritis	I
.	O

Skin	B
rashes	I
,	O
proteinuria	B
,	O
systemic	B
lupus	I
erythematosus	I
,	O
polymyositis	B
and	O
myasthenia	B
gravis	I
have	O
all	O
been	O
recorded	O
as	O
complications	O
of	O
penicillamine	O
therapy	O
in	O
patients	O
with	O
rheumatoid	B
arthritis	I
.	O

The	O
skin	B
lesion	I
resembled	O
elastosis	B
perforans	I
serpiginosa	I
,	O
which	O
has	O
been	O
reported	O
as	O
a	O
rare	O
side	O
effect	O
in	O
patients	O
with	O
Wilson	B
'	I
s	I
disease	I
but	O
not	O
in	O
patients	O
with	O
rheumatoid	B
arthritis	I
treated	O
with	O
penicillamine	O
.	O

Doxorubicin	O
cardiomyopathy	B
in	O
children	O
with	O
left	O
-	O
sided	O
Wilms	B
tumor	I
.	O

Two	O
children	O
with	O
Wilms	B
tumor	I
of	O
the	O
left	O
kidney	O
experienced	O
severe	O
anthracycline	O
cardiomyopathy	B
after	O
irradiation	O
to	O
the	O
tumor	B
bed	O
and	O
conventional	O
dosage	O
of	O
doxorubicin	O
.	O

The	O
cardiomyopathy	B
is	O
attributed	O
1	O
)	O
to	O
the	O
fact	O
that	O
radiation	O
fields	O
for	O
left	O
Wilms	B
tumor	I
include	O
the	O
lower	O
portion	O
of	O
the	O
heart	O
and	O
2	O
)	O
to	O
the	O
interaction	O
of	O
doxorubicin	O
and	O
irradiation	O
on	O
cardiac	O
muscle	O
.	O

It	O
is	O
recommended	O
that	O
doxorubicin	O
dosage	O
be	O
sharply	O
restricted	O
in	O
children	O
with	O
Wilms	B
tumor	I
of	O
the	O
left	O
kidney	O
who	O
receive	O
postoperative	O
irradiation	O
.	O

Thus	O
,	O
hyperammonemia	B
is	O
capable	O
of	O
altering	O
drug	O
action	O
and	O
must	O
be	O
considered	O
along	O
with	O
impaired	O
drug	O
metabolism	O
in	O
enhanced	O
drug	O
responses	O
associated	O
with	O
liver	B
disease	I
.	O

Levodopa	O
-	O
induced	O
dyskinesia	B
of	O
the	O
limbs	O
in	O
thirteen	O
cases	O
of	O
Parkinsonism	B
,	O
which	O
was	O
choreic	O
,	O
ballistic	O
or	O
dystonic	B
in	O
type	O
,	O
was	O
alleviated	O
almost	O
completely	O
by	O
stereotaxic	O
surgery	O
using	O
a	O
microelectrode	O
technique	O
for	O
the	O
ventralis	O
oralis	O
anterior	O
and	O
posterior	O
nuclei	O
of	O
the	O
thalamus	O
,	O
but	O
much	O
less	O
by	O
the	O
ventralis	O
intermedius	O
nucleus	O
.	O

Control	O
of	O
levodopa	O
-	O
induced	O
dyskinesias	B
by	O
thalamic	B
lesions	I
in	O
the	O
course	O
of	O
routine	O
treatment	O
of	O
Parkinsonism	B
is	O
discussed	O
.	O

Treatment	O
of	O
ifosfamide	O
-	O
induced	O
urothelial	B
toxicity	I
by	O
oral	O
administration	O
of	O
sodium	O
2	O
-	O
mercaptoethane	O
sulphonate	O
(	O
MESNA	O
)	O
to	O
patients	O
with	O
inoperable	O
lung	B
cancer	I
.	O

The	O
protective	O
effect	O
of	O
oral	O
administration	O
of	O
the	O
thiol	O
compound	O
sodium	O
2	O
-	O
mercaptoethane	O
sulphonate	O
(	O
MESNA	O
)	O
against	O
urothelial	B
toxicity	I
induced	O
by	O
ifosfamide	O
(	O
IF	O
)	O
was	O
tested	O
in	O
a	O
group	O
of	O
45	O
patients	O
with	O
inoperable	O
lung	B
cancer	I
under	O
treatment	O
with	O
IF	O
(	O
2250	O
mg	O
/	O
m2	O
on	O
days	O
2	O
-	O
5	O
)	O
as	O
part	O
of	O
a	O
polychemotherapy	O
regimen	O
repeated	O
in	O
a	O
4	O
-	O
week	O
cycle	O
.	O

Out	O
of	O
a	O
total	O
of	O
88	O
courses	O
of	O
this	O
treatment	O
we	O
observed	O
10	O
episodes	O
of	O
asymptomatic	O
microscopic	O
haematuria	B
and	O
no	O
episodes	O
of	O
gross	O
haematuria	B
.	O

In	O
this	O
group	O
there	O
were	O
1	O
complete	O
and	O
5	O
partial	O
remissions	O
(	O
total	O
24	O
%	O
)	O
,	O
but	O
nearly	O
all	O
patients	O
developed	O
either	O
gross	O
haematuria	B
and	O
/	O
or	O
symptoms	O
of	O
bladder	B
irritation	I
(	O
cystitis	B
and	O
pollakisuria	B
)	O
.	O

Myoclonic	B
,	I
atonic	I
,	I
and	I
absence	I
seizures	I
following	O
institution	O
of	O
carbamazepine	O
therapy	O
in	O
children	O
.	O

Five	O
children	O
,	O
aged	O
3	O
to	O
11	O
years	O
,	O
treated	O
with	O
carbamazepine	O
for	O
epilepsy	B
,	O
had	O
an	O
acute	O
aberrant	O
reaction	O
characterized	O
by	O
the	O
onset	O
of	O
myoclonic	B
,	I
atypical	I
absence	I
and	I
/	I
or	I
atonic	I
(	I
minor	I
motor	I
)	I
seizures	I
within	O
a	O
few	O
days	O
.	O

To	O
investigate	O
the	O
relationship	O
of	O
prostaglandins	O
(	O
PGs	O
)	O
to	O
seizure	B
induction	O
,	O
the	O
effects	O
of	O
six	O
PG	O
synthetase	O
inhibitors	O
on	O
convulsions	B
induced	O
by	O
flurothyl	O
,	O
picrotoxin	O
,	O
pentetrazol	O
(	O
PTZ	O
)	O
,	O
electroshock	O
or	O
bicuculline	O
were	O
evaluated	O
.	O

Effect	O
of	O
captopril	O
on	O
pre	O
-	O
existing	O
and	O
aminonucleoside	O
-	O
induced	O
proteinuria	B
in	O
spontaneously	O
hypertensive	B
rats	O
.	O

The	O
possibility	O
of	O
reproducing	O
the	O
same	O
renal	B
abnormality	I
with	O
captopril	O
was	O
examined	O
in	O
SHR	O
.	O

Oral	O
administration	O
of	O
captopril	O
at	O
100	O
mg	O
/	O
kg	O
for	O
14	O
days	O
failed	O
to	O
aggravate	O
proteinuria	B
pre	O
-	O
existing	O
in	O
SHR	O
.	O

Also	O
,	O
captopril	O
treatment	O
failed	O
to	O
potentiate	O
or	O
facilitate	O
development	O
of	O
massive	O
proteinuria	B
invoked	O
by	O
puromycin	O
aminonucleoside	O
in	O
SHR	O
.	O

Complete	O
heart	B
block	I
following	O
a	O
single	O
dose	O
of	O
trazodone	O
.	O

Forty	O
minutes	O
after	O
receiving	O
a	O
single	O
starting	O
dose	O
of	O
trazodone	O
,	O
a	O
patient	O
developed	O
complete	O
heart	B
block	I
.	O

Phenobarbital	O
-	O
induced	O
dyskinesia	B
in	O
a	O
neurologically	B
-	I
impaired	I
child	O
.	O

A	O
2	O
-	O
year	O
-	O
old	O
child	O
with	O
known	O
neurologic	B
impairment	I
developed	O
a	O
dyskinesia	B
soon	O
after	O
starting	O
phenobarbital	O
therapy	O
for	O
seizures	B
.	O

Known	O
causes	O
of	O
movement	B
disorders	I
were	O
eliminated	O
after	O
evaluation	O
.	O

Phenobarbital	O
should	O
be	O
added	O
to	O
the	O
list	O
of	O
anticonvulsant	O
drugs	O
that	O
can	O
cause	O
movement	B
disorders	I
.	O

Heparin	O
-	O
induced	O
thrombocytopenia	B
,	O
thrombosis	B
,	O
and	O
hemorrhage	B
.	O

Sixty	O
-	O
two	O
patients	O
with	O
a	O
heparin	O
-	O
induced	O
thrombocytopenia	B
are	O
reported	O
.	O

The	O
20	O
deaths	O
,	O
52	O
hemorrhagic	B
and	I
thromboembolic	I
complications	I
,	O
and	O
21	O
surgical	O
procedures	O
to	O
manage	O
the	O
complications	O
confirm	O
the	O
seriousness	O
of	O
the	O
disorder	O
.	O

Ventricular	B
fibrillation	I
from	O
diatrizoate	O
with	O
and	O
without	O
chelating	O
agents	O
.	O

Ventricular	B
fibrillation	I
occurred	O
significantly	O
more	O
often	O
with	O
Renografin	O
,	O
suggesting	O
that	O
chelating	O
agents	O
contribute	O
to	O
toxicity	B
in	O
coronary	O
angiography	O
.	O

Long	O
-	O
term	O
efficacy	O
and	O
toxicity	B
of	O
high	O
-	O
dose	O
amiodarone	O
therapy	O
for	O
ventricular	B
tachycardia	I
or	O
ventricular	B
fibrillation	I
.	O

Amiodarone	O
was	O
administered	O
to	O
154	O
patients	O
who	O
had	O
sustained	O
,	O
symptomatic	O
ventricular	B
tachycardia	I
(	O
VT	B
)	O
(	O
n	O
=	O
118	O
)	O
or	O
a	O
cardiac	B
arrest	I
(	O
n	O
=	O
36	O
)	O
and	O
who	O
were	O
refractory	O
to	O
conventional	O
antiarrhythmic	O
drugs	O
.	O

Sixty	O
-	O
nine	O
percent	O
of	O
patients	O
continued	O
treatment	O
with	O
amiodarone	O
and	O
had	O
no	O
recurrence	O
of	O
symptomatic	O
VT	B
or	O
ventricular	B
fibrillation	I
(	O
VF	B
)	O
over	O
a	O
follow	O
-	O
up	O
of	O
6	O
to	O
52	O
months	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
14	O
.	O
2	O
+	O
/	O
-	O
8	O
.	O
2	O
)	O
.	O

The	O
most	O
common	O
symptomatic	O
adverse	O
reactions	O
were	O
tremor	B
or	O
ataxia	B
(	O
35	O
%	O
)	O
,	O
nausea	B
and	O
anorexia	B
(	O
8	O
%	O
)	O
,	O
visual	B
halos	I
or	I
blurring	I
(	O
6	O
%	O
)	O
,	O
thyroid	B
function	I
abnormalities	I
(	O
6	O
%	O
)	O
and	O
pulmonary	B
interstitial	I
infiltrates	I
(	O
5	O
%	O
)	O
.	O

Why	O
may	O
epsilon	O
-	O
aminocaproic	O
acid	O
(	O
EACA	O
)	O
induce	O
myopathy	B
in	O
man	O
?	O

A	O
case	O
of	O
necrotizing	B
myopathy	I
due	O
to	O
a	O
short	O
epsilon	O
-	O
aminocaproic	O
acid	O
(	O
EACA	O
)	O
treatment	O
in	O
a	O
72	O
year	O
-	O
old	O
patient	O
with	O
subarachnoid	B
haemorrhage	I
(	O
SAH	B
)	O
is	O
described	O
.	O

Subarachnoid	B
and	I
cerebral	I
hemorrhage	I
was	O
noted	O
in	O
18	O
%	O
of	O
the	O
hypertensive	B
rats	O
.	O

These	O
results	O
suggest	O
that	O
PPA	O
/	O
caffeine	O
can	O
lead	O
to	O
cerebral	B
hemorrhage	I
in	O
previously	O
hypertensive	B
animals	O
when	O
administered	O
in	O
greater	O
than	O
the	O
allowed	O
dosage	O
.	O

Renal	B
papillary	I
necrosis	I
due	O
to	O
naproxen	O
.	O

A	O
31	O
-	O
year	O
-	O
old	O
man	O
with	O
rheumatoid	B
arthritis	I
,	O
who	O
had	O
previously	O
been	O
treated	O
with	O
sulindac	O
,	O
fenoprofen	O
calcium	O
,	O
high	O
dose	O
salicylates	O
and	O
gold	O
salts	O
,	O
developed	O
renal	B
papillary	I
necrosis	I
(	O
RPN	B
)	O
4	O
months	O
after	O
institution	O
of	O
naproxen	O
therapy	O
.	O

We	O
review	O
previous	O
reports	O
linking	O
RPN	B
to	O
antiinflammatory	O
drug	O
use	O
and	O
discuss	O
possible	O
advantages	O
of	O
sulindac	O
in	O
patients	O
who	O
have	O
experienced	O
renal	B
toxicity	I
from	O
other	O
antiinflammatory	O
agents	O
.	O

Thus	O
,	O
aminoglycosides	O
may	O
act	O
as	O
nephrotoxicants	O
at	O
glomerular	O
and	O
/	O
or	O
tubular	O
level	O
inducing	O
impairment	B
of	I
renal	I
reabsorption	I
and	O
accumulation	O
of	O
proteins	O
.	O

Induction	O
of	O
the	O
obstructive	B
sleep	I
apnea	I
syndrome	I
in	O
a	O
woman	O
by	O
exogenous	O
androgen	O
administration	O
.	O

We	O
documented	O
airway	O
occlusion	O
during	O
sleep	O
and	O
an	O
abnormally	O
high	O
supraglottic	O
resistance	O
while	O
awake	O
in	O
a	O
54	O
-	O
yr	O
-	O
old	O
woman	O
who	O
had	O
developed	O
physical	O
changes	O
and	O
the	O
syndrome	B
of	I
obstructive	I
sleep	I
apnea	I
while	O
being	O
administered	O
exogenous	O
androgens	O
.	O

Development	O
of	O
the	O
obstructive	B
sleep	I
apnea	I
syndrome	I
must	O
be	O
considered	O
a	O
possible	O
side	O
effect	O
of	O
androgen	O
therapy	O
.	O

8	O
of	O
the	O
10	O
monkeys	O
developed	O
congestive	B
heart	I
failure	I
at	O
an	O
average	O
cumulative	O
adriamycin	O
dose	O
(	O
310	O
mg	O
/	O
m2	O
)	O
well	O
below	O
that	O
considered	O
the	O
safe	O
upper	O
limit	O
(	O
550	O
mg	O
/	O
m2	O
)	O
in	O
man	O
.	O

Histologically	O
,	O
the	O
myocardial	B
lesions	I
resembled	O
those	O
found	O
in	O
human	O
anthracycline	O
-	O
induced	O
cardiomyopathy	B
.	O

1	O
of	O
the	O
10	O
monkeys	O
developed	O
acute	B
myeloblastic	I
leukemia	I
after	O
receiving	O
324	O
mg	O
/	O
m2	O
of	O
adriamycin	O
;	O
the	O
10th	O
monkey	O
is	O
alive	O
and	O
well	O
26	O
months	O
after	O
the	O
last	O
dose	O
of	O
drug	O
.	O

Our	O
results	O
suggest	O
that	O
adriamycin	O
is	O
a	O
more	O
potent	O
cardiotoxin	O
in	O
monkeys	O
than	O
in	O
man	O
,	O
and	O
that	O
leukemia	B
may	O
be	O
a	O
consequence	O
of	O
prolonged	O
treatment	O
with	O
this	O
drug	O
.	O

A	O
newborn	O
with	O
massive	O
tricuspid	B
regurgitation	I
,	O
atrial	B
flutter	I
,	O
congestive	B
heart	I
failure	I
,	O
and	O
a	O
high	O
serum	O
lithium	O
level	O
is	O
described	O
.	O

This	O
is	O
the	O
first	O
patient	O
to	O
initially	O
manifest	O
tricuspid	B
regurgitation	I
and	O
atrial	B
flutter	I
,	O
and	O
the	O
11th	O
described	O
patient	O
with	O
cardiac	B
disease	I
among	O
infants	O
exposed	O
to	O
lithium	O
compounds	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
.	O

Lithium	O
carbonate	O
may	O
be	O
a	O
factor	O
in	O
the	O
increasing	O
incidence	O
of	O
congenital	B
heart	I
disease	I
when	O
taken	O
during	O
early	O
pregnancy	O
.	O

It	O
also	O
causes	O
neurologic	B
depression	I
,	O
cyanosis	B
,	O
and	O
cardiac	B
arrhythmia	I
when	O
consumed	O
prior	O
to	O
delivery	O
.	O

Effects	O
of	O
the	O
novel	O
compound	O
aniracetam	O
(	O
Ro	O
13	O
-	O
5057	O
)	O
upon	O
impaired	B
learning	I
and	I
memory	I
in	O
rodents	O
.	O

The	O
effect	O
of	O
aniracetam	O
(	O
Ro	O
13	O
-	O
5057	O
,	O
1	O
-	O
anisoyl	O
-	O
2	O
-	O
pyrrolidinone	O
)	O
was	O
studied	O
on	O
various	O
forms	O
of	O
experimentally	O
impaired	B
cognitive	I
functions	I
(	O
learning	O
and	O
memory	O
)	O
in	O
rodents	O
and	O
produced	O
the	O
following	O
effects	O
:	O
(	O
1	O
)	O
almost	O
complete	O
prevention	O
of	O
the	O
incapacity	O
to	O
learn	O
a	O
discrete	O
escape	O
response	O
in	O
rats	O
exposed	O
to	O
sublethal	O
hypercapnia	B
immediately	O
before	O
the	O
acquisition	O
session	O
;	O
(	O
2	O
)	O
partial	O
(	O
rats	O
)	O
or	O
complete	O
(	O
mice	O
)	O
prevention	O
of	O
the	O
scopolamine	O
-	O
induced	O
short	O
-	O
term	O
amnesia	B
for	O
a	O
passive	O
avoidance	O
task	O
;	O
(	O
3	O

These	O
improvements	O
or	O
normalizations	O
of	O
impaired	B
cognitive	I
functions	I
were	O
seen	O
at	O
oral	O
aniracetam	O
doses	O
of	O
10	O
-	O
100	O
mg	O
/	O
kg	O
.	O

The	O
effect	O
of	O
calcium	O
chloride	O
injected	O
into	O
the	O
cerebral	O
ventricles	O
of	O
group	O
-	O
housed	O
unanaesthetized	O
cats	O
upon	O
vocalization	O
(	O
rage	O
,	O
hissing	O
and	O
snarling	O
)	O
,	O
fighting	O
(	O
attack	O
with	O
paws	O
and	O
claws	O
,	O
defense	O
with	O
paws	O
and	O
claws	O
and	O
biting	O
)	O
,	O
mydriasis	B
,	O
tremor	B
and	O
clonic	B
-	I
tonic	I
convulsions	I
produced	O
by	O
carbachol	O
and	O
eserine	O
injected	O
similarly	O
was	O
investigated	O
.	O

On	O
the	O
other	O
hand	O
,	O
mydriasis	B
,	O
tremor	B
and	O
clonic	B
-	I
tonic	I
convulsions	I
evoked	O
by	O
carbachol	O
and	O
eserine	O
were	O
not	O
significantly	O
changed	O
by	O
calcium	O
chloride	O
.	O

It	O
is	O
apparent	O
that	O
calcium	O
chloride	O
can	O
"	O
dissociate	O
"	O
vocalization	O
and	O
fighting	O
from	O
autonomic	O
and	O
motor	O
phenomena	O
such	O
as	O
mydriasis	B
,	O
tremor	B
and	O
clonic	B
-	I
tonic	I
convulsions	I
caused	O
by	O
carbachol	O
and	O
eserine	O
.	O

Thiazide	O
diuretics	O
,	O
hypokalemia	B
and	O
cardiac	B
arrhythmias	I
.	O

Circulating	O
lysosomal	O
enzymes	O
and	O
acute	B
hepatic	I
necrosis	I
.	O

The	O
activities	O
of	O
the	O
lysosomal	O
enzymes	O
acid	O
and	O
neutral	O
protease	O
,	O
N	O
-	O
acetylglucosaminidase	O
,	O
and	O
acid	O
phosphatase	O
were	O
measured	O
in	O
the	O
serum	O
of	O
patients	O
with	O
fulminant	B
hepatic	I
failure	I
.	O

Acid	O
protease	O
(	O
cathepsin	O
D	O
)	O
activity	O
was	O
increased	O
about	O
tenfold	O
in	O
patients	O
who	O
died	O
and	O
nearly	O
fourfold	O
in	O
those	O
who	O
survived	O
fulminant	B
hepatic	I
failure	I
after	O
paracetamol	O
overdose	B
,	O
whereas	O
activities	O
were	O
increased	O
equally	O
in	O
patients	O
with	O
fulminant	B
hepatic	I
failure	I
due	O
to	O
viral	B
hepatitis	I
whether	O
or	O
not	O
they	O
survived	O
.	O

Hepatic	B
veno	I
-	I
occlusive	I
disease	I
caused	O
by	O
6	O
-	O
thioguanine	O
.	O

Clinically	O
reversible	O
veno	B
-	I
occlusive	I
disease	I
of	I
the	I
liver	I
developed	O
in	O
a	O
23	O
-	O
year	O
-	O
old	O
man	O
with	O
acute	B
lymphocytic	I
leukemia	I
after	O
10	O
months	O
of	O
maintenance	O
therapy	O
with	O
6	O
-	O
thioguanine	O
.	O

This	O
case	O
presented	O
a	O
unique	O
opportunity	O
to	O
observe	O
the	O
histologic	O
features	O
of	O
clinically	O
reversible	O
hepatic	B
veno	I
-	I
occlusive	I
disease	I
over	O
time	O
,	O
and	O
may	O
be	O
the	O
first	O
case	O
of	O
veno	O
-	O
occlusive	O
related	O
solely	O
to	O
6	O
-	O
thioguanine	O
.	O

Chlorpropamide	O
-	O
induced	O
optic	B
neuropathy	I
.	O

A	O
65	O
-	O
year	O
-	O
old	O
woman	O
with	O
adult	B
-	I
onset	I
diabetes	I
treated	O
with	O
chlorpropamide	O
(	O
Diabenese	O
)	O
had	O
a	O
toxic	B
optic	I
neuropathy	I
that	O
resolved	O
with	O
discontinuation	O
of	O
chlorpropamide	O
therapy	O
.	O

Visual	B
loss	I
occurs	O
in	O
diabetics	B
for	O
a	O
variety	O
of	O
reasons	O
,	O
and	O
accurate	O
diagnosis	O
is	O
necessary	O
to	O
institute	O
appropriate	O
therapy	O
.	O

The	O
possibility	O
of	O
a	O
drug	O
-	O
induced	O
optic	B
neuropathy	I
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
visual	B
loss	I
in	O
diabetics	B
.	O

Plasma	O
and	O
urinary	O
lipids	O
and	O
lipoproteins	O
during	O
the	O
development	O
of	O
nephrotic	B
syndrome	I
induced	O
in	O
the	O
rat	O
by	O
puromycin	O
aminonucleoside	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
ascertain	O
whether	O
the	O
alterations	O
of	O
plasma	O
lipoproteins	O
found	O
in	O
nephrotic	B
syndrome	I
induced	O
by	O
puromycin	O
aminonucleoside	O
were	O
due	O
to	O
nephrotic	B
syndrome	I
per	O
se	O
,	O
or	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
aminonucleoside	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
changes	O
in	O
plasma	O
and	O
urinary	O
lipoproteins	O
during	O
the	O
administration	O
of	O
puromycin	O
aminonucleoside	O
(	O
20	O
mg	O
/	O
kg	O
for	O
7	O
days	O
)	O
and	O
the	O
subsequent	O
development	O
of	O
nephrotic	B
syndrome	I
.	O

Fatal	O
aplastic	B
anemia	I
following	O
topical	O
administration	O
of	O
ophthalmic	O
chloramphenicol	O
.	O

A	O
73	O
-	O
year	O
-	O
old	O
woman	O
died	O
of	O
aplastic	B
anemia	I
less	O
than	O
two	O
months	O
after	O
undergoing	O
cataract	B
extraction	O
and	O
beginning	O
topical	O
therapy	O
with	O
chloramphenicol	O
.	O

The	O
pattern	O
of	O
the	O
aplastic	B
anemia	I
was	O
associated	O
with	O
an	O
idiosyncratic	O
response	O
to	O
chloramphenicol	O
.	O

This	O
was	O
the	O
second	O
report	O
of	O
fatal	O
aplastic	B
anemia	I
after	O
topical	O
treatment	O
with	O
chloramphenicol	O
for	O
ocular	O
conditions	O
,	O
although	O
two	O
cases	O
of	O
reversible	O
bone	B
marrow	I
hypoplasia	I
have	O
also	O
been	O
reported	O
.	O

Any	O
other	O
suspected	O
cases	O
of	O
ocular	B
toxicity	I
associated	O
with	O
topically	O
applied	O
chloramphenicol	O
should	O
be	O
reported	O
to	O
the	O
National	O
Registry	O
of	O
Drug	O
-	O
Induced	O
Ocular	O
Side	O
Effects	O
,	O
Oregon	O
Health	O
Sciences	O
University	O
,	O
Portland	O
,	O
OR	O
97201	O
.	O

Convulsions	B
always	O
preceded	O
death	O
,	O
except	O
after	O
precipitous	O
cardiopulmonary	B
arrest	I
from	O
extreme	O
doses	O
.	O

Fatal	O
aplastic	B
anemia	I
due	O
to	O
indomethacin	O
-	O
-	O
lymphocyte	O
transformation	O
tests	O
in	O
vitro	O
.	O

Although	O
indomethacin	O
has	O
been	O
implicated	O
as	O
a	O
possible	O
cause	O
of	O
aplastic	B
anemia	I
on	O
the	O
basis	O
of	O
a	O
few	O
clinical	O
observations	O
,	O
its	O
role	O
has	O
not	O
been	O
definitely	O
established	O
.	O

A	O
case	O
of	O
fatal	O
aplastic	B
anemia	I
is	O
described	O
in	O
which	O
no	O
drugs	O
other	O
than	O
allopurinol	O
and	O
indomethacin	O
were	O
given	O
.	O

A	O
positive	O
lymphocyte	O
transformation	O
test	O
with	O
indomethacin	O
in	O
vitro	O
further	O
substantiates	O
the	O
potential	O
role	O
of	O
this	O
drug	O
in	O
causing	O
aplastic	B
anemia	I
in	O
a	O
susceptible	O
patient	O
.	O

Dose	O
-	O
effect	O
and	O
structure	O
-	O
function	O
relationships	O
in	O
doxorubicin	O
cardiomyopathy	B
.	O

The	O
cardiomyopathy	B
(	O
CM	B
)	O
produced	O
by	O
the	O
anticancer	O
drug	O
doxorubicin	O
(	O
DXR	O
)	O
(	O
Adriamycin	O
)	O
provides	O
a	O
unique	O
opportunity	O
to	O
analyze	O
dose	O
-	O
effect	O
and	O
structure	O
-	O
function	O
relationships	O
during	O
development	O
of	O
myocardial	B
disease	I
.	O

In	O
DXR	O
-	O
CM	B
myocardial	B
damage	I
is	O
proportional	O
to	O
the	O
degree	O
of	O
cytotoxic	O
insult	O
(	O
DXR	O
dose	O
)	O
while	O
myocardial	O
function	O
is	O
preserved	O
until	O
a	O
critical	O
dose	O
or	O
degree	O
of	O
damage	O
is	O
reached	O
,	O
after	O
which	O
myocardial	O
performance	O
deteriorates	O
rapidly	O
.	O

Massive	O
cerebral	B
edema	I
associated	O
with	O
fulminant	O
hepatic	B
failure	I
in	O
acetaminophen	O
overdose	B
:	O
possible	O
role	O
of	O
cranial	O
decompression	O
.	O

Cerebral	B
edema	I
may	O
complicate	O
the	O
course	O
of	O
fulminant	B
hepatic	I
failure	I
.	O

We	O
present	O
a	O
patient	O
with	O
fatal	O
acetaminophen	O
-	O
induced	O
fulminant	B
hepatic	I
failure	I
,	O
with	O
signs	O
and	O
symptoms	O
of	O
cerebral	B
edema	I
,	O
unresponsive	O
to	O
conventional	O
medical	O
therapy	O
.	O

Subjective	O
assessment	O
of	O
sexual	B
dysfunction	I
of	O
patients	O
on	O
long	O
-	O
term	O
administration	O
of	O
digoxin	O
.	O

The	O
patients	O
of	O
the	O
study	O
and	O
control	O
group	O
(	O
without	O
digoxin	O
)	O
were	O
of	O
similar	O
cardiac	O
functional	O
capacity	O
and	O
age	O
(	O
25	O
-	O
40	O
years	O
)	O
and	O
were	O
randomly	O
selected	O
from	O
the	O
rheumatic	B
heart	I
disease	I
patients	O
.	O

Tests	O
used	O
to	O
evaluate	O
the	O
changes	O
in	O
sexual	O
behavior	O
showed	O
a	O
significant	O
decrease	B
in	I
sexual	I
desire	I
,	O
sexual	O
excitement	O
phase	O
(	O
erection	O
)	O
,	O
and	O
frequency	O
of	O
sexual	O
relations	O
in	O
the	O
study	O
group	O
.	O

Endometrial	B
carcinoma	I
after	O
Hodgkin	B
disease	I
in	O
childhood	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
patient	O
developed	O
metastic	O
endometrial	B
carcinoma	I
after	O
Hodgkin	B
disease	I
in	O
childhood	O
.	O

She	O
had	O
ovarian	B
failure	I
after	O
abdominal	O
irradiation	O
and	O
chemotherapy	O
for	O
Hodgkin	B
disease	I
,	O
and	O
received	O
exogenous	O
estrogens	O
,	O
a	O
treatment	O
implicated	O
in	O
the	O
development	O
of	O
endometrial	B
cancer	I
in	O
menopausal	O
women	O
.	O

Young	O
women	O
on	O
replacement	O
estrogens	O
for	O
ovarian	B
failure	I
after	O
cancer	B
therapy	O
may	O
also	O
have	O
increased	O
risk	O
of	O
endometrial	B
carcinoma	I
and	O
should	O
be	O
examined	O
periodically	O
.	O

Acute	B
renal	I
failure	I
in	O
high	O
dose	O
carboplatin	O
chemotherapy	O
.	O

Carboplatin	O
has	O
been	O
reported	O
to	O
cause	O
acute	B
renal	I
failure	I
when	O
administered	O
in	O
high	O
doses	O
to	O
adult	O
patients	O
.	O

We	O
report	O
a	O
4	O
1	O
/	O
2	O
-	O
year	O
-	O
old	O
girl	O
who	O
was	O
treated	O
with	O
high	O
-	O
dose	O
carboplatin	O
for	O
metastatic	O
parameningeal	O
embryonal	B
rhabdomyosarcoma	I
.	O

Acute	B
renal	I
failure	I
developed	O
followed	O
by	O
a	O
slow	O
partial	O
recovery	O
of	O
renal	O
function	O
.	O

Seven	O
out	O
of	O
12	O
subjects	O
experienced	O
headache	B
of	O
a	O
short	O
duration	O
accompanying	O
facial	B
flush	I
in	O
one	O
and	O
nausea	B
in	O
one	O
,	O
especially	O
after	O
ingestion	O
of	O
CLZ	O
.	O

Pravastatin	O
-	O
associated	O
myopathy	B
.	O

A	O
case	O
of	O
acute	O
inflammatory	B
myopathy	I
associated	O
with	O
the	O
use	O
of	O
pravastatin	O
,	O
a	O
new	O
hydrophilic	O
3	O
-	O
hydroxy	O
-	O
3	O
methylglutaril	O
coenzyme	O
A	O
reductase	O
inhibitor	O
,	O
is	O
reported	O
.	O

The	O
patient	O
,	O
a	O
69	O
-	O
year	O
-	O
old	O
man	O
was	O
affected	O
by	O
non	B
-	I
insulin	I
-	I
dependent	I
diabetes	I
mellitus	I
and	O
hypertension	B
.	O

He	O
assumed	O
pravastatin	O
(	O
20	O
mg	O
/	O
day	O
)	O
because	O
of	O
hypercholesterolemia	B
.	O

He	O
was	O
admitted	O
with	O
acute	O
myopathy	B
of	O
the	O
lower	O
limbs	O
which	O
resolved	O
in	O
a	O
few	O
days	O
after	O
pravastatin	O
discontinuation	O
.	O

A	O
previously	O
unknown	O
hypothyroidism	B
,	O
probably	O
due	O
to	O
chronic	O
autoimmune	B
thyroiditis	I
,	O
was	O
evidenced	O
.	O

While	O
lovastatin	O
and	O
simvastatin	O
have	O
been	O
associated	O
with	O
toxic	O
myopathy	B
,	O
pravastatin	O
-	O
associated	O
myopathy	B
could	O
represent	O
a	O
distinct	O
,	O
inflammatory	O
entity	O
.	O

The	O
occurrence	O
of	O
a	O
myocardial	B
infarction	I
is	O
reported	O
after	O
chemotherapy	O
containing	O
etoposide	O
,	O
in	O
a	O
man	O
with	O
no	O
risk	O
factors	O
for	O
coronary	B
heart	I
disease	I
.	O

Two	O
halogenated	O
anesthetics	O
,	O
enflurane	O
and	O
isoflurane	O
,	O
have	O
been	O
associated	O
with	O
an	O
allergic	O
-	O
type	O
hepatic	B
injury	I
both	O
alone	O
and	O
following	O
previous	O
exposure	O
to	O
halothane	O
.	O

This	O
study	O
was	O
performed	O
to	O
determine	O
cross	O
-	O
reactivity	O
between	O
enflurane	O
and	O
isoflurane	O
with	O
the	O
hypersensitivity	B
induced	O
by	O
halothane	O
.	O

This	O
supports	O
and	O
extends	O
previous	O
evidence	O
for	O
a	O
mechanism	O
by	O
which	O
enflurane	O
and	O
/	O
or	O
isoflurane	O
could	O
produce	O
a	O
hypersensitivity	B
condition	O
similar	O
to	O
that	O
of	O
halothane	O
hepatitis	B
either	O
alone	O
or	O
subsequent	O
to	O
halothane	O
administration	O
.	O

A	O
patient	O
developed	O
a	O
severe	O
cholinergic	O
syndrome	O
from	O
the	O
use	O
of	O
echothiophate	O
iodide	O
ophthalmic	O
drops	O
,	O
presented	O
with	O
profound	O
muscle	B
weakness	I
and	O
was	O
initially	O
given	O
the	O
diagnosis	O
of	O
myasthenia	B
gravis	I
.	O

Seizures	B
and	O
cardiac	B
arrhythmias	I
have	O
complicated	O
its	O
use	O
in	O
adult	O
patients	O
.	O

We	O
report	O
the	O
occurrence	O
of	O
a	O
generalized	O
tonic	B
-	I
clonic	I
seizure	I
in	O
a	O
pediatric	O
patient	O
following	O
the	O
administration	O
of	O
flumazenil	O
.	O

Phase	O
I	O
trial	O
of	O
13	O
-	O
cis	O
-	O
retinoic	O
acid	O
in	O
children	O
with	O
neuroblastoma	B
following	O
bone	O
marrow	O
transplantation	O
.	O

PURPOSE	O
:	O
Treatment	O
of	O
neuroblastoma	B
cell	O
lines	O
with	O
13	O
-	O
cis	O
-	O
retinoic	O
acid	O
(	O
cis	O
-	O
RA	O
)	O
can	O
cause	O
sustained	O
inhibition	O
of	O
proliferation	O
.	O

Since	O
cis	O
-	O
RA	O
has	O
demonstrated	O
clinical	O
responses	O
in	O
neuroblastoma	B
patients	O
,	O
it	O
may	O
be	O
effective	O
in	O
preventing	O
relapse	O
after	O
cytotoxic	O
therapy	O
.	O

This	O
phase	O
I	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
maximal	O
-	O
tolerated	O
dosage	O
(	O
MTD	O
)	O
,	O
toxicities	B
,	O
and	O
pharmacokinetics	O
of	O
cis	O
-	O
RA	O
administered	O
on	O
an	O
intermittent	O
schedule	O
in	O
children	O
with	O
neuroblastoma	B
following	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
.	O

Dose	O
-	O
limiting	O
toxicities	B
in	O
six	O
of	O
nine	O
patients	O
at	O
200	O
mg	O
/	O
m2	O
/	O
d	O
included	O
hypercalcemia	B
(	O
n	O
=	O
3	O
)	O
,	O
rash	B
(	O
n	O
=	O
2	O
)	O
,	O
and	O
anemia	B
/	O
thrombocytopenia	B
/	O
emesis	B
/	O
rash	B
(	O
n	O
=	O
1	O
)	O
.	O

Serum	O
levels	O
known	O
to	O
be	O
effective	O
against	O
neuroblastoma	B
in	O
vitro	O
were	O
achieved	O
at	O
this	O
dose	O
.	O

Time	O
dependence	O
of	O
plasma	O
malondialdehyde	O
,	O
oxypurines	O
,	O
and	O
nucleosides	O
during	O
incomplete	O
cerebral	B
ischemia	I
in	O
the	O
rat	O
.	O

Incomplete	O
cerebral	B
ischemia	I
(	O
30	O
min	O
)	O
was	O
induced	O
in	O
the	O
rat	O
by	O
bilaterally	O
clamping	O
the	O
common	O
carotid	O
arteries	O
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
determination	O
of	O
malondialdehyde	O
,	O
oxypurines	O
,	O
and	O
nucleosides	O
in	O
peripheral	O
blood	O
,	O
may	O
be	O
used	O
to	O
monitor	O
the	O
metabolic	O
alterations	O
of	O
tissues	O
occurring	O
during	O
ischemic	B
phenomena	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Acute	O
renal	B
toxicity	I
of	O
doxorubicin	O
(	O
adriamycin	O
)	O
-	O
loaded	O
cyanoacrylate	O
nanoparticles	O
.	O

Acute	O
doxorubicin	O
-	O
loaded	O
nanoparticle	O
(	O
DXNP	O
)	O
renal	B
toxicity	I
was	O
explored	O
in	O
both	O
normal	O
rats	O
and	O
rats	O
with	O
experimental	O
glomerulonephritis	B
.	O

A	O
3	O
times	O
higher	O
proteinuria	B
appeared	O
in	O
animals	O
treated	O
with	O
DXNP	O
than	O
in	O
those	O
treated	O
with	O
DX	O
.	O

Free	O
NP	O
did	O
not	O
provoke	O
any	O
proteinuria	B
.	O

In	O
rats	O
with	O
immune	O
experimental	O
glomerulonephritis	B
,	O
5	O
/	O
6	O
rats	O
given	O
DX	O
died	O
within	O
7	O
days	O
,	O
in	O
contrast	O
to	O
animals	O
treated	O
by	O
DXNP	O
,	O
NP	O
,	O
or	O
untreated	O
,	O
which	O
all	O
survived	O
.	O

These	O
results	O
demonstrate	O
that	O
,	O
in	O
these	O
experimental	O
conditions	O
,	O
DXNP	O
killed	O
less	O
animals	O
than	O
free	O
DX	O
,	O
despite	O
of	O
an	O
enhanced	O
renal	B
toxicity	I
of	O
the	O
former	O
.	O

Prostaglandin	O
E2	O
-	O
induced	O
bladder	B
hyperactivity	I
in	O
normal	O
,	O
conscious	O
rats	O
:	O
involvement	O
of	O
tachykinins	O
?	O

Prostanoids	O
may	O
,	O
via	O
release	O
of	O
tachykinins	O
,	O
contribute	O
to	O
both	O
urge	O
and	O
bladder	B
hyperactivity	I
seen	O
in	O
inflammatory	O
conditions	O
of	O
the	O
lower	O
urinary	O
tract	O
.	O

Refractory	O
cardiogenic	B
shock	I
and	O
complete	O
heart	B
block	I
after	O
verapamil	O
SR	O
and	O
metoprolol	O
treatment	O
.	O

A	O
seventy	O
-	O
eight	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
complete	O
heart	B
block	I
and	O
refractory	O
hypotension	B
two	O
days	O
after	O
a	O
therapeutic	O
dose	O
of	O
sustained	O
-	O
release	O
verapamil	O
with	O
concomitant	O
use	O
of	O
metoprolol	O
.	O

The	O
patient	O
continued	O
to	O
remain	O
hypotensive	B
with	O
complete	O
heart	B
block	I
,	O
even	O
with	O
multiple	O
uses	O
of	O
intravenous	O
atropine	O
as	O
well	O
as	O
high	O
doses	O
of	O
pressor	O
agents	O
such	O
as	O
dopamine	O
and	O
dobutamine	O
.	O

However	O
,	O
shortly	O
after	O
the	O
use	O
of	O
intravenous	O
calcium	O
chloride	O
,	O
the	O
refractory	O
hypotension	B
and	O
complete	O
heart	B
block	I
resolved	O
.	O

Protective	O
effect	O
of	O
misoprostol	O
on	O
indomethacin	O
induced	O
renal	B
dysfunction	I
in	O
elderly	O
patients	O
.	O

CONCLUSION	O
:	O
Hospitalized	O
elderly	O
patients	O
are	O
at	O
risk	O
for	O
developing	O
indomethacin	O
related	O
renal	B
dysfunction	I
.	O

Addition	O
of	O
misoprostol	O
can	O
minimize	O
this	O
renal	B
impairment	I
without	O
affecting	O
pain	B
control	O
.	O

Cognitive	B
deterioration	I
from	O
long	O
-	O
term	O
abuse	O
of	O
dextromethorphan	O
:	O
a	O
case	O
report	O
.	O

The	O
drug	O
is	O
known	O
to	O
cause	O
a	O
variety	O
of	O
acute	O
toxic	O
effects	O
,	O
ranging	O
from	O
nausea	B
,	O
restlessness	B
,	O
insomnia	B
,	O
ataxia	B
,	O
slurred	O
speech	O
and	O
nystagmus	B
to	O
mood	O
changes	O
,	O
perceptual	O
alterations	O
,	O
inattention	O
,	O
disorientation	O
and	O
aggressive	B
behavior	I
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O
Devlin	O
et	O
al	O
1985	O
;	O
McCarthy	O
1971	O
;	O
Dodds	O
and	O
Revai	O
1967	O
;	O
Degkwitz	O
1964	O
;	O
Hildebrand	O
et	O
al	O
1989	O
)	O
.	O

This	O
report	O
describes	O
a	O
case	O
of	O
cognitive	B
deterioration	I
resulting	O
from	O
prolonged	O
use	O
of	O
DM	O
.	O

Effects	O
of	O
ouabain	O
on	O
myocardial	O
oxygen	O
supply	O
and	O
demand	O
in	O
patients	O
with	O
chronic	O
coronary	B
artery	I
disease	I
.	O

A	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
study	O
in	O
patients	O
without	O
heart	B
failure	I
.	O

The	O
effects	O
of	O
digitalis	O
glycosides	O
on	O
myocardial	O
oxygen	O
supply	O
and	O
demand	O
are	O
of	O
particular	O
interest	O
in	O
the	O
presence	O
of	O
obstructive	O
coronary	B
artery	I
disease	I
,	O
but	O
have	O
not	O
been	O
measured	O
previously	O
in	O
man	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
ouabain	O
(	O
0	O
.	O
015	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
parameters	O
in	O
11	O
patients	O
with	O
severe	O
chronic	O
coronary	B
artery	I
disease	I
without	O
clinical	O
congestive	B
heart	I
failure	I
.	O

We	O
conclude	O
that	O
in	O
patients	O
with	O
chronic	O
coronary	B
artery	I
disease	I
who	O
are	O
not	O
in	O
clinical	O
congestive	B
heart	I
failure	I
left	B
ventricular	I
end	I
-	I
diastolic	I
volume	I
falls	I
after	O
ouabain	O
administration	O
even	O
when	O
it	O
is	O
initially	O
normal	O
.	O

Dexamethasone	O
-	O
induced	O
ocular	B
hypertension	I
in	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

PURPOSE	O
:	O
Glucocorticoid	O
administration	O
can	O
lead	O
to	O
the	O
development	O
of	O
ocular	B
hypertension	I
and	O
corticosteroid	B
glaucoma	I
in	O
a	O
subset	O
of	O
the	O
population	O
through	O
a	O
decrease	O
in	O
the	O
aqueous	O
humor	O
outflow	O
facility	O
.	O

In	O
contrast	O
,	O
the	O
dexamethasone	O
-	O
treated	O
hypertensive	B
eyes	I
had	O
thickened	O
trabecular	O
beams	O
,	O
decreased	O
intertrabecular	O
spaces	O
,	O
thickened	O
juxtacanalicular	O
tissue	O
,	O
activated	O
trabecular	O
meshwork	O
cells	O
,	O
and	O
increased	O
amounts	O
of	O
amorphogranular	O
extracellular	O
material	O
,	O
especially	O
in	O
the	O
juxtacanalicular	O
tissue	O
and	O
beneath	O
the	O
endothelial	O
lining	O
of	O
the	O
canal	O
of	O
Schlemm	O
.	O

CONCLUSION	O
:	O
Dexamethasone	O
treatment	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
led	O
to	O
the	O
generation	O
of	O
ocular	B
hypertension	I
in	O
approximately	O
30	O
%	O
of	O
the	O
dexamethasone	O
-	O
treated	O
eyes	O
.	O

This	O
system	O
may	O
provide	O
an	O
acute	O
model	O
in	O
which	O
to	O
study	O
the	O
pathogenic	O
mechanisms	O
involved	O
in	O
steroid	B
glaucoma	I
and	O
primary	B
open	I
angle	I
glaucoma	I
.	O

In	O
four	O
patients	O
hearing	B
impairment	I
on	O
the	O
side	O
of	O
the	O
block	O
was	O
demonstrated	O
after	O
operation	O
,	O
in	O
three	O
measurements	O
on	O
the	O
day	O
of	O
surgery	O
and	O
in	O
one	O
on	O
the	O
following	O
day	O
.	O

IBPB	O
may	O
cause	O
transient	O
auditory	B
dysfunction	I
in	O
the	O
ipsilateral	O
ear	O
,	O
possibly	O
via	O
an	O
effect	O
on	O
sympathetic	O
innervation	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
combination	O
N	O
-	O
butyl	O
-	O
deoxynojirimycin	O
(	O
SC	O
-	O
48334	O
)	O
and	O
zidovudine	O
in	O
patients	O
with	O
HIV	B
-	I
1	I
infection	I
and	O
200	O
-	O
500	O
CD4	O
cells	O
/	O
mm3	O
.	O

The	O
mean	O
SC	O
-	O
48334	O
steady	O
-	O
state	O
trough	O
level	O
(	O
4	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
99	O
micrograms	O
/	O
ml	O
)	O
was	O
below	O
the	O
in	O
vitro	O
inhibitory	O
concentration	O
for	O
human	O
immunodeficiency	B
virus	O
(	O
HIV	O
)	O
.	O

Diarrhea	B
,	O
flatulence	B
,	O
abdominal	B
pain	I
,	O
and	O
weight	B
loss	I
were	O
common	O
for	O
combination	O
recipients	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
long	O
-	O
term	O
use	O
of	O
nondepolarizing	O
neuromuscular	O
blocking	O
agents	O
(	O
ND	O
-	O
NMBA	O
)	O
has	O
recently	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
prolonged	O
muscle	B
weakness	I
,	O
although	O
the	O
site	O
of	O
the	O
lesion	O
and	O
the	O
predisposing	O
factors	O
have	O
been	O
unclear	O
.	O

We	O
report	O
3	O
patients	O
(	O
age	O
37	O
-	O
52	O
years	O
)	O
with	O
acute	O
respiratory	B
insufficiency	I
who	O
developed	O
prolonged	O
weakness	B
following	O
the	O
discontinuation	O
of	O
ND	O
-	O
NMBAs	O
.	O

A	O
muscle	O
biopsy	O
in	O
this	O
patient	O
showed	O
loss	B
of	I
thick	I
,	I
myosin	I
filaments	I
.	O

The	O
weakness	B
in	O
these	O
patients	O
is	O
due	O
to	O
pathology	B
at	I
both	I
the	I
neuromuscular	I
junction	I
(	O
most	O
likely	O
due	O
to	O
ND	O
-	O
NMBA	O
)	O
and	O
muscle	O
(	O
most	O
likely	O
due	O
to	O
corticosteroids	O
)	O
.	O

Hepatic	B
dysfunction	I
and	O
acidosis	B
are	O
contributing	O
risk	O
factors	O
.	O

Failure	O
of	O
ancrod	O
in	O
the	O
treatment	O
of	O
heparin	O
-	O
induced	O
arterial	O
thrombosis	B
.	O

The	O
morbidity	O
and	O
mortality	O
associated	O
with	O
heparin	O
-	O
induced	O
thrombosis	B
remain	O
high	O
despite	O
numerous	O
empirical	O
therapies	O
.	O

Ancrod	O
has	O
been	O
used	O
successfully	O
for	O
prophylaxis	O
against	O
development	O
of	O
thrombosis	B
in	O
patients	O
with	O
heparin	O
induced	O
platelet	B
aggregation	I
who	O
require	O
brief	O
reexposure	O
to	O
heparin	O
,	O
but	O
its	O
success	O
in	O
patients	O
who	O
have	O
developed	O
the	O
thrombosis	B
syndrome	O
is	O
not	O
well	O
defined	O
.	O

The	O
authors	O
present	O
a	O
case	O
of	O
failure	O
of	O
ancrod	O
treatment	O
in	O
a	O
patient	O
with	O
heparin	O
-	O
induced	O
thrombosis	B
.	O

Light	O
chain	O
proteinuria	B
and	O
cellular	O
mediated	O
immunity	O
in	O
rifampin	O
treated	O
patients	O
with	O
tuberculosis	B
.	O

Light	O
chain	O
proteinuria	B
was	O
found	O
in	O
9	O
of	O
17	O
tuberculosis	B
patients	O
treated	O
with	O
rifampin	O
.	O

Baclofen	O
was	O
also	O
useful	O
in	O
one	O
monkey	O
against	O
a	O
more	O
dystonic	B
form	O
of	O
dyskinesia	B
.	O

Atropine	O
converted	O
the	O
dystonic	B
movements	O
into	O
chorea	B
.	O

Penicillamine	O
-	O
induced	O
rapidly	O
progressive	O
glomerulonephritis	B
in	O
a	O
patient	O
with	O
rheumatoid	B
arthritis	I
.	O

A	O
67	O
-	O
year	O
-	O
old	O
woman	O
with	O
rheumatoid	B
arthritis	I
presented	O
rapidly	O
progressive	O
glomerulonephritis	B
(	O
RPGN	B
)	O
after	O
5	O
months	O
of	O
D	O
-	O
penicillamine	O
(	O
250	O
mg	O
/	O
day	O
)	O
treatment	O
.	O

Light	O
microscopy	O
study	O
showed	O
severe	O
glomerulonephritis	B
with	O
crescent	O
formation	O
in	O
60	O
%	O
of	O
the	O
glomeruli	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
in	O
the	O
wall	O
of	O
an	O
arteriole	O
.	O

This	O
new	O
case	O
of	O
RPGN	B
in	O
the	O
course	O
of	O
D	O
-	O
penicillamine	O
treatment	O
emphasizes	O
the	O
need	O
for	O
frequent	O
monitoring	O
of	O
renal	O
function	O
and	O
evaluation	O
of	O
urinary	O
sediment	O
and	O
proteinuria	B
in	O
these	O
patients	O
.	O

A	O
case	O
of	O
polymyositis	B
in	O
a	O
patient	O
with	O
primary	B
biliary	I
cirrhosis	I
treated	O
with	O
D	O
-	O
penicillamine	O
.	O

Although	O
D	O
-	O
penicillamine	O
has	O
been	O
used	O
for	O
many	O
rheumatologic	B
diseases	I
,	O
toxicity	B
limits	O
its	O
usefulness	O
in	O
many	O
patients	O
.	O

We	O
report	O
a	O
patient	O
with	O
primary	B
biliary	I
cirrhosis	I
,	O
who	O
developed	O
polymyositis	B
while	O
receiving	O
D	O
-	O
penicillamine	O
therapy	O
.	O

Hyperalgesia	B
and	O
myoclonus	B
in	O
terminal	O
cancer	B
patients	O
treated	O
with	O
continuous	O
intravenous	O
morphine	O
.	O

Eight	O
cancer	B
patients	O
in	O
the	O
terminal	O
stages	O
of	O
the	O
disease	O
treated	O
with	O
high	O
doses	O
of	O
intravenous	O
morphine	O
developed	O
hyperalgesia	B
.	O

Liposomal	O
daunorubicin	O
in	O
advanced	O
Kaposi	B
'	I
s	I
sarcoma	I
:	O
a	O
phase	O
II	O
study	O
.	O

We	O
report	O
a	O
non	O
-	O
randomized	O
Phase	O
II	O
clinical	O
trial	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
liposomal	O
daunorubicin	O
(	O
DaunoXome	O
)	O
in	O
the	O
treatment	O
of	O
AIDS	B
related	O
Kaposi	B
'	I
s	I
sarcoma	I
.	O

Eleven	O
homosexual	O
men	O
with	O
advanced	O
Kaposi	B
'	I
s	I
sarcoma	I
were	O
entered	O
in	O
the	O
trial	O
.	O

Stabilization	O
of	O
Kaposi	B
'	I
s	I
sarcoma	I
occurred	O
in	O
the	O
remaining	O
six	O
,	O
maintained	O
until	O
the	O
end	O
of	O
the	O
trial	O
period	O
in	O
four	O
.	O

In	O
this	O
small	O
patient	O
sample	O
,	O
liposomal	O
daunorubicin	O
was	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	O
in	O
the	O
treatment	O
of	O
Kaposi	B
'	I
s	I
sarcoma	I
.	O

Forty	O
patients	O
with	O
Non	B
-	I
Hodgkin	I
'	I
s	I
Lymphoma	I
treated	O
with	O
vincristine	O
between	O
1984	O
and	O
1990	O
(	O
cumulative	O
dose	O
12	O
mg	O
in	O
18	O
-	O
24	O
weeks	O
)	O
were	O
investigated	O
in	O
order	O
to	O
evaluate	O
the	O
long	O
term	O
effects	O
of	O
vincristine	O
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

The	O
patients	O
were	O
interviewed	O
with	O
emphasis	O
on	O
neuropathic	B
symptoms	I
.	O

Twenty	O
-	O
seven	O
patients	O
reported	O
neuropathic	B
symptoms	I
.	O

Hepatic	O
adenomas	B
and	O
focal	B
nodular	I
hyperplasia	I
of	O
the	O
liver	O
in	O
young	O
women	O
on	O
oral	O
contraceptives	O
:	O
case	O
reports	O
.	O

Two	O
cases	O
of	O
hepatic	O
adenoma	B
and	O
one	O
of	O
focal	B
nodular	I
hyperplasia	I
presumably	O
associated	O
with	O
the	O
use	O
of	O
oral	O
contraceptives	O
,	O
are	O
reported	O
.	O

Histologic	O
differences	O
and	O
clinical	O
similarities	O
between	O
hepatic	O
adenoma	B
and	O
focal	B
nodular	I
hyperplasia	I
of	O
the	O
liver	O
are	O
discussed	O
.	O

In	O
situ	O
hybridization	O
methods	O
were	O
used	O
to	O
determine	O
if	O
glutamic	O
acid	O
decarboxylase	O
(	O
GAD	O
)	O
mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
are	O
vulnerable	O
to	O
seizure	B
-	O
induced	O
damage	O
in	O
a	O
model	O
of	O
chronic	O
seizures	B
.	O

Additional	O
neuronanatomical	O
studies	O
,	O
including	O
cresyl	O
violet	O
staining	O
,	O
neuronal	B
degeneration	I
methods	O
,	O
and	O
histochemical	O
localization	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
suggested	O
that	O
the	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
was	O
related	O
to	O
neuronal	B
loss	I
rather	O
than	O
to	O
a	O
decrease	O
in	O
GAD	O
mRNA	O
levels	O
.	O

The	O
results	O
indicate	O
that	O
,	O
in	O
this	O
model	O
,	O
a	O
subpopulation	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
dentate	O
gyrus	O
is	O
selectively	O
vulnerable	O
to	O
seizure	B
-	O
induced	O
damage	O
.	O

The	O
following	O
psychological	O
tests	O
were	O
performed	O
:	O
four	O
subtests	O
of	O
the	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
(	O
similarities	O
,	O
digit	O
span	O
,	O
vocabulary	O
and	O
digit	O
symbol	O
)	O
,	O
Trail	O
-	O
Making	O
tests	O
A	O
and	O
B	O
,	O
Zung	O
tests	O
(	O
self	O
-	O
rating	O
anxiety	B
scale	O
and	O
self	O
-	O
rating	O
depression	B
scale	O
)	O
and	O
two	O
-	O
part	O
memory	O
test	O
battery	O
with	O
immediate	O
and	O
delayed	O
recall	O
.	O

Apparent	O
cure	O
of	O
rheumatoid	B
arthritis	I
by	O
bone	O
marrow	O
transplantation	O
.	O

We	O
describe	O
the	O
induction	O
of	O
sustained	O
remissions	O
and	O
possible	O
cure	O
of	O
severe	O
erosive	O
rheumatoid	B
arthritis	I
(	O
RA	B
)	O
by	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
in	O
2	O
patients	O
.	O

BMT	O
was	O
used	O
to	O
treat	O
severe	O
aplastic	B
anemia	I
which	O
was	O
caused	O
by	O
gold	O
in	O
one	O
case	O
and	O
D	O
-	O
penicillamine	O
in	O
the	O
other	O
.	O

This	O
experience	O
raises	O
the	O
question	O
of	O
the	O
role	O
of	O
BMT	O
itself	O
as	O
a	O
therapeutic	O
option	O
for	O
patients	O
with	O
uncontrolled	O
destructive	O
synovitis	B
.	O

Efficacy	O
and	O
tolerability	O
of	O
lovastatin	O
in	O
3390	O
women	O
with	O
moderate	O
hypercholesterolemia	B
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
lovastatin	O
in	O
women	O
with	O
moderate	O
hypercholesterolemia	B
.	O

CONCLUSION	O
:	O
Lovastatin	O
is	O
highly	O
effective	O
and	O
generally	O
well	O
tolerated	O
as	O
therapy	O
for	O
primary	O
hypercholesterolemia	B
in	O
women	O
.	O

While	O
severe	O
hypokalemia	B
may	O
cause	O
muscle	B
weakness	I
,	O
severe	O
hypomagnesemia	B
is	O
associated	O
with	O
muscle	B
spasms	I
and	O
tetany	B
which	O
cannot	O
be	O
corrected	O
by	O
potassium	O
and	O
calcium	O
supplementation	O
alone	O
(	O
1	O
,	O
2	O
)	O
.	O

Surreptitious	O
diuretic	O
ingestion	O
has	O
been	O
described	O
,	O
mainly	O
in	O
women	O
who	O
are	O
concerned	O
that	O
they	O
are	O
obese	B
or	O
edematous	B
.	O

Ciprofloxacin	O
-	O
induced	O
nephrotoxicity	B
in	O
patients	O
with	O
cancer	B
.	O

Five	O
patients	O
with	O
cancer	B
who	O
developed	O
acute	B
renal	I
failure	I
that	O
followed	O
treatment	O
with	O
ciprofloxacin	O
are	O
described	O
and	O
an	O
additional	O
15	O
cases	O
reported	O
in	O
the	O
literature	O
are	O
reviewed	O
.	O

An	O
improvement	O
in	O
renal	O
function	O
that	O
followed	O
the	O
discontinuation	O
of	O
the	O
offending	O
antibiotic	O
supports	O
the	O
presumptive	O
diagnosis	O
of	O
ciprofloxacin	O
-	O
induced	O
acute	B
renal	I
failure	I
.	O

Although	O
some	O
studies	O
have	O
suggested	O
fewer	O
venous	B
complications	I
are	O
associated	O
with	O
midazolam	O
than	O
with	O
diazepam	O
for	O
endoscopic	O
procedures	O
,	O
this	O
variable	O
has	O
not	O
been	O
well	O
documented	O
.	O

We	O
prospectively	O
evaluated	O
the	O
incidence	O
of	O
venous	B
complications	I
after	O
intravenous	O
injection	O
of	O
diazepam	O
or	O
midazolam	O
in	O
122	O
consecutive	O
patients	O
undergoing	O
colonoscopy	O
and	O
esophagogastroduodenoscopy	O
.	O

Overall	O
,	O
venous	B
complications	I
were	O
more	O
frequent	O
with	O
diazepam	O
(	O
22	O
of	O
62	O
patients	O
)	O
than	O
with	O
midazolam	O
(	O
4	O
of	O
60	O
patients	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Smoking	O
,	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
use	O
,	O
intravenous	O
catheter	O
site	O
,	O
dwell	O
time	O
of	O
the	O
needle	O
,	O
alcohol	O
use	O
,	O
and	O
pain	B
during	O
the	O
injection	O
had	O
no	O
effect	O
on	O
the	O
incidence	O
of	O
venous	B
complications	I
.	O

Clarithromycin	O
-	O
associated	O
visual	B
hallucinations	I
in	O
a	O
patient	O
with	O
chronic	B
renal	I
failure	I
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
.	O

Visual	B
hallucinations	I
are	O
a	O
rare	O
event	O
in	O
chronic	B
renal	I
failure	I
and	O
not	O
related	O
to	O
uremia	B
per	O
se	O
.	O

Unreported	O
in	O
the	O
literature	O
is	O
visual	B
hallucinations	I
occurring	O
in	O
association	O
with	O
the	O
new	O
macrolide	O
antibiotic	O
,	O
clarithromycin	O
.	O

We	O
describe	O
such	O
a	O
case	O
in	O
a	O
patient	O
with	O
end	B
-	I
stage	I
renal	I
disease	I
(	O
ESRD	B
)	O
maintained	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O

The	O
combination	O
of	O
a	O
relatively	O
high	O
dose	O
of	O
clarithromycin	O
in	O
face	O
of	O
chronic	B
renal	I
failure	I
in	O
a	O
functionally	O
anephric	O
patient	O
,	O
with	O
underlying	O
aluminum	O
intoxication	O
,	O
may	O
have	O
facilitated	O
the	O
appearance	O
of	O
this	O
neurotoxic	B
side	O
effect	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
pharmacokinetics	O
of	O
medications	O
in	O
face	O
of	O
chronic	B
renal	I
failure	I
,	O
the	O
possibility	O
of	O
drug	O
interactions	O
,	O
and	O
how	O
these	O
factors	O
should	O
help	O
guide	O
medication	O
therapy	O
in	O
the	O
ESRD	B
patient	O
.	O

Changes	O
in	O
peroxisomes	O
in	O
preneoplastic	O
liver	O
and	O
hepatoma	B
of	O
mice	O
induced	O
by	O
alpha	O
-	O
benzene	O
hexachloride	O
.	O

Peroxisomes	O
in	O
hepatomas	B
and	O
hyperplastic	O
preneoplastic	O
liver	B
lesions	I
induced	O
in	O
mice	O
by	O
500	O
ppm	O
alpha	O
-	O
benzene	O
hexachloride	O
were	O
examined	O
histochemically	O
and	O
electron	O
microscopically	O
.	O

Although	O
most	O
of	O
the	O
hepatomas	B
were	O
well	O
-	O
differentiated	O
tumors	B
and	O
contained	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
,	O
the	O
tumor	B
cells	O
did	O
not	O
respond	O
to	O
ethyl	O
-	O
alpha	O
-	O
p	O
-	O
chlorophenoxyisobutyrate	O
with	O
proliferation	O
of	O
peroxisomes	O
.	O

Intravenous	O
infusion	O
of	O
the	O
ganglionic	O
blocker	O
hexamethonium	O
resulted	O
in	O
a	O
rapid	O
decline	O
in	O
MAP	O
that	O
eliminated	O
the	O
dietary	O
sodium	O
chloride	O
-	O
induced	O
increase	B
in	I
MAP	I
in	O
both	O
groups	O
.	O

Angioedema	B
,	O
also	O
known	O
as	O
angioneurotic	B
edema	I
or	O
Quincke	B
'	I
s	I
disease	I
,	O
is	O
a	O
well	O
-	O
demarcated	O
,	O
localized	O
edema	B
involving	O
the	O
subcutaneous	O
tissues	O
that	O
may	O
cause	O
upper	B
-	I
airway	I
obstruction	I
.	O

We	O
report	O
the	O
case	O
of	O
a	O
previously	O
healthy	O
19	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
known	O
drug	B
allergies	I
in	O
whom	O
angioedema	B
with	O
significant	O
tongue	B
swelling	I
and	O
protrusion	O
developed	O
within	O
10	O
minutes	O
of	O
the	O
administration	O
of	O
a	O
single	O
IV	O
dose	O
of	O
droperidol	O
.	O

Late	O
cardiotoxicity	B
after	O
treatment	O
for	O
a	O
malignant	O
bone	B
tumor	I
.	O

Cardiac	O
function	O
was	O
assessed	O
in	O
long	O
-	O
term	O
survivors	O
of	O
malignant	O
bone	B
tumors	I
who	O
were	O
treated	O
according	O
to	O
Rosen	O
'	O
s	O
T5	O
or	O
T10	O
protocol	O
,	O
both	O
including	O
doxorubicin	O
.	O

Eighteen	O
of	O
31	O
(	O
58	O
%	O
)	O
patients	O
showed	O
cardiac	B
toxicity	I
,	O
defined	O
as	O
having	O
one	O
or	O
more	O
of	O
the	O
following	O
abnormalities	O
:	O
late	O
potentials	O
,	O
complex	O
ventricular	B
arrhythmias	I
,	O
left	O
ventricular	B
dilation	I
,	O
decreased	O
shortening	O
fraction	O
,	O
or	O
decreased	O
ejection	O
fraction	O
.	O

The	O
incidence	O
of	O
cardiac	B
abnormalities	I
increased	O
with	O
length	O
of	O
follow	O
-	O
up	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
.	O

Absence	O
of	O
effect	O
of	O
sertraline	O
on	O
time	O
-	O
based	O
sensitization	O
of	O
cognitive	B
impairment	I
with	O
haloperidol	O
.	O

RESULTS	O
:	O
Impairment	B
of	I
cognitive	I
function	I
was	O
observed	O
6	O
to	O
8	O
hours	O
after	O
administration	O
of	O
haloperidol	O
on	O
Day	O
2	O
but	O
was	O
not	O
evident	O
23	O
hours	O
after	O
dosing	O
.	O

CONCLUSION	O
:	O
Haloperidol	O
produced	O
a	O
clear	O
profile	O
of	O
cognitive	B
impairment	I
that	O
was	O
not	O
worsened	O
by	O
concomitant	O
sertraline	O
administration	O
.	O

Coexistence	O
of	O
cerebral	B
venous	I
sinus	I
and	I
internal	I
carotid	I
artery	I
thrombosis	I
associated	O
with	O
exogenous	O
sex	O
hormones	O
.	O

A	O
forty	O
-	O
six	O
year	O
-	O
old	O
premenopausal	O
woman	O
developed	O
headache	B
,	O
nausea	B
and	O
vomiting	B
,	O
left	O
hemiparesis	B
and	O
seizure	B
two	O
days	O
after	O
parenteral	O
use	O
of	O
progesterone	O
and	O
estradiol	O
.	O

Diabetes	B
mellitus	I
(	O
DM	B
)	O
was	O
found	O
during	O
admission	O
.	O

Left	O
carotid	O
angiography	O
found	O
occlusion	B
of	I
the	I
left	I
internal	I
carotid	I
artery	I
(	O
ICA	O
)	O
.	O

Right	O
carotid	O
angiograms	O
failed	O
to	O
show	O
the	O
SSS	O
and	O
inferior	O
sagittal	O
sinus	O
,	O
suggestive	O
of	O
venous	B
sinus	I
thrombosis	I
.	O

Coexistence	O
of	O
the	O
cerebral	B
artery	I
and	I
the	I
venous	I
sinus	I
occlusion	I
has	O
been	O
described	O
infrequently	O
.	O

In	O
this	O
case	O
,	O
the	O
authors	O
postulate	O
that	O
the	O
use	O
of	O
estradiol	O
and	O
progesterone	O
and	O
the	O
underlying	O
DM	B
increased	O
vascular	O
thrombogenicity	O
,	O
which	O
provided	O
a	O
common	O
denominator	O
for	O
thrombosis	B
of	I
both	I
the	I
ICA	I
and	I
the	I
venous	I
sinus	I
.	O

Chemotherapy	O
of	O
advanced	O
inoperable	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
with	O
paclitaxel	O
:	O
a	O
phase	O
II	O
trial	O
.	O

Paclitaxel	O
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
has	O
demonstrated	O
significant	O
antineoplastic	O
activity	O
against	O
different	O
tumor	B
types	O
,	O
notably	O
ovarian	B
and	I
breast	I
carcinoma	I
.	O

Two	O
phase	O
II	O
trials	O
of	O
24	O
-	O
hour	O
paclitaxel	O
infusions	O
in	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
(	O
NSCLC	B
)	O
reported	O
response	O
rates	O
of	O
21	O
%	O
and	O
24	O
%	O
.	O

Similarly	O
,	O
grade	O
1	O
or	O
2	O
myalgia	B
/	O
arthralgia	B
was	O
observed	O
in	O
63	O
.	O
2	O
%	O
of	O
patients	O
,	O
but	O
only	O
14	O
.	O
3	O
%	O
experienced	O
grade	O
3	O
or	O
4	O
.	O

Paclitaxel	O
combined	O
with	O
carboplatin	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
ovarian	B
cancer	I
.	O

In	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
paclitaxel	O
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
given	O
as	O
a	O
3	O
-	O
hour	O
infusion	O
in	O
combination	O
with	O
carboplatin	O
administered	O
every	O
21	O
days	O
to	O
women	O
with	O
advanced	O
ovarian	B
cancer	I
,	O
paclitaxel	O
doses	O
were	O
escalated	O
as	O
follows	O
:	O
level	O
1	O
,	O
135	O
mg	O
/	O
m2	O
;	O
level	O
2	O
,	O
160	O
mg	O
/	O
m2	O
;	O
level	O
3	O
,	O
185	O
mg	O
/	O
m2	O
;	O
and	O
level	O
4	O
,	O
210	O
mg	O
/	O
m2	O
.	O

The	O
dose	O
-	O
limiting	O
toxicity	B
of	O
the	O
combination	O
was	O
myelosuppression	B
(	O
leukopenia	B
,	O
granulocytopenia	B
,	O
and	O
thrombocytopenia	B
)	O
.	O

Occasional	O
case	O
reports	O
have	O
shown	O
that	O
acute	O
myopathy	B
may	O
occur	O
in	O
patients	O
treated	O
with	O
massive	O
doses	O
of	O
corticosteroids	O
.	O

The	O
mechanism	O
of	O
this	O
myopathy	B
is	O
poorly	O
understood	O
.	O

Nutritional	O
intake	O
,	O
measured	O
daily	O
in	O
15	O
animals	O
,	O
showed	O
a	O
significant	O
reduction	B
of	I
food	I
intake	I
in	O
the	O
steroid	O
-	O
treated	O
groups	O
(	O
-	O
50	O
and	O
-	O
79	O
%	O
in	O
M	O
and	O
T	O
,	O
respectively	O
)	O
.	O

This	O
was	O
associated	O
with	O
a	O
similar	O
loss	B
in	I
body	I
weight	I
.	O

ATPase	O
staining	O
of	O
the	O
diaphragm	O
,	O
scalenus	O
medius	O
,	O
and	O
gastrocnemius	O
showed	O
type	O
IIb	O
fiber	O
atrophy	B
in	O
the	O
steroid	O
groups	O
and	O
also	O
diaphragmatic	O
type	O
IIa	O
atrophy	B
with	O
T	O
,	O
whereas	O
histologic	O
examinations	O
revealed	O
a	O
normal	O
muscular	O
pattern	O
with	O
absence	O
of	O
necrosis	B
.	O

Finally	O
,	O
a	O
pair	O
-	O
fed	O
(	O
PF	O
)	O
study	O
,	O
performed	O
in	O
18	O
rats	O
(	O
C	O
,	O
T	O
,	O
and	O
PF	O
)	O
,	O
showed	O
that	O
muscle	B
atrophy	I
was	O
considerably	O
less	O
pronounced	O
in	O
PF	O
animals	O
than	O
in	O
T	O
-	O
treated	O
animals	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
short	O
-	O
term	O
treatment	O
with	O
massive	O
doses	O
of	O
steroids	O
induced	O
severe	O
respiratory	O
and	O
limb	O
muscle	O
wasting	O
;	O
(	O
2	O
)	O
both	O
types	O
of	O
steroids	O
induced	O
predominantly	O
type	O
IIb	O
atrophy	B
,	O
resulting	O
in	O
the	O
expected	O
alterations	O
in	O
diaphragm	O
contractile	O
properties	O
;	O
(	O
3	O
)	O
neither	O
steroid	O
caused	O
muscle	O
necrosis	B
;	O
(	O
4	O
)	O
type	O
IIb	O
atrophy	B
was	O
not	O
caused	O
by	O
acute	O
nutritional	O
deprivation	O
alone	O
.	O

Leg	B
and	I
back	I
pain	I
after	O
spinal	O
anaesthesia	O
involving	O
hyperbaric	O
5	O
%	O
lignocaine	O
.	O

Thirteen	O
of	O
these	O
patients	O
experienced	O
pain	B
in	I
the	I
legs	I
and	I
/	I
or	I
back	I
after	O
recovery	O
from	O
anaesthesia	O
.	O

Leg	B
and	I
/	I
or	I
back	I
pain	I
is	O
associated	O
with	O
the	O
intrathecal	O
use	O
of	O
hyperbaric	O
5	O
%	O
lignocaine	O
.	O

Recently	O
,	O
we	O
demonstrated	O
the	O
hepatoprotective	O
effects	O
of	O
nicotinic	O
acid	O
amide	O
,	O
a	O
selective	O
inhibitor	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
;	O
EC	O
2	O
.	O
4	O
.	O
2	O
.	O
30	O
)	O
on	O
mice	O
suffering	O
from	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
hepatitis	B
,	O
suggesting	O
that	O
the	O
AAP	O
-	O
induced	O
liver	B
injury	I
involves	O
a	O
step	O
which	O
depends	O
on	O
adenoribosylation	O
.	O

In	O
these	O
animals	O
,	O
only	O
minor	O
increases	O
of	O
serum	O
transaminase	O
activities	O
were	O
measured	O
in	O
the	O
presence	O
of	O
AAP	O
,	O
and	O
unlike	O
the	O
exacerbation	O
caused	O
by	O
ethanol	O
in	O
mice	O
on	O
a	O
standard	O
diet	O
,	O
the	O
liver	B
damage	I
was	O
inhibited	O
by	O
50	O
%	O
by	O
ethanol	O
.	O

We	O
see	O
the	O
main	O
application	O
of	O
NAA	O
as	O
for	O
the	O
combinational	O
use	O
in	O
pharmaceutical	O
preparations	O
of	O
acetaminophen	O
in	O
order	O
to	O
avoid	O
hepatic	B
damage	I
in	O
patients	O
treated	O
with	O
this	O
widely	O
used	O
analgesic	O
.	O

Tramadol	O
is	O
a	O
weak	O
opioid	O
with	O
effects	O
on	O
adrenergic	O
and	O
serotonergic	O
neurotransmission	O
that	O
is	O
used	O
to	O
treat	O
cancer	B
pain	B
and	O
chronic	O
non	O
malignant	O
pain	B
.	O

This	O
drug	O
was	O
initiated	O
in	O
association	O
with	O
paroxetine	O
and	O
dosulepine	O
hydrochloride	O
in	O
a	O
tetraparetic	B
patient	O
with	O
chronic	B
pain	I
.	O

CaCl2	O
therapy	O
may	O
possibly	O
worsen	O
both	O
cardiovascular	B
and	I
central	I
nervous	I
system	I
toxicity	I
.	O

Serotonin	B
syndrome	I
from	O
venlafaxine	O
-	O
tranylcypromine	O
interaction	O
.	O

Excessive	O
stimulation	O
of	O
serotonin	O
5HT1A	O
receptors	O
causes	O
a	O
syndrome	O
of	O
serotonin	O
excess	O
that	O
consists	O
of	O
shivering	O
,	O
muscle	B
rigidity	I
,	O
salivation	B
,	O
confusion	B
,	O
agitation	B
and	O
hyperthermia	B
.	O

We	O
report	O
a	O
venlafaxine	O
-	O
MAOI	O
interaction	O
that	O
resulted	O
in	O
the	O
serotonin	B
syndrome	I
in	O
a	O
23	O
-	O
y	O
-	O
old	O
male	O
who	O
was	O
taking	O
tranylcypromine	O
for	O
depression	B
.	O

After	O
180	O
mg	O
of	O
diazepam	O
i	O
.	O
v	O
.	O
he	O
remained	O
tremulous	O
with	O
muscle	B
rigidity	I
and	O
clenched	O
jaws	O
.	O

He	O
was	O
intubated	O
for	O
airway	O
protection	O
and	O
because	O
of	O
hypoventilation	B
,	O
and	O
was	O
paralyzed	B
to	O
control	O
muscle	B
rigidity	I
.	O

His	O
subsequent	O
course	O
was	O
remarkable	O
for	O
non	O
-	O
immune	O
thrombocytopenia	B
which	O
resolved	O
.	O

Cyclophosphamide	O
associated	O
bladder	B
cancer	I
-	O
-	O
a	O
highly	O
aggressive	O
disease	O
:	O
analysis	O
of	O
12	O
cases	O
.	O

PURPOSE	O
:	O
We	O
gained	O
knowledge	O
of	O
the	O
etiology	O
,	O
treatment	O
and	O
prevention	O
of	O
cyclophosphamide	O
associated	O
urothelial	B
cancer	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
medical	O
records	O
of	O
6	O
men	O
and	O
6	O
women	O
(	O
mean	O
age	O
55	O
years	O
)	O
with	O
cyclophosphamide	O
associated	O
bladder	B
cancer	I
were	O
reviewed	O
.	O

RESULTS	O
:	O
All	O
tumors	B
were	O
grade	O
3	O
or	O
4	O
transitional	O
cell	O
carcinoma	B
.	O

The	O
remaining	O
patient	O
with	O
extensive	O
cancer	B
underwent	O
partial	O
cystectomy	O
for	O
palliation	O
and	O
died	O
3	O
months	O
later	O
.	O

CONCLUSIONS	O
:	O
Cyclophosphamide	O
associated	O
bladder	B
tumor	I
is	O
an	O
aggressive	O
disease	O
.	O

However	O
,	O
long	O
-	O
term	O
survival	O
is	O
possible	O
when	O
radical	O
cystectomy	O
is	O
performed	O
for	O
bladder	B
tumors	I
with	O
any	O
sign	O
of	O
invasion	O
and	O
for	O
recurrent	O
high	O
grade	O
disease	O
,	O
even	O
when	O
noninvasive	O
.	O

Extensive	O
experimental	O
and	O
limited	O
clinical	O
data	O
have	O
shown	O
that	O
lometrexol	O
has	O
activity	O
against	O
tumours	B
which	O
are	O
refractory	O
to	O
other	O
drugs	O
,	O
notably	O
methotrexate	O
.	O

This	O
information	O
will	O
facilitate	O
the	O
future	O
evaluation	O
of	O
this	O
class	O
of	O
compounds	O
in	O
cancer	B
therapy	O
.	O

The	O
epidemiologic	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
hypothesis	O
that	O
chronic	O
cocaine	O
use	O
disrupts	O
dopaminergic	O
function	O
and	O
,	O
when	O
coupled	O
with	O
recent	O
cocaine	O
use	O
,	O
may	O
precipitate	O
agitation	B
,	O
delirium	B
,	O
aberrant	O
thermoregulation	O
,	O
rhabdomyolysis	B
,	O
and	O
sudden	B
death	I
.	O

BACKGROUND	O
:	O
Pemoline	O
is	O
an	O
oxazolidine	O
derivative	O
that	O
is	O
structurally	O
different	O
from	O
amphetamines	O
and	O
used	O
in	O
the	O
treatment	O
of	O
attention	B
deficit	I
disorder	I
.	O

Pemoline	O
has	O
not	O
been	O
commonly	O
associated	O
in	O
the	O
literature	O
as	O
a	O
cause	O
of	O
acute	O
movement	B
disorders	I
.	O

The	O
children	O
had	O
a	O
medical	O
history	O
significant	O
for	O
attention	B
deficit	I
disorder	I
previously	O
treated	O
with	O
methylphenidate	O
without	O
success	O
.	O

The	O
children	O
gave	O
no	O
history	O
of	O
prior	O
movement	B
disorders	I
and	O
there	O
was	O
no	O
family	O
history	O
of	O
movement	B
disorders	I
.	O

CONCLUSION	O
:	O
Pemoline	O
associated	O
movement	B
disorder	I
has	O
been	O
rarely	O
reported	O
in	O
the	O
acute	O
toxicology	O
literature	O
.	O

Neutrophil	O
superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
in	O
patients	O
with	O
acute	B
liver	I
failure	I
.	O

Defects	O
in	O
superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
may	O
be	O
implicated	O
in	O
the	O
high	O
incidence	O
of	O
bacterial	B
infections	I
in	O
patients	O
with	O
acute	B
liver	I
failure	I
(	O
ALF	B
)	O
.	O

Postinfarction	O
ventricular	B
septal	I
defect	I
associated	O
with	O
long	O
-	O
term	O
steroid	O
therapy	O
.	O

Although	O
the	O
neuroactive	O
steroids	O
were	O
considerably	O
less	O
potent	O
than	O
the	O
benzodiazepine	O
clonazepam	O
in	O
protecting	O
against	O
pilocarpine	O
seizures	B
,	O
steroids	O
with	O
the	O
5	O
alpha	O
,	O
3	O
alpha	O
-	O
configuration	O
had	O
comparable	O
or	O
higher	O
protective	O
index	O
values	O
(	O
TD50	O
for	O
motor	O
impairment	O
divided	O
by	O
ED50	O
for	O
seizure	B
protection	O
)	O
than	O
clonazepam	O
,	O
indicating	O
that	O
some	O
neuroactive	O
steroids	O
may	O
have	O
lower	O
relative	O
toxicity	B
.	O

Hepatic	O
and	O
extrahepatic	O
angiotensinogen	O
gene	O
expression	O
in	O
rats	O
with	O
acute	O
nephrotic	B
syndrome	I
.	O

Plasma	O
concentration	O
and	O
urine	O
excretion	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
proteins	O
are	O
altered	O
in	O
rats	O
with	O
nephrotic	B
syndrome	I
(	O
NS	B
)	O
.	O

Neuroleptic	B
malignant	I
syndrome	I
with	O
risperidone	O
.	O

Neuroleptic	B
malignant	I
syndrome	I
is	O
thought	O
to	O
be	O
a	O
result	O
of	O
dopamine	O
D2	O
receptor	O
blockade	O
in	O
the	O
striatum	O
of	O
the	O
basal	O
ganglia	O
.	O

The	O
high	O
ratio	O
is	O
believed	O
to	O
impart	O
the	O
low	O
frequency	O
of	O
extrapyramidal	B
symptoms	I
with	O
risperidone	O
at	O
low	O
dosages	O
.	O

With	O
this	O
low	O
frequency	O
of	O
extrapyramidal	B
symptoms	I
,	O
it	O
was	O
thought	O
the	O
frequency	O
of	O
neuroleptic	B
malignant	I
syndrome	I
might	O
also	O
be	O
lowered	O
.	O

A	O
73	O
-	O
year	O
-	O
old	O
woman	O
developed	O
neuroleptic	B
malignant	I
syndrome	I
after	O
monotherapy	O
with	O
risperidone	O
.	O

It	O
appears	O
that	O
the	O
protection	O
from	O
extrapyramidal	O
side	O
effects	O
observed	O
with	O
risperidone	O
does	O
not	O
ensure	O
protection	O
from	O
neuroleptic	B
malignant	I
syndrome	I
.	O

Granulosa	B
cell	I
tumor	I
of	I
the	I
ovary	I
associated	O
with	O
antecedent	O
tamoxifen	O
use	O
.	O

Review	O
of	O
the	O
literature	O
reveals	O
an	O
association	O
between	O
tamoxifen	O
use	O
and	O
gynecologic	O
tumors	B
.	O

CASE	O
:	O
A	O
52	O
-	O
year	O
-	O
old	O
postmenopausal	O
woman	O
was	O
treated	O
with	O
tamoxifen	O
for	O
stage	O
II	O
estrogen	O
receptor	O
-	O
positive	O
breast	B
carcinoma	I
.	O

After	O
an	O
additional	O
17	O
months	O
of	O
elevated	O
serum	O
transaminases	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
a	O
stage	O
Ic	O
granulosa	B
cell	I
tumor	I
of	I
the	I
ovary	I
.	O

CONCLUSION	O
:	O
Patients	O
with	O
tamoxifen	O
-	O
induced	O
liver	B
dysfunction	I
may	O
be	O
at	O
increased	O
risk	O
for	O
granulosa	B
cell	I
tumors	I
because	O
of	O
alterations	O
in	O
tamoxifen	O
metabolism	O
.	O

AZT	O
has	O
induced	O
a	O
macrocytic	B
anemia	I
in	O
AIDS	B
patients	O
on	O
long	O
term	O
AZT	O
therapy	O
.	O

Histological	O
examination	O
on	O
9	O
of	O
10	O
mice	O
with	O
such	O
thrombocytopenia	B
showed	O
changes	O
compatible	O
with	O
myelodysplastic	B
syndrome	I
(	O
MDS	B
)	O
.	O

Above	O
mentioned	O
AZT	O
incorporation	O
may	O
have	O
induced	O
an	O
ineffective	O
hemopoiesis	O
in	O
the	O
primitive	O
hemopoietic	O
progenitor	O
cells	O
,	O
which	O
is	O
known	O
to	O
be	O
seen	O
commonly	O
in	O
the	O
myelodysplastic	B
syndrome	I
.	O

Over	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
its	O
receptor	O
during	O
the	O
development	O
of	O
estrogen	O
-	O
induced	O
rat	O
pituitary	B
tumors	I
may	O
mediate	O
estrogen	O
-	O
initiated	O
tumor	B
angiogenesis	O
.	O

Estrogens	O
,	O
which	O
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
human	O
and	O
animal	O
cancers	B
,	O
can	O
induce	O
tumor	B
angiogenesis	O
in	O
the	O
pituitary	O
of	O
Fischer	O
344	O
rats	O
.	O

The	O
mechanistic	O
details	O
of	O
tumor	B
angiogenesis	O
induction	O
,	O
during	O
estrogen	O
carcinogenesis	B
,	O
are	O
still	O
unknown	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
estrogen	O
in	O
the	O
regulation	O
of	O
tumor	B
angiogenesis	O
in	O
the	O
pituitary	O
of	O
female	O
rats	O
,	O
the	O
density	O
of	O
blood	O
vessels	O
was	O
analysed	O
using	O
factor	O
VIII	O
related	O
antigen	O
(	O
FVIIIRAg	O
)	O
immunohistochemistry	O
and	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
/	O
vascular	O
permeability	O
factor	O
(	O
VEGF	O
/	O
VPF	O
)	O
was	O
examined	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
analysis	O
.	O

The	O
high	O
tumor	B
angiogenic	O
potential	O
was	O
associated	O
with	O
an	O
elevated	O
VEGF	O
/	O
VPF	O
protein	O
expression	O
in	O
the	O
E2	O
exposed	O
pituitary	O
of	O
ovariectomized	O
(	O
OVEX	O
)	O
rats	O
.	O

These	O
findings	O
suggest	O
that	O
over	O
expression	O
of	O
VEGF	O
and	O
its	O
receptor	O
(	O
VEGFR	O
-	O
2	O
)	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
initial	O
step	O
of	O
the	O
regulation	O
of	O
estrogen	O
induced	O
tumor	B
angiogenesis	O
in	O
the	O
rat	O
pituitary	O
.	O

Persistent	O
nephrogenic	B
diabetes	I
insipidus	I
following	O
lithium	O
therapy	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
severe	O
hypernatraemic	O
dehydration	B
following	O
a	O
head	B
injury	I
.	O

Ten	O
years	O
previously	O
he	O
had	O
been	O
diagnosed	O
to	O
have	O
lithium	O
-	O
induced	O
nephrogenic	B
diabetes	I
insipidus	I
,	O
and	O
lithium	O
therapy	O
had	O
been	O
discontinued	O
.	O

He	O
remained	O
thirsty	O
and	O
polyuric	B
despite	O
cessation	O
of	O
lithium	O
and	O
investigations	O
on	O
admission	O
showed	O
him	O
to	O
have	O
normal	O
osmoregulated	O
thirst	O
and	O
vasopressin	O
secretion	O
,	O
with	O
clear	O
evidence	O
of	O
nephrogenic	B
diabetes	I
insipidus	I
.	O

Lithium	O
induced	O
nephrogenic	B
diabetes	I
insipidus	I
is	O
considered	O
to	O
be	O
reversible	O
on	O
cessation	O
of	O
therapy	O
but	O
polyuria	B
persisted	O
in	O
this	O
patient	O
for	O
ten	O
years	O
after	O
lithium	O
was	O
stopped	O
.	O

We	O
discuss	O
the	O
possible	O
renal	O
mechanisms	O
and	O
the	O
implications	O
for	O
management	O
of	O
patients	O
with	O
lithium	O
-	O
induced	O
nephrogenic	B
diabetes	I
insipidus	I
.	O

The	O
findings	O
suggest	O
that	O
NIK	O
-	O
247	O
may	O
be	O
a	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
Alzheimer	B
'	I
s	I
disease	I
.	O

The	O
clinical	O
utility	O
of	O
dopamine	O
(	O
DA	O
)	O
D1	O
receptor	O
agonists	O
in	O
the	O
treatment	O
of	O
Parkinson	B
'	I
s	I
disease	I
(	O
PD	B
)	O
is	O
still	O
unclear	O
.	O

Neuropeptide	O
-	O
Y	O
immunoreactivity	O
in	O
the	O
pilocarpine	O
model	O
of	O
temporal	B
lobe	I
epilepsy	I
.	O

Neuropeptide	O
-	O
Y	O
(	O
NPY	O
)	O
is	O
expressed	O
by	O
granule	O
cells	O
and	O
mossy	O
fibres	O
of	O
the	O
hippocampal	O
dentate	O
gyrus	O
during	O
experimental	O
temporal	B
lobe	I
epilepsy	I
(	O
TLE	B
)	O
.	O

This	O
expression	O
may	O
represent	O
an	O
endogenous	O
damping	O
mechanism	O
since	O
NPY	O
has	O
been	O
shown	O
to	O
block	O
seizure	B
-	O
like	O
events	O
following	O
high	O
-	O
frequency	O
stimulation	O
in	O
hippocampal	O
slices	O
.	O

The	O
pilocarpine	O
(	O
PILO	O
)	O
model	O
of	O
epilepsy	B
is	O
characterized	O
by	O
an	O
acute	O
period	O
of	O
status	B
epilepticus	I
followed	O
by	O
spontaneous	O
recurrent	O
seizures	B
and	O
related	O
brain	B
damage	I
.	O

Posteroventral	O
medial	O
pallidotomy	O
in	O
advanced	O
Parkinson	B
'	I
s	I
disease	I
.	O

BACKGROUND	O
:	O
Posteroventral	O
medial	O
pallidotomy	O
sometimes	O
produces	O
striking	O
improvement	O
in	O
patients	O
with	O
advanced	O
Parkinson	B
'	I
s	I
disease	I
,	O
but	O
the	O
studies	O
to	O
date	O
have	O
involved	O
small	O
numbers	O
of	O
patients	O
and	O
short	O
-	O
term	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
Parkinson	B
'	I
s	I
disease	I
underwent	O
serial	O
,	O
detailed	O
assessments	O
both	O
after	O
drug	O
withdrawal	O
(	O
"	O
off	O
"	O
period	O
)	O
and	O
while	O
taking	O
their	O
optimal	O
medical	O
regimens	O
(	O
"	O
on	O
"	O
period	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
late	O
-	O
stage	O
Parkinson	B
'	I
s	I
disease	I
,	O
pallidotomy	O
significantly	O
reduces	O
levodopa	O
-	O
induced	O
dyskinesias	B
and	O
off	O
-	O
period	O
disability	O
.	O

Effect	O
of	O
glyceryl	O
trinitrate	O
on	O
the	O
sphincter	B
of	I
Oddi	I
spasm	I
evoked	O
by	O
prostigmine	O
-	O
morphine	O
administration	O
.	O

OBJECTIVE	O
:	O
In	O
this	O
study	O
the	O
effect	O
of	O
glyceryl	O
trinitrate	O
on	O
the	O
prostigmine	O
-	O
morphine	O
-	O
induced	O
sphincter	B
of	I
Oddi	I
spasm	I
was	O
evaluated	O
in	O
nine	O
female	O
patients	O
with	O
sphincter	B
of	I
Oddi	I
dyskinesia	I
.	O

METHOD	O
:	O
Sphincter	B
of	I
Oddi	I
spasm	I
was	O
induced	O
by	O
prostigmine	O
-	O
morphine	O
administration	O
(	O
0	O
.	O
5	O
mg	O
prostigmine	O
intramuscularly	O
and	O
10	O
mg	O
morphine	O
subcutaneously	O
)	O
and	O
visualized	O
by	O
quantitative	O
hepatobiliary	O
scintigraphy	O
.	O

CONCLUSION	O
:	O
These	O
results	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
effectiveness	O
of	O
glyceryl	O
trinitrate	O
on	O
the	O
morphine	O
-	O
induced	O
sphincter	B
of	I
Oddi	I
spasm	I
in	O
humans	O
.	O

Since	O
glyceryl	O
trinitrate	O
is	O
able	O
to	O
overcome	O
even	O
the	O
drastic	O
effect	O
of	O
morphine	O
,	O
it	O
might	O
be	O
of	O
relevance	O
in	O
the	O
treatment	O
of	O
sphincter	B
of	I
Oddi	I
dyskinesia	I
.	O

Immunopathology	O
of	O
penicillamine	O
-	O
induced	O
glomerular	B
disease	I
.	O

Four	O
patients	O
with	O
rheumatoid	B
arthritis	I
developed	O
heavy	O
proteinuria	B
after	O
five	O
to	O
12	O
months	O
of	O
treatment	O
with	O
D	O
-	O
penicillamine	O
.	O

The	O
findings	O
were	O
similar	O
to	O
those	O
in	O
early	O
membranous	B
glomerulonephritis	I
,	O
differences	O
being	O
observed	O
however	O
in	O
the	O
results	O
of	O
staining	O
for	O
the	O
early	O
-	O
acting	O
complement	O
components	O
C1q	O
and	O
C4	O
.	O

Using	O
a	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
it	O
was	O
shown	O
recently	O
that	O
in	O
migraine	B
without	O
aura	O
certain	O
areas	O
in	O
the	O
brain	O
stem	O
were	O
activated	O
during	O
the	O
headache	B
state	O
,	O
but	O
not	O
in	O
the	O
headache	B
free	O
interval	O
.	O

It	O
was	O
suggested	O
that	O
this	O
brain	O
stem	O
activation	O
is	O
inherent	O
to	O
the	O
migraine	B
attack	O
itself	O
and	O
represents	O
the	O
so	O
called	O
'	O
migraine	B
generator	O
'	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
performed	O
an	O
experimental	O
pain	B
study	O
in	O
seven	O
healthy	O
volunteers	O
,	O
using	O
the	O
same	O
positioning	O
in	O
the	O
PET	O
scanner	O
as	O
in	O
the	O
migraine	B
patients	O
.	O

Using	O
the	O
same	O
stereotactic	O
space	O
limits	O
as	O
in	O
the	O
above	O
mentioned	O
migraine	B
study	O
no	O
brain	O
stem	O
activation	O
was	O
found	O
in	O
the	O
acute	O
pain	B
state	O
compared	O
to	O
the	O
pain	B
free	O
state	O
.	O

Value	O
of	O
methylprednisolone	O
in	O
prevention	O
of	O
the	O
arthralgia	B
-	O
myalgia	B
syndrome	O
associated	O
with	O
the	O
total	O
dose	O
infusion	O
of	O
iron	O
dextran	O
:	O
a	O
double	O
blind	O
randomized	O
trial	O
.	O

In	O
40	O
%	O
of	O
treated	O
patients	O
,	O
an	O
arthralgia	B
-	O
myalgia	B
syndrome	O
develops	O
.	O

These	O
data	O
demonstrate	O
that	O
administration	O
of	O
MP	O
before	O
and	O
after	O
TDI	O
reduces	O
the	O
frequency	O
and	O
severity	O
of	O
the	O
arthralgia	B
-	O
myalgia	B
syndrome	O
.	O

Prolongation	B
of	I
the	I
QT	I
interval	I
related	O
to	O
cisapride	O
-	O
diltiazem	O
interaction	O
.	O

Cisapride	O
,	O
a	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
substrate	O
,	O
is	O
widely	O
prescribed	O
for	O
the	O
treatment	O
of	O
gastrointestinal	B
motility	I
disorders	I
.	O

Prolongation	B
of	I
QT	I
interval	I
,	O
torsades	B
de	I
pointes	I
,	O
and	O
sudden	B
cardiac	I
death	I
have	O
been	O
reported	O
after	O
concomitant	O
administration	O
with	O
erythromycin	O
or	O
azole	O
antifungal	O
agents	O
,	O
but	O
not	O
with	O
other	O
CYP3A4	O
inhibitors	O
.	O

A	O
possible	O
drug	O
interaction	O
occurred	O
in	O
a	O
45	O
-	O
year	O
-	O
old	O
woman	O
who	O
was	O
taking	O
cisapride	O
for	O
gastroesophageal	B
reflux	I
disorder	I
and	O
diltiazem	O
,	O
an	O
agent	O
that	O
has	O
inhibitory	O
effect	O
on	O
CYP3A4	O
,	O
for	O
hypertension	B
.	O

The	O
patient	O
was	O
in	O
near	O
syncope	B
and	O
had	O
QT	B
-	I
interval	I
prolongation	I
.	O

These	O
results	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
an	O
hyperkinetic	B
abnormal	B
involuntary	I
movement	I
,	O
like	O
L	O
-	O
dopa	O
-	O
induced	O
peak	O
dose	O
dyskinesia	B
,	O
is	O
due	O
to	O
a	O
disinhibition	O
of	O
the	O
primary	O
and	O
associated	O
motor	O
cortex	O
secondary	O
to	O
an	O
excessive	O
outflow	O
of	O
the	O
pallidothalamocortical	O
motor	O
loop	O
.	O

The	O
most	O
common	O
drug	O
-	O
related	O
adverse	O
events	O
were	O
diarrhea	B
,	O
flatulence	B
,	O
and	O
nausea	B
;	O
most	O
adverse	O
events	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
.	O

Iatrogenic	O
risks	O
of	O
endometrial	B
carcinoma	I
after	O
treatment	O
for	O
breast	B
cancer	I
in	O
a	O
large	O
French	O
case	O
-	O
control	O
study	O
.	O

Since	O
tamoxifen	O
is	O
widely	O
used	O
in	O
breast	B
cancer	I
treatment	O
and	O
has	O
been	O
proposed	O
for	O
the	O
prevention	O
of	O
breast	B
cancer	I
,	O
its	O
endometrial	O
iatrogenic	O
effects	O
must	O
be	O
carefully	O
examined	O
.	O

We	O
have	O
investigated	O
the	O
association	O
between	O
endometrial	B
cancer	I
and	O
tamoxifen	O
use	O
or	O
other	O
treatments	O
in	O
women	O
treated	O
for	O
breast	B
cancer	I
in	O
a	O
case	O
-	O
control	O
study	O
.	O

Cases	O
of	O
endometrial	B
cancer	I
diagnosed	O
after	O
breast	B
cancer	I
(	O
n	O
=	O
135	O
)	O
and	O
467	O
controls	O
matched	O
for	O
age	O
,	O
year	O
of	O
diagnosis	O
of	O
breast	B
cancer	I
and	O
hospital	O
and	O
survival	O
time	O
with	O
an	O
intact	O
uterus	O
were	O
included	O
.	O

Women	O
who	O
had	O
received	O
tamoxifen	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
endometrial	B
cancer	I
diagnosed	O
than	O
those	O
who	O
had	O
not	O
(	O
crude	O
relative	O
risk	O
=	O
4	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Women	O
who	O
had	O
endometrial	B
cancer	I
and	O
had	O
received	O
tamoxifen	O
had	O
more	O
advanced	B
disease	I
and	O
poorer	O
prognosis	O
than	O
those	O
with	O
endometrial	B
cancer	I
who	O
had	O
not	O
received	O
this	O
treatment	O
.	O

Our	O
results	O
suggest	O
a	O
causal	O
role	O
of	O
tamoxifen	O
in	O
endometrial	B
cancer	I
,	O
particularly	O
when	O
used	O
as	O
currently	O
proposed	O
for	O
breast	B
cancer	I
prevention	O
.	O

Pelvic	O
radiotherapy	O
may	O
be	O
an	O
additional	O
iatrogenic	O
factor	O
for	O
women	O
with	O
breast	B
cancer	I
.	O

Endometrial	B
cancers	I
diagnosed	O
in	O
women	O
treated	O
with	O
tamoxifen	O
have	O
poorer	O
prognosis	O
.	O

Women	O
who	O
receive	O
tamoxifen	O
for	O
breast	B
cancer	I
should	O
be	O
offered	O
gynaecological	O
surveillance	O
during	O
and	O
after	O
treatment	O
.	O

A	O
long	O
-	O
term	O
evaluation	O
of	O
the	O
risk	O
-	O
benefit	O
ratio	O
of	O
tamoxifen	O
as	O
a	O
preventive	O
treatment	O
for	O
breast	B
cancer	I
is	O
clearly	O
warranted	O
.	O

5	O
,	O
7	O
-	O
dichlorokynurenic	O
acid	O
(	O
5	O
,	O
7	O
-	O
DCKA	O
)	O
,	O
a	O
selective	O
glycine	O
site	O
antagonist	O
,	O
injected	O
in	O
doses	O
of	O
2	O
.	O
5	O
and	O
4	O
.	O
5	O
microg	O
/	O
0	O
.	O
5	O
microl	O
bilaterally	O
,	O
into	O
the	O
rostral	O
region	O
of	O
the	O
striatum	O
,	O
decreased	O
both	O
the	O
haloperidol	O
-	O
induced	O
muscle	B
rigidity	I
(	O
MMG	O
)	O
and	O
the	O
enhanced	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
.	O

However	O
,	O
the	O
use	O
of	O
CBDCA	O
higher	O
-	O
intensity	O
schedules	O
and	O
the	O
association	O
with	O
other	O
neurotoxic	B
drugs	O
in	O
polychemotherapy	O
may	O
cause	O
some	O
concern	O
about	O
its	O
safety	O
with	O
respect	O
to	O
peripheral	B
nervous	I
system	I
damage	I
.	O

RESULTS	O
:	O
CBDCA	O
administration	O
induced	O
dose	O
-	O
dependent	O
peripheral	B
neurotoxicity	I
.	O

Effects	O
of	O
cisapride	O
on	O
symptoms	O
and	O
postcibal	O
small	O
-	O
bowel	O
motor	O
function	O
in	O
patients	O
with	O
irritable	B
bowel	I
syndrome	I
.	O

BACKGROUND	O
:	O
Irritable	B
bowel	I
syndrome	I
is	O
a	O
common	O
cause	O
of	O
abdominal	B
pain	I
and	O
discomfort	O
and	O
may	O
be	O
related	O
to	O
disordered	B
gastrointestinal	I
motility	I
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
effects	O
of	O
long	O
-	O
term	O
treatment	O
with	O
a	O
prokinetic	O
agent	O
,	O
cisapride	O
,	O
on	O
postprandial	O
jejunal	O
motility	O
and	O
symptoms	O
in	O
the	O
irritable	B
bowel	I
syndrome	I
(	O
IBS	B
)	O
.	O

METHODS	O
:	O
Thirty	O
-	O
eight	O
patients	O
with	O
IBS	B
(	O
constipation	B
-	O
predominant	O
,	O
n	O
=	O
17	O
;	O
diarrhoea	B
-	O
predominant	O
,	O
n	O
=	O
21	O
)	O
underwent	O
24	O
-	O
h	O
ambulatory	O
jejunal	O
manometry	O
before	O
and	O
after	O
12	O
week	O
'	O
s	O
treatment	O
[	O
cisapride	O
,	O
5	O
mg	O
three	O
times	O
daily	O
(	O
n	O
=	O
19	O
)	O
or	O
placebo	O
(	O
n	O
=	O
19	O
)	O
]	O
.	O

RESULTS	O
:	O
In	O
diarrhoea	B
-	O
predominant	O
patients	O
significant	O
differences	O
in	O
contraction	O
characteristics	O
were	O
observed	O
between	O
the	O
cisapride	O
and	O
placebo	O
groups	O
.	O

In	O
cisapride	O
-	O
treated	O
diarrhoea	B
-	O
predominant	O
patients	O
the	O
mean	O
contraction	O
amplitude	O
was	O
higher	O
(	O
29	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
2	O
versus	O
24	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
Hg	O
,	O
cisapride	O
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
pretreatment	O
,	O
25	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
0	O
mm	O
Hg	O
)	O
,	O
the	O
mean	O
contraction	O
duration	O
longer	O
(	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
sec	O
,	O
cisapride	O
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O

Prevention	O
of	O
breast	B
cancer	I
with	O
tamoxifen	O
:	O
preliminary	O
findings	O
from	O
the	O
Italian	O
randomised	O
trial	O
among	O
hysterectomised	O
women	O
.	O

BACKGROUND	O
:	O
Tamoxifen	O
is	O
a	O
candidate	O
chemopreventive	O
agent	O
in	O
breast	B
cancer	I
,	O
although	O
the	O
drug	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
endometrial	B
cancer	I
.	O

METHODS	O
:	O
In	O
October	O
,	O
1992	O
,	O
we	O
started	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
,	O
randomised	O
trial	O
of	O
tamoxifen	O
in	O
women	O
(	O
mainly	O
in	O
Italy	O
)	O
who	O
did	O
not	O
have	O
breast	B
cancer	I
and	O
who	O
had	O
had	O
a	O
hysterectomy	O
.	O

The	O
primary	O
endpoints	O
are	O
the	O
occurrence	O
of	O
and	O
deaths	O
from	O
breast	B
cancer	I
.	O

41	O
cases	O
of	O
breast	B
cancer	I
occurred	O
so	O
far	O
;	O
there	O
have	O
been	O
no	O
deaths	O
from	O
breast	B
cancer	I
.	O

There	O
is	O
no	O
difference	O
in	O
breast	B
-	I
cancer	I
frequency	O
between	O
the	O
placebo	O
(	O
22	O
cases	O
)	O
and	O
tamoxifen	O
(	O
19	O
)	O
arms	O
.	O

There	O
is	O
a	O
statistically	O
significant	O
reduction	O
of	O
breast	B
cancer	I
among	O
women	O
receiving	O
tamoxifen	O
who	O
also	O
used	O
hormone	O
-	O
replacement	O
therapy	O
during	O
the	O
trial	O
:	O
among	O
390	O
women	O
on	O
such	O
therapy	O
and	O
allocated	O
to	O
placebo	O
,	O
we	O
found	O
eight	O
cases	O
of	O
breast	B
cancer	I
compared	O
with	O
one	O
case	O
among	O
362	O
women	O
allocated	O
to	O
tamoxifen	O
.	O

INTERPRETATION	O
:	O
Although	O
this	O
preliminary	O
analysis	O
has	O
low	O
power	O
,	O
in	O
this	O
cohort	O
of	O
women	O
at	O
low	O
-	O
to	O
-	O
normal	O
risk	O
of	O
breast	B
cancer	I
,	O
the	O
postulated	O
protective	O
effects	O
of	O
tamoxifen	O
are	O
not	O
yet	O
apparent	O
.	O

There	O
were	O
no	O
deaths	O
from	O
breast	B
cancer	I
recorded	O
in	O
women	O
in	O
the	O
study	O
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
effect	O
of	O
folic	O
acid	O
-	O
containing	O
multivitamin	O
supplementation	O
in	O
epileptic	B
women	O
before	O
and	O
during	O
pregnancy	O
in	O
order	O
to	O
determine	O
the	O
rate	O
of	O
structural	O
birth	B
defects	I
and	O
epilepsy	B
-	O
related	O
side	O
effects	O
.	O

One	O
epileptic	B
woman	O
delivered	O
a	O
newborn	O
with	O
cleft	B
lip	I
and	I
palate	I
.	O

She	O
developed	O
status	B
epilepticus	I
and	O
later	O
symptoms	O
of	O
systemic	B
lupus	I
erythematodes	I
.	O

CONCLUSIONS	O
:	O
The	O
epileptic	B
pregnant	O
patient	O
'	O
s	O
autoimmune	B
disease	I
(	O
probably	O
drug	O
-	O
induced	O
lupus	B
)	O
could	O
damage	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
therefore	O
the	O
therapeutic	O
dose	O
(	O
>	O
or	O
=	O
1	O
mg	O
)	O
of	O
folic	O
acid	O
triggered	O
a	O
cluster	O
of	O
seizures	B
.	O

Physiological	O
dose	O
(	O
<	O
1	O
mg	O
)	O
of	O
folic	O
acid	O
both	O
in	O
healthy	O
and	O
60	O
epileptic	B
women	O
,	O
all	O
without	O
any	O
autoimmune	B
disease	I
,	O
did	O
not	O
increase	O
the	O
risk	O
for	O
epileptic	B
seizures	I
.	O

The	O
association	O
of	O
cocaine	O
and	O
amphetamine	O
use	O
with	O
hemorrhagic	O
and	O
ischemic	B
stroke	B
is	O
based	O
almost	O
solely	O
on	O
data	O
from	O
case	O
series	O
.	O

Acute	B
renal	I
failure	I
subsequent	O
to	O
the	O
administration	O
of	O
rifampicin	O
.	O

A	O
clinical	O
presentation	O
is	O
made	O
of	O
a	O
2	O
-	O
3	O
year	O
follow	O
-	O
up	O
of	O
six	O
cases	O
of	O
acute	B
renal	I
failure	I
that	O
have	O
been	O
reported	O
earlier	O
.	O

The	O
patients	O
had	O
developed	O
transient	O
renal	B
failure	I
after	O
the	O
intermittent	O
administration	O
of	O
rifampicin	O
.	O

Although	O
in	O
the	O
acute	O
stage	O
the	O
renal	B
lesions	I
histologically	O
appeared	O
toxic	O
,	O
evidence	O
suggestive	O
of	O
an	O
immunological	O
mechanism	O
cannot	O
be	O
excluded	O
.	O

Chronic	O
effects	O
of	O
a	O
novel	O
synthetic	O
anthracycline	O
derivative	O
(	O
SM	O
-	O
5887	O
)	O
on	O
normal	O
heart	O
and	O
doxorubicin	O
-	O
induced	O
cardiomyopathy	B
in	O
beagle	O
dogs	O
.	O

Animals	O
which	O
received	O
over	O
six	O
courses	O
of	O
doxorubicin	O
demonstrated	O
the	O
electrocardiogram	O
(	O
ECG	O
)	O
changes	O
,	O
decrease	O
of	O
blood	O
pressure	O
and	O
high	O
-	O
grade	O
histopathological	O
cardiomyopathy	B
,	O
while	O
animals	O
which	O
were	O
terminally	O
sacrificed	O
after	O
the	O
SM	O
-	O
5887	O
administration	O
did	O
not	O
show	O
any	O
changes	O
in	O
ECG	O
,	O
blood	O
pressure	O
and	O
histopathological	O
examinations	O
.	O

To	O
examine	O
a	O
possibly	O
deteriorating	O
cardiotoxic	B
effect	O
of	O
SM	O
-	O
5887	O
,	O
low	O
-	O
grade	O
cardiomyopathy	B
was	O
induced	O
in	O
dogs	O
by	O
four	O
courses	O
of	O
doxorubicin	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
SM	O
-	O
5887	O
treatment	O
did	O
not	O
progress	O
the	O
grade	O
of	O
cardiomyopathy	B
.	O

Risk	O
for	O
valvular	B
heart	I
disease	I
among	O
users	O
of	O
fenfluramine	O
and	O
dexfenfluramine	O
who	O
underwent	O
echocardiography	O
before	O
use	O
of	O
medication	O
.	O

BACKGROUND	O
:	O
Because	O
uncontrolled	O
echocardiographic	O
surveys	O
suggested	O
that	O
up	O
to	O
30	O
%	O
to	O
38	O
%	O
of	O
users	O
of	O
fenfluramine	O
and	O
dexfenfluramine	O
had	O
valvular	B
disease	I
,	O
these	O
drugs	O
were	O
withdrawn	O
from	O
the	O
market	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
risk	O
for	O
new	O
or	O
worsening	O
valvular	B
abnormalities	I
among	O
users	O
of	O
fenfluramine	O
or	O
dexfenfluramine	O
who	O
underwent	O
echocardiography	O
before	O
they	O
began	O
to	O
take	O
these	O
medications	O
.	O

The	O
primary	O
outcome	O
was	O
new	O
or	O
worsening	O
valvulopathy	B
,	O
defined	O
as	O
progression	O
of	O
either	O
aortic	B
or	I
mitral	I
regurgitation	I
by	O
at	O
least	O
one	O
degree	O
of	O
severity	O
and	O
disease	O
that	O
met	O
U	O
.	O
S	O
.	O

RESULTS	O
:	O
Two	O
patients	O
(	O
4	O
.	O
3	O
%	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
6	O
%	O
to	O
14	O
.	O
8	O
%	O
]	O
)	O
receiving	O
fenfluramine	O
-	O
phentermine	O
developed	O
valvular	B
heart	I
disease	I
.	O

The	O
second	O
patient	O
developed	O
new	O
moderate	O
aortic	B
insufficiency	I
.	O

CONCLUSION	O
:	O
Users	O
of	O
diet	O
medications	O
are	O
at	O
risk	O
for	O
valvular	B
heart	I
disease	I
.	O

In	O
TD	O
group	O
,	O
three	O
patients	O
developed	O
decreased	B
auditory	I
function	I
,	O
of	O
which	O
one	O
presented	O
with	O
an	O
auditory	B
loss	I
of	O
-	O
30	O
dB	O
,	O
whereas	O
in	O
the	O
OD	O
group	O
only	O
one	O
patient	O
presented	O
decreased	B
auditory	I
function	I
.	O

Structural	B
and	I
functional	I
impairment	I
of	I
mitochondria	I
in	O
adriamycin	O
-	O
induced	O
cardiomyopathy	B
in	O
mice	O
:	O
suppression	O
of	O
cytochrome	O
c	O
oxidase	O
II	O
gene	O
expression	O
.	O

The	O
use	O
of	O
adriamycin	O
(	O
ADR	O
)	O
in	O
cancer	B
chemotherapy	O
has	O
been	O
limited	O
due	O
to	O
its	O
cumulative	O
cardiovascular	B
toxicity	I
.	O

Our	O
results	O
indicated	O
that	O
1	O
)	O
treatment	O
of	O
mice	O
with	O
ADR	O
caused	O
cardiovascular	B
arrhythmias	I
characterized	O
by	O
bradycardia	B
,	O
extension	O
of	O
ventricular	O
depolarization	O
time	O
(	O
tQRS	O
)	O
,	O
and	O
failure	O
of	O
QRS	O
at	O
high	O
concentrations	O
(	O
10	O
-	O
14	O
mg	O
/	O
kg	O
body	O
weight	O
cumulative	O
dose	O
)	O
;	O
2	O
)	O
the	O
heart	O
mitochondria	O
underwent	O
swelling	B
,	O
fusion	O
,	O
dissolution	O
,	O
and	O
/	O
or	O
disruption	O
of	O
mitochondrial	O
cristae	O
after	O
several	O
weeks	O
of	O
treatment	O
.	O

Knowing	O
that	O
heart	O
mitochondria	O
represent	O
almost	O
40	O
%	O
of	O
heart	O
muscle	O
by	O
weight	O
,	O
we	O
conclude	O
that	O
the	O
deteriorating	O
effects	O
of	O
ADR	O
on	O
cardiovascular	O
function	O
involve	O
mitochondrial	B
structural	I
and	I
functional	I
impairment	I
.	O

